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ABSTRACT 
 
 
PART I: SYNTHESIS AND BIOLOGICAL EVALUATIONS OF 
POTENT CLASS l SELECTIVE HISTONE DEACETYLASE 
INHIBITORS 
 
Part II: AQUEOUS COMPLEXES FOR EFFICIENT SIZE-BASED 
SEPARATION OF AMERICIUM FROM CURIUM 
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THEIR APPLICATION FOR OXAXINANONES DERIVATIZATION 
AND THE AZA-HENRY REACTION 
 
 
BY 
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Part I:  SYNTHESIS AND BIOLOGICAL EVALUATIONS OF POTENT CLASS l 
SELECTIVE HISTONE DEACETYLASE INHIBITORS 
 
Histone deacetylase inhibitors (HDACi) have 
found a wide variety of medicinal uses and are most 
noted for their specific apoptotic action towards cancer 
cells1. Several hydroxamates and tetrapeptides HDACi 
have since been moved on to phase 1 and 2 clinical 
trials, with FK228 & SAHA having already been 
approved for treatment of advanced cutaneous T-cell lymphoma (CTCL). FK228 
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Thailandepsin A, TDP-A
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& SAHA are pan-HDACi which d compounds describes the unselective inhibition 
for any of the 11 Zn2+-dependent HDAC isoforms.   Research in the past five 
years, has shifted towards developing selective HDACi instead of developing 
pan-HDACi since they have higher cytotoxicity in vitro and vivo.   The research 
presented involves exploration of a new class of HDACi that resemble the natural 
product Thailandepsin A, (TDP-A) but still retains adequate HDAC inhibitory 
activity and antitumor activity while increasing the maximum tolerated 
dose  levels (MTD). 
 
Part II: AQUEOUS COMPLEXES FOR EFFICIENT SIZE-BASED 
SEPARATION OF AMERICIUM FROM CURIUM 
 
Separation of the 
adjacent actinide (An) elements 
americium and curium (An = 
Am, or Cm) is important to 
concepts for advanced nuclear 
fuel cycles proposed to reduce 
the transuranic content of nuclear waste placed in geological repositories,2 but 
the similar chemistries of Am and Cm make this separation among the most 
difficult in the periodic table.2  The work presented in this section examines the 
design and synthesis of new aqueous ligands with complexation of the adjacent 
actinide ions americium(III) and curium(III).  The ligand N,N′-bis[6-carboxy-2-
v	  
	  
pyridylm-ethyl]-1,7-diaza-18crown6 (H2bp18c6) and its derivatives in an 
aqueous solution were studied to quantify and characterize their 
americium/curium selectivity. 
Part III: DESIGNING STRONG CHIRAL BRONSTED ACIDS AND THEIR 
APPLICATION FOR OXAXINANONES DERIVATIZATION AND THE AZA-
HENRY REACTION  
Nature uses chiral Brønsted acids catalytically for numerous organic 
reactions. Organic chemists have until only very recently realized the importance 
of this unique class of catalyst. As a result, there are very few known chiral 
Brønsted acids used in traditional asymmetric organic reactions. In recent years, 
due to the tremendous need for new asymmetric organic reactions in the 
pharmaceutical and food industries, interest in strong chiral Brønsted acids has 
been steadily growing. Currently, there are only a few of these acids known that 
have been used successfully for organic reactions. The research presented here 
involves exploration of a new class of chiral Brønsted acids for organic reactions. 
In addition, this research focuses on the importance of strong acidity as well as 
asymmetry for aza-Henry reaction. Binaphthyl sulfur-containing acid systems, 
which are analagous to sulfuric acid (H2SO4), were found to be especially 
attractive. This dissertation reports on the use of an innovative application of 
these asymmetric chiral sulfonate/sulfate systems in conjunction with a strong 
Brønsted acid. These new catalytic systems were very successful for obtaining 
asymmetry in the aza-Henry reaction.  
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Part I: Synthesis and Biological Evaluations of Potent Class I 
Selective Histone Deacetylase inhibitors 
 
1.1 Introduction 
1.1.1 Gene Expression by Histone Deacetylase (HDAC) proteins 
 The nucleosome is a basic unit of DNA in eukaryotes which is wrapped in 
sequence around eight histone protein cores (two molecules of each core histone) 
which can be compared to string wrapped around a rod.   Nucleosomes are used 
to pack the enormous eukaryotic genomes into the nucleus while still ensuring 
appropriate 
 
Figure 1.1: Cartoon of chromosome to DNA (left diagram), cartoon and molecular 
diagram of octamer of core histones (H2A, H2B, H3 and H4)(right diagrams). 
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access to it (mammalian cells have approximately 2 m of linear DNA which is 
packed into a nucleus that is 10 µm in diameter)1.  Nucleosomes are folded 
through a sequence of successively advanced ordered structures to ultimately 
form chromosomes (figure 1.1). The nucleosome core particle consists of about 
146 base pairs (bp) of DNA wrapped in 1.67 left-handed helical turns around the 
octameric core2.  This octamer consist of two copies of each core histones, which 
are H2A, H2B, H3, and H43 (figure 1.1).  Linker histones (connects adjacent 
octameric core histones) such as H1 and its isoforms are involved in chromatin 
condensing and sit at the base of the nucleosome near the DNA entry and exit site 
which bind to the linker region of the DNA4.  Histone H1 is similar to a clamp by 
holding the DNA to the octamer when attached and releasing the DNA from the 
octamer when not clamped5-8.  Non-condensed nucleosomes without the linker 
histone resemble “beads on a string of DNA” under an electron microscope.   
Neighboring octamers are joined by a fragment of free DNA deemed the “linker 
DNA” which varies from 12-85 bp in length depending on the cell’s class and 
tissue type9-12.  The nucleosomes carry epigenetically inherited material in the 
covalent alterations of the core histones.  
The N-terminal tails of histones protruding from the nucleosome are subject 
to various posttranslational modifications.  These include phosphorylation13, 
acetylation14, methylation15, sumoylation16, ADP-ribosylation17 and ubiquitination18.  
The manner that these posttranslational modifications take place can modulate the 
chromatin structure and therefore regulate gene expression.   By an overwhelming 
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amount, acetylation/ deacetylation19-25 of core histones has been the most studied 
and therefore, best understood of the posttranslational modifications.   
 
Figure 1.2: The equilibrium activities of histone acetyltransferase (HAT) and 
deacetylase (HDAC) 
 
In cells, acetylation/deacetylation regulates many protein functions such as 
protein-protein interactions26, DNA recognition27 and protein stability28, which acts 
as a signaling mechanism that is similar to phosphorylation29-31. Histone 
acetylation and deacetylation in eukaryotic cells is delicately maintained by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). These enzymes 
are responsible for modifications to chromatin structures that can regulate gene 
transcription32.  In general, HAT acetylation activity leads to an increase in gene 
transcription33-35 by neutralizing the positive charge on lysine residuals of histones, 
which loosens their interactions with the negatively charged DNA backbone, 
leading to a more active chromatin framework.   Acetyl CoA36 transfers the acetyl 
group to the lysine terminal of the histone. In contrast, HDACs catalyze the 
removal of the acetyl groups on lysine residuals located on the amino-terminal tails 
of core histones, which leads to gene repression by chromatin condensation37 
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(figure 1.2). As a result, inhibition of HATs leads to a gene that is always 
deactivated while inhibition of HDACs leads to general hyperacetylation of 
histones, which is followed by the transcriptional activation of certain genes 
through relaxation of the DNA conformations.  HAT/HDAC inhibition and 
posttranslational modifications are essential for the regulation of many cellular 
processes such as transcription38, cell division39, cell survival40 and 
differentiation40.  
 
 1.1.2: Classification of HDAC proteins 
Table 1.1: Four classes of HDAC proteins42-45 
 
Zn2+ cationic dependent proteins 
NAD+ 
dependent 
proteins 
Class I Class II Class IV Class III 
Class IIa Class IIb 
HDAC 1 
HDAC 2 
HDAC 3 
HDAC 8 
HDAC 6 
HDAC 10 
 
HDAC 4 
HDAC 5 
HDAC 7 
HDAC 9 
 
HDAC 11 
 
SIRT 1 
SIRT 2 
SIRT 3 
SIRT 4 
SIRT 5 
SIRT 6 
SIRT 7 
 
Histone deacetylases or HDACs are a family of epigenetic enzymes that 
catalyze the hydrolysis of acetylated ε-amino groups (not the alpha carbon amino 
group) of lysine in histone tails.  There are roughly 30 lysine residuals on each 
histone, (H3, H4, H2A and H2B) which are all subjects to deacetylation by 
HDACs45.  Removal of the acetyl groups restores the positive charge of lysine 
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residues, enabling them to interact back with negative charged phosphate groups 
of DNA, following chromatin condensing and transcriptional repression46.  The first 
human HDAC was discovered and cloned by the Schreiber laboratory47 (Stuart L. 
Schreiber, Ph.D. Director of Chemical Biology at and a Founding Member of the 
Broad Institute of Harvard and MIT). To date, there are 18 known human HDACs 
protiens48-51 that are grouped into four classes based on their size51, number of 
catalytic sites51, subcellular localization51, and their sequence homology to yeast 
counterparts51. Class I (HDACs 1, 2, 3 and 8), class II (HDACs 4, 5, 6, 7, 9 and 
10), and class IV (HDAC 11) are all Zn2+-dependent enzymes48-52 (table 1.1) 
(figure 1.3).  Class III proteins, called sirtuins, (SIRTs 1–7) are defined by their 
dependency on the coenzyme, electron transporter, nicotinamide adenine  
 
Figure 1.3 Evolutionary relationship between the HDACs 
The actual distances may be greater than shown.  Class I HDACs (red) are related 
to yeast (Saccharomyces cerevisiae, RPD3) and class II HDACs (blue) are related 
to the yeast HDA1 enzyme.  HDAC 11 (Black) does not show enough identity with 
Class I or Class II HDACs to be placed in either class53. 
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dinucleotide (NAD+).    Class I HDACs are predominantly located in the nucleus 
while class II HDACs can shuttle between the nucleus and cytoplasm54. Classes I, 
II and IV HDACs are all Zn2+-dependent proteins and are the main proteins that 
are studied in this dissertation.  Class I HDACs are widely expressed in most cells 
whereas class II and IV show various degrees of tissue specificity.  It has been 
revealed that Zn2+-dependent HDACs, especially class I and class II enzymes play 
a role in tumorigenesis and cell development54.  
Class I HDACs (HDAC1, 2, 3, and 8) are smaller in size of the zinc 
dependent enzymes and are the most closely related to the yeast 
(Saccharomyces cerevisiae) transcriptional regulator RPD3 (figure 1.4).  They 
have any range between 377 to 488 base pairs of amino acids51-54.  These 
proteins are all located in the nucleus.  The main role of HDAC 1, 2, and 8 are all 
transcription corepressor while HDAC3 is not well understood yet.  Knockout 
studies have shown that class I HDACs are involved in cell proliferation and 
survival3.   Also, research has shown that class I enzymes are the most important 
class when implied in cancer progression/tumorigenesis54. 
Class II is the largest of the three groups of zinc dependent enzymes, and 
is divided into two subgroups: class IIa and IIb (figure 1.4).  Class IIa is 
represented by HDAC4, HDAC 5, HDAC 7 and HDAC 9, while class IIb is HDAC6 
and HDAC10.  These proteins range in size from 669 to 1215 bp and can shuttle 
between the nucleus and cytoplasm55.    They are most closely related to the yeast 
(Saccharomyces cerevisiae) transcriptional regulator HAD155. 
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Class IV is the smallest class consisting of its solo protein, HDAC11 (figure 
1.4). This isoform is only located in the nucleus and main role is unknown.  It is the 
smallest protein of all the HDACs containing only 347 base pairs51-54.  The reason 
it is in its own class is due to the fact it is not related to any other HDAC protein 
and its catalytic domain is very different from all other HDAC proteins.   
 
 
 
Figure 1.4: The figure shows the class I (HDAC1, 2, 3 and 8), class IIa (HDAC4, 
5, 7 and 9), class IIb (HDAC6 and 10) and class IV (HDAC11) HDACs with the 
various structural/functional domains listed.  Schematic depictions of HDAC 
isoforms and their sub-cellular localization. Bars depict the length of each isoform. 
Colored (green/blue) regions depict the metal ion-dependent catalytic domain. 
Light grey depicts the inactive domain sequence (IDS). Each protein starts with the 
N-terminus (left) and ends with the C-terminus (right)53.   
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1.1.3: Histone Deacetylases Involvement with Different Types of Cancers 
Class I HDACs  are expressed at much higher rates than normal cells in 
numerous types of cancers such as prostate, ovarian (HDAC 1, HDAC 2, & HDAC 
3), colorectal, lung cancers (HDAC 1 and HDAC 3), gastric pancreatic (HDAC 2) 
and hepatocellular carcinomas, but are not found in normal, resting endothelial 
cells and normal organs56 (table 1.2).  Class I HDACs are produced at elevated 
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levels in ovarian cancers compared to normal ovarian tissues, as measured using 
small interfering RNA procedures56.  
HDAC 3 was produced at higher levels in 92% of non-small cell lung 
carcinomas by immunoblot analysis57. HDAC 2 was elevated in 44/71 gastric 
tumors58.  Class IIa HDAC 6 protein was observed in breast and ovarian cancer 
tissues58.    HDAC 5 is down regulated in colon cancers and acute myeloid 
leukemia.HDAC inhibition in cancer cells induces expression of genes including 
tumor suppressor genes that lead to cell growth arrest, differentiation, apoptosis, 
antiangiogenic effects and regression of cancer56-61.  Learning what HDAC 
proteins/classes are associated with what types of cancer formation has been 
given much attention over the last decade to pharmaceutical and carcinoma 
studies.  
Since discovery of higher levels of each individual HDAC protein in the 
formation of specific types of cancer tumors, the role of each isoform in 
tumorigenesis is not yet well understood.  Therefore, clarifying the detailed 
mechanism linking the HDAC activity of each isoform to cancer formation would 
facilitate studies that lead to faster treatment and more precise classification of 
each type of tumor.  Key development of selective HDAC inhibitors is fully required 
to completely understand the role of each individual HDAC protein in all stages of 
cancer development.   
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Table 1.2: Implication of zinc dependant HDACs in different types of cancers62 
 
 
To date, X-ray co-crystallographic information is available for HDACs 2, 4, 7 and 8 
in complex with several different small molecule inhibitors63.  This data is of great 
use for the development of molecular modeling methods and also run 
computational studies of new targets that are very selective for few HDAC’s active 
site.   
 
 
Group Tumor Implication Tumor 
expressiona 
Class I (type  RPD3) 
HDAC1 Possible prognostic indicator for lung and 
breast cancers. Over expressed in prostate 
cancers (hormone-refractory), gastric, and 
colorectal. 
++ 
HDAC2 Over expressed in colorectal and gastric 
cancers. Loss of antigen presenting cells in 
colorectal cancers gave HDAC2 over 
expression. 
++ 
HDAC3 Over expressed in lung cancers and 
several solid tumors 
++ 
HDAC8 Knock down inhibits cell growth in several 
human tumor cells. 
++ 
Class II (type HAD1) 
HDAC4 Unknown ++ 
HDAC5 Down regulated in colon cancers and acute 
myeloid leukemia 
- - 
HDAC6 Ambiguous prognostic in breast cancer  
HDAC7 Unknown  
HDAC9 Unknown  
HDAC10 Unknown  
Class IV  
HDAC11 Unknown  
a: ++ indicated an over expression in tumor.  - - indicates a reduced 
expression 
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Figure 1.5: HDAC2 Crystal structure (three domains are in different colors) and 
the active site with TDP-A bound (PDB: 3MAX)  
 
 
 
Zinc dependent class I histone deacetylase (HDAC) enzymes, HDAC1, 
HDAC2, HDAC3 and HDAC8, are known to play important roles in tumorigenesis64 
and are often over-expressed in many different types of cancers.  Inhibiting the 
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functionalities of class I HDACs by using small molecules, known as HDAC 
inhibitors (HDACi) resulted in terminal differentiation, growth arrest and apoptosis 
of cancerous cells64.   
 
1.1.4 HDAC Inhibitors 
 
 Over the last decade, there has been extensive research and devolvement 
of many HDACi which has lead to very promising results in treating cancer cells 
and other various diseases.   Several HDACi drugs are in clinical trials for 
treatment of cancers and diseases.  The first HDACi, suberoyl anilide 
hydroxamic acid (SAHA, Vorinostat) was approved by the Food and Drug 
Administration (FDA) for treatment of T-Cell lymphoma (CTCL) in the early 2000s.  
Then, in 2009 the FDA approved romidepsin/FK-228 also for CTCL65.  SAHA is 
considered to be a pan-inhibitor, which means it has no selective to any class or 
specific HDAC protein and inhibits the majority of the 11 zinc dependent HDAC 
isoforms.   However, FK-228 is considered a class I selective inhibitor (inhibiting 
only HDAC1 and HDAC2).   This is the selectivity in HDACi that research is trying 
to design.    
There are many different types of HDACi but the four most promising 
classes of HDACi discovered thus far are 1) hydroxamic acids, 2) short-chain fatty 
acids (SCFA), cyclic peptides and benzamide/ketone derivatives66-67 (figure 1.6 
and table 1.3). 
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Figure 1.6. Four Main classes of HDACi67 
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Table 1.3: Properties of HDACi including stuctural class, IC50, Activated genes, 
Repressed genes and in vitro effect68 
Inhibitor Structural Range Activated genes Repressed 
genes 
In vitro 
effect 
Butyrates  Short chain 
fatty acids 
mM CDKN1A,GATA2,PKCD, 
MHC1, MHC2, BAK, IL8, 
RARβ, TG1, cyclin E, CPA3, 
CD86, ICAM1 
Cyclin D1, 
cyclin A, 
BCL2, IL2, 
BCLXL 
Apoptosis 
Differentiation 
Cell-cycle 
arrest 
Trichostatin   hydroxamic 
acid 
 nM CDKN1A, GATA2 HSP86, 
CDKN1B, PKCD,HDAC1, 
IGFBP3, DHFR, TGFB1, ER, 
CD86, cyclin E, FNG, IFNB, 
TP53, VHL, MHC1, MHC2, 
CPA3, P107, BAX, BAK, TG1, 
CDNK2A, MLH1, TIMP3 
Cyclin A, 
CDKN1C, 
BCLXL, 
PU.1, HIF1A, 
VEGF, IL2, 
IL10 
Apoptosis 
Differentiation 
Cell-cycle 
arrest 
Suberoylanilid 
hydroxamic  
acid (SAHA) 
hydroxamic 
acid 
µM CDKN1A CMYC, 
CMYB, 
BMYB 
Apoptosis 
Differentiation 
Cell-cycle 
arrest 
FR901228  
(Depsipeptide) 
Tetrapeptide µM CDKN1A, MAGE3, 
NY–ESO1, CD86 
CD95L, 
CMYC cyclin 
D, 
Apoptosis 
Cell-cycle 
arrest 
MS-27-275  Benzamidine µM CDKN1A, gelsolin, TGFBR2  Cell-cycle 
arrest 
 
BAK, BCL2 antagonist/killer protein; BAX, B-cell-associated X protein; BCL2, B-cell lymphoma 
protein 2; BCLXL, BCL2-related protein, long form; CD95L, CD95 ligand; CDKN1A, cyclin-
dependent-kinase inhibitor 1A; CDKN1B, cyclin-dependent-kinase inhibitor 1B; CDKN1C, cyclin-
dependent-kinase inhibitor 1C; PCPA3, carboxypeptidase A3; CT, cyclic tetrapeptide; DHFR, 
dihydrofolate reductase; ER, oestrogen receptor; GATA2, GATA-binding protein 2; HA, hydroxamic 
acid; HDAC, histone deacetylase; HIF1A, hypoxia-inducible factor 1, α-subunit inhibitor; HSP86, 
heat-shock protein (90 kDa); ICAM1, intercellular adhesion molecule 1; IFNB, interferon-β; IFNG, 
interferon-γ; IGFBP3, insulin-like-growth-factor binding protein 3; IL, interleukin; MAGE3, 
melanoma antigen, family A, 3; MHC, major histocompatibility complex; MLH1, mutL homologue 1; 
BMYB, v-myb myeloblastosis viral oncogene homolog (avian)-like 2; CMYB, v-myb myeloblastosis 
viral oncogene homologue (avian); CMYC, v-myc myelocytomatosis viral oncogene homologue 
(avian); AI2, plasminogen activator inhibitor type 2; PKCD, protein kinase C-δ; PU.1, PU.1 
transcription factor; RARβ, retinoic-acid receptor-β; SCFA, short-chain fatty acid; TG1, 
transglutaminase type1; TGFB1, transforming growth factor-β1; TGFBR2, TGF-β receptor 2; 
TIMP3, tissue inhibitor of metalloproteinase 3; VEGF, vascular endothelial growth factor; VHL, von 
Hippel–Lindau syndrome 
 
All of the four groups of HDACi have similar trends structurally.  The 
structure of HDACi are characterized by these main features:  a coordinating 
group/zinc binding group (ZBG) (such as a thiol or hydroxamic acid) to chelate to 
Zn2+ in the active site, a hydrophobic region (capping group), and a 5 to 7 carbon 
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linker that connects the cap group to ZBG68.  HDAC inhibitors generally adopt a 
“monkey wrench” scaffold in which a C5 (or C6 in some cases) linker connects a 
cap region and a zinc-binding group (ZBG)68. The cap is relatively flexible and 
mediates surface-to-surface interactions between drug and protein target; the ZBG 
is critical for HDAC inhibitory activity by chelating a zinc ion in the catalytic center 
of HDACs.  
 
1.1.5  Mechanisms of HDACs 
In 1999, the first experiments were carried out to study and to understand 
how HDACi bind to their enzymes69. The enzyme used in this binding studying 
was histone deacetylase-like protein (HDLP), a homolog from the 
hyperthermophilic bacterium Aquifex aeolicus. This HDLP shares a similar 
sequence with Class I protein, HDAC1 by 35.2%69.  The main goal of Dr. Finnin’s 
work was to determine the structure of the binding pocket and also what main 
parts of the inhibitors were binding to the enzyme/pocket.  The structure of the 
complexes of TSA and SAHA with HDLP were clearly measured to 2.0 angstroms 
(Å) resolution.  Analysis of the X-ray crystal revealed that the region interacting 
with TSA or SAHA of HDLP contains three main features (figure 1.7), 1) a surface 
recognition section, 2) a tube-like, 11 Å deep channel and 3) a 14 Å long, tapered 
pocket which attaches to the channel70.  
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Figure 1.7: SAHA bound to active site of HDAC170 
 
 
 
 
HDACi treatment is estimated to alter the expression level of approximately 
2%–10% of genes, with as many genes downregulated as upregulated70. The 
most studied of the upregulated genes is CDKN1A, which encodes the cell cycle 
inhibitor kinase p2170. Although the antiproliferative effect of HDACi can be 
explained by having this gene re-expressed, cell-cycle arrest is not crucial for 
HDACi-mediated tumour suppression because HDACis causes cell-cycle arrest in 
normal and cancer cells alike, and unlike many chemotherapeutic drugs, HDACis 
can kill proliferating cancer cells71. As for the method of this tumour cell killing, 
there are a plethora of routes through which it can occur. The main process 
through which HDACis induce cancer cell cytotoxicity is apoptosis71 (programmed 
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cell death). Apoptosis can occur through the extrinsic (death-receptor) or the 
intrinsic (characterized by cytochrome C release from mitochondria71) 
Figure 1.8: How HDACi mechisam of Apoptosis, Differentiation, Cell-cycle arrest, 
and Immune modulation72 
 
Pathway72. Interestingly, the pro-apoptotic transcription factor p5372 does not 
appear to be required for HDACi-induced apoptosis. Rather, the pro-apoptotic Bax 
and BH3-only proteins Bid or Bim are necessary for this effect73. Lastly, 
overexpression of the antiapoptotic proteins Bcl2 or BclXL leaves apoptosis 
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induction by HDACi73. Apoptosis induced by HDACi also depends on high levels in 
reactive oxygen species (ROS) fueled by HDACi treatment. This occurrence likely 
mimics the inability of tumour cells to upregulate thioredoxin (an antioxidant 
protein) during HDACi-induced ROS accumulation73. HDACis can also stimulate 
genomic volatility by impairing DNA damage repair34 and by causing mitotic 
disaster (mis-segregation of chromosomes because of defects in the mitotic 
spindle checkpoint)74. Also, HDACis can still induce cancer cell death by an 
autophagy-dependent processes74 which were demonstrated in an experiment 
with conditions blocking apoptosis. This is exciting for future research in the 
development of new HDACi, because it shows that HDACis may still be valuable 
against cancers with apoptosis defects74. Additionally, HDACis can sensitize 
tumour cells for destruction by the immune system75 with stimulation of the host 
immune system. In summary, HDACis can stimulate diverse cellular and 
physiologic processes that operate together to prevent the initiation and 
progression of cancer. 
 
1.1.6  Use of HDAC Inhibitor in Combination with Other 
Chemotherapies 
 
 The most beneficial and favorable use of HDACis is extremely likely to be in 
combination with other anticancer therapies. Many studies have shown that 
HDACis can join with a large set of other chemotherapeutic drugs (etoposide, 
cisplatin, bortezomib, and gemcitabine).76-77 
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 Recent research has shown synergism between HDACis and other 
compounds which can be combined to form a single hybrid compound. The first 
compound of this kind is triciferol (figure 1.9), in which the side chain of 1,25-
vitamin D3 is replaced with the dienyl hydroxamic acid of TSA78 which ultimally 
possesses characteristics of both 1,25-D3 (vitamin D receptor agonism) and TSA 
(histone hyperacetylation) and exhibits property similar to co-treatment with the 
two original compounds in terms of cancer cell cytotoxicity in vitro78. It will be a 
troumdous step forward to see in the future if this compound is just as effective  in 
animal studies and human clinical trials, as it was in cancer cell cytotoxicity in vitro.  
HDACis will be combined with other new drugs to form new antitumorigenic, 
antibactreal and antiviral hybrid compounds. 
 
Figure 1.9: Triciferol exhibits effects similar to co-treatment with both compounds 
(cholecalciferol and TSA) in terms of cancer cell cytotoxicity in vitro.79 
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1.2  Rationale design and biological evulatuions  of Frangents 
Thailandepsin A (TDP-A) is a natural product that was isolated from the 
bacteria Burkholderia thailandensis E264 by post-doctoral studunt Dr. Cheng 
Wang in Dr. Yi-Qiang Cheng’s  laboratory in the Biological Sciences Department 
at the University of Wisconsin-Milwaukee. Dr. Cheng’s extensive studies of FK228 
biosynthesis in Chromobacterium violaceum no. 968  have led to the discovery of 
thailandepsin A (TDP-A) and thailandepsin B (TDP-B) (figure 1.10), two new 
natural analogues of FK228.  This work represents a remarkable example of 
genomics-guided smart discovery of new chemical entities. TDPs exhibited potent 
inhibitory activities against class I HDACs, which is outlined in table 1.4. 
 
Figure 1.10: How TDP-A is produced from the bacteria Burkholderia thailandensis 
E264 
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TDP-A had IC50 values of 14nM and 3.5nM in HDAC1 and HDAC2 respectively. 
National Cancer Institute-60 (NCI-60) screening showed that TDP-A and TDP-B 
possess broad-spectrum antiproliferative activities (GI50 values in single to sub nM 
range) and potent cytotoxic activities (LC50 values in sub µM range) towards 
human cancer cell lines derived from colon, melanoma, ovarian, breast, CNS, non-
small cell lung and renal cancers. However, one problem that currently exists is 
TDPs have low solubility in water and showed undesirable levels of cytotoxicity 
(LC50) in NCI testing (table 1.5).  
 
Table 1.4: Enzyme Inhibition on HDAC proteins (IC50 values are in µM) 
Enzyme Inhibition on HDAC proteins (IC50 values are in µM) 
Inhibitor  HDAC1  HDAC2  HDAC 3  HDAC4  HDAC6  HDAC7  HDAC8  HDAC9  
2 6.7 1.5 0.018 >50 12 >50 >50 >50 
2*a 0.0053 0.0039 0.0053 0.47 0.33 3.2 0.026 12 
6 7.5 39 0.087 >50 9.9 >50 >50 >50 
6*a 0.014 0.0035 0.0048 42 0.38 11 1.2 12 
7 7.7 4.5 0.023 22 11 27 30 >50 
7*a 0.0065 0.0067 0.0094 18 0.61 24 1.0 30 
a Compounds were reduced/activated prior to being assayed.  
Thailandepsin A (R=SCH3) (6)
(Burkholdac B)
Thailandepsin B (R=CH2CH3) (7)
Reduced Thailandepsin A (6*)
Reduced Thailandepsin B (7*)
Reduction
Oxidation
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Oxidation
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O O
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22	  
	  
Table 1.5: National Cancer Institute-60 (NCI-60) screening 
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In order to obtain new compound derivatives or fragments that have 
reduced cytotoxicity but still retain adequate HDAC inhibitory activity as well as 
antitumor activity, structure activity relationship (SAR) studies must be carried out 
on TDP-A .  The goal of these SAR studies is to find a compound that is more 
selective to one or two Class I HDAC proteins. To reduce cytotoxicity, it is crucial 
to design a compound that is selective to just one or two HDAC proteins because 
in theory, the inhibitor will be more specific to the substrate it binds to and not bind 
to a general protein class.   Rational design and synthesis of 18 designer 
compounds (figure 1.11) are based on the scaffolds of 
 
Figure 1.11: Rational design and synthesis of 24 designer compounds 
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TDP-A, TDP-B, SAHA and FK228.  
Therefore, our designer molecules will keep a critical ZBG (the thiol group 
from FK228/TDPs or the hydroxamic acid group from SAHA) and the C5 linker 
(figure 1.11). TDF1, TDF2, TDF3 and TDF1t, TDF2m, TDF3m (Set 1) are TDP-A 
fragments with gradual increasing sizes; this set of compounds is designed to test 
the influence of molecule size on bioactivity and has the highest priority.  TDF4, 
TDF5, TDF6 and TDF4m, TDF5m, TDF6m (Set 2) all have the same size as TDF2 
but with different hydrophobic side chains. This set of compounds is designed to 
test the influence of different side chains on bioactivities. TDF7, TDF8, TDF9 and 
TDF7m, TDF8m, TDF9m (Set 3) contain a hydroxamic acid ZBG  inspired by 
SAHA in place of a thiol ZBG as seen in all activated FK228/TDP-class HDAC 
inhibitors. This set of compounds is designed to test the effect of an alternative 
ZBG in combination with different molecule sizes. Once all compounds are 
synthesized, they will be purified by HPLC and characterized by LC-MS, HRMS 
and NMR (1H and 13C).   
 
1.2.2 In vitro and in vivo testing parameters: 
After characterization is complete, the in vitro testing will begin.  The HDAC 
inhibitory activity of compounds (including all synthetic compounds, and SAHA, 
FK228, TDP-A and TDP-B as references) will be determined with a fluorogenic 
assay which had been successfully applied to TDPs79. Each compound will be 
assayed against three isoforms of human HDACs (HDAC1, HDAC4 and HDAC6, 
25	  
	  
which represent class I, class IIa and class IIb HDACs, respectively), and the IC50 
value (in µM) will be determined accordingly.  
After in vitro testing is complete, in vivo testing will begin.  The 
antiproliferative activity of compounds will be evaluated with an MTT assay used 
routinely by the NCI-DTP program (detailed protocol available at 
http://dtp.nci.nih.gov/branches/ btb/ivclsp.html). The cancer lines that will be tested 
are cervical (HeLa), colon (HCT-116 and COLO-205), renal (RFX-393), breast 
(MDA-MB-231) and prostate (DU-145).  These cells lines have shown to be 
sensitive to TDPs in our previous study. The GI50 value (in µM) will be determined 
accordingly. 
Next, the acute toxicity of compounds will be assessed in healthy mice 
following the standard NCI-DTP protocol (available at 
http://dtp.nci.nih.gov/branches/btb/acute_tox.html)79. Because HDAC inhibitors are 
known or expected to be very potent or toxic, a single mouse is given a single IV 
dose of 100 mg/kg, a second mouse receives a dose of 50 mg/kg and a third 
mouse receives a single dose of 25 mg/kg. The mice are observed for a period of 
two weeks. They are sacrificed if they lose more than 20% of their body weight or 
if there are other signs of significant toxicity. If all three mice must be sacrificed, 
the next three dose levels (12.5, 6.25 and 3.125 mg/kg) are tested in a similar 
manner. This process is repeated until a tolerated dose is found, and the MTD 
value is determined according. 
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1.3  Synthesis of natural product derivatives 
 Natural HDAC inhibitors such as SAHA, FK228 TDP-A and TDP-B have 
synthetic routes previously published, but none of the previous work focused on 
fragments or modifications from the natural product TDP-A.  Having a good 
amount of TDP-A in-hand, we decided to synthesis three derivatives from the 
natural product.   The initial three compounds that were synthesized were TDC1, 
TDC2, and TDC3.  This first set of compounds was designed from natural product 
TDP-A by modifying the hydroxyl handle. Dr. Weiping Tang’s group (Xiaoyun Li) at 
the University of Wisconsin-Madison added the corresponding group on these 
three derivatives.  The synthetic procedure for TDP-A analogues is shown in 
scheme 1.1.  TDP-A was reacted under basic conditions (pyridine, DMAP) with 
the corresponding acid chloride to produce TDC1 (82% yield, R=benzoyl), TDC2 
(85% yield, R=ethyl formate) and TDC3 (92% yield, R=acetyl).  
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Scheme 1.1. Reagents and conditions: (a) pyridine (1 mL), DMAP (one crystal), 
RCOCl (1.5 equiv), 0°C to 25°C, 40 h,  TDC1-82%,TDC2-85%,TDC3-92%, 
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Scheme 1.2: Retrosynthesis of TDF3 
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1.3.2 Synthesis of fragments related to TDP-A 
 The rest of the compounds designed in this project were small molecule 
fragments related to the natural product TDP-A which all test specific traits of the 
natural product (toxicity, solubility and amino acid specificity).  We envisioned that 
the preparation of the key intermediate, achiral β-hydroxy acid 4 (scheme 1.2), 
would follow a similar procedure developed by Simon and Ganesan80 from the 3 
carbon starting material acrolein.  Next, we would assemble the two amino acids 
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by a peptide coupling reaction to yield dipeptide (MetCys).  Then finally, 4 and 
MetCys would be coupled together with another peptide coupling reaction. 
 The actual synthetic route for the β-hydroxy acid and fragments TDF1 and 
TDF1t are outlined in scheme 1.3.  The SN2 reaction with Triphenymethyl 
mercaptan and acrolien 1 followed by the Wittig reaction provided aldehyde 2. This 
one pot protocol to form α,β-unsaturated aldehyde 2 gave 65% overall yield in two 
steps81. The desired aldol product 3 was achieved in 85% yield from the 
condensation of aldehyde 2 and t-butyl acetate as the enolate source.  Hydrolysis 
of the t-butyl ester 3 with lithium hydroxide provided the β-hydroxy acid 4 in 95% 
yield.  The β-hydroxy acid 4 and the β-hydroxy t-butyl ester 3 were treated with 
iodine in the presence of sodium acetate to give the disulfide dimers TDF1 and 
TDF1t in 68% and 52% yield, respectively.  NMR, HRMS and HPLC data 
confirmed the products. 
Turning our attention to the synthesis of TDF2 and TDF3 (scheme 1.4), β-
hydroxy acid 4 was reacted with D-methione methyl ester hydrochloride in the 
presence of the coupling reagent PyBOP (benzotriazol-1-
yloxytripyrrolidinophosphonium hexafluoro-phosphate) and Hunig’s base 
(DIPEA)81. This yielded the coupled product 6 in 81% yield.  Saponification with 
lithium hydroxide of the methyl ester 6 provided carboxylic acid 7 in 90% yield.  
The coupling reaction with the amino acid D-cystine methyl ester hydrochloride 
produced dipeptide product 8 in 81% yield. The hydrolysis of the methyl ester 9 
with lithium hydroxide gave the free carboxylic acid 10.  Deprotection of trityl with 
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iodine and sodium acetate of the carboxylic acid 9 produced the disulfide product 
TDF3 in 36% yield.   
 
Scheme 1.3. Reagents and conditions: (a) (1) HSCPh3 (1.0 equiv), Et3N (1.4 
equiv), CH2Cl2, 25 °C, 1 h, 99%, (2) (triphenylphosphoranylidene) acetaldehyde 
(1.0 equiv), benzene, 80 °C, 12 h, 60%, (b) t-butyl acetate (5.0 equiv), n-BuLi (5.5 
equiv), DIPEA (5.5 equiv), -78 °C, 2 h, 82% (c) LiOH (20 equiv),  THF/H2O(4:1),  
50 °C, 12h, 95% (d) I2 (0.5 equiv), NaOAc (1.0 equiv) MeOH/CH2Cl2 (10:1)  0 °C, 
12 h,TDF1t 52%, TDF1 68%. 
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Other disulfide products TDF2, TDF2m, TDF3m were synthesized from 6, 7, 8, 
and 9 under the same iodine conditions giving 35%, 26%, and 30%, yields 
respectively.  From a practical point of view, the aldol sequence is concise, 
providing the disulfide product of TDF2 in six steps and TDF3 in eight steps from 
acrolein 1. The overall yield for disulfide products of TDF2 and TDF3 was 13% and 
7%, respectively, from acrolien.  The synthesis can routinely be performed on a 
multigram scale.  All coumpounds were confirmed by NMR, HRMS and HPLC and 
are in the appendix.  
 
Scheme 1.4. Reagents and conditions: (a) D-methionine methyl ester 
hydrochloride (1.0 equiv), PyBop (1.0 equiv), DIPEA (3.0 equiv), CH2Cl2, 25 °C, 6 
h, 81% (b) LiOH (20 equiv),  THF/H2O(4:1), 25 °C, 12h, 90% (c) D-cystine (Trt)-
OH (1.5 equiv), PyBop (1.0 equiv), DIPEA (3.0 equiv), CH2Cl2, 25 °C, 6 h, 81% (d) 
LiOH (20 equiv),  THF/H2O(4:1), 25 °C, 12h, 90% (e)  I2 (0.5 equiv), NaOAc (1.0 
equiv) MeOH/CH2Cl2 (10:1)  0 °C, 12 h.  % Yield:  TDF2m: 25.7%, TDF2: 34.8%, 
TDF3m: 29.4%, TDF3: 35.6%. 
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Derivatives TDF4, TDF5 and TDF6 which have different aliphatic side chain 
amino acids were synthesized by a similar sequence using the β-hydroxy acid and 
PyBop coupling agent to attach the amino acid followed by deprotection of the 
methyl esters with lithum hydroxide to produce 14, 15, and 16 (scheme 1.5). Then 
carboxylic acids 14, 15, 16 were treated in iodine and sodium acetate conditions to 
yield disulfide products TDF4 (25.4%), TDF5 (32.4%) and TDF6 (42.4%).  The 
corresponding methyl esters 11, 12, 13 were reacted using similar iodine/sodium 
acetate conditions to yield the disulfide dimers TDF4m (52%), TDF5m (34%) and 
TDF6m (15%), respectively. 
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1.3.3  Trouble-shooting synthesis of fragments 
In amino acid chemistry, protecting groups are vital in peptide coupling.  
Triphenylmethane, or trityl (Trt), is an important protecting group commonly used 
for sulfur containing amino acids such as in the amino acid cysteine, and is often 
employed in reactions that involve disulfide bond formation. Common methods to 
cleave trityl groups (R-S-Trt) involve acidification82-84 to form the thiol (R-S-H). The 
difficulty of this process is that the reaction with acid would cleave allylic alcohols 
to yield a dehydrated product.  If we wanted to use this method, employing a 
protecting group on the allylic alcohol would be the most plausible opinion  
 Iodine (I2) has been an attractive tool used previously in the literature for 
disulfide bond formation with the protecting group triphenylmethane.  Using iodine 
deprotects the sulfur (R-STrt) while simultaneously forming the coupled product 
(R-S-S-R).   
Table 1.6: Acid trials to remove trityl protecting group 
 
 
 
entry  reagent(s) (equiv) solvent  temp(ºC)  time  yield  
1 TFA (>10)  DCM 25  1 h  N.R. 
2 TFA (5) DCM  25  2 h  N.R. 
3  TFA (1)  DCM  25  24 h  trace 
4  TFA(1),(i-Pr)3SiH(2) DCM  25  24 h  N.R. 
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Table 1.6: Hg2+ and Ag+ cations trials to remove trityl protecting group 
 
 
 
 
 
 
 
 
 
Entry Reagent(s) 
(equiv) 
Solvent Temp 
(ºC) 
Time Yield 
1 Hg(OAc)2 (1 eq.),  DTE (1 eq.),  EtOH  25  10 h N.R. 
2 Hg(OAc)2 (1 eq.),  DTE (1 eq.),  
NaOAc (1 eq.) 
EtOH  25  10 h N.R. 
3 Hg(OAc)2 (1 eq.), DTE (1 eq.),  
NaOAc (1 eq.) 
MeOH/THF (3:1)  25  10 h N.R. 
4 Hg(OAc)2 (1 eq.), DTE (1 eq.),  EtOH 25 10 h N.R. 
5 Hg(OAc)2 (1 eq.), DTE (1 eq.),  
NaOAc (1 eq.) 
EtOH 25 10 h N.R. 
6 Ag(NO3) (1 eq.), DTE (1 eq.),  MeOH/THF (3:1) 25 10 h N.R. 
7 Ag(NO3) (1 eq.), DTE (1 eq.),  
NaOAc (1 eq.) 
MeOH/THF (3:1) 25 10 h N.R. 
8 Ag(NO3) (1 eq.), DTE (1 eq.), 
NaOAc (1 eq.) 
MeOH/THF (3:1) 25 10 h N.R. 
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When running β-hydroxy acid 4 in trifluoroacetic acid (TFA) we observed the 
deprotection of the trityl group, and also the α,β-unsaturated alcholol group 
dehydrated to form the conjugated product 40.  The results are shown in table 1.6.  
Furthermore, cleavage of the protecting group with reactive metals85 such as silver 
and mercury react readily to give the metal-sulfur intermediate, but are difficult to 
further remove the metal and obtain the thiol product (table 1.7).  Next we turned 
to iodine.  After studying a large variety of reaction conditions with iodine, we 
found a straightforward approach to deprotect the sulfur (R-STrt) and 
simultaneously form the disulfide bond (R-S-S-R) without affecting the allylic 
alcohols to any extent.  Those results are summarized in table 1.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38	  
	  
Table 1.8: Iodine reactions to cleave trytl protecting group 
 
 
 
entry  reagent(s)  
(equiv)  
solvent  temp  
 (ºC)  
time  yield  
1 I2 (10) MeOH  25 1 h  0  
2 I2 (5) MeOH  25  1 h  0  
3  I2 (1) MeOH  25  1 h  trace  
4 I2 (5), NaOAc (5)  MeOH/DCM (1:1) 25  1 h  10  
5 I2 (2), NaOAc (1) MeOH/DCM (1:1) 25  2 h  46 
6 I2 (10) MeOH/DCM (1:10)  25 1 h  0  
7 I2 (5) MeOH/DCM (1:10)  25 1 h  12 
8 I2 (1) MeOH/DCM (1:10)  25 1 h  17 
9 I2 (10), NaOAc (10) MeOH/DCM (1:10)  25 1 h  13  
10 I2 (5), NaOAc (5) MeOH/DCM (1:10)  25 1 h  34 
11 I2 (2), NaOAc (2) MeOH/DCM (1:10)  25 2 h  59 
12 I2 (2), NaOAc (1) MeOH/DCM (1:10)  25 2 h  68 
13 I2 (2), NaOAc (1) MeOH/DCM (1:10)  -78 2 h  N/A  
 
 
39	  
	  
1.4  Biological evaluations 
1.4.1 Isozyme Selectivity.  
 The pure compounds of all fragments and natural product derivatives were 
evaluated for inhibitory effects on three different groups of HDAC proteins (class I, 
IIa, and IIb).  The natural products FK228, SAHA, TDP-A, and TDP-B were used 
as controls.   All activity was determined by using a fluorescence-based in vitro 
assay (HDAC-GloTM I/II Assay and Screening System (Promega)).  Class I HDAC 
proteins evaluated were HDAC1, HDAC2, HDAC3 and HDAC8.  Class IIa HDAC 
protein was HDAC4 and the Class IIb HDAC protein was HDAC6.  The results of 
the enzyme assays are shown in table 1.9.   
 The first group designed and analyzed was the TDP-A derivatives TDC1, 
TDC2, and TDC3 which had different aliphatic groups on the alcohol.  TDC1 had 
the largest group (benzoyl), TDC3 had the smallest chain (acetyl group) and TDC2 
had a medium chain attached (ethyl formate).  All showed similar HDAC inhibition 
compared to the natural products to all class of HDAC proteins (HDAC I, IIa,and  
IIb).  TDC3 had the best inhibition of the three derivatives.  Having a large group 
(benzoyl group) on the hydroxyl handle in TDC1 nearly abolished selectivity 
toward Class IIb HDAC (HDAC4) (table 1.9).  TDC3 showed internal selectivity to 
class I HDACs (HDAC1: 2.7nm, HDAC2: 44nm, HDAC3:245nm, and HDAC8: 
10,000nm).  By adding a group to the alcohol in TDP-A,  the general results in 
similar inhibition to HDAC1, HDAC2 and HDAC8, a 100 fold decrease in activity to 
HDAC3, and roughly a 10 fold decrease to HDAC4 and HDAC6.  This decrease in 
activity is presumably due to the cap group interacting with the protein surface 
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outside the catalytic pocket.  On TDP-A, the alcohol group has a hydrogen bond 
donor while the R groups added are a hydrogen bond accepter.  Overall, the 
natural product derivatives (TDC1, TDC2, TDC3) are less selective than the pan-
HDAC inhibitor TDP-A, while increasing selectivity to Class I HDACs.  Next, with 
the linker and ZBG groups (R-S-H) very specific in our natural products (TDP-A, 
TDP-B and FK228), we investigated the cap group.  The first fragment designed 
was TDF1, which had the same linker and ZBG as the natural products (an allylic 
alcohol connected by 5 carbons to a thiol).  TDF1 had very potent inhibitory activity 
to HDAC1 (6nm) and HDAC2  (44nm) while exhibiting very poor activity against 
Class IIa (HDAC4) and IIb (HDAC 6) (table 1.9).  Intrigued by the selectivity to 
class I HDACs, we sought to further increase the selectivity for HDAC1 and 
HDAC2 inhibition.  The first change we made was to add a t-butyl group onto the 
carboxylic acid cap end (TDF1t) to decrease the hydrogen bonding to surface 
interactions.  However, this change actually resulted in increased inhibition of 
HDAC6 (class IIa) by roughly five-fold.  
 Encouraged by the initial results, we added two amino acids to our next 
fragments (methione first, cysteine second) in sequence for the next four 
fragments (TDF2, TDF2m TDF3 and TDF3m) (table 1.9).  In general, HDAC 
inhibition for this set of fragments was similar to that observed for TDF1. 
Interestingly, while TDF2 and TDF2m showed some inhibitory activity toward 
Class II HDACs, HDAC6 (high micromolar), TDF3 and TDF3m showed no 
inhibitory activity.  TDF3 and TDF3m was the first closed ring fragments used in 
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this study.  Also, replacing the carboxylic acid and adding a methyl ester to the 
fragments instead kept inhibition the same. 
 The last set of compounds that were designed was based on the first 
fragment TDF1 which had the best selectivity for class I HDACs.  TDF4, TDF5 and 
TDF6 tested the different aliphatic side chains to see the importance between the 
natural product side chains (TDP-A: R=SCH3, TDP-B: R=CH2CH3) with the amino 
acids norleucine and valine.  This set of fragments had very similar activity, except 
all of the methyl esters fragments (TDF4m, TDF5m and TDF6m), which were 
about 10-fold less active than the carboxylic acid derivative toward all class I 
HDACs.   
 In summary, TDC3 had the best inhibition for the natural product derivatives 
and for the fragments TDF1t and TDF5 showed similar inhibition.  All fragments 
showed high selective inhibition to Class I over Class II.  Furthermore, all 
fragments showed 100 to 1000-fold better selectivity than FDA approved SAHA 
for  HDAC1 to HDAC8 ratios, which exemplify and highlight the internal selectivity 
to class I HDACs (last two columns in table I.9). 
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Table 1.9. HDAC inhibitory activity (IC50 in µM) 
 
 
 
 
 
 
 
 
 Class I HDAC Class 
IIb 
HDAC 
Class 
IIa 
HDAC 
Class I 
selectivit
y 
Class I vs. 
Class IIa 
Compoun
d 
IC50 of 
HDAC
1 
IC50 of 
HDAC2 
IC50 of 
HDAC
3 
IC50 of 
HDAC8 
IC50 of 
HDAC4 
IC50 of 
HDAC6 
Ratio 
HDAC 1 
/HDAC8 
Ratio 
HDAC 1 
/HDAC6 
SAHA 0.0207 0.0694 0.1697 7.04 116.73 0.1794 0.01399 0.12 
FK228 0.0038 0.0183 0.0187 1.48 2.37 0.5075 0.00035 0.0075 
TDP-B 0.0022 0.0256 0.0482 10.90 27.93 0.6503 0.00026 0.0034 
TDP-A 0.0024 0.0081 0.0077 8.44 20.48 0.2734 0.00065 0.0088 
TDC1 0.0109 0.0510 0.6398 3.67 ~500 5.49 0.00252 0.0020 
TDC2 0.0096 0.0370 0.7010 4.33 134.57 1.49 0.00096 0.0064 
TDC3 0.0027 0.0442 0.2452 10.03 40.48 1.34 0.00006 0.0020 
TDF1 0.0068 0.0443 0.5791 41.91 >1000 165.94 0.00020 0.00004 
TDF1t 0.0024 0.0245 0.5401 34.21 ~500 41.31 0.00016 0.0001 
TDF2 0.0095 0.0902 0.8098 27.03 >1000 166.37 0.00043 0.00006 
TDF2m 0.0109 0.0726 0.3528 22.31 >1000 46.32 0.00017 0.00024 
TDF3 0.0229 0.0875 0.8186 62.85 >1000 >1000 0.00036 N/A 
TDF3m 0.0125 0.0942 0.6226 63.03 >1000 >1000 0.00028 N/A 
TDF4 0.0039 0.0365 0.7135 43.89 >1000 >1000 0.00003 N/A 
TDF4m 0.0303 2.12 0.0971 116.90 >1000 >1000 0.00061 N/A 
TDF5 0.0026 0.0459 0.8393 49.38 >1000 >1000 0.00002 N/A 
TDF5m 0.0265 1.66 0.1241 133.30 >1000 >1000 0.00159 N/A 
TDF6 0.0035 0.1106 0.0416 16.63 >1000 >1000 0.00003 N/A 
TDF6m 0.0302 1.93 0.1002 100.41 >1000 >1000 N/A N/A 
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1.4.2 Cellular Assays.   
 The anti-proliferative activities of the compounds described above were tested 
against breast, colon, cervical prostate, and renal tumor cell lines in an MTT using the 
natural products FK228, SAHA, TDP-A and TDP-B as positive controls.  The MTT 
assay is a colorimetric assay for assessing cell viability86. NAD(P)H-dependent cellular 
oxidoreductase enzymes may reflect the number of viable cells present. These enzymes 
are capable of reducing the tetrazolium dye MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide to its insoluble formazan, which has a purple color. The 
absorbance of this colored solution can be quantified by measuring at a 
certain wavelength (normally between 500 to 600 nm) by a spectrophotometer. The 
degree of light absorption depends on the solvent and how many living cells reduced MTT 
(yellow) to formazan (purple)87.  
 Surprisingly, modifications of TDP-A (TDC1, TDC2, and TDC3) increased the GI50 
by 100 to 1000-fold (table 1.10 and table 1.11) despite having similar HDAC inhibition 
profiles (table 1.9). The synthetic compounds TDF1t, TDF3, TDF3m, and TDF5 had GI50 
values 8-fold lower (GI50 values of 0.5 µM, 0.6µM, 0.4µM and 0.5µM, respectively) against 
all tumor cell lines that were tested compared to SAHA, a synthetic FDA approved 
analogue known to have GI50 values in the range of 2.5-3 µM.  By contrast, TDF2, 
TDF2m, TDF4 and TDF6 had moderate levels of anti-proliferative activity with GI50 values 
within 2µM, 6µM, 5µM and 4µM, respectively, against all three tumor cell lines. Since 
different tumor cells are known to have different sensitivity to HDAC inhibitors, the top four 
fragments (TDC1, TDF1t, TDF3m, and TDF5) were tested against four other tumor cell 
lines derived from ovarian, prostate, breast and colon cancers. In general, the results of 
these studies were consistent with those obtained using the previous tumor cell lines.  
Specifically, TDP-A showed the strongest anti-proliferative activity and all fragments 
showing great inhibitory activity when compared to SAHA (table 1.11).  
44	  
	  
Table 1.10. Antiproliferative Activity    Table 1.11. Antiproliferative Activity 
(GI50 in µM)       (GI50 in µM) 
 
Cpds Colon 
HCT-
116 
Cervic
al HeLa 
Renal 
RFX39
3 
SAHA 2.7 2.8 2.5 
FK228 0.0012 0.0013 0.0012 
TDP-B 0.002 0.0021 0.0022 
TDP-A 0.00093 0.00036 0.00047 
TDC1 0.0247 0.2248 0.0351 
TDC2 0.056 0.1412 0.0510 
TDC3 0.1205 0.332 0.1067 
TDF1 2.1 1.4 1.1 
TDF1t 0.3 0.2 0.4 
TDF2 1.4 1.1 1.9 
TDF2
m 
2.3 2.6 5.9 
TDF3 0.3 0.6 0.2 
TDF3
m 
0.2 0.4 0.3 
TDF4 3.7 4.8 4.1 
TDF4
m 
31 20.1 32.1 
TDF5 0.4 0.4 0.5 
TDF5
m 
32.6 30.2 40.1 
TDF6 1.3 3.6 3.1 
TDF6
m 
   28.4    25.6     31.7 
Individual values were derived from the 
average of triplicate experiments with standard 
error within 20%  margin. 
 
 
 
Cpds Ovaria
nSKOV
-3 
Prostat
e DU-
145 
Breast 
MDA-
MB-231 
Colon 
COLO-
205 
SAHA 1.5 2 1.5 0.5 
TDP-A 0.002 0.001 0.003 0.0035 
TDC1 0.03 0.08 0.04 0.07 
TDF1t 0.3 0.2 0.5 0.7 
TDF3m 0.5 0.3 0.6 0.9 
TDF5 0.7 0.6 0.5 0.9 
Individual values were derived from the average of triplicate 
experiments with standard error within 20%  margin. 
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Table 1.12. Solubility and MTD (mg/kg)   1.4.3 MTD Studies 
Maximum Tolerated Dose (MTD) Studies and 
Solubility. Synthetic compounds demonstrated 
significantly higher MTD levels than the natural 
products studied in this work.  To determine the 
MTD in vivo, the compounds listed above were 
injected intraperitoneally into BALB/c mice and 
morbidity88 and mortality were monitored over two 
weeks. The parental compounds TDP-A, TDP-B 
and FK228 were used as positive controls and 
showed very high toxicity with animals being able to 
tolerate doses of 6.25 mg/kg for both TDP-A and 
TDP-B and 3.25 mg/kg for FK228 (table 1.12). By 
contrast, the synthetic compounds (fragments and 
natural product derivatives) were found to be much 
less toxic to animals with a MTD of more than 200 
mg/kg for all except natural product derivatives 
TDC1 and TDC2. Solubility increased for all 
fragments that contained an acidic carboxylic acid 
group (Table 1.12). Generally, the smaller 
molecules were much more soluble as well.   
 
 
 
 
Cpds Solubility MTD 
(mg/kg) 
SAHA Not soluble >200 
FK228 Partially soluble 3.125 
TDP-B Not soluble 6.25 
TDP-A Not soluble 6.25 
TDC1 Not soluble 50 
TDC2 Not soluble 12.5 
TDC3 Not soluble >200 
TDF1 Soluble >200 
TDF1t Mostly soluble >200 
TDF2 Soluble >200 
TDF2m Partially soluble >200 
TDF3 Soluble  >200 
TDF3m Partially soluble  >200 
TDF4 Mostly soluble  >200 
TDF4m Soluble  >200 
TDF5 Mostly soluble  >200 
TDF5m Soluble  >200 
TDF6 Soluble  >200 
TDF6m Soluble  >200 
10mg/ml cpd in 20% DMSO/saline and in 
healthy BALB/c mice, IP.   Individual 
values were derived from the average of 
triplicate experiments with standard error 
within 20% margin. 
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1.4.4 Molecular Modeling 
Among the 11 classified HDAC isoforms, four have their X-ray structures in 
the Protein Data Bank (PDB): HDAC2 (3MAX), HDAC3 (4A69), HDAC7 (3C0Z), 
and HDAC8 (1T69)89-92.  Many of these X-ray crystals have their active site bound 
with small molecules.  For this study we docked TDP-A and fragments TDF1 and 
TDF3 in HDAC2 (3MAX).  HDAC2 (figure 1.12) is also the most potent isoform 
available of the four X-ray structures and is the protein structure we are trying to 
selectively inhibit.   
The results showed that the natural product TDP-A have similar binding 
modes and orientation as FK228 and SAHA in the active site (figure 1.13).  The 
thiol of TDP-A chelates with the zinc ion and residuals His 146 and Tyr 308 which 
centers the molecule in the middle of the catalytic pocket.    Also, amino acid 
residual Asp 104 is important in hydrogen bonds on the surface of the protein with 
all molecules (figure 1.14).  From the data we also concluded that small fragments 
like TDF1 could chelate to the zinc ion in reverse manner (figure 1.15) while the 
carboxylic acid is hydrogen bonding to the Tyr 29 residual and water.  This may be 
a great reason why the smaller fragments have increased HDAC1 and HDAC2 
inhibition.   
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Figure 1.12: The lowest energy conformation of crystal structure, HDAC 2(PDB: 
3MAX),using the software packages of MOE.  It is a trimer which has 3 individual 
catalytic sites and has a MW of 55.4 kDa and has approximately 488 amino acid 
residuals. 
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Figure 1.13: The lowest energy conformation of TDP-A in HDAC2 catalytic core.  
Natural product TDP-A was docked into a model based on the crystal structure of 
HDAC2 (PDB: 3MAX), using the software packages of MOE.  Surface view of 
TDP-A was docked in HDAC2 catalytic pocket (1st diagram).  Schematic 
representation (2nd diagram) of TDP-A binding in HDAC 2. The thiol is 
coordinating to the zinc (Zn2+) cation deep in the pocket.  The residuals His 146 
and Tyr 308 play a key role in centering the molecule in the active site.  Also, 
residual Asp 104 hydrogen bonds to the amide hydrogen in TDP-A.  The areas 
that are highlighted in blue on the protein interaction diagram (2nd diagram) are 
areas of TDP-A that are outside of the active site.  These highlighted areas would 
have surface interactions with the protein.   
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Figure 1.14: The lowest energy conformation of TDF1 and TDF3 in HDAC2 
catalytic core.  Fragments TDF1 and TDF3 were docked into a model based on 
the crystal structure of HDAC 2 (PDB: 3MAX), using the software packages of 
MOE.  Surface view of TDF1 and TDF3 docked in HDAC2 catalytic pocket (1st 
diagram).  Schematic representation (2nd diagram) of TDF3 binding in HDAC 2.  
The thiol in both inhibitors (yellow) is coordinating to the zinc (Zn2+) cation in the 
middle of the pocket (1st diagram). The residuals His 145, His 146 and Gly 154 
play a key role in centering the two fragments in the active site.  Also, residual Asp 
104 hydrogen bonds to the amide hydrogen and the carboxylic acid hydrogen in 
TDF3.  The areas that are highlighted in blue on the protein interaction diagram 
(2nd diagram) are areas of TDF3 that are outside of the active site.  These 
highlighted areas would have surface interactions with the protein. 
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Figure 1.15: The lowest energy conformation of TDF1 in the HDAC2 catalytic 
core.  Fragment TDF1 was docked into a model based on the crystal structure of 
HDAC 2 (PDB: 3MAX), using the software packages of MOE.  Surface view of 
TDF1 docked in HDAC2 catalytic pocket (1st diagram).  Schematic representation 
(2nd diagram) of TDF1 binding in HDAC 2.  The thiol in TDF1 (yellow) is 
coordinating to the zinc (Zn2+) cation in the middle of the pocket. The residuals His 
145, His 146  and Gly 154  play a key role in centering the fragments in the active 
site.  Also, residual Asp 104 hydrogen bonds to the carboxylic acid hydrogen in 
TDF1.  This figure is especially important due to the fact that the smallest fragment 
(TDF1) that was synthesized was the only fragment that can potential bind in the 
active site in the reverse direction so it does not “stick” out of the pocket.  
 
 
 
 
 
 
 
 
 
 
 
 
 
53	  
	  
I.5  Conclusion and Future Directions 
 
HDAC inhibitors have broad implications for the treatment of cancer and other 
human diseases. The design of this project was to develop HDAC inhibitors that 
resemble TDP-A as anticancer drugs.  The need for additional HDAC inhibitors is 
well justified by the recent approval of SAHA and FK228 for clinical use. Our 
successful discovery of thailandepsins and their demonstrated potent HDAC 
inhibitory activities warrant systematic SAR studies of thailandepsin-based 
fragment compounds. Future research can take lead compounds from these 
studies for further evaluations by NCI DTP, and can be used to utilize the obtained 
data for application of extramural funding. 
Since some HDAC inhibitors also have positive implications in central nerve 
system (CNS) disorders and autoimmune disease, it could be interesting to assess 
the applications of our acquired compounds for those disorders and diseases as 
well in the future. 
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1.6  Experimental for Biological Evaluations  
 
HDAC inhibition assays 
HDAC-GloTM I/II Assay and Screening System (Promega) was used to 
determine the HDAC inhibitory activity. Recombinant human HDAC1, HDAC2, 
HDAC3, HDAC4, HDAC6 and HDAC8 were purchased from BPS Bioscience Inc. 
The inhibitory activities of the test compounds against recombinant HDAC were 
performed according to reagent suppliers’ protocols.  
All test compounds were firstly dissolved in DMSO to make 10 mM stock 
solution. A certain amount of stock solution was diluted to 1 mM by DMSO and 
then reduced +--+(TCEP) in a molar ration of 1:1.5 for 20 min at ambient 
temperature prior to being assayed. After reduction, a series of fivefold dilutions of 
each reduced compound were prepared with HDAC-Glo buffer and 25 µl of each 
dilution was added into a well on a 96-well plate. HDAC enzymes were diluted to 
the desired concentrations with HDAC-Glo buffer and 25 µl of each diluted enzyme 
was dispensed into a well to mix with 25 µl of testing compound at room 
temperature up for 30-60 seconds. After the reaction mixture had been incubated 
at room temperature for 1 hour, 50 µl of HDAC-Glo reagent was added to each 
reaction well and mixed up for 30-60 seconds. Finally, the plate was incubated at 
room temperature for an additional 30 minutes before the luminescence was 
measured on a Synergy HT plate reader (Bio-Tek). The luminescence intensity 
data were analyzed using GraphPad Prism 5 (GraphPad Software). In the 
absence of any test compound, the luminescence intensity (I100) in each data set 
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was defined as 100% activity. In the absence of both of HDAC enzymes and test 
compound, the luminescence intensity (I0) in each data set was defined as 0% 
activity. The relative activity (%) in the presence of each compound was calculated 
according to the following equation: %activity = (I-I0)/(I100-I0), where I = the 
luminescence intensity if a compound is present in the reaction. Experiments were 
performed in triplicate and the calculated mean values were used for plotting. 
 
Anti-proliferative assay 
The cytotoxicity of the compounds against the HeLa (cervical cancer, ATCC), 
RXF393 (renal cancer, ATCC) and HCT-116 (colon cancer, ATCC), SKOU-
3(ovarian cancer, ATCC), DU-145 (prostate cancer, ATCC), MDA-MB-231 (breast 
cancer, ATCC), and COLO-205 (colon cancer, ATCC) cell lines was determined 
using the MTT assay as previously described (Ref). Briefly, the tumor cells 
(1x104cells/well) were seeded in 96-well microtiter plates and incubated for 24 h at 
37ºC.  Following incubation, the media was replaced with fresh media containing 
the above compounds at concentrations ranging from 1 µM to 1 pM diluted in 
DMSO and incubated for an additional 48 h. Drugs were run in duplicate or 
triplicate and control cells received fresh media with DMSO concentration 
equivalent to the treatment groups. Thereafter, the wells were washed twice with 
warm PBS and incubated for another 4 h with RPMI 1640 media containing 250 
µg/mL of MTT.  After aspirating the culture medium, 200 µL of DMSO was added 
to dissolve the precipitate and the resulting solution was measured for absorbance 
at 570 nm with a reference wavelength of 690 nm using a microplate reader 
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(Infinite M200 Pro TECAN). Results were used to determine the growth inhibition- 
50% (GI50) of each drug. 
 
Solubility and Maximum tolerated dose (MTD)  
BALB/c mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and 
used between 7 and 10 weeks of age. Mice were housed in a conventional animal 
vivarium and were given free access to food and water. All studies and procedures 
were approved by the Animal Care and Use Committee of the University of 
Wisconsin, Milwaukee.  
Each animal was initially weighed using a digital scale and then intraperitoneally 
(IP) injected with the compounds (listed in Table 1). A single mouse was given a 
single IP dose of 200 mg/kg, body weight, a second mouse received a dose of 100 
mg/kg and a third mouse received a single dose of 50 mg/kg. The mice were 
observed and weighed every day for a period of 8 days. They were euthanized if 
they lost more than 20% of their body weight or if there were other signs of 
significant toxicity. If none of the mice survived with the first three doses, the next 
3 dose levels (25 mg/kg, 12.5 mg/kg and 6.25 mg/kg) were tested in a similar 
manner. This process was repeated until a tolerated dose was found, and the 
MTD value was determined.  
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1.7 Experimental for chemical synthesis 
General Considerations.	  
All reactions were performed under argon atmosphere via schlenk line in oven-
dried glassware with magnetic stirring unless otherwise stated. Air and moisture-
sensitive liquids and solutions were transferred via oven-dried, stainless steel 
syringe and were introduced into the reaction vessel through rubber septa. All 
reactants and reagents were purchased from Ark Pharm, Inc. unless otherwise 
stated. CH2Cl2 and DMF (dimethylformamide) were distilled from calcium hydride. 
THF (tetrahydrofuran) was distilled from sodium-benzophenone. Anhydrous 
acetonitrile was purchased from Sigma Aldrich. Previously reported compounds 
were identified by 1H NMR (nuclear magnetic resonance) spectrum.  All new 
compounds were characterized by additional 13C NMR and mass spectroscopy. 
1H and 13C NMR spectra were performed on a Bruker NMR at 300 and 75 MHz, 
respectively. 1H NMR data are reported as follows: chemical shift (δ) in parts per 
million (ppm) from tetramethylsilane as an internal standard (CDCl3 δ7.26 ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = 
doublet of doublets). 13C data were reported as follows: chemical shifts (δ) are 
reported in parts per million (ppm) from tetramethylsilane with the solvent as an 
internal indicator (CDCl3 δ77.16 ppm).  
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O
STrt  
 
  (E)-5-(tritylthio)pent-2-enal. A round bottom flask was charged with 3-
(tritylthio)propanal (3.77 g, 11.3 mmol) and 2-(triphenylphosphoranylidene) (3.8 g, 
12.5 mmol, 1.1 equiv.).  The flask was put under argon and the contents of the 
flask were dissolved in benzene (90 mL).  The solution was then refluxed 
overnight.  The reaction mixture was allowed to cool to room temperature and was 
then concentrated in vacuo.  The crude product was separated twice via column 
chromatography.  The first column was run with a 20% ethyl acetate/hexane 
solution until the product spot eluted.  A second column was run and the product 
eluted with 10% ether/hexane to give 2.83 g (70%) of pure product.  1H NMR (500 
MHz, CDCl3, 25 °C) δ (ppm) 9.45-9.44 (d, 1H), 7.44-7.24 (m, 15H), 6.64 (t, 1H), 
6.02-5.97 (dd, 1H), 2.36-2.32 (m, 4H); <ju112211> Exp 1 13C NMR (CDCl3, 150 
MHz) δ (ppm)  193.6, 155.6, 144.5, 133.6, 129.5, 127.9, 126.7, 31.6, 29.9 Fuse, 
Shinichiro, et al. Total Synthesis of Spiruchostatin B Aided by an Automated 
Synthesizer. Org. Biomol. Chem. 2011, 9, 3825-3833. 
20% EtOAc/Hexane 
C S P  
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OH
STrt
O
t-BuO  
    (E)-1-tert-butoxy-4-hydroxy-8-(tritylthio)oct-5-en-2-one. To a 50 mL round 
bottom flask was charged with THF (100 mL) and cooled to -78°C. Next, 
diisopropylethylamine (DIPEA) (4.86 mL, 27.89 mmol, 5.5 equiv.) and n-
butyllithium (12.27 mL, 30.68 mmol, 5.5 equiv.) were added dropwise at -78°C and 
let stir for 1 hr. Tert-butyl acetate (3.7 mL, 27.6 mmol, 5 eqv.) was added at -78°C 
and was allowed to stir for 1 hr.  Lastly, (E)-5-(tritylthio)pent-2-enal (2.0 g, 5.579 
mmol, 1 equiv.) was added and let stir for 45 min at -78°C. The reaction was 
quenched with a saturated solution of NH4Cl (50 mL) at -78°C and then 
concentrated in vacuo to remove the organic solvent. Then dichloromethane was 
added to aqueous mixture and the two phases were separated. Then the aqueous 
layer was extracted two more times with dichloromethane and the organic layers 
were combined. The organic layer was washed with NaHCO3, brine, then dried 
over anhydrous Na2SO4, and concentrated in vacuo.  Chromatography on SiO2 
(ethyl acetate/ hexane, 1:9)  gave 2.06 g (78%) of product as a white solid. 1H 
NMR (300 MHz, CDCl3, 25 °C) δ (ppm) 7.43 (d, 6H), 7.30 (m, 9H), 5.62-5.55 (m, 
1H), 5.47-5.40 (dd, 1H), 4.42 (s, 1H), 3.09 (bs, OH), 2.43 (m, 2H), 2.23 (m, 2H), 
2.10 (m, 2H), 1.47 (s, 9H) <ju010411> Exp 2; 13C NMR (75 MHz, CDCl3, 25 °C)  δ 
(ppm) 172.8, 144.9, 132.1, 129.9, 129.6, 127.9, 126.6, 81.3, 69, 66.6, 42.4, 31.5, 
31.4, 28.2  <bs061812> Exp 5. 
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20% EtOAc/Hexane 
C S P  
 
OH
STrt
O
HO  
 
   (E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid. (E)-1-tert-butoxy-4-hydroxy-8-
(tritylthio)oct-5-en-2-one (400 mg, 0.843 mmol, 1.0 equiv.) was dissolved in a 4:1 
ratio of THF/water (10 mL). Next, lithium hydroxide (620 mg, 25.89 mmol, 25 
equiv.) was added. The solution was then heated to 50ºC and stirred for 12 hr. 
The reaction was then diluted with water (10 mL) and then acidified to a pH of 4-5 
with KHSO4. The aqueous layer was extracted with ethyl acetate (10 mL) four 
times. The organic layers were combined and washed with water, brine, dried over 
anhydrous sodium sulfate, and concentrated in vacuo.  Chromatography on SiO2 
(ethyl acetate/hexane, 9:10) gave 353 mg (95%) of product as a white solid.  1H 
NMR (300 MHz, CDCl3, 25 °C) δ 7.47-7.23 (m, 15H), 5.64-5.57 (m, 1H), 5.49-5.42 
(dd, 1H), 4.49 (q, 1H), 2.55 (d, 2H) 2.24 (m, 2H), 2.09 (m, 2H) <BS072312> Exp 5; 
13C NMR (125 MHz, CDCl3, 25 °C) δ (ppm) 171.9, 144.9, 131.7, 130.7, 129.6, 
128.0, 126.7, 68.6, 66.7, 41.3, 31.5, 31.4 <ju072412> Exp 6.  
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50% EtOAc/Hexane 
C S P  
 
 
OH
S
O
HO
*
2  
    (4E,4'E)-7,7'-disulfanediylbis(3-hydroxyhept-4-enoic acid).  Iodine (52.2 mg, 
0.206 mmol, 0.5 equiv.) and sodium acetate (33.7 mg, 0.411 mmol, 1.0 equiv.) 
were dissolved in a 10:1 solution of CH2Cl2/MeOH (10 mL). (E)-3-hydroxy-7-
(tritylthio)hept-4-enoic acid (172 mg, 0.411 mmol, 1 equiv.) was dissolved in a 10:1 
solution of CH2Cl2/MeOH (5 mL) and was added dropwise at 0°C over 20 minutes 
to the solution containing iodine and sodium acetate.  This solution was then 
allowed to stir for 2 hr.  The reaction was quenched by adding a saturated sodium 
thiosulfate (Na2S2O3) solution until the reaction mixture turned clear.  Then, brine 
(5 mL) was added and the phases were separated.  The aqueous layer was 
extracted with dichloromethane (3 x 15 mL) and then with ethyl acetate (3 x 15 
mL).  The organic layers were combined, dried over Na2SO4, and concentrated in 
vacuo. The crude reaction mixture was first purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
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collected at 8-12min. Then this peak was injected in the HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 40 % ACN/H2O 
was used to elute the column under the flow rate of 8 ml/min. The wavelength was 
set at 200 nm to detect the compound and 46 mg of the pure compound was 
collected at 12-14.5 min. (31.9% yield.)  1H NMR (500 MHz, DMSO, 25 °C) δ 
(ppm) 5.71 (m, 1H), 5.54 (dd, 1H), 4.43 (m, 1H), 2.69 (m, 2H), 2.48 (m, 2H), 2.38 
(m, 2H) <ju062012> Exp 1; 13C NMR (125 MHz, CD3OD, 25 °C) δ (ppm) 173.6, 
133.3, 128.7, 68.6, 42.0, 37.7, 31.5  <ju062112> Exp 2. 
 
OH
S
O
t-BuO
*
2  
Di-tert-butyl 7,7'-disulfanediyl(4E,4'E)-bis(3-hydroxyhept-4-enoate).  Iodine 
(58.9 mg, 0.232 mmol, 1.0 equiv.) and sodium acetate (19.0 mg, 0.464 mmol, 2.0 
equiv.) were dissolved in a 10:1 solution of CH2Cl2/MeOH (5 mL). (E)-1-tert-
butoxy-4-hydroxy-8-(tritylthio)oct-5-en-2-one (110 mg, 0.232 mmol, 1.0 equiv.) was 
dissolved in a 10:1 solution of CH2Cl2/MeOH (5 mL) and was added dropwise at 
0°C over 20 minutes to the first solution containing iodine and sodium acetate.  
This solution was then allowed to stir for 2 hr.  The reaction was quenched by 
adding a saturated sodium thiosulfate (Na2S2O3) solution until the reaction mixture 
turned clear.  Then, brine (5 mL) was added and the phases were separated.  The 
aqueous layer was extracted with dichloromethane (3 x 15 mL) and then with ethyl 
acetate (3 x 15 mL).  The organic layers were combined, dried over Na2SO4, and 
concentrated in vacuo. The crude reaction mixture was first purified by Hi-Flash 
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Column (ODS-C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% 
ACN/H2O 20ml/min and the detection wave length was set up at 210 nm. The 
peak was collected at 15-20 min. Then this peak was injected in the HPLC (Varian 
ProStar) with the column (Prep-C18, 21.2x250 mm, 10 um) system and 70 % 
ACN/H2O was used to elute the column under the flow rate of 8ml/min. The 
wavelength was set at 200 nm to detect the compound and 140 mg of the pure 
compound was collected at 22-25 min. (65.5 % yield.) 1H NMR (300 MHz, CD3OD, 
25 °C) δ (ppm) 5.75 (m, 1H), 5.66 (dd, 1H), 4.47 (m, 1H), 2.78 (m, 2H), 2.44 (m, 
4H), 1.50 (s, 9H) <bs062712> Exp 2; 13C NMR (75 MHz, CD3OD, 25 °C) δ (ppm) 
170.9, 133.4, 128.8, 80.5, 68.8, 43.4, 37.7, 31.5, 27.1 <bs062712> Exp 4. 
 
20% EtOAc/Hexane 
C S P  
 
 
 
 (2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-enamido]-4-
(methylsulfanyl)butanoic acid. Methyl (2R)-2-[(4E)-3-hydroxy-7-
[(triphenylmethyl)sulfanyl]hept-4-enamido]-4-(methylsulfanyl)butanoate (333 mg, 
64	  
	  
0.591 mmol, 1.0 equiv.) was dissolved in a 4:1 ratio of THF/water (10 mL). Next 
was added lithium hydroxide (353 mg, 14.8 mmol, 25 equiv.). The solution was 
then heated to 50ºC and stirred for 12 hr. The reaction was then diluted with water 
(10 mL) and then acidified to a pH of 4-5 with KHSO4. The aqueous layer was 
extracted with ethyl acetate (10 mL) four times. The organic layers were combined 
and washed with water, brine, dried over anhydrous Na2SO4, and concentrated in 
vacuo.  Chromatography on SiO2 (ethyl acetate/hexane, 1:1)  gave 290 mg (89%) 
of product as a white solid. 1H NMR (500 MHz, CDCl3, 25 °C) δ (ppm) 7.43-7.21 
(m, 15H), 6.95-6.85 (m, NH), 5.60 (m, 1H), 5.46 (m, 1H), 4.68 (m, 1H), 4.46 (m, 
1H), 4.44 (bs, OH), 2.56 (t, 2H), 2.43 (m, 2H), 2.23 (t, 3H), 2.10 (s, 3H) 2.08 (m, 
2H), 2.02 (m, 1H) <ju072412> Exp 8; 13C NMR (125 MHz, CDCl3, 25 °C) δ (ppm) 
174.4, 172.71, 144.9, 132.0, 131.9, 130.4, 130.3, 129.6, 126.7, 69.2, 66.7, 51.8, 
43.4, 42.8, 31.4, 31.0, 30.1, 15.4 <ju072412> Exp 12. 
65% EtOAc/Hexane 
C S P  
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Methyl (2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-enamido]-
4-(methylsulfanyl)butanoate. (E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid (410 
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mg, 0.980 mmol, 1.2 equiv.) and D-methionine methyl ester hydrochloride salt 
(163 mg, 0.816, 1.0 equiv.) were dissolved in dichloromethane (anhydrous) (35 
mL) under Ar. The reaction was cooled to 0ºC and then benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (510 mg, 0.980 
mmol, 1.2 equiv.) was added. The solution stirred for 10 min and then DIPEA 
(0.208 mL, 1.19 mmol, 4 equiv.) was added. The reaction was allowed to warm to 
25ºC and stirred for 12 hr. It was then quenched with a saturated NH4Cl, extracted 
with dichloromethane (3 x 15 mL), washed with brine, dried over Na2SO4, and then 
concentrated in vacuo. Chromatography on SiO2 (ethyl acetate/hexane, 2:3) gave 
360 mg (81%) of product as a white solid. 1H NMR (300 MHz, CDCl3, 25 °C) δ 
7.43-7.41(m, 6H), 7.27 (m, 9H), 6.67 (s, NH), 5.56 (m, 1H), 5.45 (dd, 1H), 4.73 (m, 
1H), 4.44 (m, 1H), 3.76 (s, 3H), 3.51 (s, OH), 2.52 (t, 2H), 2.41 (m, 2H), 2.21 (m, 
3H), 2.15-1.95 (m, 6H) <ju012712> Exp 2; 13C NMR (125 MHz, CDCl3, 25 °C) δ 
(ppm) 172.7, 171.4, 144.9, 132.4, 129.9, 129.6 127.9, 126.7, 69.1, 66.6, 52.7, 
51.4, 42.8, 36.7, 31.4,, 30.0, 24.8, 15.5  <ju072412> Exp 4. 
50% EtOAc/Hexane 
C S P  
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Methyl (2R)-2-[(4E)-3-hydroxy-7-{[(3E)-5-hydroxy-6-{[(2R)-1-methoxy-4-
(methyl-sulfanyl)-1-oxobutan-2-yl]carbamoyl}hex-3-en-1-yl]disulfanyl}hept-4-
enamido]-4-(methylsulfanyl)butanoate. Iodine (59.2 mg, 0.233 mmol, 1 equiv.) 
and sodium acetate (38.2 mg, 0.466 mmol, 2 equiv.) were dissolved in a 10:1 
solution of CH2Cl2/MeOH (5 mL). Methyl (2R)-2-[(4E)-3-hydroxy-7-
[(triphenylmethyl)sulfanyl]hept-4-enamido]-4-(methylsulfanyl)butanoate (526 mg, 
0.233 mmol, 1 equiv.) was dissolved in a 10:1 solution of CH2Cl2/MeOH (5 mL) 
and was added dropwise at 0°C over 20 minutes to the first solution containing 
iodine and sodium acetate.  This solution was then allowed to stir for 2 hr.  The 
reaction was quenched by adding a saturated sodium thiosulfate (Na2S2O3) 
solution until the reaction mixture turned clear.  Then brine (5 mL) was added and 
the phases were separated.  The aqueous layer was extracted with 
dichloromethane (3 x 15 mL) and then with ethyl acetate (3 x 15 mL).  The organic 
layers were combined, dried over Na2SO4, and concentrated in vacuo. The crude 
reaction mixture was first purified by Hi-Flash Column (ODS-C18, 3.0x16.5 cm, 50 
um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and the detection 
wavelength was set at 210 nm. The peak was collected at 12-15 min. Then this 
peak was injected in the HPLC (Varian ProStar) with the column (Prep-C18, 
21.2x250 mm, 10 um) system and 40 % ACN/H2O was used to elute the column 
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under the flow rate of 8ml/min. The wave length was set at 200 nm to detect the 
compound and 40 mg of the pure compound was collected at 19-21min. (25.7 % 
yield.)   1H NMR (300 MHz, CDCl3, 25 °C) δ (ppm) 7.60 (s, NH), 5.77-5.70 (m, 1H), 
5.67-5.61 (dd, 1H), 4.62 (m, 1H), 4.49-4.40 (m, 1H), 4.39 (s, OH), 3.71 (s, 3H), 
2.86-2.77 (m, 2H), 2.55 (m, 2H), 2.45-2.41 (m, 4H), 2.15-2.05 (m, 1H) 2.09 (s, 3H), 
1.96 (m, 1H) <djm070312> Exp 4;  13C NMR (125 MHz, (CD3)2CO, 25 °C) δ (ppm) 
173.5, 172.4, 135.5, 135.4,129.1, 129.0, 70.0, 52.8, 52.4, 44.4, 39.3, 33.0, 32.7,  
31.0, 15.6 <ju071112>  Exp 5. 
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 (2R)-2-[(4E)-7-{[(3E)-6-{[(1R)-1-carboxy-3-(methylsulfanyl)propyl]carbamoyl}-
5-hydroxyhex-3-en-1-yl]disulfanyl}-3-hydroxyhept-4-enamido]-4-
(methylsulfanyl)butanoic acid. Iodine (66.8 mg, 0.258 mmol, 1 equiv.) and 
sodium acetate (42.4 mg, 0.517 mmol, 2 equiv.) were dissolved in a 10:1 solution 
of CH2Cl2/MeOH (5 mL).  (2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-
4-enamido]-4-(methylsulfanyl)butanoic acid (142 mg, 0.258 mmol, 1 equiv.) was 
dissolved in a 10:1 solution of CH2Cl2/MeOH (5 mL) and was added dropwise at 
0°C over 20 minutes to the first solution containing iodine and sodium acetate.  
This solution was then allowed to stir for 2 hr.  The reaction was quenched by 
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adding a saturated sodium thiosulfate (Na2S2O3) solution until the reaction mixture 
turned clear.  Then brine (5 mL) was added and the phases were separated.  The 
aqueous layer was extracted with dichloromethane (3 x 15 mL) and then with ethyl 
acetate (3 x 15 mL).  The organic layers were combined, dried over Na2SO4, and 
concentrated in vacuo. The crude reaction mixture was first purified by Hi-Flash 
Column (ODS-C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% 
ACN/H2O 20ml/min and the detection wave length was set at 210 nm. The peak 
was collected at 8-12min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 35 % ACN/H2O 
was used to elute the column under the flow rate of 8ml/min. The wavelength was 
set at 200 nm to detect the compound and 55 mg of the pure compound was 
collected at 16-20 min. (34.8 % yield.) 1H NMR (300 MHz, CD3OD, 25 °C) δ (ppm) 
5.72 (m, 1H), 5.62 (dd, 1H), 4.57 (m, 1H), 4.45 (m, 1H), 2.76 (m, 2H), 2.57 (m, 
2H), 2.45 (m, 4H), 2.20-2.14 (m, 1H), 2.11 (s, 3H), 1.96 (m, 1H) <djm070312> Exp 
9; 13C NMR (75 MHz, CD3OD, 25 °C) δ (ppm) 173.8, 172.2, 133.4, 129.1, 69.1, 
51.3, 43.4, 37.6, 31.6, 30.9, 29.7 13.8 <djm070312> Exp 1. 
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 Methyl-(2S)-2-[(2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-
enamido]-4-(methylsulfanyl)-butanamido]-3-
[(triphenylmethyl)sulfanyl]propanoate. (2R)-2-[(4E)-3-hydroxy-7-
[(triphenylmethyl)sulfanyl]-hept-4-enamido]-4-(methylsulfanyl)butanoic acid. (416 
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mg, 0.757 mmol, 1.2 equiv.) and S-trityl-D-cysteine (275 mg, .631 mmol 1.0 
equiv.) were dissolved in dichloromethane (anhydrous) (35 mL) under Ar. The 
reaction was cooled to 0ºC and then benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (433 mg, 0.832 
mmol, 1.1 equiv.) was added. The solution stirred for 10 min and then DIPEA 
(0.394 mL, 2.27 mmol, 3.0 equiv.) was added. The reaction was allowed to warm 
to 25ºC and stirred for 14 hr. It was then quenched with a saturated NH4Cl, 
extracted with dichloromethane (3 x 15 mL), washed with brine, dried over Na2-
SO4, and then concentrated in vacuo. Chromatography on SiO2 (ethyl 
acetate/hexane, 2:3)  gave 381 mg (55%) of product as a white solid. 1H NMR 
(500 MHz, CDCl3, 25 °C) δ (ppm) 7.48-7.40 (m, 12H), 7.35-7.21 (m, 18H), 7.20-
6.85 (m, 2H, NH), 5.55 (m, 1H), 5.45 (m, 1H), 4.70 (m, 1H), 4.54 (m, 1H), 4.46 (bs, 
1H), 3.70 (d, 3H), 3.62-3.28 (bs, OH), 2.80-2.63 (m, 2H), 2.60 (t, 2H), 2.37 (m, 
2H), 2.25 (m, 2H), 2.19-2.03 (m, 6H), 1.99 (m, 1H) <ju073012> Exp 1; 13C NMR 
(300 MHz, CDCl3, 25 °C)  δ (ppm) 171.7, 170.9, 170.7, 144.9, 144.2, 132.5, 130.1, 
129.6, 129.5, 128.1, 127.9, 127.0, 126.6, 69.5, 66.9, 66.6, 52.7, 52.1, 51.4, 43.8, 
42.7,  33.5, 31.5, 31.2, 30.0, 15.3  < BS072612> Exp 2. 
 
65% EtOAc/Hexane 
C S P  
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 (2S)-2-[(2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-enamido]-
4-(methylsulfanyl)-butanamido]-3-[(triphenylmethyl)sulfanyl]propanoic acid.   
Methyl (2S)-2-[(2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-
enamido]-4-(methylsulfanyl)butanamido]-3-[(triphenylmethyl)-sulfanyl]-propanoate 
(400 mg, 0.440 mmol, 1.0 equiv.) was dissolved in a 4:1 ratio of THF/water (50 
mL). Next was added lithium hydroxide (263 mg, 11.0 mmol, 25 equiv.). The 
solution was then stirred for 12 hr. The reaction was then diluted with water (30 
mL) and then acidified to a pH of 4-5 with KHSO4. The aqueous layer was 
extracted with ethyl acetate (15 mL) four times. The organic layers were combined 
and washed with water, brine, dried over anhydrous Na2SO4, and concentrated in 
vacuo.  Chromatography on SiO2 (ethyl acetate/hexane, 3:1) gave 327 mg (83%) 
of product as a white solid.  1H NMR (300 MHz, CDCl3, 25 °C) δ (ppm) 7.54-7.14 
(m, 30H), 7.09 (m, NH), 6.59 (m, NH), 6.48 (bs, OH), 5.54 (m, 1H), 5.42 (dd, 1H), 
4.66 (m, 1H), 4.44-4.28 (m, 2H), 2.85-2.65 (m, 2H), 2.52 (t, 2H), 2.38 (m, 2H), 2.24 
(m, 2H), 2.15-1.90 (m, 7H)  <BS073112> Exp 4; 13C NMR (75 MHz, CDCl3, 25 °C)  
δ (ppm) 172.4, 172.2, 171.4, 144.9, 144.3, 132.3, 130.0, 129.6, 129.5, 128.2, 
127.9, 127.0, 126.7, 69.3, 67.1, 66.7, 52.4, 51.7, 43.4, 33.2, 31.5, 31.4, 31.1, 30.0, 
15.3  <BS073112> Exp 5. 
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(4S,7R,12E)-11-hydroxy-7-[2-(methylsulfanyl)ethyl]-6,9-dioxo-1,2-dithia-5,8-
diazacyclopentadec-12-ene-4- carboxylic acid.  Iodine (44.5 mg, 0.172 mmol, 
1.0 equiv.) and sodium acetate (28.2 mg, 0.344 mmol, 2.0 equiv.) were dissolved 
in a 10:1 solution of CH2Cl2/MeOH (25 mL). (2S)-2-[(2R)-2-[(4E)-3-hydroxy-7-
[(triphenylmethyl)-sulfanyl]hept-4-enamido]-4-(methylsulfanyl)butanamido]-3-
[(triphenylmethyl)sulfanyl]propanoic acid (154 mg, 0.172 mmol, 1.0 equiv.) was 
dissolved in a 10:1 solution of CH2Cl2/MeOH (5 mL) and was added dropwise at 
0°C over 20 minutes to the first solution containing iodine and sodium acetate.  
This solution was then allowed to stir for 2 hr.  The reaction was quenched by 
adding a saturated sodium thiosulfate (Na2S2O3) solution until the reaction mixture 
turned clear.  Then brine (5 mL) was added and the phases were separated.  The 
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aqueous layer was extracted with dichloromethane (3 x 15 mL) and then with ethyl 
acetate (3 x 15 mL).  The organic layers were combined, dried over Na2SO4, and 
concentrated in vacuo. The crude reaction mixture was first purified by Hi-Flash 
Column (ODS-C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% 
ACN/H2O 20ml/min and the detection wavelength was set at 210 nm. The peak 
was collected at 8-10min. Then this peak was injected in the HPLC (Varian 
ProStar) with the column (Prep-C18, 21.2x250 mm, 10 um) system and 35 % 
ACN/H2O was used to elute the column under the flow rate of 8 ml/min. The 
wavelength was set at 200 nm to detect the compound and 25 mg of the pure 
compound was collected at 10-13.5 min. (35.6 % yield.)  1H NMR (500 MHz, 
CD3OD, 25 °C) δ (ppm)  5.74 (m, 1H), 5.62-5.42 (m, 1H), 4.79 (bs, 2 OH), 4.64-
4.20 (m, 3H),  2.93-2.78 (m, 2H), 2.78-2.65 (m, 2H), 2.64-2.44 (m, 4H), 2.42-2.31 
(m, 2H), 2.14-2.08 (d, 3H), 2.05-1.87 (m, 2H)  <ju081512> Exp 5; 13C NMR (125 
MHz, CD3OD, 25 °C) δ (ppm) 172.3, 170.7, 169.3, 133.2, 129.8, 70.0, 52.4, , 51.9, 
43.8, 39.3, 33.0, 31.4, 29.4, 28.7, 13.6  <ju081512> Exp 8. 
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Methyl (4S,7R,12E)-11-hydroxy-7-[2-(methylsulfanyl)ethyl]-6,9-dioxo-1,2-
dithia-5,8-diazacyclopentadec-12-ene-4-carboxylate.  Iodine (93 mg, 0.364 
mmol, 1.1 equiv.) and sodium acetate (52 mg, 0.661 mmol, 2 equiv.) were 
dissolved in a 10:1 solution of CH2Cl2/MeOH (25 mL). Methyl (2S)-2-[(2R)-2-[(4E)-
3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-enamido]-4-
(methylsulfanyl)butanamido]-3-[(triphenylmethyl)sulfanyl]-propanoate (300 mg, 
0.330 mmol, 1 equiv.) was dissolved in a 10:1 solution of CH2Cl2/MeOH (5 mL) 
and was added dropwise at 0°C over 20 minutes to the first solution containing 
iodine and sodium acetate.  This solution was then allowed to stir for 2 hr.  The 
reaction was quenched by adding a saturated sodium thiosulfate (Na2S2O3) 
solution until the reaction mixture turned clear.  Then brine (5 mL) was added and 
the phases were separated.  The aqueous layer was extracted with 
dichloromethane (3 x 15 mL) and then with ethyl acetate (3 x 15 mL).  The organic 
layers were combined, dried over Na2SO4, and concentrated in vacuo.  The crude 
reaction mixture was first purified by Hi-Flash Column (ODS-C18, 3.0x16.5 cm, 50 
um, Yamazen A1-580), 0-20 min 20-100% ACN/H2O 20 ml/min and the detection 
wavelength was set up at 210 nm. The peak was collected at 12-15 min. Then this 
peak was injected in the HPLC (Varian ProStar) with the column (Prep-C18, 
21.2x250 mm, 10 um) system and 40 % ACN/H2O was used to elute the column 
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under the flow rate of 8 ml/min. The wavelength was set up at 200 nm to detect 
the compound and 41 mg of the pure compound was collected at 17-19 min. (29.4 
% yield.)  1H NMR (300 MHz, (CD3)2SO, 25 °C) δ (ppm) 8.85-8.30 (m, NH), 8.15-
7.95  (m, NH),  5.65-5.48 (m, 1H), 5.48-5.26 (m, 1H), 5.06 -4.73 (m, OH), 4.72-
4.51 (m, 1H), 4.50-4.32 (m, 1H), 4.31-4.10 (m, 1H),  3.70-3.60 (m, 3H), 3.26-3.10 
(m, 2H), 2.96-2.69 (m, 2H), 2.67-2.12 (m, 6H), 2.04 (s, 3H), 1.92-1.65 (m, 2H) 
<ju091312> Exp 1; 13C NMR (75 MHz, (CD3)2SO, 25 °C)  δ (ppm) 172.2, 171.3, 
170.4, 133.9, 128.7, 70.0, 52.8, 51.6, 51.2, 44.8, 40.0,  33.5, 32.7, 32.2, 29.7, 16.5 
<BS122912> Exp 6.  
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methyl (2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-enamido]-
3-methylbutanoate.  (E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid (150 mg, 0.358 
mmol, 1.2 equiv.) and D-valine methyl ester hydrochloride salt (50 mg, 0.298 
mmol, 1.0 equiv.) were dissolved in dichloromethane (anhydrous) (25 mL) under 
Ar. The reaction was cooled to 0ºC and then benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (186 mg, 0.298 
mmol, 1.2 equiv.) was added. The solution stirred for 10 min and then DIPEA 
(0.208 mL, 1.19 mmol, 4 equiv.) was added. The reaction was allowed to warm to 
25ºC and stirred for 14 hr. It was then quenched with a saturated NH4Cl, extracted 
with dichloromethane (3 x 15 mL), washed with brine, dried over Na2SO4, and then 
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concentrated in vacuo. Chromatography on SiO2 (ethyl acetate/hexane, 3:7) gave 
127 mg (82%) of product as a white solid. 1H NMR (300 MHz, CDCl3, 25 °C) δ 
(ppm) 7.50-7.25 (m, 15H), 6.41 (m, NH), 5.57 (m, 1H), 5.46 (dd, 1H), 4.57 (m, 1H), 
4.44 (m, 1H), 3.76 (s, 3H), 3.36 (s, OH), 2.43 (m, 2H), 2.20-2.11 (m, 5H), 0.94 (m, 
6H) <ju011712> Exp 3; 13C NMR (75 MHz, CDCl3, 25 °C) δ (ppm) 172.6, 171.8, 
144.9, 132.2, 130.2, 129.6,127.9, 126.6, 69.3, 66.6, 56.9, 52.3, 43.0, 31.5, 31.4, 
31.0, 19.0, 17.8 <ju011812> Exp 2. 
 50%EtOAc/Hexane 
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(2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-enamido]-3-
methylbutanoic acid.  Methyl (2R)-2-[(4E)-3-hydroxy-7-
[(triphenylmethyl)sulfanyl]hept-4-enamido]-3-methylbutanoate (122 mg, 0.229 
mmol, 1.0 equiv.) was dissolved in a 4:1 ratio of THF/water (15 mL). Next was 
added lithium hydroxide (137 mg, 5.74 mmol, 25 equiv.). The solution was then 
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stirred for 12 hr. The reaction was then diluted with water (10 mL) and then 
acidified to a pH of 4-5 with KHSO4. The aqueous layer was extracted with ethyl 
acetate (15 mL) four times. The organic layers were combined and washed with 
water, brine, dried over anhydrous Na2SO4, and concentrated in vacuo.  
Chromatography on SiO2 (ethyl acetate/hexane, 1:2) gave 99.5 mg (83%) of 
product as a white solid.  1H NMR (300 MHz, CDCl3, 25 °C) δ (ppm) 7.41 (m, 6H), 
7.29 (m, 9H), 6.95- 6.82 (m, NH), 5.54 (m, 1H), 5.45 (dd, 1H), 4.62-4.38 (m, 2H), 
2.44 (m, 2H), 2.22 (m, 3H), 2.07 (m, 2H), 0.95 (m, 6H) <djm061912> Exp 1; 13C 
NMR (75 MHz, CDCl3, 25 °C) δ (ppm) 173.9, 172.4, 144.9, 132.18, 130.1, 129.6, 
127.9, 126.6, 69.3, 66.6, 56.9, 43.0, 31.5, 31.4, 30.6, 19.0, 17.8  <BS013112> Exp 
2. 
 
50% EtOAc/Hexane 
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 (2R)-2-[(4E)-7-{[(3E)-6-{[(1R)-1-carboxy-2-methylpropyl]carbamoyl}-5-
hydroxyhex-3-en-1-yl]disulfanyl}-3 hydroxyhept-4-enamido]-3-
methylbutanoic acid.  Iodine (128 mg, 0.504 mmol, 1.1 equiv.) and sodium 
acetate (75.1 mg, 0.916 mmol, 2.0 equiv.) were dissolved in a 10:1 solution of 
CH2Cl2/MeOH (7 mL). (2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-
enamido]-3-methylbutanoic acid (237 mg, 0.458 mmol, 1.0 equiv.) was dissolved 
in a 10:1 solution of CH2Cl2/MeOH (5 mL) and was added dropwise at 0°C over 20 
minutes to the first solution containing iodine and sodium acetate.  This solution 
was then allowed to stir for 2 hr.  The reaction was quenched by adding a 
saturated sodium thiosulfate (Na2S2O3) solution until the reaction mixture turned 
clear.  Then, brine (5 mL) was added and the phases were separated.  The 
aqueous layer was extracted with dichloromethane (3 x 15 mL) and then with ethyl 
acetate (3 x 15 mL).  The organic layers were combined, dried over Na2SO4, and 
concentrated in vacuo. The crude reaction mixture was first purified by Hi-Flash 
Column (ODS-C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20 min 20-100% 
ACN/H2O 20ml/min and the detection wavelength was set at 210 nm. The peak 
was collected at 8-12min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 35 % ACN/H2O 
was used to elute the column under the flow rate of 8 ml/min. The wavelength was 
set at 200 nm to detect the compound and 40 mg of the pure compound was 
78	  
	  
collected at 13-18.5 min.  (15.5 % yield.) 1H NMR (300 MHz, CD3OD, 25 °C) δ 
(ppm) 5.75 (m, 1H), 5.62 (m, 1H), 4.49 (m, 1H), 4.37 (m, 1H), 2.75 (t, 2H), 2.58-
2.37 (m, 4H), 2.25 (m, 1H), 1.00 (m, 6H) <BS062612> Exp 2; 13C NMR (75 MHz, 
CDCl3/CD3OD, 25 °C) δ (ppm) 178.0, 176.2, 136.8, 133.2, 72.9, 61.3, 42.9, 35.6, 
34.7, 34.6, 22.9, 21.5 <ju062012> Exp 1. 
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methyl 2-[(4E)-3-hydroxy-7-{[(3E)-5-hydroxy-6-[(1-methoxy-3-methyl-1-
oxobutan-2-yl)carbamoyl]hex-3-en-1 yl]disulfanyl}hept-4-enamido]-3-
methylbutanoate.  Iodine (118 mg, 0.465 mmol, 1.1 equiv.) and sodium acetate 
(69.4 mg, 0.846 mmol, 2 equiv.) were dissolved in a 10:1 solution of CH2Cl2/MeOH 
(15 mL). Methyl (2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-
enamido]-3-methylbutanoate (225 mg, 0.423 mmol, 1 equiv.) was dissolved in a 
10:1 solution of CH2Cl2/MeOH (5 mL) and was added dropwise at 0°C over 20 
minutes to the first solution containing iodine and sodium acetate.  This solution 
was then allowed to stir for 2 hr.  The reaction was quenched by adding a 
saturated sodium thiosulfate (Na2S2O3) solution until the reaction mixture turned 
clear.  Then brine (5 mL) was added and the phases were separated.  The 
aqueous layer was extracted with dichloromethane (3 x 15 mL) and then with ethyl 
acetate (3 x 15 mL).  The organic layers were combined, dried over Na2SO4, and 
concentrated in vacuo. The crude reaction mixture was first purified by Hi-Flash 
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Column (ODS-C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20 min 20-100% 
ACN/H2O 20ml/min and the detection wavelength was set up at 210 nm. The peak 
was collected at 12-15 min. Then this peak was injected in the HPLC (Varian 
ProStar) with the column (Prep-C18, 21.2x250 mm, 10 um) system and 50 % 
ACN/H2O was used to elute the column under the flow rate of 8 ml/min. The 
wavelength was set up at 200 nm to detect the compound and 90 mg of the pure 
compound was collected at 12-17 min. (37.0 % yield.) 1H NMR (300 MHz, CD2Cl2, 
25 °C) δ (ppm) 6.82 (m, NH), 5.75 (m, 1H), 5.62 (dd, 1H), 4.49 (m, 2H), 3.95 (bs, 
OH), 3.75 (s, 3H), 2.79 (t, 2H), 2.54-2.39 (m, 4H), 2.25 (m, 1H), 0.95 (m, 6H)  
<BS101512> Exp 1; 13C NMR (75 MHz, CD2Cl2, 25 °C) δ (ppm) 172.3, 171.8, 
133.2, 129.1, 69.1, 57.1, 52.1, 42.7, 38.3, 31.7,  31.1, 18.9, 17.6  <BS101512> 
Exp 2. 
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Methyl (2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-
enamido]hexanoate. 
(E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid (1.0 g, 2.39 mmol, 1.0 eqv.) and D-
norleucine methyl ester hydrochloride salt (346 g, 0.264 mmol, 1.1 equiv.) were 
dissolved in dichloromethane (anhydrous) (75 mL) under Ar. The reaction was 
cooled to 0ºC and then benzotriazol-1-yl-oxytripyrrolidinophosphonium 
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hexafluorophosphate (PyBOP) (1.5 g, 2.88 mmol, 1.2 equiv.) was added. The 
solution stirred for 10 min and then DIPEA (1.51 mL, 8.32 mmol, 3.5 equiv.) was 
added. The reaction was allowed to warm to 25ºC and stirred for 14 hr. It was then 
quenched with a saturated NH4Cl, extracted with dichloromethane (3 x 50mL), 
washed with brine, dried over Na2SO4, and then concentrated in vacuo. 
Chromatography on SiO2 (ethyl acetate/hexane, 3:7) gave 1.12 g (86%) of product 
as a white solid. 1H NMR (300 MHz, CDCl3, 25 °C) δ (ppm) 7.50-7.20 (m, 15H), 
6.61 (t, 1H), 5.65 (m, 1H), 5.46 (dd, 1H) 4.62 (m, 1H), 4.45 (m, 1H), 3.74 (s, 3H), 
2.40 (m, 2H), 2.23 (m, 2H), 2.10 (m, 2H), 1.83 (m, 1H), 1.68 (m, 1H), 1.32 (m, 4H), 
0.91 (t, 3H) <BS0127122> Exp 1;  13C NMR (75 MHz, CDCl3, 25 °C) δ (ppm) 
172.5, 171.7, 144.9, 132.2, 129.9, 129.1, 127.5, 126.6, 69.2, 66.6, 52.5, 52.3, 
43.2, 31.5, 31.4, 30.0, 27.9, 22.2, 14.2 <ju012712> Exp 3. 
50%EtOAc/Hexane 
C P S.M.  
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(2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-enamido]hexanoic 
acid.  Methyl (2R)-2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-
enamido]hexanoate (320 mg, 0.586 mmol, 1.0 equiv.) was dissolved in a 4:1 ratio 
of THF/water (15 mL). Next was added lithium hydroxide (351 mg, 14.7 mmol, 25 
equiv.). The solution was then stirred for 12 hr. The reaction was then diluted with 
water (10 mL) and then acidified to a pH of 4-5 with KHSO4. The aqueous layer 
was extracted with ethyl acetate (15 mL) four times. The organic layers were 
combined and washed with water, brine, dried over anhydrous Na2SO4, and 
concentrated in vacuo.  Chromatography on SiO2 (ethyl acetate/hexane, 4:6) gave 
296 mg (95%) of product as a white solid.  1H NMR (300 MHz, CDCl3, 25 °C) δ 
(ppm) 7.50-7.15 (m, 15H), 7.03-6.91 (m, 1H), 5.55 (m, 1H), 5.44 (dd, 1H), 4.56 (q, 
1H), 4.45 (m, 1H), 2.43 (m, 2H), 2.24 (m, 2H), 2.10 (m, 2H), 1.87 (m, 1H), 1.71 (m, 
1H), 1.35-1.26  (m, 4H), 0.91 (t, 3H)  <BS013112>  Exp 3; 13C NMR (75 MHz, 
CDCl3, 25 °C) δ (ppm) 175.4, 172.5, 145.1, 132.0, 129.7, 129.6, 127.9, 126.7, 
69.2, 66.6, 52.5, 43.4, 31.5, 31.4, 30.4, 27.5, 22.3, 13.9 <BS013112> Exp 4. 
50% EtOAc/Hexane 
C P S.M.  
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(2R)-2-[(4E)-7-{[(3E)-6-{[(1R)-1-carboxypentyl]carbamoyl}-5-hydroxyhex-3-en-
1-yl]disulfanyl}-3-hydroxyhept-4-enamido]hexanoic acid.  Iodine (134 mg, 
0.562 mmol, 1.0 equiv.) and sodium acetate ( 173mg, 1.12 mmol, 2.0 equiv.) were 
dissolved in a 10:1 solution of CH2Cl2/MeOH (10 mL). (2R)-2-[(4E)-3-hydroxy-7-
[(triphenylmethyl)sulfanyl]hept-4-enamido]hexanoic acid (280 mg, 0.526 mmol, 1.0 
equiv.) was dissolved in a 10:1 solution of CH2Cl2/MeOH (5 mL) and was added 
dropwise at 0°C over 20 minutes to the first solution containing iodine and sodium 
acetate.  This solution was then allowed to stir for 2 hr.  The reaction was 
quenched by adding a saturated sodium thiosulfate (Na2S2O3) solution until the 
reaction mixture turned clear.  Then brine (5 mL) was added and the phases were 
separated.  The aqueous layer was extracted with dichloromethane (3 x 15 mL) 
and then with ethyl acetate (3 x 15 mL).  The organic layers were combined, dried 
over Na2SO4, and concentrated in vacuo.  The crude reaction mixture was first 
purified by Hi-Flash Column (ODS-C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 
0-20min 20-100% ACN/H2O 20 ml/min and the detection wavelength was set at 
210 nm. The peak was collected at 8-12 min. Then this peak was injected in the 
HPLC (Varian ProStar) with the column (Prep-C18, 21.2x250 mm, 10 um) system 
and 40 % ACN/H2O was used to elute the column under the flow rate of 8ml/min. 
The wavelength was set at 200 nm to detect the compound and 75 mg of the pure 
compound was collected at 17-24.5 min. (24.1 % yield.). 1H NMR (500 MHz, 
DMSO, 25 °C) δ (ppm)  5.62 (m, 1H), 5.49 (m, 1H), 4.35 (s, 2H), 2.60 (t, 2H), 2.37 
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(m, 4H), 1.75 (m, 1H), 1.57 (m, 1H), 1.23 (m, 4H), 0.75 (m, 3H) <ju062012> Exp 4; 
13C NMR (75 MHz, CD3OD, 25 °C) δ (ppm) 174.2, 172.1, 133.2, 128.9, 69.0, 52.2, 
43.3, 37.6, 31.6, 29.4, 27.6, 22.0, 13.0 <BS062612> Exp 4. 
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methyl (2R)-2-[(4E)-3-hydroxy-7-{[(3E)-5-hydroxy-6-{[(2R)-1-methoxy-1-
oxohexan-2-yl]carbamoyl}hex-3-en-1-yl]disulfanyl}hept-4-
enamido]hexanoate.  Iodine (169 mg, 0.669  mmol, 1.1 equiv.) and sodium 
acetate (99.7 mg, 1.22 mmol, 2.0 equiv.) were dissolved in a 10:1 solution of 
CH2Cl2/MeOH (15 mL).  Methyl (2R)-2-[(4E)-3-hydroxy-7-
[(triphenylmethyl)sulfanyl]hept-4-enamido]hexanoate (332 mg, 0.608 mmol, 1.0 
equiv.) was dissolved in a 10:1 solution of CH2Cl2/MeOH (5 mL) and was added 
dropwise at 0°C over 20 minutes to the first solution containing iodine and sodium 
acetate.  This solution was then allowed to stir for 2 hr.  The reaction was 
quenched by adding a saturated sodium thiosulfate (Na2S2O3) solution until the 
reaction mixture turned clear.  Then brine (5 mL) was added and the phases were 
separated.  The aqueous layer was extracted with dichloromethane (3 x 15 mL) 
and then with ethyl acetate (3 x 15 mL).  The organic layers were combined, dried 
over Na2SO4, and concentrated in vacuo.  The crude reaction system was first 
purified by Hi-Flash Column (ODS-C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 
0-20min 20-100% ACN/H2O 20 ml/min and the detection wavelength was set up at 
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210 nm. The peak was collected at 12-15 min. Then this peak was injected in the 
HPLC (Varian ProStar) with the column (Prep-C18, 21.2x250 mm, 10 um) system 
and 50 % ACN/H2O was used to elute the column under the flow rate of 8 ml/min. 
The wavelength was set up at 200 nm to detect the compound and 135 mg of the 
pure compound was collected at 27-32 min. (36.7 % yield.)  1H NMR (300 MHz, 
CD2Cl2, 25 °C) δ (ppm) 7.11 (d, 1H), 5.71 (m, 1H), 5.58 (dd, 1H), 4.53 (m, 1H), 
4.45 (m, 1H), 4.18 (bs, OH), 3.73 (s, 3H), 2.76 (t, 2H), 2.44 (m, 4H), 1.88 (m, 1H), 
1.68 (m, 1H), 1.32 (m, 4H), 0.91 (t, 3H) <BS101512>  Exp.  3; 13C NMR (75 MHz, 
CD2Cl2, 25 °C) δ (ppm) 173.1, 171.9, 133.3, 128.9, 69.1, 52.2, 52.1, 42.9, 38.2, 
31.8, 31.7, 27.5, 22.3, 13.7 <BS101512>  Exp.  4. 
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Methyl 2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-enamido]-3-
methylpentanoate. 
(E)-3-hydroxy-7-(tritylthio)hept-4-enoic acid (600 mg, 1.43 mmol, 1.0 eqv.) and DL-
isoleucine methyl ester (188 mg, 1.43 mmol, 1.0 equiv.) were dissolved in 
dichloromethane (anhydrous) (40 mL) under Ar. The reaction was cooled to 0ºC 
and then benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
(PyBOP) (821 mg, 1.58 mmol, 1.1 equiv.) was added. The solution stirred for 10 
min and then DIPEA (0.781 mL, 4.30 mmol, 3.0 equiv.) was added. The reaction 
was allowed to warm to 25ºC and stirred for 14 hr. It was then quenched with a 
saturated NH4Cl, extracted with dichloromethane (3 x 20 mL), washed with brine, 
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dried over Na2SO4, and then concentrated in vacuo. Chromatography on SiO2 
(ethyl acetate/hexane, 3:7) gave 457 mg (58%) of product as a white solid.  1H 
NMR (300 MHz, CDCl3, 25 °C) δ (ppm) 7.44-7.15 (m, 15H), 6.48 (m, 1H), 5.54 (m, 
1H), 5.45 (dd, 1H), 4.75-4.58 (m, 1H), 4.43 (m, 1H), 3.9 (m, OH),  3.74 (s, 3H), 
2.40 (m, 2H), 2.22 (q, 2H), 2.09 (m, 2H), 1.90 (m, 1H), 1.39 (m, 1H), 1.16 (m, 1H), 
0.95 (m, 6H) <ju021712> Exp 1; 13C NMR (75 MHz, CDCl3, 25 °C) δ (ppm) 172.8, 
171.8, 144.9, 132.2, 130.1, 129.5, 127.9, 126.6, 69.2, 66.6, 56.3, 52.2, 43.0, 37.7, 
31.5, 31.4, 26.3, 16.3, 11.6 <ju021712> Exp 2. 
50% EtOAc/Hexane 
C P S.M.  
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2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-enamido]-3-
methylpentanoic acid. 
Methyl 2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-4-enamido]-3-
methylpentanoate (456 mg, 0.836 mmol, 1.0 equiv.) was dissolved in a 4:1 ratio of 
THF/water (15 mL). Next was added lithium hydroxide (500 mg, 20.9 mmol, 25 
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equiv.). The solution was then stirred for 12 hr. The reaction was then diluted with 
water (15 mL) and then acidified to a pH of 4-5 with KHSO4. The aqueous layer 
was extracted with ethyl acetate (20 mL) four times. The organic layers were 
combined and washed with water, brine, dried over anhydrous sodium sulfate, and 
concentrated in vacuo.  Chromatography on SiO2 (ethyl acetate/hexane, 4:6) gave 
422 mg (95%) of product as a white solid.  1H NMR (300 MHz, CDCl3, 25 °C) δ 
(ppm) 7.43 (m, 6H), 7.30-7.25 (m, 9H), 7.08-6.79 (m, 1H), 5.55 (m, 1H), 5.46 (m, 
1H), 4.67-4.55 (m, 1H), 4.48 (m, 1H), 2.44 (m, 2H), 2.22 (m, 2H), 2.00 (m, 2H), 
1.97-1.85 (m, 1H), 1.40 (m, 1H), 1.20 (m, 1H), 0.91 (m, 6H) <djm061912> Exp 2; 
13C NMR (75 MHz, CDCl3, 25 °C) δ (ppm) 175.8, 172.3 145.1, 132.0, 130.3, 129.6, 
127.9, 126.6, 69.3, 66.5, 56.5, 43.2, 37.3, 31.4, 29.7, 26.3, 16.8, 11.6 <ju022012> 
Exp 2. 
50% EtOAc/Hexane 
C P S.M.  
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2-[(4E)-7-{[(3E)-6-[(1-carboxy-2-methylbutyl)carbamoyl]-5-hydroxyhex-3-en-1-
yl]disulfanyl}-3-hydroxyhept-4-enamido]-3-methylpentanoic acid.  Iodine (200 
mg, 0.788 mmol, 1.0 equiv.) and sodium acetate (129 mg, 1.57 mmol, 2.0 equiv.) 
were dissolved in a 10:1 solution of CH2Cl2/MeOH (15 mL). 2-[(4E)-3-hydroxy-7-
[(triphenylmethyl)sulfanyl]hept-4-enamido]-3-methylpentanoic acid (420 mg, 0.788 
mmol, 1.0 equiv.) was dissolved in a 10:1 solution of CH2Cl2/MeOH (5 mL) and 
was added dropwise at 0°C over 20 minutes to the first solution containing iodine 
and sodium acetate.  This solution was then allowed to stir for 2 hr.  The reaction 
was quenched by adding a saturated sodium thiosulfate (Na2S2O3) solution until 
the reaction mixture turned clear.  Then brine (5 mL) was added and the phases 
were separated.  The aqueous layer was extracted with dichloromethane (3 x 15 
mL) and then with ethyl acetate (3 x 15 mL).  The organic layers were combined, 
dried over Na2SO4, and concentrated in vacuo. The crude reaction mixture was 
first purified by Hi-Flash Column (ODS-C18, 3.0x16.5 cm, 50 um, Yamazen A1-
580), 0-20 min 20-100% ACN/H2O 20ml/min and the detection wavelength was set 
up at 210 nm. The peak was collected at 8-12 min. Then this peak was injected in 
the HPLC (Varian ProStar) with the column (Prep-C18, 21.2x250 mm, 10 um) 
system and 40 % ACN/H2O was used to elute the column under the flow rate of 8 
ml/min. The wavelength was set up at 200 nm to detect the compound and 63 mg 
of the pure compound was collected at 15.5-21 min. (13.9 % yield.)  1H NMR (300 
MHz, CD3OD, 25 °C) δ (ppm) 5.75 (m, 1H), 5.61 (m, 1H), 4.57-4.40 (m, 2H), 3.37 
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(s, OH),  2.75 (t, 2H), 2.47 (m, 4H), 2.01-1.88 (m, 1H), 1.60-1.40 (m, 1H), 1.27 (m, 
1H), 0.96 (m, 6H) <ju062112> Exp 1;  13C NMR (75 MHz, CD3OD, 25 °C) δ (ppm) 
173.5, 172.0, 133.3, 129.0, 69.0, 56.7, 43.1, 37.6, 37.0, 31.6, 26.4, 15.3, 10.7 
<ju062112> Exp 2. 
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Methyl 2-[(4E)-3-hydroxy-7-{[(3E)-5-hydroxy-6-[(1-methoxy-3-methyl-1-
oxopentan-2-yl)carbamoyl]hex-3-en-1-yl]disulfanyl}hept-4-enamido]-3-
methylpentanoate.  Iodine (134 mg, 0.529 mmol, 1.0 equiv.) and sodium acetate 
(86.8 mg, 1.06 mmol, 2.0 equiv.) were dissolved in a 10:1 solution of 
CH2Cl2/MeOH (10 mL). Methyl 2-[(4E)-3-hydroxy-7-[(triphenylmethyl)sulfanyl]hept-
4-enamido]-3-methylpentanoate (289 mg, 0.529 mmol, 1.0 equiv.) was dissolved 
in a 10:1 solution of CH2Cl2/MeOH (5 mL) and was added dropwise at 0°C over 20 
minutes to the first solution containing iodine and sodium acetate.  This solution 
was then allowed to stir for 2 hr.  The reaction was quenched by adding a 
saturated sodium thiosulfate (Na2S2O3) solution until the reaction mixture turned 
clear.  Then brine (5 mL) was added and the phases were separated.  The 
aqueous layer was extracted with dichloromethane (3 x 15 mL) and then with ethyl 
acetate (3 x 15 mL).  The organic layers were combined, dried over Na2SO4, and 
concentrated in vacuo. The crude reaction mixture was first purified by Hi-Flash 
Column (ODS-C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20 min 20-100% 
ACN/H2O 20ml/min and the detection wave length was set at 210 nm. The peak 
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was collected at 12-15 min. Then this peak was injected in the HPLC (Varian 
ProStar) with the column (Prep-C18, 21.2x250 mm, 10 um) system and 50 % 
ACN/H2O was used to elute the column under the flow rate of 8 ml/min. The 
wavelength was set at 200 nm to detect the compound and 52 mg of the pure 
compound was collected at 25-31 min. (16.3 % yield.)   1H NMR (300 MHz, 
CD2Cl2, 25 °C) δ (ppm) 6.60 (s, NH), 5.74 (m, 1H), 5.65 (dd, 1H), 4.70-4.54 (m, 
1H), 4.53-4.43 (s, 1H), 3.75, (s, 3H), 3.70 (bs, OH), 2.78 (t, 2H), 2.56-2.35 (m, 4H), 
1.90 (m, 1H), 1.45 (m, 1H), 1.23 (m, 1H), 0.99-0.89 (m, 6H) < ju101412> Exp 1;  
13C NMR (75 MHz, CD2Cl2, 25 °C) δ (ppm) 172.4, 171.6, 133.1, 129.2, 69.2, 56.4, 
52.2, 42.6, 38.3, 37.7, 31.7, 26.2, 15.3, 11.3 <ju101412> Exp 2. 
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(2R)-1-methoxy-4-(methylsulfanyl)-1-oxobutan-2-aminium chloride.  
Chlorotrimethylsilane (8.51 mL, 67.02 mmol, 2 equiv.) was added dropwise to a 
round bottom flask containing D-methionine hydrochloride (5.00g, 33.51mmol, 1.0 
equiv.) under Ar.  Then anhydrous methanol (50 mL) was added and the solution 
was stirred for 22 hr.  The contents of the flask were then concentrated in vacuo.  
1H NMR (300 MHz, D2O, 25 °C) δ (ppm) 4.24 (t, 1H), 3.79 (s, 3H), 2.62 (t, 2H), 
2.33-2.09 (m, 2H), 2.05 (s, 3H) <ju072312> Exp 2; 13C NMR (125 MHz, D2O, 25 
°C) δ (ppm) 170.51, 53.67, 51.72, 28.72, 28.44, 13.87 <ju072412> Exp 7. 
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1-methoxy-3-methyl-1-oxopentan-2-aminium chloride.  Chlorotrimethylsilane 
(1.93 mL, 15.25 mmol, 2 equiv.) was added dropwise to a round bottom flask 
containing DL-Isoleucine hydrochloride (1.0g, 7.62 mmol, 1.0 equiv.)  under Ar.  
Then anhydrous methanol (20 mL) was added and the solution was stirred for 22 
hr.  The contents of the flask were then concentrated in vacuo.  1H NMR (300 
MHz, D2O, 25 °C) δ (ppm) 4.05 (m, 1H), 3.76 (s, 3H), 2.15-1.94 (m, 1H), 1.49-1.32 
(m, 1H), 1.32 -1.16 (m, 1H), 0.95-0.81 (m, 6H) <djm091312> Exp 1; 13C NMR (75 
MHz, D2O, 25 °C) δ (ppm) 170.20, 57.22, 53.40, 35.50, 24.87, 14.01, 10.68 
<djm091212> Exp 4. 
 
 
 
 (2R)-1-methoxy-1-oxohexan-2-aminium chloride.  Chlorotrimethylsilane (1.93 
mL, 15.247 mmol, 2 equiv.) was added dropwise to a round bottom flask 
containing D-norleucine hydrochloride (1.00g, 7.62mmol, 1.0 equiv.)  under Ar.  
Then anhydrous methanol (20 mL) was added and the solution was stirred for 22 
hr.  The contents of the flask were then concentrated in vacuo.  1H NMR (300 
MHz, D2O, 25 °C) δ (ppm) 4.06 (t, 1H), 3.76 (s, 3H), 1.95-1.75 (m, 2H), 1.35-1.27 
(m, 4H), 0.79 (t, 3H) <ju091412> Exp 1; 13C NMR (75 MHz, D2O, 25 °C) δ (ppm) 
171.0, 53.4, 52.9, 29.3, 26.1, 21.4, 12.8 <ju091412> Exp 2. 
NH3
O
O
Cl
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methyl (2S)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-
[(triphenylmethyl)sulfanyl]propanoate.  Chlorotrimethylsilane (2.17 mL, 15.07 
mmol, 2 equiv.) was added dropwise to a round bottom flask containing (2S)-2-
{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-[(triphenylmethyl)sulfanyl]propanoic 
acid (5.00 g, 8.54 mmol, 1.0 equiv.)  under Ar.  Then anhydrous methanol (40 mL) 
was added and the solution was stirred for 22 hr.  The contents of the flask were 
then concentrated in vacuo. 
 
 
 
methyl (2R)-2-amino-2-[(triphenylmethyl)sulfanyl]acetate.  (9H-fluoren-9-
yl)methyl (R)-(methoxycarbonyl)(tritylthio)methylcarbamate (450 mg, 0.750 mmol, 
1 equiv.) was dissolved in anhydrous acetonitrile (10 mL).  Then, excess 
diethylamine (2 mL) was added and the solution was stirred for 2 hr.  The contents 
of the flask were concentrated in vacuo.  The solid was re-dissolved in chloroform 
and the solvent was removed in vacuo.  1H NMR (300 MHz, CDCl3, 25 °C) δ (ppm) 
7.50-7.20 (m, 15H), 3.66 (s, 3H), 3.24 (t, 1H), 2.63 (m, 1H), 2.51 (m, 1H), 2.00-
1.42 (bs, NH2) < djm072412> Exp 1; 13C NMR (125 MHz, CDCl3, 25 °C) δ (ppm) 
171.0, 144.8, 129.1, 128.0, 126.8, 66.5, 53.8, 52.1, 37.0 <ju072412> Exp 14. 
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General remarks 
All reactions in non-aqueous media were conducted under a positive pressure of 
dry argon in glassware that had been oven dried prior to use unless noted 
otherwise. Anhydrous solutions of reaction mixtures were transferred via an oven 
dried syringe or cannula. All solvents were dried prior to use unless noted 
otherwise. 1H and 13C Nuclear magnetic resonance spectra (NMR) were obtained 
on a Varian Unity-Inova 400 MHz or 500 MHz recorded in ppm (δ) downfield of 
TMS (δ = 0). Signal splitting patterns were described as singlet (s), doublet (d), 
triplet (t), quartet (q), quintet (quint),or multiplet (m), with coupling constants (J) in 
hertz. High resolution mass spectra (HRMS) were performed by UW Biotech 
Center on an Electron Spray Injection (ESI) mass spectrometer. 
 
General strategies for the preparation of substrates: 
 
 
 
 
 
NH
OOH
O
O
HN
O
S
S
O
NH
S
RCOCl, DMAP, Py
NH
OOCOR
O
O
HN
O
S
S
O
NH
S
TDPA R = Bz, TDPA-18
CO2Et, TDPA-19
Ac, TDPA-20
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Representative experimental procedures: 
For substrate 18:  
To a stirred solution of TDPA (27 mg, 0.5 mmol) and DMAP (one crystal) in 
anhydrous pyridine (1 mL) was added benzoyl chloride (12 mg, 0.75 mmol) at 0oC. 
The reaction mixture was allowed to warm to room temperature and stirred for 40 
h. The reaction mixture was poured into H2O (20 mL) and extracted with Et2O (3 × 
10 mL). The combined organic layers were washed with brine (1 × 10 mL), dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was 
purified by flash column chromatography (Hexane/Ethyl acetate = 50 : 50) to yield 
TDPA-18 (27 mg, 82%). 
TDPA-19 (25mg, 85%) and TDPA-20 (30mg, 92%) were obtained according to the 
same procedure described for TDPA-18.  
 
1H NMR (400 MHz, CDCl3, TMS): δ 0.88-0.98 (m, 7H), 1.19-1.28 (m, 1H), 1.39-
1.48 (m, 1H), 1.88-1.91 (m, 1H), 2.09-2.16 (m, 1H), 2.21 (s, 3H), 2.30-2.36 (m, 
1H), 2.46 (s, 1H), 2.63-2.85 (m, 6H), 2.96 (dd, J = 11.6, 3.2 Hz, 1H), 3.20-3.33 (m, 
NH
OO
O
O
HN
O
S
S
O
NH
S
TDPA-18
O
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3H), 3.40-3.48 (m, 2H), 4.41-4.44 (m, 1H), 5.00 (s, 1H), 5.59 (s, 1H), 5.71 (d, J = 
12.8 Hz, 1H), 6.10-6.13 (m, 1H), 6.32 (s, 1H), 6.83 (d, J = 7.6 Hz, 1H), 7.43-7.48 
(m, 3H), 7.56-7.59 (m, 1H), 7.67 (d, J = 2.8 Hz, 1H), 8.10 (d, J = 6.8 Hz, 1H). 13C 
NMR (100 MHz, CDCl3, TMS): δ 11.8, 15.5, 15.7, 20.5, 22.5, 27.1, 28.0, 28.6, 
31.5, 36.9, 37.3, 41.4, 57.7, 58.1, 59.9, 69.9, 70.2, 109.9, 128.7, 130.0, 130.3, 
133.3, 133.3, 165.9, 169.2, 169.4, 170.4, 171.3. HRMS (ESI) m/z calcd for 
C30H41N3O7S3 (M+Na) 674.1999, found 674.2016. 
 
 
1H NMR (400 MHz, CDCl3, TMS): δ 0.90-0.93 (m, 6H), 1.18-1.27 (m, 2H), 1.33 (t, 
J = 5.6 Hz, 3H), 1.39-1.47 (m, 1H), 1.84-1.87 (m, 1H), 2.05-2.12 (m, 1H), 2.20 (s, 
3H), 2.29-2.35 (m, 1H), 2.47 (s, 1H), 2.58-2.66 (m, 2H), 2.66-2.73 (m, 3H), 2.78-
2.81 (m, 1H), 2.95 (dd, J = 11.6, 3.2 Hz, 1H), 3.05-3.10 (s, 1H), 3.19 (dd, J = 10.8, 
5.6 Hz, 2H), 3.27-3.31 (m, 1H), 4.20-4.26 (m, 2H), 4.37-4.41 (m, 1H), 4.98 (s, 1H), 
5.63 (s, 1H), 5.67-5.72 (m, 2H), 6.33 (s, 1H), 6.76 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 
5.6 Hz, 1H), 7.58 (d, J = 3.5 Hz, 1H). 13C NMR (100 MHz, CDCl3, TMS): δ 11.8, 
NH
OO
O
O
HN
O
S
S
O
NH
S
O
O
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14.5, 15.2, 15.8, 27.2, 28.0, 31.6, 36.7, 37.1, 41.4, 57.8, 58.0, 64.5, 70.1, 73.2, 
129.6, 133.2, 154.4, 169.0, 169.4, 170.3, 171.2. HRMS (ESI) m/z calcd for 
C26H41N3O8S3 (M+Na) 642.1948, found 642.1959. 
 
1H NMR (400 MHz, CDCl3, TMS): δ 0.91 (t, J = 6.0 Hz, 6H), 1.15-1.31 (m, 1H), 
1.37-1.45 (m, 1H), 1.81-1.86 (m, 1H), 2.07-2.12 (m, 1H), 2.13 (s, 3H), 2.20 (s, 3H), 
2.28-2.34 (m, 1H), 2.44-2.46 (m, 1H), 2.60-2.72 (m, 5H), 2.78-2.85 (m, 1H), 2.87 
(dd, J = 8.4, 4.8 Hz, 1H), 3.05-3.12 (s, 1H), 3.20-3.27 (m, 3H), 4.38-4.41 (m, 1H), 
4.96 (s, 1H), 5.61 (s, 1H), 5.69 (d, J = 12.4 Hz, 1H), 5.79-5.83 (m, 1H), 6.30 (s, 
1H), 6.78 (d, J = 7.6 Hz, 1H), 7.35 (d, J = 5.6 Hz, 1H), 7.62 (d, J = 3.5 Hz, 1H). 13C 
NMR (100 MHz, CDCl3, TMS): δ 11.7, 15.4, 15.7, 20.3, 21.5, 22.5, 27.1, 28.0, 
28.6, 31.5, 36.7, 36.9, 41.4, 57.7, 58.0, 59.6, 69.7, 70.1, 129.5, 133.2, 169.3, 
170.4, 170.5, 171.2. HRMS (ESI) m/z calcd for C25H39N3O7S3 (M+Na) 612.1842, 
found 612.1858. 
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HPLC Data for separation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TDF1:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
collected at 8-12min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 40 % 
 FC 
condition 
Rt-FC HPLC 
condition 
Rt-
HPLC 
Pure 
amount 
TDF1 0-20min 
20-
100%ACN 
20ml/min 
8-
12min 
40% 
ACN 
12-
14.5min 
95mg 
TDF1t  15-
20min 
70% 
ACN 
22-25 
min 
185mg 
TDF2  8-
12min 
35% 
ACN 
16-
20min 
25mg 
TDF2m  12-
15min 
40% 
ACN 
19-
21min 
185mg 
TDF3  8-
10min 
35% 
ACN 
8ml/min 
10-
13.5min 
125mg 
TDF3m  12-
15min 
40% 
ACN 
17-19 
min 
158mg 
TDF4  8-
12min 
40% 
ACN 
15.5-
21min 
31mg 
TDF4m  12-
15min 
50% 
ACN 
25-31 
min 
87mg 
TDF5  8-
12min 
40% 
ACN 
17-
24.5min 
146mg 
TDF5m  12-
15min 
50% 
ACN 
27-32 
min 
130mg 
TDF6  8-
12min 
35% 
ACN 
13-
18.5min 
40mg 
TDF6m  12-
15min 
50% 
ACN 
12-17 
min 
90mg 
97	  
	  
ACN/H2O was used to eluted the column under the flow rate of 8ml/min. The 
wave length was set up at 200 nm to detect the compound and the pure 
compound was collected at 12-14.5min 
TDF1t:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
collected at 15-20 min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 70 % 
ACN/H2O was used to elute the column under the flow rate of 8ml/min. The 
wave length was set up at 200 nm to detect the compound and the pure 
compound was collected at 22-25min.  
TDF2:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
collected at 8-12min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 35 % 
ACN/H2O was used to elute the column under the flow rate of 8ml/min. The 
wave length was set up at 200 nm to detect the compound and the pure 
compound was collected at 16-20min.  
TDF2m:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
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collected at 12-15 min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 40 % 
ACN/H2O was used to elute the column under the flow rate of 8ml/min. The 
wave length was set up at 200 nm to detect the compound and the pure 
compound was collected at 19-21min.  
TDF3:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
collected at 8-10min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 35 % 
ACN/H2O was used to elute the column under the flow rate of 8ml/min. The 
wave length was set up at 200 nm to detect the compound and the pure 
compound was collected at 10-13.5min.  
TDF3m:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
collected at 12-15 min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 40 % 
ACN/H2O was used to elute the column under the flow rate of 8ml/min. The 
wave length was set up at 200 nm to detect the compound and the pure 
compound was collected at 17-19 min.  
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TDF4:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
collected at 8-12min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 40 % 
ACN/H2O was used to eluted the column under the flow rate of 8ml/min. The 
wave length was set up at 200 nm to detect the compound and the pure 
compound was collected at 15.5-21min.  
TDF4m:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
collected at 12-15 min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 50 % 
ACN/H2O was used to elute the column under the flow rate of 8ml/min. The 
wave length was set up at 200 nm to detect the compound and the pure 
compound was collected at 25-31min.  
TDF5:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
collected at 8-12min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 40 % 
ACN/H2O was used to elute the column under the flow rate of 8ml/min. The 
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wave length was set up at 200 nm to detect the compound and the pure 
compound was collected at 17-24.5min.  
TDF5m:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
collected at 12-15 min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 50 % 
ACN/H2O was used to elute the column under the flow rate of 8ml/min. The 
wave length was set up at 200 nm to detect the compound and the pure 
compound was collected at 27-32min. 
TDF6:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
collected at 8-12min. Then this peak was injected in HPLC (Varian ProStar) 
with the column (Prep-C18, 21.2x250 mm, 10 um) system and 35 % 
ACN/H2O was used to eluted the column under the flow rate of 8ml/min. The 
wave length was set up at 200 nm to detect the compound and the pure 
compound was collected at 13-18.5min.  
TDF6m:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-
C18, 3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 
20ml/min and the detection wave length was set up at 210 nm. The peak was 
collected at 12-15 min. Then this peak was injected in HPLC (Varian ProStar) 
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with the column (Prep-C18, 21.2x250 mm, 10 um) system and 50 % 
ACN/H2O was used to elute the column under the flow rate of 8ml/min. The 
wave length was set up at 200 nm to detect the compound and the pure 
compound was collected at 12-17min. 
 
 
	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
102	  
	  
1.8  References 
 
1.   Haberland, M.; Montgomery, R. L.; Olson, E. N. The many roles of histone 
deacetylases in development and physiology: Implications for disease and 
therapy. Nat. Rev. Genet. 2009, 10, 32−42.  
2.  Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone 
deacetylase inhibitors. Nat. Rev. Drug Discovery 2006, 5, 769−784.  
3. Emanuele, S.; Lauricella, M.; Tesoriere, G. Histone deacetylase inhibitors: 
Apoptotic effects and clinical implications. Int. J. Oncol. 2008, 33, 637−646.  
4.  Verdin, E.; Dequiedt, F.; Kasler, H. Class II histone deacetylasesVersatile 
regulators. Trends Genet. 2003, 19, 286−293. 
 
5. Bernstein, B. E., Meissner, A., and Lander, E. S. The mammalian epigenome, 
Cell 2007, 128, 669-681.  
 
6. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of 
epigenetic (and more) treatments for cancer. Nature Rev. Cancer 2006, 6, 
38−51.  
 
7. Haberland, M.; Montgomery, R. L.; Olson, E. N. The many roles of histone 
deacetylases in development and physiology: implications for disease and 
therapy. Nature Rev. Genet. 2009, 10, 32−42.  
 
8.  Fass, D. M.; Kemp, M. M.; Schroeder, F. A.; Wagner, F. F.; Wang, Q.; Holson, 
E. B. Histone Acetylation and Deacetylation. In Epigenetic Regulation and 
103	  
	  
Epigenomics: Advances in Molecular Biology and Medicine; (Wiley-VCH Vrlag 
& Co. KGaA: Weinheim, 2012; pp 515−561. 
 
9. Marks, P. A., Histone deacetylase inhibitors: a chemical genetics approach to 
understanding cellular functions. Biochim Biophys Acta 2010, 1799:717-725.  
 
10. Wiech NL, Fisher JF, Helquist P, Wiest O: Inhibition of histone deacetylases: a 
pharmacological approach to the treatment of non-cancer disorders. Curr Top 
Med Chem 2009, 9:257-271.   
 
11. Wagner JM, Hackanson B, Lübbert M, Jung M: Histone deacetylase (HDAC) 
inhibitors in recent clinical trials for cancer therapy. Clin 
Epigenetics 2010, 1:117-136.   
 
12. Haberland M, Montgomery RL, Olson EN: The many roles of histone 
deacetylases in development and physiology: implications for disease and 
therapy. Nat Rev Genet 2009, 10:32-42.   
 
13. (a) Marks, P. A.; Richon, V. M.; Miller, T.; Kelly, W. K. Histone Deacetylase 
Inhibitors. Adv. Can. Res. 2004, 91, 137−168.  
 
14.  de Ruijter, A. J. M.; Van Gennip, A. H.; Caron, H. N.; Kemp, S.; Van 
Kuilenburg, A. B. P. Histone deacetylases (HDACs): characterization of the 
classical HDAC family. Biochem. J. 2003, 370, 737−749.  
 
104	  
	  
15. Glaser, K. B.; Staver, M. J.; Waring, J. F.; Stender, J.; Ulrich, R. G.; Davidsen, 
S. K. Gene expression profiling of multiple histone deacetylase (HDAC) 
inhibitors: defining a common gene set produced by HDAC inhibition in T24 
and MDA carcinoma cell lines. Mol. Cancer Ther. 2003, 2, 151−163.  
 
16. Spange, S.; Wagner, T.; Heinzel, T.; Kramer, O. H. Acetylation of non-histone 
proteins ̈ modulates cellular signalling at multiple levels. Int. J. Biochem. Cell 
Biol. 2009, 41, 185−198.  
 
17. Bertrand, P. Inside HDAC with HDAC inhibitors. European Journal of Medicinal 
Chemistry. 2010, 45, 2095-2116. 
 
18. (a) Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone 
deacetylase inhibitors. Nature Rev. Drug Discovery 2006, 5, 769−784.  
 
19.  Khan, O.; La Thangue, N. B. HDAC inhibitors in cancer biology: emerging 
mechanisms and clinical applications. Immunol. Cell Biol. 2012, 90, 85−94.  
 
20. Witt, O.; Deubzer, H. E.; Milde, T.; Oehme, I. HDAC family: What are the 
cancer relevant targets. Cancer Lett. 2009, 277, 8−21.  
 
21. (a) Chuang, D. M.; Leng, Y.; Marinova, Z.; Kim, H. J.; Chiu, C. T. Multiple roles 
of HDAC inhibition in neurodegenerativeconditions. Trends Neurosci. 2009, 32, 
591−601.  
105	  
	  
 
22. Gray, S. G. Epigenetic treatment of neurological disease. Epigenomics 2011, 
3, 431−450.  
 
23. Grayson, D. R.; Kundakovic, M.; Sharma, R. P. Is there a future for histone 
deacetylase inhibitors in the pharmacotherapy of psychiatric disorders. Mol. 
Pharmacol. 2010, 77, 126−135.  
 
24. Beurel, E. HDAC6 regulates LPS-tolerance in astrocytes. PLoS One 2011, 6, 
e25804.  
 
25.  McQuown, S. C.; Barrett, R. M.; Matheos, D. P.; Post, R. J.; Rogge, G. A.; 
Alenghat, T.; Mullican, S. E.; Jones, S.; Rusche, J. R.; Lazar, M. A.; Wood, M. 
A. HDAC3 is a critical negative regulator of long-term memory formation. J. 
Neurosci. 2011, 31, 764−774.  
 
26. Guan, J.-S.; Haggarty, S. J.; Giacometti, E.; Dannenberg, J.-H.; Joseph, N.; 
Gao, J.; Nieland, T. J. F.; Zhou, Y.; Wang, X.; Mazitschek, R.; Bradner, J. E.; 
DePinho, R. A.; Jaenisch, R.; Tsai, L.-H. HDAC2 negatively regulates memory 
formation and synaptic plasticity. Nature 2009, 459, 55−60. 
 
27. (a) Rotilli, D.; Simonetti, G.; Savarino, A.; Palamara, A. T.; Migliaccio, A. R.; 
Mai, A. Non-cancer uses of histone deacetylase inhibitors: effects on infectious 
diseases and beta-hemoglobinopathies. Curr. Top. Med. Chem. 2009, 9, 
272−291.  
 
106	  
	  
28. Andrews, K. T.; Haque, A.; Jones, M. K. HDAC inhibitors in parasitic diseases. 
Immunol. Cell Biol. 2012, 90, 66−77. (7)  
 
29. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; 
Yoshida, M.; Wang, X.-F.; Yao, T.-P. HDAC6 is a microtubule-associated 
deacetylase. Nature 2002, 417, 455−458.  
 
30. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. 
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. 
EMBO J. 2003, 22, 1168−1179.  
 
31. Zou, H.; Wu, Y.; Navre, M.; Sang, B.-C. Characterization of the two catalytic 
domains in histone deacetylase 6. Biochem. Biophys. Res. Commun. 2006, 
341, 45−50.  
 
32. Zhang, Y.; Gilquin, B.; Khochbin, S.; Matthias, P. Two catalytic domains are 
required for protein deacetylation. J. Biol. Chem. 2006, 281, 2401−2404. 
 
33. (a)Verdin, E.; Dequiedt, F.; Kasler, H. Class II histone deacetylases: Versatile 
regulators. Trends Genet. 2003, 19, 286−293.  
 
34. Haberland, M.; Montgomery, R. L.; Olson, E. N. The many roles of histone 
deacetylases in development and physiology: Implications for disease and 
therapy. Nat. Rev. Genet. 2009, 10, 32−42.  
 
107	  
	  
35. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone 
deacetylase inhibitors. Nat. Rev. Drug Discovery 2006, 5, 769−784.  
 
36.  De Ruijter, A. J. M., Van Gennip, A. H., Caron, H. N., Kemp, S., Van 
Kuilenburg, A. B. P., Histone deacetylases (HDACs): characterization of the 
classical HDAC family. Biochem. J. 2003. 370, 737-749. 
 
37.  (a)Emanuele, S.; Lauricella, M.; Tesoriere, G. Histone deacetylase inhibitors: 
Apoptotic effects and clinical implications. Int. J. Oncol. 2008, 33, 637−646.   
 
38. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment 
of cancer. Nat. Rev. Drug Discovery. 2002, 1, 287−299.   
 
39. Dokmanovic, M.; Clarke, C.; Marks, P. A. Histone deacetylase inhibitors: 
Overview and perspectives. Mol. Cancer Res. 2007, 5, 981− 989.  
 
40. (a)De Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, 
A. B. Histone deacetylases(HDACs): Characterization of the classical HDAC 
family. Biochem. J. 2003, 370, 737−749.  
 
41.  Weichert, W.; Röske, A.; Gekeler, V.; Beckers, T.; Stephan, C.; Jung, K.; 
Fritzsche, F. R.; Niesporek, S.; Denkert, C.; Dietel, M.; Kristiansen, G. Histone 
deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 
expression is associated with shorter PSA relapse time after radical 
prostatectomy. Br. J. Cancer 2008, 98, 604− 610.  
108	  
	  
 
42.  Weichert, W.; Röske, A.; Niesporek, S.; Noske, A.; Buckendahl, A.-C.; Dietel, 
M.; Gekeler, V.; Boehm, M.; Beckers, T.; Denkert, C. Class I histone 
deacetylase expression has independent prognostic impact on human 
colorectal cancer: Specific role of class I histone deacetylases in vitro and in 
vivo. Clin. Cancer Res. 2008, 14, 1669−1677. 
 
43. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment 
of cancer. Nat. Rev. Drug Discovery. 2002, 1, 287−299. Dokmanovic, M.; 
Clarke, C.; Marks, P. A. Histone deacetylase inhibitors: Overview and 
perspectives. Mol. Cancer Res. 2007, 5, 981− 989.  
 
44. de Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, A. 
B. Histone deacetylases(HDACs): Characterization of the classical HDAC 
family. Biochem. J. 2003, 370, 737−749.  
 
45. Rikimaru, T.; Taketomi, A.; Yamashita, Y.; Shirabe, K.; Hamatsu, T.; Shimada, 
M.; Maehara, Y. Clinical significance of histone deacetylase 1 expression in 
patients with hepatocellular carcinoma. Oncology 2007, 72, 69−74.  
 
46. Miyake, K.; Yoshizumi, T.; Imura, S.; Sugimoto, K.; Batmunkh, E.; Kanemura, 
H.; Morine, Y.; Shimada, M. Expression of hypoxiainducible factor-1alpha, 
histone deacetylase 1, and metastasisassociated protein 1 in pancreatic 
carcinoma: correlation with poor prognosis with possible regulation. Pancreas 
109	  
	  
2008, 36 (3), e1−e9. (f) Ropero, S.; Esteller, M. The role of histone 
deacetylases (HDACs) in human cancer. Mol. Oncol. 2007, 1, 19−25.  
 
47. (a) Lane, A. A.; Chabner, B. A. Histone deacetylase inhibitors in cancer 
therapy. J. Clin. Oncol. 2009, 27, 5459−5468.  
 
48. Grant, S.; Easley, C.; Kirkpatrick, P. Vorinostat. Nat. Rev. Drug Discovery. 
2007, 6, 21−22.    
 
49. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of 
epigenetic treatments for cancer. Nat. Rev. Cancer. 2006, 6, 38−51.  
 
50.  Karagiannis, T. C.; El-Osta, A. Will broad-spectrum histone deacetylase 
inhibitors be superseded by more specific compounds? Leukemia 2007, 21, 
61−65. 
 
51. Finnin, M. S., Donigian, J. R., Cohen, A.,  Richon, V. M., Rifkind, R. A., Marks, 
P. A., Breslow, R. Pavletich, N. P., Structures of a histone deacetylase 
homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193 
 
52. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of 
epigenetic (and more) treatments for cancer. Nature Rev. Cancer 2006, 6, 
38−51.  
 
110	  
	  
53. Haberland, M.; Montgomery, R. L.; Olson, E. N. The many roles of histone 
deacetylases in development and physiology: implications for disease and 
therapy. Nature Rev. Genet. 2009, 10, 32−42.  
 
54.  Fass, D. M.; Kemp, M. M.; Schroeder, F. A.; Wagner, F. F.; Wang, Q.; Holson, 
E. B. Histone Acetylation and Deacetylation. In Epigenetic Regulation and 
Epigenomics: Advances in Molecular Biology and Medicine; (Wiley-VCH Vrlag 
& Co. KGaA: Weinheim, 2012; pp 515−561. 
 
55. Marks, P. A., Histone deacetylase inhibitors: a chemical genetics approach to 
understanding cellular functions. Biochim Biophys Acta 2010, 1799:717-725.  
 
56. Wiech NL, Fisher JF, Helquist P, Wiest O: Inhibition of histone deacetylases: a 
pharmacological approach to the treatment of non-cancer disorders. Curr Top 
Med Chem 2009, 9:257-271.   
 
57. Wagner JM, Hackanson B, Lübbert M, Jung M: Histone deacetylase (HDAC) 
inhibitors in recent clinical trials for cancer therapy. Clin 
Epigenetics 2010, 1:117-136.   
 
58. Haberland M, Montgomery RL, Olson EN: The many roles of histone 
deacetylases in development and physiology: implications for disease and 
therapy. Nat Rev Genet 2009, 10:32-42.   
 
111	  
	  
59. (a) Marks, P. A.; Richon, V. M.; Miller, T.; Kelly, W. K. Histone Deacetylase 
Inhibitors. Adv. Can. Res. 2004, 91, 137−168.  
 
60.  de Ruijter, A. J. M.; Van Gennip, A. H.; Caron, H. N.; Kemp, S.; Van 
Kuilenburg, A. B. P. Histone deacetylases (HDACs): characterization of the 
classical HDAC family. Biochem. J. 2003, 370, 737−749.  
 
61. Glaser, K. B.; Staver, M. J.; Waring, J. F.; Stender, J.; Ulrich, R. G.; Davidsen, 
S. K. Gene expression profiling of multiple histone deacetylase (HDAC) 
inhibitors: defining a common gene set produced by HDAC inhibition in T24 
and MDA carcinoma cell lines. Mol. Cancer Ther. 2003, 2, 151−163.  
 
62. Spange, S.; Wagner, T.; Heinzel, T.; Kramer, O. H. Acetylation of non-histone 
proteins ̈ modulates cellular signalling at multiple levels. Int. J. Biochem. Cell 
Biol. 2009, 41, 185−198.  
 
63. Bertrand, P. Inside HDAC with HDAC inhibitors. European Journal of Medicinal 
Chemistry. 2010, 45, 2095-2116. 
 
64. (a) Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone 
deacetylase inhibitors. Nature Rev. Drug Discovery 2006, 5, 769−784.  
 
65.  Khan, O.; La Thangue, N. B. HDAC inhibitors in cancer biology: emerging 
mechanisms and clinical applications. Immunol. Cell Biol. 2012, 90, 85−94.  
 
112	  
	  
66. Witt, O.; Deubzer, H. E.; Milde, T.; Oehme, I. HDAC family: What are the 
cancer relevant targets. Cancer Lett. 2009, 277, 8−21.  
 
67. (a) Chuang, D. M.; Leng, Y.; Marinova, Z.; Kim, H. J.; Chiu, C. T. Multiple roles 
of HDAC inhibition in neurodegenerativeconditions. Trends Neurosci. 2009, 32, 
591−601.  
 
68. Gray, S. G. Epigenetic treatment of neurological disease. Epigenomics 2011, 
3, 431−450.  
 
69. Grayson, D. R.; Kundakovic, M.; Sharma, R. P. Is there a future for histone 
deacetylase inhibitors in the pharmacotherapy of psychiatric disorders. Mol. 
Pharmacol. 2010, 77, 126−135.  
 
70. Beurel, E. HDAC6 regulates LPS-tolerance in astrocytes. PLoS One 2011, 6, 
e25804.  
 
71.  McQuown, S. C.; Barrett, R. M.; Matheos, D. P.; Post, R. J.; Rogge, G. A.; 
Alenghat, T.; Mullican, S. E.; Jones, S.; Rusche, J. R.; Lazar, M. A.; Wood, M. 
A. HDAC3 is a critical negative regulator of long-term memory formation. J. 
Neurosci. 2011, 31, 764−774.  
 
72. Guan, J.-S.; Haggarty, S. J.; Giacometti, E.; Dannenberg, J.-H.; Joseph, N.; 
Gao, J.; Nieland, T. J. F.; Zhou, Y.; Wang, X.; Mazitschek, R.; Bradner, J. E.; 
113	  
	  
DePinho, R. A.; Jaenisch, R.; Tsai, L.-H. HDAC2 negatively regulates memory 
formation and synaptic plasticity. Nature 2009, 459, 55−60. 
 
73. (a) Rotilli, D.; Simonetti, G.; Savarino, A.; Palamara, A. T.; Migliaccio, A. R.; 
Mai, A. Non-cancer uses of histone deacetylase inhibitors: effects on infectious 
diseases and beta-hemoglobinopathies. Curr. Top. Med. Chem. 2009, 9, 
272−291.  
 
74. Andrews, K. T.; Haque, A.; Jones, M. K. HDAC inhibitors in parasitic diseases. 
Immunol. Cell Biol. 2012, 90, 66−77. (7)  
 
75. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; 
Yoshida, M.; Wang, X.-F.; Yao, T.-P. HDAC6 is a microtubule-associated 
deacetylase. Nature 2002, 417, 455−458.  
 
76. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. 
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. 
EMBO J. 2003, 22, 1168−1179.  
 
77. Zou, H.; Wu, Y.; Navre, M.; Sang, B.-C. Characterization of the two catalytic 
domains in histone deacetylase 6. Biochem. Biophys. Res. Commun. 2006, 
341, 45−50.  
 
78. Zhang, Y.; Gilquin, B.; Khochbin, S.; Matthias, P. Two catalytic domains are 
required for protein deacetylation. J. Biol. Chem. 2006, 281, 2401−2404. 
 
114	  
	  
 
79. (a)Verdin, E.; Dequiedt, F.; Kasler, H. Class II histone deacetylases: Versatile 
regulators. Trends Genet. 2003, 19, 286−293.  
 
80. Haberland, M.; Montgomery, R. L.; Olson, E. N. The many roles of histone 
deacetylases in development and physiology: Implications for disease and 
therapy. Nat. Rev. Genet. 2009, 10, 32−42.  
 
81. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone 
deacetylase inhibitors. Nat. Rev. Drug Discovery 2006, 5, 769−784.  
 
82.  De Ruijter, A. J. M., Van Gennip, A. H., Caron, H. N., Kemp, S., Van 
Kuilenburg, A. B. P., Histone deacetylases (HDACs): characterization of the 
classical HDAC family. Biochem. J. 2003. 370, 737-749. 
 
83.  (a)Emanuele, S.; Lauricella, M.; Tesoriere, G. Histone deacetylase inhibitors: 
Apoptotic effects and clinical implications. Int. J. Oncol. 2008, 33, 637−646.   
 
84. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment 
of cancer. Nat. Rev. Drug Discovery. 2002, 1, 287−299.   
 
85. Dokmanovic, M.; Clarke, C.; Marks, P. A. Histone deacetylase inhibitors: 
Overview and perspectives. Mol. Cancer Res. 2007, 5, 981− 989.  
 
115	  
	  
86. (a)De Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, 
A. B. Histone deacetylases(HDACs): Characterization of the classical HDAC 
family. Biochem. J. 2003, 370, 737−749.  
 
87.  Weichert, W.; Röske, A.; Gekeler, V.; Beckers, T.; Stephan, C.; Jung, K.; 
Fritzsche, F. R.; Niesporek, S.; Denkert, C.; Dietel, M.; Kristiansen, G. Histone 
deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 
expression is associated with shorter PSA relapse time after radical 
prostatectomy. Br. J. Cancer 2008, 98, 604− 610.  
 
88.  Weichert, W.; Röske, A.; Niesporek, S.; Noske, A.; Buckendahl, A.-C.; Dietel, 
M.; Gekeler, V.; Boehm, M.; Beckers, T.; Denkert, C. Class I histone 
deacetylase expression has independent prognostic impact on human 
colorectal cancer: Specific role of class I histone deacetylases in vitro and in 
vivo. Clin. Cancer Res. 2008, 14, 1669−1677. 
 
89. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment 
of cancer. Nat. Rev. Drug Discovery. 2002, 1, 287−299. Dokmanovic, M.; 
Clarke, C.; Marks, P. A. Histone deacetylase inhibitors: Overview and 
perspectives. Mol. Cancer Res. 2007, 5, 981− 989.  
 
 
 
 
116	  
	  
Chapter II: AQUEOUS COMPLEXES FOR EFFICIENT SIZE-BASED 
SEPARATION OF AMERICIUM FROM CURIUM 
 
 
2.1  Overview 
Nuclear Energy has much better curb appeal to older energy methods such 
as burning coal or oil.  A single 20 gram fuel pellet of Uranium can produce the 
same amount of energy as 400 kilograms of coal, 410 litres of oil, or 350 cubic 
metres of natural gas1(figure 2.1).   When the whole life cycle of power generation 
is taken into account, nuclear power is one of the cleanest forms of energy, only 
behind hydroelectric and wind power5.  The main problem with nuclear power is 
the radioactive waste that is generated.  The high level wastes generated by 
reprocessing spent nuclear fuels are vitrified or converted in to glass today. These 
wastes, which will ultimately be disposed of in deep underground repositories2, 
contain long-lived radionuclides, including the minor actinides neptunium (Np), 
americium (Am) and curium (Cm) with half-lives ranging from hundreds to millions 
of years3. A new management protocol for these wastes could be developed if the 
long-lived radionuclides are separated from the short/medium lived radionuclides 
and then transmuted into short lived nuclides by nuclear means4.  
 
Figure 2.1: Energy comparison of Uranium, coal, oil, and natural gas5 
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However, it is well-known that the chemical properties of these elements 
are similar: they form trivalent cations (M3+) in solution as their most stable 
oxidation states, and they have similar ionic radii6-11. These similarities give rise to 
the difficulty in the separation of these elements. The research presented in this 
chapter aims to investigate and develop of new molecules for the difficult 
separation of the minor actinides americium (Am) from curium (Cm).   
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2.2  Introduction 
A drawback of the generation of electricity by nuclear energy is its 
unavoidable by-product of radioactive waste. Electricity production by nuclear 
power/nuclear reactions is responsible for more than 95% of the radioactivity of 
the total amount of nuclear waste12-14. Radioactive waste arises from all stages of 
the nuclear fuel cycle (figure 2.2), but more than 99% of the radioactivity involved 
in electricity generation by nuclear power plants is concentrated within the spent 
fuel discharged from reactors15-18. Public approval of nuclear power as a long term 
source of sustainable energy highly depends on the impact of the radioactive 
waste on the environment and the atmosphere. 
 
Figure 2.2: Nuclear power cycle 19 
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 The removal of these radioactive wastes is a serious environmental crisis for 
which there is, as of yet, no universally accepted solution. It is one of the most 
pressing scientific and political problems that face mankind globally. 
Radioactive waste from nuclear reactors usually contains radionuclides with 
a wide range of half-lives20-22. The majority of these nuclides have small half-lives 
ranging from less than a second up to a couple of years and disappear in a 
moderately short period of time representing very small risks during waste 
handling and storage. However, some radionuclides still exist after thousands or 
even millions of years, so their separation from all global ecosystems must be 
guaranteed for an extremely long time.  An example of a storage system like this 
would be a deep geological formation of rocks or a deep ocean valley. The 
majority of the long-lived radionuclides determining the long-term safety of the 
waste within a repository belongs to the actinide group and more specifically, 
neptunium (Np), americium (Am) and curium (Cm)23 (figure 2.3 and figure 2.4). 
 
Figure 2.3: Radiotocicity inventory for 1 ton of spent fuel from a pressurized water reactor 
(PWR) with a 4% 235U enrichment and burn-up of 40 GWd/tHM (tHM = Ton heavy 
metal)24  
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Figure 2.4: Contributions to the decay heat generated by spent PWR fuel 
irradiated to 50 GWd/tHM25 
 
With the current reprocessing technology today, the time perspective for the 
confinement of radioactive waste in a repository decreases from one-million years 
to 100,000 years of storage26-29.  This is still to large of a time table for the storage 
of radioactive waste geological formation.  Also, if 99.9% of radioactive uranium 
and plutonium could be separated during reprocessing, the radiotoxicity of the 
remaining waste would only decrease one order of magnitude30.  This statistic 
makes it very that the small byproducts of nuclear reactions contain the majority of 
the radioactive waste.  The contaminated lifetime high level waste is determined 
by the presence of minor actinides (237Np, 241Am, 243Am, and 245Cm)31-33 and long-
lived fission products (99Tc, 129I, 79Se, 93Zr, 135Cs)34-35. 
Separating the minor actinide americium (Am) from curium (Cm) and the 
lanthanide fission products in used nuclear fuel is a critical part of minor actinide 
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recycle/transmutation in advanced nuclear fuel cycles36. The first step in recycling 
the waste the lanthanides elements must be separated first because they are 
much more abundant than the minor actinides and also are powerful neutron 
poisons which would inhibit fission of Am37-40. Removal of Cm is important to 
simplify fuel fabrication and to halt the buildup of neutron-emitting transcurium 
actinides when the used fuel is recycled repeatedly. To date, several processes 
have been developed to co-separate Am and Cm from the lanthanides by-
products in nuclear waste. Am and Cm separation to date is still a very difficult 
processes and still remains very challenging and problematic.    The objective of 
this project is to rationally design new molecules that can efficiently separate Am 
from both Cm and the lanthanides.  
Recent work in the Office of Nuclear Energy-funded Sigma Team for Minor 
Actinide Separations at Argonne national laboratory shows that steric strain in 
coordination complexes can amplify normally small differences in the complexation 
free energies of similar metal ions, such as Am3+ and Cm3+. This produces free 
energy differences (or separation factors) large enough for convenient solvent 
extraction separations41.	   That work also demonstrated that the sterically 
constrained ligand, N,N’-bis[(6-carboxy-2-pyridyl)methyl]-4,13-diaza-18-crown-6 
(H2bp18c6, figure 2.5)	  shows a distinct thermodynamic preference for Am3+ over 
Cm3+ and could produce a high purity Am stream from a mixture of equal amounts 
of Am and Cm in as few as six contacts. Computational studies also suggested 
derivatives of bp18c6 could be even more selective for Am over Cm42.	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Figure 2.5: (1) H2bp18c6 
N
O
ON
O
O
N
N
O
OH
O
HO
H2bp18c6 (1)  
While the Am/Cm selectivity of bp18c6 is impressive, a more selective 
ligand would make practical applications more economical by reducing the number 
of separation stages and eliminating contamination of the Am product with light 
lanthanides (i.e. La and Ce). The work presented in this chapter is the rationally 
design, synthesize and screen for new ligands that could improve the separation 
of americium from curium and the lanthanides.  
Our general hypothesis is that tuning the steric constraints and electron 
donating strength of the bp18c6 molecule will produce molecules with better 
selectivity for Am. Our two specific aims are for this project are (1) Rationally 
design new aqueous ligands and chemically synthesize these designer ligands, 
and (2) Evaluate the potential of these synthetic ligands for americium selectivity. 
The outcome of this work will be a unique aqueous ligand for a straightforward and 
efficient separation of americium from curium and the lanthanides. This will enable 
a simple and efficient separation process that will be important for improving the 
efficiency of advanced fuel cycles. As an aqueous ligand, we expect the 
derivatives that will be developed would be deployable as a simple americium-
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selective variation on one or more established or developing process concepts 
such as TALSPEAK, ALSEP, or SANEX43. 
 
 
2.3 Rationally Design of bp18c6 Derivatives 
 
The hypothesis underlying this research program is that that tuning the 
steric constraints and electron donating strength of the already sterically 
constrained bp18c6 molecule will produce molecules with even better selectivity 
for Am. This hypothesis is based on work conducted by the Sigma Team for Minor 
Actinide Separations at Argonne National laboratory, with whom we are 
collaborating with Dr. Mark Jensen. We propose that changing the steric 
constraints of the ligands will alter their cation size-based selectivity (i.e. the 
Am/Cm selectivity), while changing the chemical softness of the pyridine nitrogen 
donors by adding electron donating groups to the pyridine groups of bp18c6 will 
alter the Am/lanthanide selectivity. The ligand H2bp18c6 has already been shown 
to have different affinities for americium and curium and lanthanides, but improving 
this selectivity is needed to reduce the number of stripping stages (making the 
separation more efficient and economical) and to eliminate light lanthanide  
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Figure 2.6: Ligands 1-3, increases in the size of the picolinic acid arms 
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contamination of the Am. Thus we will focus on understanding the interplay 
between the most relevant steric and electronic factors underlying the Gibbs free 
energies that drive the actual separation. Computational studies of the bp18c6 
ligand system suggest that ligand strain indeed increases as the actinide or 
lanthanide cations become smaller, and that the crown ether nitrogen atoms are 
key donor groups affected by the strain. The computations also suggest that 
increasing the length of the arms attached to the crown ether could tune the 
relative strain in the complexes and improve the size selectivity of the ligands. 
These findings are supported by literature reports on the structures of lanthanide-
crown ether complexes44-46. Therefore, our designer molecules will keep the 
critical 6-carboxy-2-pyridyl (picolinic acid) group and the diaza-18-crown-6 ring 
size. Ligands 2 and 3 (Figure 2.6) with longer picolinic acid arms are designed to 
test the influence of the strain induced in the metal complexes by the complexing 
picolinate arms.   
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Figure 2.7: Ligands 4-9 have electron donating groups or a more rigid crown rings 
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Ligands  4-7 (figure 2.7) contain the more rigid 18-crown-6 ether ring 
system. This set of ligands is designed to test how further constraining the ring 
system affects the Am/Cm selectivity. To make constrained ligands such as 6 and 
7 more water soluble, which is critical for aqueous separation, we will introduce 
hydrophilic groups     (-OCH3) at the benzene ring (ligands 8-9).  
 
Figure 2.8: Ligands 10-12 with electron donating methoxy groups 
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Ligands 10-12 (figure 2.8) all have the same ring size as bp18c6 with 
electron donating methoxy group(s) on the pyridine ring to enhance the softness of 
the nitrogen atom. The methoxy group(s) will also enhance the aqueous solubility 
of the ligands. Computational modeling suggested that softer pyridine nitrogen will 
improve Am/lanthanide selectivity. The synthesized ligands will be screened for 
solubility and size selectivity using the lanthanides Nd3+ and Sm3+ (which are close 
in cationic size with Am3+ and Cm3+, respectively44). Ligands passing the size 
selectivity screen will be further evaluated for Am/Cm and Am/lanthanide 
selectivity and when suitable, full thermodynamic characterization by our Sigma 
Team collaborator will take place. The results from these studies will be used to 
inform additional improvements to the base ligand, particularly with respect to 
substituents on the pyridine rings (ligands 10-12). From these combined studies, 
we will design a unique ligand for Am separation that will enable new separations 
important to advanced fuel cycles. 
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2.4   Results and Discussion 
 
Ligand H2bp18c6 (Scheme 1)(N,N’-bis[(6-carboxy-2-pyridyl)methyl]-4,13-
diaza-18-crown-6)(1) was synthesized by the produce of Rodriguez-Blas and 
coworkers with a few small modifications45-46.   This ligand was obtained in four 
steps from dimethylpyridine-2,6- dicarboxylate (13) with an overall yield of 28% 
(scheme 2.1). This first step is the reduction of one methyl ester of the starting 
material dimethylpyridine-2,6- dicarboxylate (13) to yield 6-Hydroxymethylpyridine-
2-carboxylic Acid Methyl Ester (14)  in 51%47.  Next, Bromination of (14) with PBr3 
at 0º C in CHCl3 formed 6-Bromomethylpyridine-2-carboxylic Acid Methyl Ester 
(15) in good yield of 99%48.  In the Alkylation reaction 15 was treated with 4,13-
diaza-18-crown-6 (16) in refluxing acetonitrile in the presence of Na2CO3 to give 
compound N,N′-Bis[(6-methoxycarbonyl-2-pyridyl)methyl]-4,13-diaza-18-crown-6 
(17) in 67% yield. Full deprotection of the methyl esters of 17 was cleanly 
achieved with 6 M HCl at reflux to yield the desired ligand, H2bp18c6 (1)(scheme 
2.1)(N,N’-bis[(6-carboxy-2-pyridyl)methyl]-4,13-diaza-18-crown-6). After ligand 1 
was successfully characterized and confirmed by NMR and HRMS, we began 
synthesis on ligand 2. 
Scheme 2.1: Synthesis of H2bp18c6 (1) 
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We envisioned again starting with the same starting material as for ligand 
(1), dimethylpyridine-2,6- dicarboxylate (13). Reduction of starting material 
dimethylpyridine-2,6- dicarboxylate (13) and then brominated  with PBr3 yielded 6-
Bromomethylpyridine-2-carboxylic Acid Methyl Ester (15) in two step overall yield 
of 50%.  The carbon extension step followed and gave a lot more problems than 
we originally hoped.  The first proposed synthesis is outline in scheme 2.2. 
 
Scheme 2.2: Proposed synthesis of 6,6'-((1,4,10,13-tetraoxa-7,16-diazacyclo-
octadecane-7,16-diyl)bis(ethane-2,1-diyl))dipicolinic acid (2).	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addition of a strong organic base (n-Butyl lithium) followed by quenching the 
reaction with CO2, and then acid which would produce 2-(6-
(methoxycarbonyl)pyridin-2-yl)acetic acid (18).  We tried numerous attempts to 
use n-butyllithium with different ratios of equivalents of base and S.M. and also at 
different temperatures. None were successful. Next, our lab used Mg metal in 
hopes that the Grignard reagent would form.   After repeated reactions (equation 
2.1), none were found to have any 2-(6-(methoxycarbonyl)pyridin-2-yl)acetic acid 
(18) present.  	  
 
Equation 2.1: 2-(6-(methoxycarbonyl)pyridin-2-yl)acetic acid 
 
 
 
 
 
After the unsuccessful attempts to add the carbon with the CO2, we turned 
to sodium cyanide for the carbon extension.  The reaction of 6-
Bromomethylpyridine-2-carboxylic acid methyl ester (15) with 3 eqv. NaCN 
refluxed in ethanol and yielded (equation 2.2) methyl 6-(cyanomethyl)-picolinate 
(23) in quantitative yield.    The nitrile was then subjected to hydrolysis with HCl to 
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form the carboxylic acid (18).  The basic function of the pyridine ring made this 
reaction extremely hard to work up and isolate the product.  We also tried 
Diisobutylaluminium hydride49 (DIBAL or DIBALH) to reduce the nitrile with an 
aqueous workup.  Neither attempt was successful (scheme 2.3).  
 
 
Equation 2.2: Methyl 6-(cyanomethyl)-picolinate 
N
O
O Br
NaCN (3 eqv.)
EtOH ref lux
100%
N
O
O CN
15 23
 
 
 
Scheme 2.3: Synthesis of 2-(6-(methoxycarbonyl)pyridin-2-yl)acetic acid (18) and 
methyl 6-(2-oxoethyl)picolinate (24)  from methyl 6-(cyanomethyl)-picolinate (23). 
N
O
O CN
HCl
N
O
O
O
OH
N
O
O
O
N
O
O
O
DIBAL, THF
0°C
-78°C
DIBAL, THF
23
18
24
24  
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With no successful method for the carbon extension, we decided to switch 
gears and try coupling reactions for addition of the carbon to the pyridyl ring 
(Suzuki50, Negishi51, Heck52, Sonogashira53, and Stille54).  A new proposed 
synthesis which includes the coupling reaction is outlined in scheme 2.4.  Methyl 
6-bromopyridine-2-carboxylate is commercial available from Aldrich for $50 US for 
1.0 gram.   
Scheme 2.4: Proposed synthesis of Ligand (2) using a coupling reaction for 
carbon extension 
N
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O
N
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N
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O
OH
BH3
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O
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N
O
O
O
O
N
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O
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N
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toluene
O
O
N
O
O
N
N
OH
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N
OH
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Coupling reaction
21 22
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16
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The Suzuki reaction (equation 2.3) was carried out with Pd(PPh3)4  (tetrakis 
(triphenyl-phosphine) palladium), a boronic acid and a base.  The best Suzuki 
coupling reaction (table 2.1, entry 8) was run with 10 mol% Pd(PPh3)4, 1.5 eqv. of 
vinylboronic acid pinacol ester, 2 eqv. of Na2CO3, and run in toluene to yield 44%.  
Professor Molander’s (Penn University) BF3K salts (boronic acid) produced very 
small amounts of coupled products (table 2.1, entry 11-24). 
 
Equation 2.3: Coupling reactions for the synthesis of methyl 6-vinylpicolinate (22). 
O
O
N Br
O
O
B
BF3K
O
O
N
Pd0
Boronic Acid
or BF3K salt
Base, Solvent, heat
MIDA =
Vinylboronic acid
MIDA ester
B
N
O
O
O
O
Pd(dppf)Cl2CH2Cl2 = 1',1-
Bis(diphenyl-phosphino)
ferrocene
dicholoropalladium
Fe
P
P
Pd
Ph
Ph
Ph
Ph
Cl
Cl
XPhos =
PCy2
Pd(PPh3)4 = Tetrakis
(triphenylphosphine) palladium
Sources ofPdo
Potassium
vinyltrif luoro-
borate
Vinylboronic
Acid Pinacol
Ester
SPhos =
OO
PCy2
21 22
LigandsBoronic Acids Sources
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Table 2.1: Optimization of coupling reactions for the synthesis of methyl 6-vinyl-
picolinate (22) 
Entry Pd Boronic Acid or 
BF3K salt 
(1.5 eqv.) 
 
Base 
(2 eqv.) 
Solvent Yield 
1 Tetrakis (10 mol %) Pinacol Ester Na2CO3 Dioxane Trace 
2 Tetrakis (10 mol %) Pinacol Ester Na2CO3 DME 8% 
3 Tetrakis (10 mol %) Pinacol Ester NaOH Dioxane N.R. 
4 Tetrakis (10 mol %) Pinacol Ester NaOH DME 13% 
5 Tetrakis (10 mol %) Pinacol Ester CsCO3 Toluene trace 
6 Tetrakis (10 mol %) Pinacol Ester CsCO3 Dioxane N.R. 
7 Tetrakis (10 mol %) Pinacol Ester CsCO3 DME N.R. 
8 Tetrakis (10 mol %) Pinacol Ester Na2CO3	   Toluene 44% 
9 Tetrakis (5 mol %) Pinacol Ester Na2CO3	   Toluene 23% 
10 Tetrakis (10 mol %) Pinacol Ester Na2CO3	   Tolu./MeOH 
(10:1) 
N.R. 
11 Pd(dppf)Cl2CH2Cl2 BF3K salt t-BuNH2 i-PrOH/H2O(2:1) N.R. 
12 Pd(dppf)Cl2CH2Cl2 BF3K salt t-BuNH2 i-PrOH/ H2O (2:1) N.R. 
13 Pd(dppf)Cl2CH2Cl2 BF3K salt (i-
Pr)2NEt 
i-PrOH/ H2O (2:1) N.R. 
14 Pd(dppf)Cl2CH2Cl2 BF3K salt CsCO3 i-PrOH/ H2O (2:1) 14% 
15 Pd(dppf)Cl2CH2Cl2 BF3K salt Na2CO3 i-PrOH/ H2O (2:1) N.R. 
16 Pd(dppf)Cl2CH2Cl2 BF3K salt CsCO3 THF 8% 
17 Pd(dppf)Cl2CH2Cl2 BF3K salt Na2CO3 THF 20% 
18 Pd(dppf)Cl2CH2Cl2 BF3K salt NaOH THF N.R. 
19 Pd(dppf)Cl2CH2Cl2 BF3K salt Et3N i-PrOH/ H2O (2:1) N.R. 
20 Pd(dppf)Cl2CH2Cl2 BF3K salt Et3N DME/DMF N.R. 
21 Pd(dppf)Cl2CH2Cl2 BF3K salt Na2CO3 DME/DMF N.R. 
22 Tetrakis (10 mol %) BF3K salt CsCO3 THF/ H2O Trace 
23 Tetrakis (10 mol %) BF3K salt Na2CO3 THF/ H2O Trace 
24 Pd(dppf)Cl2CH2Cl2 BF3K salt CsCO3 THF/ H2O N.R. 
25 Tetrakis (10 mol %) MIDA with XPhos K3PO4 i-PrOH/H2O (2:1) N.R. 
26 Tetrakis (10 mol %) MIDA with XPhos Na2CO3 i-PrOH/ H2O (2:1) N.R. 
27 Tetrakis (10 mol %) MIDA with SPhos K3PO4 i-PrOH/ H2O (2:1) N.R. 
28 Tetrakis (10 mol %) MIDA with SPhos N/A	   i-PrOH/ H2O (2:1) N.R. 
29 Tetrakis (10 mol %) Pinacol Ester (2.0 
eqv) 
Na2CO3	   Toluene 35% 
30 Tetrakis (10 mol %) Pinacol Ester (2.5 
eqv) 
Na2CO3	   Toluene 41% 
31 Tetrakis (10 mol %) Pinacol Ester (3.0 
eqv) 
Na2CO3	   Toluene 45% 
32 Tetrakis (10 mol %) Tribuyl(vinyl) tin Na2CO3 Dioxane 55% 
33 Tetrakis (10 mol %) Tribuyl(vinyl) tin Na2CO3 DME 45% 
34 Tetrakis (10 mol %) Tribuyl(vinyl) tin N/A Dioxane 85% 
35 Tetrakis (5 mol %) Tribuyl(vinyl) tin N/A Dioxane 70% 
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Stille coupling was the next reaction carried out.  The conditions were 
similar to Suzuki coupling just the boronic acid was changed to tribuyl(vinyl) tin 
(table 2.1, entry 32-35).  Stille coupling by far worked the best on (equation 2.4) 
methyl 6-bromopyridine-2-carboxylate (21) with the conditions of 10mol% 
Pd(PPh3)4, 1.5 eqv.  tribuyl(vinyl) tin, and dioxane for a solvent to yield 85% methyl 
6-vinylpicolinate (22)  
 
Equation 2.4: Final conditions for synthesis of methyl 6-vinylpicolinate (22)  
O
O
N Br
O
O
Ndioxane, 80 °C, 16hr
Pd(PPh3)4 (10mol%)
Sn
4
85%21 22  
  
With much motivation that the reaction yield was high, we continued to the 
hydroboration (equation 2.5) of the alkene (22) with borane (BH3).  The results 
are highlighted in table 2.2 for which entry 8 has the best yield of methyl 6-(2-
hydroxyethyl)picolinate (20) at 41% isolated. 
 
Equation 2.5: Synthesis of methyl 6-(2-hydroxyethyl)picolinate (20). 
O
O
N
O
O
N OH
BH3-S(CH3)2 (1eqv.)
NaOOH (4eqv.) in Methanol
THF, 0°C22 20
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Table 2.2:  Optimization of hydroboration workup for the synthesis of methyl 6-(2-
hydroxyethyl)picolinate (20). 
 
Entry  Reagents  Oxidation method  Solvent  Temp  Yield  
1  BH3-S(CH3)2 (1eqv.)  NaOOH (4eqv.)  THF  27°C  N.R.  
2 BH3-S(CH3)2 (2.2 eqv.)  NaOOH (4eqv.) in Methanol THF  0°C 5%  
3 BH3-S(CH3)2 (0.3 eqv.)  NaOOH 4eqv.) in Methanol THF  0°C 8%  
4 BH3-S(CH3)2 (0.3 eqv.)  NaOOH (excess) in MeOH THF  0°C N.R.  
5 BH3-S(CH3)2 (2.2 eqv.)  NaBO3(4 eqv.)  THF  0°C 17%  
6 BH3-S(CH3)2 (2.2 eqv.)  NaBO3(10 eqv.) in 100eqv H2O  THF  0°C 20%  
7 BH3-S(CH3)2 (2.2 eqv.)  NaBO3(10eqv.) 100eqv H2O  THF  27°C  15%  
8 BH3-S(CH3)2  (2.2 eqv.)  NaBO3(10 eqv.) 100eqv H2O  THF  0°C 41%  
 
 
Next, the alkyl alcohol (20) was screened with halogenations reactions.  For 
bromination, PBr3 and CH3Br were tested but unfortunately no product (methyl 6-
(2-chloroethyl)-picolinate (21)) formation was observed.  Next, chlorination was 
examined with POCl3 and SOCl2.  Thioyl chloride (SOCl2) in dichloromethane at 
room temperature achieved the alkyl halide (21a) in quantitative yield.  These 
results are outlined in equation 2.6 and table 2.3. 
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Equation 2.6:  Halogenation of 6-(2-hydroxyethyl)picolinate (20) for synthesis of 
(methyl 6-(2-chloroethyl)picolinate (21a) or methyl 6-(2-bromoethyl)picolinate 
(22b). 
 
N
O
O
XN
O
O
OH
21a X = Cl and 21b X = Br
PBr3 or CH3Br
POCl3 or SOCl2
Tempature
Solvent20
	  
	  
Table 2.3: Optimization of halogenation of 6-(2-hydroxyethyl)picolinate (20) for 
synthesis of (methyl 6-(2-chloroethyl)picolinate (21a) or methyl 6-(2-
bromoethyl)picolinate (22b). 
 
	  
	  
	  
	  
 
 
 
 
 
Entry  Reagents  Solvent  Temperature  Yield  
1  PBr3 (1 eqv.)  CH2Cl2  27°C  N.R.  
2 PBr3 (1 eqv.)  CH2Cl2 0°C N.R. 
3 PBr3 (1 eqv.)  CH2Cl2 27°C  N.R.  
4 CBr4 , PPh3(1 eqv.)  CH2Cl2 27°C  N.R  
5 POCl3 (1 eqv.)  CH2Cl2 27°C  N.R  
6 SOCl2  CH2Cl2 0°C  95  
7 SOCl2(1 eqv.)  CH2Cl2 27°C  Quant  
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Now with the alkyl halide in hand, we focused on the alkylation with 1,10-
diaza-18-crown-6 in basic conditions (scheme 2.5).  The reaction was refluxed for 
30 hours and yielded dimethyl 6,6'-((1,4,10,13-tetraoxa-7,16-
diazacyclooctadecane-7,16-diyl)bis(ethane-2,1-diyl))dipicolinate (22) in 67% 
isolated yield.  Next, (22) reacted with 6 M hydrochloric acid for 12 hrs to deprotect 
the methyl esters to carboxylic acids to produce the final ligand 6,6'-((1,4,10,13-
tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(ethane-2,1-diyl))dipicolinic acid 
(2) in 43% yield.   
 
Scheme 2.5: Final steps of synthesis of  6,6'-((1,4,10,13-tetraoxa-7,16-
diazacycloo-ctadecane-7,16-diyl)bis(ethane-2,1-diyl))dipicolinic acid (2). 
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Characterization of ligand (2) was carried out with 1H, 13C NMR, and 
HRMS.  The overall synthesis’ yield is 10% in a short, concise 5 step procedure.  
The most problematic step in synthesizing ligand (2) was the addition of a carbon 
in the two position of the pyridyl ring.   
 With ligand (2) completed, we turned our attention to ligand (3) (6,6'-
((1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(propane-3,1-
diyl))dipicolinic acid) which had a 3 carbon extension from the crown function to 
the pyridyl  ring.  The proposed synthesis is outlined in scheme 2.6. 
 
Scheme 2.6: Proposed synthesis of Ligand (2) 6,6'-((1,4,10,13-tetraoxa-7,16-
diazacyclo-octadecane-7,16-diyl)bis(propane-2,1-diyl))dipicolinic acid (3). 
N
O
O Br N
O
O OH
PBr3 (1.1 equiv)
CHCl3, 0 °C, 3.5 hN
O
O O
O
NaBH4 (2.4 equiv)
CH3OH, 4 h, 0 °C N
O
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From the previous synthesis of ligand 2, there were many grams of 
intermediate 15 which worked out in our advantage due to using it in this 
synthesis.  The first reaction is conversion of the alkyl halide 15 to methyl 6-(3-
hydroxypropyl)picolinate 25 with formation of the Grignard reagent with 
Magnesium metal (scheme 2.6).  This method would also have countless 
problems with any product formation which was the same case in the synthesis of 
ligand 2. With no successful method for the carbon extension again, we decided to 
try coupling reactions (Suzuki, Negishi, Heck, Sonogashira, and Stille).  A 
proposed synthesis for ligland (3) based on the first reaction being a C-C formation 
reaction (scheme 2.7).  Methyl 6-bromopyridine-2-carboxylate is commercial and 
readly available from Aldrich which makes it a good starting material.  
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Scheme 2.7: Proposed synthesis of Ligand (3) using a coupling reaction for 
carbon extension
N
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Next, we turned to coupling reactions for the carbon extension in ligand 3 
since we had previous success for ligand 2. These reactions are in equation 2.7 
and table 2.4. 
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Equation 2.7: Optimization of reactions for the synthesis of methyl 6-allylpicolinate 
(28) 
 
O
O
N Br
O
O
B
BF3K
O
O
N
Pd0
Boronic Acid
or BF3K salt
Base, Solvent, heat
MIDA =
Vinylboronic acid
MIDA ester
Pd(dppf)Cl2CH2Cl2 = 1',1-
Bis(diphenyl-phosphino)
ferrocene
dicholoropalladium
Fe
P
P
Pd
Ph
Ph
Ph
Ph
Cl
Cl
XPhos =
PCy2
Pd(PPh3)4 = Tetrakis
(triphenylphosphine) palladium
Sources of Pd0
Potassium
vinyltrif luoro-
borate
Vinylboronic
Acid Pinacol
Ester
SPhos =
OO
PCy2
21 28
Boronic Acid Sources Ligands
B
N
O
O
O
O
	  
	  
Table 2.4: Optimization of coupling reactions for the synthesis of methyl 6-allylpicolinate 
(22) 
Entry Pd Boronic Acid or 
BF3K salt (1.5 eqv.) 
 
Base 
(2 eqv.) 
Solvent Yield 
1 Tetrakis (10 mol 
%) 
Pinacol Ester Na2CO3 Dioxane 32% 
2 Tetrakis (10 mol 
%) 
Pinacol Ester Na2CO3 DME 24% 
3 Tetrakis (10 mol 
%) 
Pinacol Ester NaOH Dioxane 21% 
4 Tetrakis (10 mol 
%) 
Pinacol Ester NaOH DME 13% 
5 Tetrakis (10 mol 
%) 
Pinacol Ester CsCO3 Toluene 9% 
6 Tetrakis (10 mol 
%) 
Pinacol Ester CsCO3 Dioxane N.R. 
7 Tetrakis (10 mol 
%) 
Pinacol Ester CsCO3 DME N.R. 
8 Tetrakis (10 mol Pinacol Ester Na2CO3	   Toluene 44% 
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%) 
9 Tetrakis (5 mol %) Pinacol Ester Na2CO3	   Toluene 28% 
10 Tetrakis (10 mol 
%) 
Pinacol Ester Na2CO3	   Toluene/MeOH 
(10:1) 
N.R. 
11 Pd(dppf)Cl2CH2Cl2 BF3K salt t-BuNH2 i-PrOH/H2O(2:1) N.R. 
12 Pd(dppf)Cl2CH2Cl2 BF3K salt t-BuNH2 i-PrOH/ H2O (2:1) N.R. 
13 Pd(dppf)Cl2CH2Cl2 BF3K salt (i-Pr)2NEt i-PrOH/ H2O (2:1) N.R. 
14 Pd(dppf)Cl2CH2Cl2 BF3K salt CsCO3 i-PrOH/ H2O (2:1) 17% 
15 Pd(dppf)Cl2CH2Cl2 BF3K salt Na2CO3 i-PrOH/ H2O (2:1) 22% 
16 Pd(dppf)Cl2CH2Cl2 BF3K salt CsCO3 THF 8% 
17 Pd(dppf)Cl2CH2Cl2 BF3K salt Na2CO3 THF 20% 
18 Pd(dppf)Cl2CH2Cl2 BF3K salt NaOH THF N.R. 
19 Pd(dppf)Cl2CH2Cl2 BF3K salt Et3N i-PrOH/ H2O (2:1) N.R. 
22 Tetrakis (10 mol 
%) 
BF3K salt CsCO3 THF/ H2O N.R. 
25 Tetrakis (10 mol 
%) 
MIDA with XPhos K3PO4 i-PrOH/H2O (2:1) N.R. 
26 Tetrakis (10 mol 
%) 
MIDA with XPhos Na2CO3 i-PrOH/ H2O (2:1) 28% 
27 Tetrakis (10 mol 
%) 
MIDA with SPhos K3PO4 i-PrOH/ H2O (2:1) N.R. 
28 Tetrakis (10 mol 
%) 
MIDA with SPhos N/A	   i-PrOH/ H2O (2:1) N.R. 
29 Tetrakis (10 mol 
%) 
Pinacol Ester (2.0 
eqv) 
Na2CO3	   Toluene 51% 
30 Tetrakis (10 mol 
%) 
Pinacol Ester (2.5 
eqv) 
Na2CO3	   Toluene 61% 
31 Tetrakis (15 mol 
%) 
Pinacol Ester (3.0 
eqv) 
Na2CO3	   Toluene 68% 
  
Suzuki coupling was carried out first with allylboronic acid pinacol ester in 
Na2CO3 and dioxane with palladium having an oxidation state of zero (table 4, 
entry 1, yield =32%).   BF3K salts (boronic acid) did not work the best and 
produced at the highest yield of only 22% of coupled product (table 4, entry 11-
22). 
Suzuki coupling by far worked the best on methyl 6-bromopyridine-2-
carboxylate (21) with allylboronic acid pinacol ester (3.0-3.5 eqv.) in Na2CO3 (2 
eqv.) and dioxane with 15 mol% Pd(PPh3)4 (table 4, entry 31, yield: 68%) to yield 
methyl 6-allylpicolinate (28) (equation 2.8).  
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Equation 2.8: Final conditions for synthesis of methyl 6-allylpicolinate (28) using 
Suzuki coupling. 
 
O
O
N Br
O
O
NToluene, 80 °C, 16hr
Pd(PPh3)4 (15 mol%)
68%21 28
O O
B
3.0 eqv.
	  
 
 
With much excitement that the reaction yield was high and working well, we 
continued to the hydroboration (equation 2.9) of the alkene (28) with borane 
(BH3).  The results are highlighted in table 5 for which entry 8 has the best 
isolated yield of methyl 6-(2-hydroxyethyl)picolinate (20) at 41%.  
 
 
Equation 2.9: Hydroboration reaction with borane used for the synthesis of methyl 
6-(2-hydroxyethyl)picolinate (20). 
O
O
N
O
O
N
BH3-S(CH3)2 (1eqv.)
NaOOH (4eqv.) in Methanol
THF, 0°C28 25
OH
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Table 2.5:  Optimization of hydroboration workup for the synthesis of methyl 6-(2-
hydroxyethyl)picolinate (20). 
 
Entry  Reagents  Oxidation method  Solvent  Temperature  Yield  
1  BH3   S(CH3)2 (1eqv.)  NaOOH (4eqv.)  THF  27°C  10%  
2 BH3  S(CH3)2 (2.2 eqv.)  NaOOH (4eqv.) in Methanol THF  0°C 5%  
3 BH3  S(CH3)2 (0.3 eqv.)  NaOOH 4eqv.) in Methanol THF  0°C 8%  
4 BH3  S(CH3)2 (0.3 eqv.)  NaOOH (excess) in Methanol THF  0°C N.R.  
5 BH3  S(CH3)2 (2.2 eqv.)  NaBO3(4 eqv.)  THF  0°C 17%  
6 BH3  S(CH3)2 (2.2 eqv.)  NaBO3(10 eqv.) in 100eqv 
H2O  
THF  0°C 20%  
7 BH3  S(CH3)2 (2.2 eqv.)  NaBO3(10eqv.) 100eqv H2O  THF  27°C  31%  
8 BH3  S(CH3)2 (2.2 
eqv.)  
NaBO3(10 eqv.) 100eqv H2O  THF  0°C 57%  
 
Next, the alkyl alcohol (28) was screened with halogenations reactions.  For 
bromination, PBr3 and CH3Br were tested.  No product (methyl 6-(2-chloropropyl)-
picolinate (25)) formation was observed.  Next, chlorination was examined with 
POCl3 and SOCl2.  No product formation was formed with these chlorinated agents 
as well.  So this was very strange due to the halogenations reaction worked well 
for ligand (2). When purification was being conducted for any of these reactions, 
the amount of mass to the column was always about 80% less than the mass out 
of the column.  So we used very polar solvents to wash anything that was left in 
the column out and we found  
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Equation 2.10:  Halogenation of 6-(2-hydroxyethyl)picolinate (25) produced 5-
(methoxycarbonyl)-2,3-dihydro-1H-indolizin-4-ium (29a or 29b) with corresponding 
anion.   
 
 
 
 
 
 
 
 
 
 
 
 
a large enough quantity in mass to analyze by 1H NMR and HRMS.  After 
spectrum were generated and analyzed, it was clear that the product was a 
cyclized version of the alkyl hailde (equation 2.10). 
5-(methoxycarbonyl)-2,3-dihydro-1H-indolizin-4-ium (29a or 29b)  could be  
reacted  under basic conditions (NaH) with the crown ether molecule (equation 
2.11) to theoretically synthesize (27) dimethyl 6,6'-((1,4,10,13-tetraoxa-7,16-
diazacyclo-octadecane-7,16-diyl)bis(propane-3,1-diyl))dipicolinate.  The reaction 
did not work. 
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Equation 2.11: Synthesis of dimethyl 6,6'-((1,4,10,13-tetraoxa-7,16-diazacyclo-
octadecane-7,16-diyl)bis(propane-3,1-diyl))dipicolinate. 
 
 
 
 
 
 
 
 
 
 
 
 
Next, Aldrich had compound (30) 2-(3-bromopropyl)-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane commercial available  for $38 US for 1.0 gram.  The crown 
ether was reacted with n-butyllithium and then with (30)  2-(3-bromopropyl)-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane to produce 7,16-bis(3-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)propyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane in a 
68% yield (equation  2.12).  Following this basic reaction, the coupling reaction 
was tested with many different bases and solvents in which product was not 
formed in any case.   
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Equation 2.12: Synthesis of 7,16-bis(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)propyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane (31) and synthesis of 
dimethyl 6,6'-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis 
(propane-3,1-diyl))dipicolinate (3). 
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2.5  Conclusion 
In conclusion, this chapter investigates the synthesis of ligands for the 
separation of Am/Cm from nuclear waste.  Ligands 1 and ligand 2 were sent to the 
Office of Nuclear Energy-funded Sigma Team for Minor Actinide Separations at 
Argonne national laboratory under the supervision of Dr. Mark Jensen.  A paper 
was recently published in Inorganic chemistry with ligand 1 for the separation of 
americium (Am) from curium (Cm) (DOI: 10.1021/ic500244p). Future work will 
make new ligands in hopes to have more efficiently separation of americium from 
curium.  Further derivatization of ligands and exploring further applications of this 
new class of is still under investigation. 
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2.6 Experimental 
I. General Considerations. 
All reactions were performed under argon atmosphere via schlenk line in oven-
dried glassware with magnetic stirring unless otherwise stated. Air and moisture-
sensitive liquids and solutions were transferred via oven-dried, stainless steel 
syringe and were introduced into the reaction vessel through rubber septa. All 
reactants and reagents were purchased from Ark Pharm, Inc. unless otherwise 
stated. CH2Cl2 and DMF (dimethylformamide) were distilled from calcium hydride. 
THF (tetrahydrofuran) was distilled from sodium-benzophenone. Anhydrous 
acetonitrile was purchased from Sigma Aldrich. Previously reported compounds 
were identified by 1H NMR (nuclear magnetic resonance) spectrum.  All new 
compounds were characterized by additional 13C NMR and mass spectroscopy. 1H 
and 13C NMR spectra were performed on a Bruker NMR at 300 and 75 MHz, 
respectively. 1H NMR data are reported as follows: chemical shift (δ) in parts per 
million (ppm) from tetramethylsilane as an internal standard (CDCl3 δ7.26 ppm), 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = 
doublet of doublets). 13C data were reported as follows: chemical shifts (δ) are 
reported in parts per million (ppm) from tetramethylsilane with the solvent as an 
internal indicator (CDCl3 δ77.16 ppm).  
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II. Experimental Procedures 
 
 
 
 
N
O
O OH
 
 
a. 6-Hydroxymethylpyridine-2-carboxylic Acid Methyl Ester (1) 
NaBH4 (4.310 g, 114.02 mmol) was added in small portions over a period of 0.5 h 
to a stirred solution of dimethylpyridine-2,6-dicarboxylate (7.445 g, 38.17 mmol) in 
MeOH (300 mL) at 0 °C. The mixture was stirred at 0 °C for 3 h and then a 
saturated NaHCO3 aqueous solution (200 mL) was added. The MeOH was 
removed in a rotary evaporator and the resulting aqueous solution was extracted 
with CHCl3 (5 × 100 mL). The combined organic extracts were dried over MgSO4 
and evaporated to give 4.370 g of product (69%) as a white solid. Anal. Calcd for 
C8H9NO3: C, 57.5; H, 5.4; N, 8.4%. Found: C, 56.9; H, 5.3; N, 8.3%. δH (solvent 
CDCl3, 295 K, 300 MHz): 8.02 (d, 1H, py, 3J = 7.7 Hz); 7.84 (t, 1H, py); 7.54 (d, 
1H, py, 3J = 7.8 Hz); 4.86 (s, 2H, -CH2-); 3.99 (s, 3H, -OCH3). δC (solvent CDCl3, 
295 K, 75.5 MHz): 52.6 (primary C); 64.6 (secondary C); 137.7, 124.0, 123.8 
(tertiary C); 165.5, 160.3, 146.9 (quaternary C). IR: 1740 ν(C═O), 1591 
ν(C═N)py cm−1. FAB-MS (m/z(%BPI)): 168 (100) [M + H]+. 
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b. 6-Bromomethylpyridine-2-carboxylic Acid Methyl Ester (2) 
PBr3 (5 mL) was added over 6-Hydroxymethylpyridine-2-carboxylic Acid 
Methyl Ester (1.20 g, 7.18 mmol) at 0 °C under an inert atmosphere (Ar). The 
mixture was stirred at 0 °C for 1 h, and the excess of PBr3  was removed under 
reduced pressure. The residue was dissolved in toluene (50 mL), and the organic 
solution, washed with a 1 M NaHCO3 aqueous solution. The organic extract was 
evaporated, and the resulting oily residue was precipitated by addition of diethyl 
ether to give 1.09 g of product (92%) as a pale yellow solid. Anal. Calcd for 
C8H8BrNO2:. FAB-MS (m/z(%BPI)): 22.973(100) [M + 1]+.δH(solvent CDCl3, 295 K, 
300 MHz): 8.09 (d, 1H, py, 3J = 7.6 Hz); 7.90 (t, 1H, py); 7.75 (d, 1H, py,3J = 7.6 
Hz); 4.59 (s, 2H, -CH2-); 3.94 (s, 3H, -OCH3). δC (solvent CDCl3, 295 K, 75.5 
MHz): 33.1 (primary C); 53.1 (secondary C); 138.2, 127.1, 124.4 (tertiary C); 
165.3, 157.4, 147.6 (quaternary C). IR: 1738 ν(C═O), 1581 ν(C═N)py cm−1.  
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c. N,N′-Bis[(6-methoxycarbonyl-2-pyridyl)methyl]-1,7-diaza-12-
crown-4(3).   
6-Bromomethyl-pyridine-2-carboxylic Acid Methyl Ester (2.000 g, 10.78 mmol) and 
Na2CO3 (3.400 g, 32.08 mmol) were added to a solution of 1,7-diaza-12-crown-4 (0.946 g, 
5.43 mmol) in acetonitrile (75 mL). The mixture was heated to reflux with stirring for a 
period of 24 h, and then the excess of Na2CO3 was filtered off. The filtrate was 
concentrated to dryness, and the yellow residue partitioned between equal volumes (200 
mL) of H2O and CH2Cl2. The organic phase was separated, dried over MgSO4, filtered, 
and evaporated to dryness. Addition of hexane gave 1.922 g of 3 (75%) as a pale yellow 
solid. Anal. Calcd for C24H32N4O6: C, 61.0; H, 6.8; N, 11.8%. Found: C, 60.4; H, 6.7; N, 
11.5%. δH (solvent CDCl3, 295 K, 300 MHz): 8.09 (d, 2H, py, 3J = 8.6 Hz); 8.01 (d, 2H, 
py,3J = 7.6 Hz); 7.82 (t, 2H, py); 4.00 (s, 6H, -OCH3); 3.97 (s, 4H, -CH2-); 3.63 (t,3J = 4.6 
Hz 8H, -CH2-); 2.83 (m, 8H, -CH2-). δC (solvent CDCl3, 295 K, 75.5 MHz): 52.9 (primary 
C); 55.3, 62.2, 69.5 (secondary C); 123.5, 126.3, 137.3 (tertiary C); 147.1, 161.4, 165.9 
(quaternary C). IR: 1709 ν(C═O), 1589 ν(C═N)pycm−1. FAB-MS (m/z(%BPI)): 473(100) 
[M + H]+. 
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d. N,N′-Bis[(6-carboxy-2-pyridyl)methyl]-1,7-diaza-12-crown-4 
(H2bp12c4·4HCl).   
A solution of compound N,N′-Bis[(6-methoxycarbonyl-2-pyridyl)methyl]-1,7-diaza-12-
crown-4 (3) (1.000 g, 2.12 mmol) in 6 M HCl (10 mL) was heated to reflux for 12 h. After 
cooling to room temperature the white solid formed was collected by filtration to give 1.044 
g (81%) of the desired product. Anal. Calcd for C22H28N4O6·4HCl·H2O: C, 43.4; H, 5.6; N, 
9.2%. Found: C, 43.4; H, 6.4; N, 9.1%. δH (solvent D2O, 295 K, 300 MHz, pD = 8.0): 7.98 
(t, 2H, py); 7.89 (d, 2H, py, 3J = 7.7 Hz); 7.65 (d, 2H, py, 3J = 7.6 Hz); 4.07 (s, 4H, -CH2-); 
3.55 (t, 3J = 4.6 Hz, 8H, -CH2-); 3.02 (t, 3J = 4.6 Hz, 8H, -CH2-). δC (solvent D2O, 295 K, 
75.5 MHz, pD = 8.0): 55.4, 62.8, 68.3 (secondary C); 140.3, 128.7, 124.9 (tertiary C); 
174.6, 156.1, 155.1 (quaternary C). IR: 1697 ν(C═O), 1592 ν(C═N)py cm−1. FAB-MS 
(m/z(%BPI)): 445(100) [H3bp12c4]+. 
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e. Methyl 6-(2-vinyl)picolinate.  To a flask containing methyl-6-
bromoprydine-2-carboxylate (12.0g) (55.6mmol) dissolved in freshly distilled DMF 
(125ml) was dry loaded tetrakis(triphenylphosphine) palladium(0) (3.21g) 
(2.78mmol) under positive argon. To the reaction mixture was added tributyl(vinyl) 
tin (16.23ml) (55.6mmol) via syringe and then the reaction mixture was stirred at 
90 °C for 24 h. The reaction mixture was cooled to r.t. and extracted by adding 
EtOAc (250mL) and washing with DI water (3x125mL) to remove DMF. The 
aqueous portions were added together and extracted with EtOAc (3x250mL).  
The organic layers were combined and dried over anhydrous Na2SO4 and the 
solvent was removed by rotovap. Pure methyl 6-(2-vinyl)picolinate was obtained 
via silica column with 20% ethyl acetate/hexane as the eluent giving the desired 
product (7.33g) (81% yield) as a pale yellow oil. 1H NMR (300MHz, CDCl3) δ 7.86 
(d, 1H, J = 9.0), 7.67 (t, 1H, J = 9.0), 7.47 (d, 1H, J = 9.0), 6.81 (dd, 1H, J = 12, 
18), 6.10 (d, 1H, J = 18), 5.45 (d, 1H J = 12), 4.00 (s, 3H) 
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f. Methyl 6-(2-hydroxyethyl)picolinate. To a flask containing 
methyl 6-(2-vinyl)picolinate (1.00g, 6.13mmol) dissolved in freshly distilled THF 
(20ml) was added BH3·S(Me)2 (6.44mL, 2M solution in THF, 12.9mmol) at 0°C via 
syringe. This was allowed to warm to r.t. while stirring for 2 h. The reaction flask 
was then cooled to 0°C and removed from positive argon. NaBO3·4H2O (4.72g, 
30.6mmol) and DI water (1ml) were added and the reaction mixture was warmed 
to r.t. and allowed to mix overnight. THF was removed under reduced pressure by 
rotovap. EtOAc (100ml) was added and the solution was washed with DI water 
(100ml) and the wash was extracted with ethyl acetate (3x100ml). The organic 
layers were combined and dried over anhydrous Na2SO4 and the solvent was 
removed by rotovap. The crude mixture was purified by silica column with 45, 65, 
100% EtOAc/hexane as the eluent giving the desired product (223mg) (20% yield) 
as a cloudy yellowing oil. 1H NMR (300MHz, CDCl3) δ 7.97 (d, 1H, J = 6.0), 7.76 (t, 
1H, J = 7.5), 7.38 (d, 1H, J = 9.0), 4.04 (t, 2H, J = 4.5), 3.96 (s, 3H), 3.09 (t, 2H, J 
= 4.5) 
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g. Methyl 6-(2-chloroethyl)picolinate.   To a dry round bottom 
flask containing methyl 6-(2-hydroxyethyl)picolinate (500mg, 2.76mmol) dissolved 
in distilled dichloromethane (25ml) was added SOCl2 (242µL, 3.31mmol) at 0°C 
via syringe. The reaction mixture was warmed to r.t. and stirred for 3 h. The 
solution was washed with DI water (50mL) and extracted with dichloromethane 
(3x50mL), giving pure methyl 6-(2-chloroethyl)picolinate (545mg) (99% yield). 1H 
NMR (300MHz, CDCl3) δ 8.04 (d, 1H, J = 9.0), 7.80 (t, 1H, J = 7.5), 7.43 (d, 1H, J 
= 6.0), 4.01 (s, 3H), 3.95 (t, 2H, J = 6.0), 3.35 (t, 2H, J = 7.5) 
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h. 2-Pyridinecarboxylic acid, 6,6'-[(1,4,10,13-tetraoxa-7,16-
diazacyclooctadecane-7,16-diyl)bis(ethylene)]bis-, 2,2'-dimethyl ester. To a 
dry two neck flask equipped with condenser and stir bar was dry loaded 1,4,10,13-
Tetraoxa-7,16-diazacyclooctadecane (178mg, 0.564mmol) and Na2CO3 (398mg, 
3.76) while under positive N2. To this was added methyl 6-(2-chloroethyl)picolinate 
(250mg, 1.25mmol) dissolved in anhydrous acetonitrile (2mL) via syringe. The 
reaction mixture was then heated to 90 °C and stirred overnight. The reaction 
mixture was cooled to r.t. and passed through a celite plug and the acetonitrile 
was removed by rotovap. The crude mixture was purified via neutral alumina 
column (0, 2, 10% MeOH/EtOAc) giving pure 2-Pyridinecarboxylic acid, 6,6'-[(1,4,
10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(ethylene)]bis-, 2,2'-
dimethyl ester (79mg) (20% yield).1H NMR (300MHz, CDCl3) δ 7.92 (d, 1H, J = 
6.0), 7.70 (t, 1H, J = 7.5), 7.39 (d, 1H, J = 9.0), 3.96 (s, 3H), 3.53 (t, 16H), 3.02 (t, 
2H, J = 6.6), 2.91 (t, 2H, J = 6.6), 2.80 (t, 8H, J = 6.0) 13C NMR (75 MHz, CDCl3): 
δ 165.97, 161.31, 147.44, 136.97, 126.92, 122.74, 70.66, 69.91, 55.51, 53.90, 
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52.92, 36.03  MS (DUIS): Calculated (m/z) for C30H45N4O8 (M+H)+ : 589.32, Found 
598.7.  
 
i. 6,6'-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-
diyl)bis(ethane-2,1-diyl))dipicolinic acid.  To a round bottom flask containing 2-
Pyridinecarboxylic acid, 6,6'-[(1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-
diyl)bis(ethylene)]bis-, 2,2'-dimethyl ester (150mg, 0.255mmol) was added 6M HCl 
(2mL) and refluxed overnight. The reaction mixture was cooled to r.t. and 
crystalized by the slow addition of MeOH, THF then acetone with intermideeate 
cooling to -78 °C . Giving pure 2-Pyridinecarboxylic acid, 6,6'-[(1,4,10,13-tetraoxa-
7,16-diazacyclooctadecane-7,16-diyl)bis(ethylene)]bis (28mg) (20% yield) as a 
white powdery solid. 1H NMR (300MHz, CDCl3) δ 8.12-8.09 (comp, 4H), 7.71 
(comp, 2H), 4.00 (comp, 8H), 3.81-3.68 (comp, 16H), 3.45 (comp, 4H), 3.33 (t, 4H)   
MS (DUIS): Calculated (m/z) for C28H41N4O8 (M+H)+ : 561.29, Found 561.7.  
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PART III:  DESIGNING STRONG CHIRAL BRØNSTED ACIDS AND THEIR 
APPLICATION FOR OXAZINANONES DERIVATIZATION AND THE AZA-
HENRY REACTION 
 
Overview: 
An essential challenge of organic chemistry is the future development and 
synthesis of complex organic molecules.   The addition of useful functional 
groups in a short, concise and cheap fashion is vital in synthesizing these types 
of molecules.   There is an overwhelming need for these types of reactions that 
install numerous functionalities, in few synthetic steps and with high selectivity 
and yield.  Carbon-carbon(C-C) bond formation is the framework of synthesizing 
any advanced molecule/drug candidate.   C-C bond formation allows for the 
transformation of cheap starting material into expensive/important organic 
compounds.  In the last decade, much effort has been devoted to organocatalytic 
C-C bond forming reactions.  The work in this chapter focuses on the first 
BrØnsted acid catalyzed carbon-carbon bond formation by an unprecedented 
tandem Mannich reaction.  In the presence of a simple, achiral BrØnsted acid, 
tetrafluroboric acid or trifllc acid, catalyze N-tert-butoxycarbonl (N-Boc)-imines to 
yield cyclic 1, 3-oxazinan-2-ones in very good yields.  Following the achiral 
reactions, we then turn to devolping a chiral BrØnsted acid reaction that is used 
in place of tetrafluroboric acid or trifllc acid. 
 
 
 
169 
 
 
3.1 Introduction 
The Mannich reaction is a classic method for the synthesis of β-amino 
carbonyl compounds which makes it very attractive in complex molecule 
formation development which is why it is such an important carbon-carbon bond 
formation reaction in organic synthesis.  The imagination of chemist’s has long 
been motivated by this reaction’s flexibility and capability to generate both 
functional and structural diversity compounds.  For example, the Mannich 
reaction has been used for many decades in natural product synthesis and in 
medicinal chemistry derivatization.   
Chiral nitrogen-containing compounds form an enormous group in 
biologically active natural products.1 These nitrogen-containing units play a key 
role in biologically active molecules to provide binding sites. Imines are an 
important class of starting materials and play a key role in synthesizing various 
nitrogen-containing biologically active target molecules. 
Nucleophilic addition to imines also provides an easy route to a vast array 
of nitrogen-containing biologically active compounds (Figure 3.1). Without  
 
. 
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Figure 3.1: Imine provides a vast array of nitrogen containing compounds 
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additional enantiocontrol elements, the obtained product would be racemic since 
the nucleophile will have equal opportunity to attack from either the re or si face 
of the prochiral substrate. Traditionally, the control elements are attached to the 
imines as one or more substituents, or as the attacking nucleophiles. This 
requires pre-existing stereochemistry or a chiral auxiliary. In the former case, the 
stereochemical outcome is hard to control; and, in the later case, the chiral 
auxiliary has to be removed after the initial reaction has been performed. In any 
case, the enantiocontrol element must be used in a stoichiometric (1eqv.) 
amount for efficient induction. Catalysis can be applied to avoid wasteful 
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stoichiometric amounts. The development of efficient chiral catalysts in recent 
years has revolutionized the way in which chiral compounds are made. 
Imines are less electrophilic compared to carbonyl compounds. One or 
more α-hydrogen containing imines are more susceptible to deprotonation and 
side reactions (such as tautomerization to enamines). The electrophilicity of an 
imine can be enhanced by using an activating group that can coordinate to the 
nitrogen atom, typically a Lewis acid. Unfortunately, the nitrogen containing imine 
and its product after nucleophilic addition reaction can also strongly bind to the 
activator. Therefore, the catalytic process is difficult to achieve. Predicting and 
controlling stereochemistry of the reaction of imines are also difficult due to the 
presence of both syn- and anti-isomers, which may be present in equilibrium. 
The catalytic asymmetric addition to C=N is in an early stage even though it has 
great potential in organic synthesis. These difficulties and potentials have 
attracted a variety of research groups in recent years. As a result, a significant 
amount of advancement has been witnessed in this area. Many of the successful 
methods involve transition metal catalysis and organocatalysis.2 The most 
effective catalysts almost always operate in a multifunctional mode. They usually 
bind with both the imine substrate and the nucleophile, although not necessarily 
at the same center; and are arranged such a way that they can interact only in a 
very specific fashion, thereby not only reducing the activation energy, but also 
providing the desired enatioselectivity – as in much the same way enzymes 
catalyze chemical reactions. 
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3.1  Aza-Henry Reaction 
 Continuous growth in high-throughput screening for enantiomerically pure 
biologically active agents has increased the demand for the development of 
enantioselective synthetic methods that can provide exceptional stereoselectivity. 
Organic compounds containing vicinal nitrogenated functionalities are receiving 
ever-increasing attention by synthetic organic chemists because of this growing 
need. The nucleophilic additions of nitroalkanes to imines using aza-Henry or 
nitro-Mannich reactions are a powerful transformation that can generate the 
carbon-carbon bond with simultaneous generation of two vicinal stereogenic 
centers bearing both nitro and amino functional groups.3,4,5,6 
The first catalytic aza-Henry reaction was reported by Shibasaki in 1999 
following their successful introduction of a catalyst for the imine class of 
compounds involving the analogous nitro-aldol reaction (Equation 1).7 The 
reaction of nitromethane and N-phosphinoyl benzaldimine was catalyzed by a 
hetero-bimetallic complex (1) prepared in situ from Yb(OiPr)3, KOtBu, and 
binaphthol in a 1:1:3 molar ratio. Slow addition of excess nitromethane to the 
imines, and the use of non-polar solvents (toluene/THF 7/1) at low temperature (-
40oC) and high catalyst loading (20 mol%) were essential to ensure good yield 
and %ee. This catalyst prepared from (R)-binaphthol produced the nitroamine 
product with an (R)-stereoconfigeration at the newly formed stereogenic center.  
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Equation 3.1: First catalytic aza-Henry reaction reported by Shibasaki. 
Ph N
Ph2
P
O
+ CH3NO2
Catalyst (20 mol%)
toluene/THF (7/1)
-40oC, 60h
Ph N
H
Ph2
P
O
NO2
79% yield, 91% ee
O O
OO
Yb
O O
OO
Yb
O O
OO
YbK K KK
1 (YbPB)
 
 Shibasaki et. al. later reported that an (R)-ALB-KOtBu combination was a 
more effective catalyst for nitro compounds other than nitromethane (Equation 
3.2).8 The ee range was, however, not quite as impressive (60-83%). It was 
found that the diastereoselectivity of the reaction could therefore be controlled by 
choosing an appropriate solvent. In CH2Cl2, formation of the anti-isomer was 
favored over the syn-isomer by ratios ranging from 75:25 – 88:12. The catalyst 
prepared from (R)-binaphthol provided the nitroamine product with a (1R, 2S)-
configeration. The (R)-ALB catalyst (2) alone did not promote the reaction at low 
temperature, while at room temperature, only racemic product was formed in 
good yield. An example of a two-step transformation to optically active 1,2-
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diamine is presented in Equation 3.3. The methodology has been applied to the 
synthesis of the substance-P antagonist, CP-99994. 
 
Equation 3.2: Shibasaki’s (R)-ALB-KOtBu catalyst for asymmetric aza-Henry 
reaction. 
Ar N
Ph2
P
O
+
Catalyst (10-20 mol%)
KOtBu (9-18 mol%)
CH2Cl2, -40oC, 48h
Ar
NH
Ph2P
O
NO2
R
NO2
R
Ar = Ph, 4-MeOC6H4, 4-CH3C6H4, 4-ClC6H4; R = Me, Et, (CH2)2OBn
yield = 68 - 98%, ant i:syn = 3:1 - 7:1; ee (ant i) = 60 - 83%
O
O O
O
Al
Li
(R)-ALB
2  
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Equation 3.3: Synthesis of CP-99994 antagonist using asymmetric aza-Henry 
reaction.
Ph N
Ph2
P
O
+
(S)-ALB-KO tBu (20 mol%)
CH2Cl2, -40oC
Ph
NH
Ph2P
O
NO2O2N
OTBS
OTBS
90% yield
anti:syn = 86:14
77% ee (anti)
HN
NH
MeO
Ph
CP-99994   
 
 
Jørgensen later used Cu-bisoxazoline complexes as catalysts for addition 
of silyl notronates to an imine of glyoxalic ester (Equation 3.4).9 In this case even 
N-PMP imine could be a good substrate due to the more electrophilic nature of 
glyoxylic imines compared to benzaldimines, and the additional coordinating 
ability of the CO2Et group to the catalyst. The catalysts prepared from CuPF6 or 
Cu(SbF6)2 and (4R,5S)-DiPhBOX ligand (3a) were found to be the best, providing 
almost or over 90% ee of silylnitronates derived from 1-nitropropane, 1-
nitropentane and 2-phenylnitroethane. For silylnitronate of nitroethane, (S,S)-
PhBOX ligand (3b) gave better results. In accordance to previous works,3,8 
formation of the anti-products is favored up to 97:3 diastereoselectivity. A similar 
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Cu-(R,R)-PhBOX (3c) catalyst in the combination with a catalytic amount of 
triethylamine allowed direct nitro-Mannich reaction of unmodified nitroalkanes 
and glyoxalic imines (Equation 3.5).10 The reaction could be performed in CH2Cl2 
under ambient condition without the requirement of dry  
 
Equation 3.4: Cu-(R,S)-bisoxazoline complex catalyzed aza-Henry reaction. 
TMSO
N
R
PMP
N
CO2Et
O
+
CuXn-(4R,5S)-3a or
(S,S)-3b (20 mol%)
CH2Cl2, -100oC
NO2
R
NH
EtO2C
PMP
or
NO2
R
NH
EtO2C
PMP
N
OO
N
Ph
Ph Ph
Ph
(4R,5S)-3a
Xn = ClO4, PF6, (OTf)2, (SbF6)2
R = Me, Et, nC5H11, PhCH2; Yield 67 - 94%
ant i:syn = 83:17 - 97:3
ee (ant i) = 83 - >98%
From 3a From 3b
 
 
or inert atmosphere. The same set of nitroalkanes gave very good ee (74-99%) 
and diastereoselectivity (anti:syn > 90:10 for nitroalkanes with α-substituents 
larger than methyl group) (Equation 5). Nitroethane gave only 70:30 selectivity 
and phnylnitromethane gave almost 50:50 diastereomeric mixture, probably due 
to Et3N assisted equilibrium. Nitroethanol and ethylnitroacetate gave the products 
with lower enantioselectivity than unfunctionalized nitroalkanes. Yet ee of 70% 
was obtained with nitroethanol. A model was proposed to explain the selectivity. 
Reduction of nitro group with Raney Ni followed by oxidative deprotection of the 
PMP group by ceric ammonium nitrate (CAN) provided a convenient route to α,β-
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diamino acid. A similar bis(oxazoline)-Cu(II) complex conveniently grafted onto a 
mesoporous silica provided comparable enantioselectivities and even higher 
diastereoselectivities than the unsupported catalyst under similar conditions.11  
 
Equation 3.5: Cu-(R,R)-bisoxazoline complex catalyzed asymmetric aza-Henry 
reaction. 
PMP
N
CO2Et
Cu(OTf)2-(R,R)-3c
(10-20 mol%)
Et3N (10-20 mol%)
CH2Cl2, 0
oC, rt
NO2
R
NH
EtO2C
PMP
R = Me, Et, nC5H11, PhCH2,Ph; Yield 38 - 81%
anti :syn = 55:45 - 95:5
ee (anti) = 74 - 99%;ee (syn) = 77 - 98%
+
R
O2N
 
 
A protocol for the enantioselective nitro-Mannich coupling between alkyl, aryl, 
and heterocyclic p-methoxybenzylimines and trimethylsilylnitropropanate 
catalyzed by a chiral tBu-BOX Cu(II) catalyst is reported by Anderson et. al.12 It 
uses the lowest reported loading of commercially available metal catalyst and 
chiral ligand, and gives the highest yields and selectivities for a broad substrate 
range including nonaromatic aldimines. The resultant nitroamines are obtained in 
70-94% enantiomeric excess in good yield and can be readily reduced to 
synthetically useful 1,2-diamines. 
Recently metal-free organocatalysts were reported to catalyze asymmetric 
aza-Henry reaction. A structurally simple thiourea derivative from 1,2-
diaminocyclohexane was prepared by Takemoto and was found to be the 
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effective organocatalyst for the reaction between nitormethane and imines.13 The 
catalyst was designed with a hypothesis that the nitro compound would bind to 
the urea by hydrogen bonding, and its proton would be abstracted by the vicinal 
tertiary amine to create a chiral nitronate complex, which could add to imine with 
high selectivity (Equation 6). Indeed a range of N-phosphinoylaldimines lacking 
α-hydrogens was good substrates providing ee in the range of 63-76% (Equation 
3.7). Nitroethane could also be the source of nitronate although the 
diastereoselectivity and enantioselectivity were not quite satisfactory (73:27 and 
67%). The reaction worked best in nonpolar solvents and the presence of an 
amino group in the vicinity of the urea function was essential for the catalytic 
activity. It should also be noted that N-tosylimine gave almost racemic product 
and N-phenylimine was unreactive, therefore, phosphinoyl group must play some 
important role in determining the enantioselectivity. 
 
 
Equation 3.6: Mechanism for the formation of chiral nitronate complex. 
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Equation 3.7: Asymmetric aza-Henry reaction using thiourea derivative as a 
catalyst. 
N
Ar H
PPh2
O
+ CH3NO2
4 (10 mol%)
CH2Cl2, rt HN
Ar
PPh2
O
NO2
F3C
CF3
H
N
H
N
S
NMe2
4
Ar = Ph, substituted phenyl, 2-naphthyl, cinnamyl, heteroaryl
Yield =57-87%; ee = 63-76%
 
 
 
A chiral bis-amidinium salt (5) found to catalyze the enantioselective aza-
Henry reaction between N-Boc-benzaldimines and nitroalkanes (Equation 3.8).14 
Addition of nitromethane and nitroethane provided the β-nitro-N-Boc-amines in 
moderate yield and a fairly good to excellent enantiocontrol. In addition, a good 
diastereocontrol was observed for addition of nitroethane, with the anti-isomer 
being favored (anti:syn = 88 : 12 – 95 : 5).  
Further improvement was attained by modification of bulkiness of chiral 
bis-amidinium salt (6).15 The new bulkier catalyst (6) helps to achieve better 
selectivity than the previous catalyst (5) (Equation 3.9).  
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Equation 3.8: Asymmetric aza-Henry reaction catalyzed by chiral bis-amidinium 
salt. 
N
Ar H
Boc +
5 (10 mol%)
-20oC
HN
Ar
Boc
NO2
Ar = Ph, 2-, 3-, and 4-NO2C6H4, 4-CF3C6H4, 4-ClC6H4, 4-CF3OC6H4;
R = H, Me; Yield = 50 - 69%; ant i:syn = 88:12 - 95:5; ee = 60 - 95%
NO2
R R
N
NN
N H
H
H
H
H OTf
5  
 
Equation 3.9: Bulkier chiral bis-amidinium salt catalyzed asymmetric aza-Henry 
reaction. 
 
N
H
N
H
NN H
HH
OTf
H
N
BOC
NO2
CO2tBu
+
Cl
N
BOC
Cl
H
NO2
CO2tBu
6
Catalyst dr(a) dr(b) %ee(b) yield
5 1:2 1:2 84 80
6 5:1 5:1 95 88
N
BOC
Cl
H
NH2
CO2tBu
5% catalyst,
toluene, -78oC
NaBH4, CoCl2
 
 
181 
 
 
Rueping and co-workers have reported the development of chiral 
Brønsted-acid-catalysed diastereo- and enantioselective nitro-Mannich reactions 
between α-imino esters and diverse nitroalkanes, providing valuable β-nitro-α-
amino esters (Equation 3.10).16 The authors postulated a plausible reaction 
mechanism in which they assume that the chiral Brønsted acid 10 plays a 
bifunctional role. On the one hand, the α-imino ester would be activated by 
protonation, resulting in the formation of the chiral ion pair. It can be assumed 
that the adjustment of the nitroalkane/nitronate equilibrium should also be 
accelerated by 10.  
 
Equation 3.10: Scope of aza-Henry reaction catalyzed by chiral phosphoric acid. 
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3.2  Brønsted Acids for Organic Reactions 
 The cyclopentadienyl dicarbonyl iron Lewis acid, [(η5-
C5H5)Fe+(CO)2(THF)]BF4-, 11 (Figure 3.2), has been found by the Hossain group 
to catalyze a variety of organic reactions including cyclopropanation,17 
aziridination,18 and Diels-Alder reactions.19 Recently Hossain group reported the 
synthesis of 3-hydroxy-2-arylacrylic acid ethyl esters (3-hydroxyacrylates) along 
with 3-oxo-3-arylpropanoic acid ethyl esters (β-keto esters) from aromatic 
aldehydes and ethyl diazoacetate (EDA) catalyzed by 11 (Equation 3.11).20 The 
potential wide scope of this reaction encouraged further investigation of the 
reaction and catalyst. This endeavor led to the exploration of the catalytic activity 
of HBF4.Et2O.21 which proved to be a unique Brønsted acid to perform this 
reaction. 
 
Figure 3.2: Cyclopentadienyl dicarbonyl iron Lewis acid is also known as 
Hossain’s catalyst. 
Fe
O
C
CO
O
BF4
+
11  
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Equation 3.11: 3-Hydroxyacrylate formation from an aldehyde and ethyl 
diazoacetate (EDA). 
COOEt
OHH
CHO
CH2Cl2
R R
11 or HBF4+ N2CHCOOEt
arylaldehdyes 3-hydroxypropenoicacid esters(EDA)  
 
There are numerous examples of use of HBF4 and its complexes as a 
strong Brønsted acid catalyst.22 HBF4.Et2O in particular works as a catalyst for 
cyclopropanation (Equation 3.12)23, hemiacetal formation (Equation 3.13)24 and  
 
Equation 3.12: Brønsted acid catalyzed cyclopropanation reaction. 
H
O
+ N2CHCOOEt
10 % HBF4.Et2O
Solvent
COOEt
O
H
Ethyl-2-formylcyclopropanecarboxylate
 
 
Equation 3.13: Brønsted acid catalyzed hemiacetal formation reaction. 
CHO
CH2Cl2, 0oCOH O
COOEt
OH
HBF4.Et2O (10 mol%)
EDA
14 h Hemiacetal  
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aziridination (Equation 3.14). These findings opened the possibility of developing 
a new metal-free chiral Brønsted acid catalyst. The present research presents 
the development of a completely new metal-free chiral Brønsted acid catalyst 
and its application to the asymmetric aza-Henry reaction (Equation 3.15).5,25 
 
Equation 3.14: Brønsted acid catalyzed aziridination reaction. 
Ar
N
H CO2Et
N2
Ar
N
CO2Et
(1.2 equiv)
HBF4.Et2O (0.1 equiv)
CH2Cl2, -78oC  
 
Equation 3.15: Brønsted acid catalyzed aza-Henry reaction. 
Ph H
N
Ph
CH3O2N Ph
NO2
NH
Ph
+
HBF4.Et2O (10 mol%)
RT  
 
3.2.1  Designing Chiral Brønsted Acids for Organic Reactions 
The concept of Brønsted acid has been known for long time. The quest to 
understand the nature and use of Brønsted acids is continuously growing, but 
manipulations and tailoring of different Brønsted acids to the needs of different 
asymmetric reactions are new. Lewis acids are convenient to tune by changing 
the electron donating and withdrawing groups bound to the metal center. Steric 
features of a Lewis acid can also be tuned by designing the steric environment of 
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the ligands precisely. On the other hand, it is very hard to control the steric 
feature and hydrogen donating ability of a small Brønsted acid.  
By definition, the strength of a Brønsted acid depands on the capability of 
its proton donation. This implies that the stronger the acid, the easier it is to 
remove the hydrogen from the loosely bound anionic part. Since hydrogen is a 
very small cation, controlling acid strength has always been a challenge to the 
chemists. At the same time adding a steric directional feature to generate a chiral 
Brønsted acid has increased the challenge while this idea has been very 
attractive. To get an idea of relative acidity of different acids, a table of pKa 
values for different Brønsted acids is presented in Table 3.1.  
 
Table 3.1: Published pKa values for different Brønsted acids26,27,28 
 
Substrate pKa 
 In water In DMSO 
H2O 15.7 32 
H3O -1.7  
HBF4 -5  
H2SO3 1.9, 7.21  
H2SO4 -3.0, 1.99  
H3PO4 2.12, 7.21, 12.32  
PhOH  18.0 
PhSH  10.3 
PhSeH  7.1 
S
O
H
 
-1.8  
Ph
S
O
OH  
2.1  
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Me
S
O
OH
O
 
-2.6  
Me
S
O
Me
O
 
 31.1 
Me
S
O
CF3
O
 
 18.8 
Et
S
O
Et
O
 
 32.8 
Me
S
OO
 
 22.3 
Ph
S
CH2Ph
Me
 
 16.3 
Me3S+=O  18.2 
 
In recent years there has been a developing need of organo-catalysts in 
the competitive pharmaceutical industry and food industry because of residual 
metal contamination from organometallic catalysts. This phenomenon is reflected 
in the increase in the number of research publications in this area (Figure 3.3).29 
This new trend in the area of chiral Brønsted acids is helping to meet the 
increasing need of organocatalyst (Figure 3.4). Recently, the Hossain group 
found the Brønsted acid (HBF4) to possess catalytic activity that is comparable to 
the Iron Lewis acid 11 in the same reactions.21 With these findings our aim is to 
develop an efficient chiral Brønsted acid or chiral Brønsted acid-containing 
complex as a catalyst for different reactions, namely cyclopropanation (Equation 
3.12),23 hemiacetal formation (Equation 3.13),24 azirdination (Equation 3.14), and 
aza-henry reaction (Equation 3.15).25 It is envisioned that the newly developed 
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catalyst will also be applicable in other acid catalyzed reactions for organic 
synthesis.  
Figure 3.3: Increasing number of publications in recent years in the area of 
organocatalyst. (SciFinder Scholar). 
 
Figure 3.4: Continuous publications about chiral Brønsted acid reflects the 
importance of this area. (SciFinder Scholar). 
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1.2.2  Metal-assisted Chiral Brønsted Acids  
Metal-assisted designer chiral Brønsted acids played an important role in 
the continuing advancement of the chiral Brønsted acids.30,31 Yamamoto et al 
reported the asymmetric Diels-Alder reaction of naphthoquinone derivatives and 
various dienes in the presence of a chiral boron reagent derived from B(OMe)3 
and an (R,R)-(+)-tartaric aciddiamide (Equation 3.16).32 The rate enhancement 
and  
 
Equation 3.16: Asymmetric Diels-Alder reaction using chiral complex of boron 
and (R,R)-(+)-tartaric aciddiamide. 
OH
O
O
N
O
N
O
OHHO
HH
B(OMe)3
(1.2 equiv)
N
O
N
O
OO
HH
B
O
O
O
HH
CH2Cl2
OSiEt3
0oC to RT
23 h
OH
O
O
H
H
OSiEt3
73% yield
92% ee
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high enantioselectivity observed in this reaction was attributed to Brønsted acid 
assisted Lewis acid catalysis.33 Brønsted acid assisted chiral Lewis acid (BLA) 
promotes high selectivity through the dual effects of intramolecular hydrogen-
bonding interactions and the attractive π−π donor-acceptor interactions in the 
transition state (Equation 3.17).34 High enantioselectivity (> 99% ee) and exo-
selectivity (> 99%) are obtained for the cycloaddition in presence of BLA. 
Yamamoto also developed other catalysts that give high selectivity for Diels-
Alder reactions (Scheme 3.1).  
 
 
Equation 3.17: Asymmetric Diels-Alder reaction using chiral complex of boron 
and BINOL. 
Br CHO
Br
CHO
O
O
O
O
B
H
+
BLA 2 (5 mol %)
CH2Cl2, -78oC
99 % yield (exo/endo > 99:1)
99 % ee
12
 
 
 Shibasaki developed a lanthanum-binaphthol (La-BINOL) complex for the 
asymmetric Michael reaction (> 99% ee) with broad generality (Equation 18).35 
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This powdered complex was found to be very stable and reusable. The activity of 
the chiral Lewis acid is increased by the added Brønsted acid. There are 
numerous other examples where a chiral Lewis acid accompanied by Brønsted 
acid give better selectivity and reactivity.36,37 
 
Scheme 3.1: Asymmetric Diels-Alder reactions catalyzed by Brønsted acid 
assisted Lewis acids (BLA). 
O
O
B
O
H
CF3
CF3
O
O
O
O
B
H
Br
CHO
CHO
CHO
>99% ee exo
exo/endo = 90:10
99% ee exo
exo/endo >99:1
95 % ee endo
exo/endo = 3:97
40% ee endo
exo/endo = 9:91
95 % ee endo
exo/endo =10:90
36 % ee endo
exo/endo = 11:89
13
12
 
 Lewis	   acid	   assisted	   Brønsted	   acid	   (LBA), 15 can be generated in situ from 
optically pure BINOL and SnCl4.38 The protonation of silyl enol ether was 
performed by LBA in 97% ee (Equation 3.19). Later LBA was used for the regio 
and stereoselective reactions.39  
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Equation 3.18: Asymmetric Michael reaction catalyzed by lanthanum-binaphthol 
(La-BINOL) complex (14). 
O
O
La
O
O
O
H
(R,R)-La-BINOL (14)
10 mol %
DME, 4oC, 85 h
O
COOBn
COOBn
O
COOBn
COOBn
+
98% yield
> 99% ee
14
 
 
Equation 3.19: Asymmetric BINOL and SnCl4 complex (15) as a catalyst. 
OSiMe3
Ph
O
O
SnCl4
H
H
O
Ph1 equiv. 15
toluene, -78oC, 1 h
100% conversion 97% ee
15
 
 
The planar-chiral pyrrolidinopyridine derivative (16) proved to possess 
high Brønsted acid catalytic activity (Equation 3.20).40 Through a series of kinetic 
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studies it was established that the planer-chiral catalyst functions as a Brønsted 
acid catalyst in the rate-limiting and enantioselectivity-determining step. 
 
Equation 3.20: Planer-chiral pyrrolidinopyridine derivative as an asymmetric 
catalyst through H-transfer mechanism. 
NH
CN O
C
Ar
R
Fe
N
N
N
CN
R
O
Ar
N
CN
R
O
Ar
Fe
N
N
+
80-91% yield
81-98% ee
R = Et, Ar = aryl
16
+ 6-H
rate limiting and
enantioselectivity
determining step
16  
 
3.2.3  Chiral Diol Based Brønsted Acid 
In recent years development of different derivatives of weakly acidic chiral 
BINOL-derived provided great tools for organocatalysis. Schaus and co-workers 
reported the BINOL-derived enantioselective catalyst for Morita-Baylis-Hillman 
process (Equation 3.21).41 The phenolic hydroxyl groups have weak acidity 
(Table 3.1). Thus, this acid catalytic activity may be considered as a borderline 
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case between the hydrogen bond catalysis and chiral Brønsted acid catalysis. 
The reaction yielded 39-88% product with high enantioselectivity (67-96% ee). 
 
Equation 3.21: BINOL catalyzed asymmetric Morita-Baylis-Hillman reaction. 
R
RR
R
OH HO
R1 H
O
O
R1
OH O
+
catalyst (usually 10 mol%)
Et3P, THF, -10
oC
17 R = CH3
18 R = CF3
30-88% yield
34-96% ee
R1= alkyl, alkenyl, aryl 
 
Sasai and co-workers developed a bifunctional BINOL-derived 
organocatalyst (19) for the aza Morita-Baylis-Hillman reaction (Equation 3.22).42 
The 3-pyridyl moiety functiones as a Lewis-basic site and the binaphthol moiety 
as a Brønsted-acidic site. Introduction of the N-isopropyl-N-3-pyridylaminomethyl 
moiety at the 3-position is essential to attain high enantioselectivity. Development 
of catalyst 20 with phosphine ligand improved yield and enantioselectivity of the 
reaction.43 
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Equation 3.22: Asymmetric Morita-Baylis-Hillman reaction with modified BINOL 
at 3-position. 
OH
OH
N
i-Pr N
R
O
+
Ar H
NTs
Catalyst 19 (10 mol%)
Toluene:CPME
-15oC
R
O NHTs
OH
OH
PPh2
19 20
 
 
Dixon and co-workers reported that tetrol (21) catalyzes the addition 
reaction of methyleneaminopyrrolidine to imines, thereby giving rise to R-
aminohydrazone in 17-75% ee (Equation 3.23).44 
Use of enamine as nucleophile resulted in the enamine Mannich reaction 
in which diol 22 shows high catalytic activity (Equation 3.24).45 
 
 
 
 
195 
 
 
Equation 3.23: Tetrol catalyzed addition reaction of methyleneaminopyrrolidine 
to imines. 
OH
OH
Ph Ph
OH
Ph Ph
OH
Ar H
N
Boc
+ N
N
Ar
N
N
NH
Boc
Catalyst 21 (20 mol%)
CDCl3, RT
21
 
 
Equation 3.24: Asymmetric diol catalyzed enamine Mannich reaction. 
OH
OH
Ar1 H
N
Boc
N
O
Ar2
+
1) Catalyst 22 (20 mol%)
Toluene, -30oC, 48 h
2) H3O+ Ar
1
Ar2
NH
Boc
O
45-98% (60-84% ee)
22
 
 
Yamamoto and co-workers reported the nitroso Diels-Alder reaction of 
diene with nitrosobenzene catalyzed by a binaphthol (BINOL) derivative 
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produces bicyclo ketones with excellent enantioselectivities (Equation 3.25).46 
Interestingly, use of morpholino-4,4-dimethylcyclohexene resulted in R-amination 
with excellent enantioselectivity (Equation 3.26). This suggests the involvement 
of a sequential process, namely, the N-nitroso aldol reaction, followed by Michael 
addition. 
 
Equation 3.25: Asymmetric nitroso Diels-Alder reaction catalyzed by BINOL 
derivative. 
OH
OH
Si(m-xylyl)3
Si(m-xylyl)3
N
O
O
N
Ar+
1) Catalyst 23 (30 mol%)
Pentane-CH2Cl2
-78oC, 12-24 h
2) 1N HCl/THF
N
O
O
Ar
52-90% (80-92% ee)
23
 
 
Yamamoto and co-workers designed a Brønsted-acid-assisted chiral 
Brønsted-acid catalyst bearing a bis(triflyl)methyl group 24 (Equation 3.27).47 The 
enantioselective Mannich-type reaction of a ketene silyl acetal with aldimines 
catalyzed by 24 in the presence of a stoichiometric amount of an achiral proton 
source gave (S)-β-amino esters in high yields with good enantiomeric excesses.  
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Equation 3.26: Asymmetric nitroso Diels-Alder reaction followed by Michael 
addition reaction. 
N
O
O
N
Ph+
Catalyst 13 (30 mol%)
Pentane-CH2Cl2
-78oC, 24 h
54% (94% ee)
O
N
OH
Ph
 
 
Equation 3.27: Asymmetric Mannich-type reaction of ketene silyl acetal with 
aldimines. 
OH
Tf
Tf
H
ArN
Ph +
OMe
OSiEt3
Catalyst 24 (10 mol%)
2,6-xylenol (100 mol%)
n-PrCl, -78oC
Ar OMe
O
H
N
Ph
24
 
 
Yamamoto et. al. reported that an enamine reacted with nitrosobenzene 
by means of 25 gives an N-nitroso aldol product (Equation 3.28). In contrast, use 
of glycolic  acid derivative 26 gave an O-nitroso aldol product with high 
enantioselectivity.48 
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Equation 3.28: Asymmetric nitroso aldol reaction. 
N
Ph
N
O
O
O
Ar Ar
OH
OH
ArAr
O
OH
OH
+
Ar = 1-naphthyl
Catalyst 25 (30 mol%)
Toluene, -78oC, 2 h
Catalyst 26 (30 mol%)
Et2O, -78oC, 12 h
O
N
OH
Ph
O
O
NHPh
81% (83% ee)
79% (92% ee)
25a
26
 
 
VAPOL (27)-BH3 found to catalyze the asymmetric aziridination reaction of 
benzhydryl imines with ethyl diazo acetate (EDA).49 This catalyst was prepared 
by treating S-VAPOL with 3 equivalent of BH3-THF complex, heating at 55°C for 
1h to remove the volatiles and then heating the residue at 55 °C for 30 minutes 
under high vacuum. The aziridination reaction yielded very high cis 
diastereoselectivity and up to 99% ee (Equation 3.29). Success of this reaction 
199 
 
 
depends on the purity of the BH3-THF complex used to generate the catalyst. 
This observation led to the development of a new more reliable catalyst system.  
 
Equation 3.29: Asymmetric boron-diol complex catalyzed aziridination reaction. 
R N Ph
PhH
H COOEt
N2
N
COOEt
R
Ph
Ph
Ph N
Ph
H
H
R
COOEt
Ph N
Ph
H
R
H
COOEt
OH
Ph OH
Ph
(S)-VAPOL
Ph
OH
OH
Ph
OH
OH
OH
OH
Ph
Ph
Ph OH
OHPh
(S)-VAPOL/B(OPh)3
(10 mol %)
CH2Cl2, 22oC
+ +
a) R = Ph 77 %, 95 % ee
b) R = p-BrPh 91 %, 98 % ee
c) R = n-Pr 54 %, 91 % ee
d) R = t-Bu 78 %, 91 % ee
(S)-VANOL
(S)-BINOL
(S)-BANOL (S)-Ph-VAPOL
27 28
29
30 31  
 
200 
 
 
Among different borate systems, B(OPh)3 was found to form a better catalytic 
system. Further optimization was done by making the catalyst from B(OPh)3 and 
VAPOL (27) or VANOL (28).50 Other ligand systems such as BINOL (29) or 
BANOL (30) were not found to be as efficient as VAPOL (27) or VANOL (28). 
The antibiotic (-)-choramphenicol has been synthesized in only four steps from p-
nitro-benzaldehyde in optically pure form from an asymmetric catalytic 
aziridination reaction with a chiral catalyst prepared from B(OPh)3 and the (R)-
VAPOL (27) ligand. 51 Catalysts generated from the VAPOL (27) and VANOL 
(28) ligands give much higher asymmetric induction than do catalysts prepared 
from 6,6’-diphenyl-VAPOL (31), BINOL (29), and BANOL (30) ligands. 
 Rawal et. al. used TADDOL (32) as a catalyst for Diels-Alder reactions of 
aminosiloxydienes and substituted acroleins to afford the products in good yields 
and high enantioselectivities (up to 92% ee) (Equation 3.30).52 The credit of 
these remarkable reactions were assigned to hydrogen bonding. The gross 
structure of the TADDOL (32) has been found to have a profound influence on 
both the rate and the enantioselectivity of the cycloadditions. 
 
3.2.4  Chiral Phosphoric Acids 
 Chiral phosphoric acid (33) is already known as a ligand system in 
different organometallic reactions.53 Akiyama et. al.54 (Equation 3.31) and Terada 
et. al.55 (Equation 3.32) independently developed the most popular use of chiral 
phosphoric acid and their different derivatives as chiral Brønsted acid catalysts. 
201 
 
 
Chiral phosphoric acids claimed enormous attention after these phenomenal 
discoveries (Figure 3.5 and Figure 3.6). 56,57  
 
Equation 3.30: TADDOL catalyzed asymmetric Diels-Alder reaction. 
TBSO
N
CHO
+
O
O OH
OH
Ar Ar
Ar Ar
32a Ar = 1-naphthyl
32b Ar = phenyl
32c Ar = 2-naphthyl
PhCH3, -80
oC, 2 day CHO
N
TBSO
OH
O
1) LiAlH4, Et2O
-78oC to rt, 2h
2) HF/CH3CN
0oC to rt, 0.5h
Catalyst
 
Figure 3.5: Increasing importance of chiral phosphoric acid is revealed by the 
number of increasing publications in this area. (SciFinder Scholar). 
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Figure 3.6: Representative derivatives of chiral BINOL-phosphoric acids. 
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O
OH
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O
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O
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O
O
P
O
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Cl
Cl
O
O
P
O
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P
O
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P
O
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3.2.4.1 Mannich-type Reaction 
Akiyama et al used chiral phosphoric acid as an efficient catalyst for 
Mannich-type reactions (Equation 3.31).54,58 Theoretical studies found that the 
two-point hydrogen bonding interaction makes the dicoordination pathway 
overwhelmingly favored over the monocoordination pathway in the Mannich-type 
reaction (Scheme 3.2, Figure 3.7 and Figure 3.8).59 The reaction proceeds 
through the protonation followed by the nucleophilic attack via zwitterionic and 
nine-membered cyclic transition state (TS). The intriguing issue of the re-facial 
selectivity was also well rationalized. The two-point hydrogen-bonding moiety 
and aromatic stacking interaction between the 4-nitrophenyl group and N-aryl 
group are significantly important to fix the geometry of aldimine on the 
zwitterionic TS. The si-facial attacking TS is structurally less favored than the re-
facial alternative due to repulsive interaction of the 3,3’-aryl substituents. 
 
Equation 3.31: Chiral phosphoric acid catalyzed asymmetric Mannich-type 
reaction. 
N
Ph
HO
OTMS
OMe+
33 (30 mol%)
Toluene
-78oC
OH
NH
Ph
O
OMe
33a 57% yield, 0% ee
33b 100% yield, 27% ee
33c 96% yield, 87% ee   
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Scheme 3.2: Proposed reaction mechanism of the Mannich-Type reaction with 
chiral Phosphoric acid catalysts. 
O
N
Ar
H
H
O
O
P
O
O
*
Me3SiO OMe
OH
NH
Ar
O
SiMe3
OMe
O
O
P
O
O
*
O
NH
Ar
O
OMe
O
O
P
O
O
*
H
SiMe3
OH
O
P
O
O
*
OSiMe3
NH
Ar
O
OMe
OH
NH
Ar
O
OMe
H3O
+
HO
N
Ar
 
 
Terada et. al. used chiral phosphoric acids for the direct Mannich reaction 
(Equation 3.32).55 Electron withdrawing groups were found to play an important 
role in the reactivity and selectivity of the reactions. The beneficial effects of the 
3,3’-bisaryl substituents of the catalysts on the enantioselectivity are greatly 
appreciated. This process provide an attractive way to construct β-aminoketones 
under extremely mild conditions. The stereochemical course of this reaction was 
established through the synthesis of Boc-(S)-phenylglycine methylester. The 
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transformation thus demonstrated is applicable as a useful method for the 
synthesis of various phenylglycine derivatives. 
 
Figure 3.7: Structures of transition states (TSs) in (a) dicoordination pathway and 
(b) monocoordination pathway. Bond lengths are in Å, and natural charges are 
underlined and bold. 
 
 
Figure 3.8: 3D structures of transition states (TSs) in (a) re-face attack and (b) 
si-face attack. Bond lengths are in Å 
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Equation 3.32: Chiral phosphoric acid catalyzed direct Mannich reaction. 
N
Ar H
Boc
OO
+
33 (2 mol%)
CH2Cl2, RT
Ar
Ac
Ac
NH
Boc
 
 
 The three-component direct Mannich reaction (Equation 3.33) was 
recently reported by Guo et al, wherein H8-BINOL derivatives 34 were employed 
(Figure 3.9).60 A catalytic amount of the chiral phosphoric acid was sufficient to 
promote an  
 
Figure 3.9: Chiral H8-BINOL phosphoric acids. 
O
O
P
O
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O
O
P
O
OH
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O
P
O
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Cl
Cl
O
O
P
O
OH
34a 34b
34c 34d  
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anti-selective direct asymmetric Mannich reaction of cycloketones with high 
diastereo- (anti/syn 98:2) and enantioselectivity (up to 98% ee). Mannich 
reactions between aldimines and aromatic ketones were performed with fairly 
good enantioselectivity (ee). Cyclohexanone derivatives were found to be good 
substrates for this direct Mannich reaction. 
 
Equation 3.33: Asymmetric phosphoric acid catalyzed three-component direct 
Mannich reaction. 
O
HAr
+ PhNH2 +
X
O
X
R
OPhHN
33d (0.5 mol%) or
34b (2 mol%)
toluene, 0oC
 
 
Giere et. al. have shown that vinylketene silyl N,O-acetals (35) readily 
participate in Brønsted acid-catalyzed vinylogous Mukaiyama-Mannich reactions 
with aromatic and heteroaromatic aldimines and furnish δ-amino-α,β-unsaturated 
amides (36) in good yields and enantioselectivities (Equation 3.34).61 Direct 
three-component vinylogous Mannich reactions deliver the products with almost 
identical yield and enantioselectivity, thus avoiding the synthesis of the imines in 
a separate step. The utility of the vinylogous Mannich products are demonstrated 
through their conversion into various functional building blocks including a short 
209 
 
 
synthesis of the enantiomerically highly enriched 2-phenylpiperidine. 33q 
resulted higher ee compared to 33h. 
 
Equation 3.34: Chiral phosphoric acid catalyzed Mukaiyama-Mannich reaction. 
NAr +
33h or 33q (1 mol%)
solvent mixture,
-30oCPMP N
OTBS
N
O
Ar
NH
PMP
up to 92% ee
up to 99% yield
35 36
 
 
Vinylogous Mannich reaction of acyclic silyl dienolates reported by 
Schneider et. al. furnished valuable δ-amino α,β-unsaturated carboxylic esters in 
high yields, complete regioselectivity and good to very good enantioselectivities 
(Equation 3.35).62 Although an excess of nucleophile has been typically 
employed for the purpose of increasing the reaction rate, almost identical results 
have been obtained with a nearly stoichiometric ratio of reactants and longer 
reaction times. This process is further facilitated by the discovery that it may be 
executed successfully as a three component Mannich reaction, which avoids the 
need to synthesize the imine in a separate step. Wide application of the reaction 
was explored with various substituents. 
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Equation 3.35: Chiral phosphoric acid catalyzed Mannich reaction of acyclic silyl 
dienolates. 
+
Catalyst (3 mol%)
toluene, 0oC
OEt
OTBS
OEt
O
Ph
NH
PMP
N
PMP
Ph H
O
O
P
O
OH
33a
yield 97%, er 59:41
O
O
P
O
OH
33h
yield 52%, er 85:15
O
O
P
O
OH
33i
yield 40%, er 70:30
O
O
P
O
OH
33m
yield 77%, er 81:19  
 
Hydrophosphonylation of aldimine with dialkyl phosphate proceeded using 
a catalytic amount (10 mol%) of chiral phosphoric acid (33) to give R-
aminophosphonates in a highly enantioselective manner (Equation 3.36).63 
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Aldimines, in particular, derived from cinnamaldehyde derivatives exhibit high 
enantioselectivity. Bulky electron withdrawing substituent on the binephthyl 
system of the catalyst (33g) helped to attain higher yield and ee. 
 
Equation 3.36: Asymmetric hydrophosphonylation of aldimine with dialkyl 
phosphate. 
N
Ph
OMe
P
O
H Oi-Pr
Oi-Pr+
33g (10 mol%)
m-xylene
rt
N
H
R P
O
OMe
O i-Pr
O i-Pr
O
O
P
O
OH
CF3
CF3
CF3
CF333g
58% yield, 87% ee  
 
3.2.4.2 Nucleophilic Addition to Aldimines 
Terada and co-workers reported the aza Friedel-Crafts alkylation of furan to 
aldimines by means of 2 mol % of 33q (Equation 3.37).64 The present reaction 
provided an atom-economical route to furan-2-ylamine derivatives (37) in a highly 
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enantioselective fashion. The synthetic utility of these products is demonstrated 
by oxidative cleavage of the furan ring (aza-Achmatowicz reaction) to form a 1,4-
dicarbonyl compound (38) that could, in turn, be derivatized to a γ-butenolide 
(39). 
 
Equation 3.37: Asymmetric aza Friedel-Crafts alkylation of furan to aldimines. 
Ph H
N
Boc O
OMe
O
OMe
Ph
NH
Boc
33q (2 mol%)
(CH2Cl)2, -35oC+
NBS, NaHCO3
Et2O/H2O, 0oC
30 min
OMe
Ph
NH
Boc
O
OO OMe
Ph
NH
Boc
CeCl3.7H2O
NaBH4, MeOH
-78oC to rt, 5h
39
95% yield
syn/anti = 85/15
38
90% yield
37
 
 
You and co-workers demonstrated that indoles are also suitable 
nucleophiles for addition to aldimines catalyzed by ent-33r (Equatioin 3.38).65 
High yields and excellent ee’s were achieved for a wide range of aromatic 
aldimines. 
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Equation 3.38: Asymmetric nucleophilic addition of indoles. 
N
HX R
N
Ts
+
33k (10 mol%)
toluene, - 60oC
N
HX
R
HN
Ts
 
 
The Pictet-Spengler reaction is important for preparation of tetrahydro-β-
carbolines and tetrahydroquinolines.66 List and co-workers used phosphoric acid 
to catalyze the Pictet-Spengler reaction starting from geminally disubstituted 
tryptamines (Equation 3.39).67 The presence of the bis-(ethoxycarbonyl) group 
facilitated the cyclization reactions by virtue of the Thorpe-Ingold effect. Aliphatic 
as well as aromatic aldehydes were found to be good substrates. The 
requirement of a geminal diester functionality is a major constraint of this 
procedure. This limitation could be used to advantage in organic synthesis with a 
good retro-synthetic plan.  
 
Equation 3.39: Asymmetric phosphoric acid catalyzed Pictet-Spengler reaction 
starting from geminally disubstituted tryptamines. 
N
H
+
33i (20 mol%)
Na2SO4
toluene, - 30oC
3-6 days
N
H
CO2Et
NH2
CO2Et
R1 R1 NH
R2
EtO2C CO2Et
R2CHO
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Recently optically active tetrahydro-β-carbolines were synthesized via an 
(R)-BINOL-phosphoric acid-catalyzed asymmetric Pictet-Spengler reaction of N-
benzyltryptamine with a series of aromatic and aliphatic aldehydes (Equation 
3.40).68 The tetrahydro-β-carbolines were obtained in yields ranging from 77% to 
97% and with ee values up to 87%. The 3,3’-triphenylsilyl-substituted BINOL-
phosphoric acid (33r) proved to be the catalyst of choice for the reaction with 
aromatic aldehydes. For the aliphatic aldehydes, 3,5-bistrifluoromethylphenyl-
substituted BINOL-phosphoric acid (33g) was identified as the best catalyst. In 
addition, this scaleable method shortens the synthesis toward the 
pharmaceutically very relevant PDE5 inhibitors of the pyrroloquinolone class by 
three steps. 
 
Equation 3.40: Asymmetric synthesis of tetrahydro-β-carbolines via an (R)-
BINOL-phosphoric acid-catalyzed asymmetric Pictet-Spengler reaction of N-
benzyltryptamine. 
N
H
+
Catalyst 33 (20 mol%)
4 Ao MS, toluene, 70oC
24h
N
H
NHBn
NBn
R
RCHO
 
 
Phosphoric acid 33m, bearing the 9-anthryl group, catalyzed the direct 
alkylation of aldimines with α-diazo ester to furnish β-amino-α-diazoester with 
excellent enantioselectivity (Equation 3.41).69 Diazoacetate is commonly 
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employed in aziridine ring formation reactions (aza-Darzens reaction) under 
Lewis acidic70 and Brønsted-acidic71 conditions. 
 
Equation 3.41: Asymmetric direct alkylation of aldimines with α-diazo ester to 
furnish β-amino-α-diazoester. 
+
33m (2 mol%)
toluene, rtt-BuO2C H
N2
O
R
N
ArH
t-BuO2C
N2
Ar
HN
R
O
 
 
Rueping and co-workers reported the Strecker reaction catalyzed by 33l 
(Equation 3.42).72 They proposed a transition state model based on the X-ray 
crystal structure of 33l and optimized the structure with a complex derived from 
33l and an imine. 
 
Equation 3.42: Asymmetric Strecker reaction catalyzed by chiral phosphoric 
acid. 
+
33l (10 mol%)
toluene, -40oC
Ar H
N
Ph
HCN
Ar H
HN
Ph
 
 
216 
 
 
Enecarbamate proved to be an efficient nucleophile in the phosphoric 
acid-catalyzed aza ene-type addition to aldimines.73 It is noted that a 
concentration as low as 0.1 mol % of chiral phosphoric acid catalyst worked well 
to afford the adducts with excellent enantioselectivities (Equation 3.43).74,75 
 
Equation 3.43: Asymmetric phosphoric acid-catalyzed aza ene-type addition to 
aldimines. 
+
1) 33 (0.1 mol%)
toluene, - 40oC
R H
N
O
Ph
Ph
NH
O
MeO
2) H3O+ Ph
H
N
R Ph
O O
 
 
Terada and co-workers subsequently employed the enecarbamate as a 
precursor of iminium salt, which was trapped by the indole (Equation 3.44).76 The 
phosphoric acid activates the electron-rich alkene in place of imine to give 1-
indolyl-1-alkylamine derivatives, which have pharmaceutical and biological 
importance, with excellent enantioselectivity. 
 
Equation 3.44: Electrophilic addition using chiral phosphoric acid as a catalyst. 
33 (5 mol%)
CH3CN, 0oC
N
HR1 R2
R3
H
HN
Boc
+
N
HR1
H
NBoc
R2
R3
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Rueping and co-workers recently reported the iminoazaenamine reaction 
catalyzed by partially hydrogenated phosphoric acid 34b (Equatiion 3.45).77  
 
Equation 3.45: Asymmetric iminoazaenamine reaction. 
+
34 (10 mol%)
CHCl3, 0oC
Ar H
N
Boc
N
N
Ar
N
N
NHBoc
 
 
Antilla and co-workers have successfully developed the first catalytic 
asymmetric addition of alcohols to N-acyl imines catalyzed by chiral phosphoric 
acids (Equation 3.46).78 The chiral N,O-aminal could be prepared in a 
straightforward procedure in high yields with excellent enantiomeric excess under 
mild reaction conditions. 
 
Equation 3.46: Asymmetric addition of alcohols to N-acyl imines catalyzed by 
chiral phosphoric acids. 
NCOPhR1
NHCOPh
R1 OR2
Catalyst 33 (5 mol%)
EtOAc, RT, 24 h
+ R2OH  
 
A new highly enantioselective Brønsted acid catalyzed imino-azaenamine 
reaction of various N-Boc-protected aldimines and methylene-aminopyrrolidine 
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was developed by Rueping et al (Equation 3.47).79 The corresponding valuable 
aminohydrazones have been isolated in good yields and with high 
enantioselectivities. The mild reaction conditions of this metal-free process 
together with the operational simplicity and practicality not only render this a 
useful procedure for the synthesis of optically active aminohydrazones but also 
further expand the repertoire of enantioselective BINOL-phosphate catalyzed 
transformations. 
 
Equation 3.47: Enantioselective Brønsted acid catalyzed imino-azaenamine 
reaction of various N-Boc-protected aldimines and methylene-aminopyrrolidine. 
R
N
R
N
H
H
PG
N
Ar H
Ar
N
N
RR
HN
PG
+
Catalyst 33 (5-10 mol%)
CHCl3, 0oC
 
 
3.2.4.3 Aza Diels Alder Reactions 
 Akiyama et al found that Danishefsky’s diene80 undergoes the aza Diels-
Alder reaction with aldimine in the presence of phosphoric acid to give 
cycloadducts (Equation 3.48).81 Interestingly, addition of acetic acid significantly 
improved both the chemical yield and enantioselectivity. Bulkiness of chiral 
phosphoric acid was found to be effective in increasing the yield and ee of the 
reaction. 
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Equation 3.48: Asymmetric aza Diels-Alder reaction with aldimine in the 
presence of phosphoric acid to give cycloadducts. 
NAr
HO
Me
+
OTMS
OMe AcOH (1.2 equiv.)
33 (5 mol%)
toluene
- 78oC
N
Ar
OAr
 
 
Brassard’s diene82 is more reactive than Danishefsky’s diene. Although 
the diastereoselective aza Diels-Alder reaction of Brassard’s diene with aldimines 
has already been reported,83 the catalyzed enantioselective version of the 
reaction has not yet been realized. A phosphoric acid bearing a 9-anthryl group 
at the 3,3’-position (33m) is effective for the aza-Diels-Alder reaction. 
Interestingly, use of a pyridinium salt, 40, improved the yield. Supposedly, the 
use of less acidic pyridinium salt 40 suppressed decomposition of Brassard’s 
diene in the reaction medium. Aldimines derived from aliphatic aldehydes as well 
as aromatic aldehydes worked well to give the corresponding cycloadducts after 
acid treatment with excellent enantioselectivity (Equation 3.49).84 The promising 
success of this reaction directed toward scale-up the reaction to 1.01g scale. 
The reverse electron-demand aza Diels-Alder reaction of electron-rich 
alkene with 2-aza diene was catalyzed by chiral phosphoric acid to give 
tetrahydroquinoline derivatives in favor of the cis-isomer with excellent 
enantioselectivities (Equation 3.50).85 Cyclic enol ethers as well as acyclic enol 
ether were found to be excellent substrates. 
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Equation 3.49: Aza Diels-Alder reaction of Brassard’s diene with aldimines. 
O
O
P
O
O
HN
HO
CH3N
Ph
OTMS
OMe OMe
+
1) 3% catalyst 40, masitylene, - 40oC
2) PhCOOH (5.0 equiv.)
N
O
OMe
Ar
Ph
1.01g, 4.76 mmol 3.0 equiv.
1.40g
O
O
P
O
OH
33m
72% yield, 92% ee
40
95% yield, 94% ee
 
The aza Diels-Alder reaction of aldimine with cyclohexenone was 
independently developed by Rueping86 and Gong.87 While Rueping employed 33l 
and 33m in combination with acetic acid (Equation 3.51), Gong used H8-
BINOLderived phosphoric acid 34c bearing p-ClC6H4 groups at the 3,3’-positions 
(Equation 3.52). Gong proposed that cyclohexenone is equilibrated to the enol 
form by acetic acid, thus promoting the aza Diels-Alder reaction. To	  optimize	  the	  reaction	  further,	  binol	  phosphate	  catalysts,	  various	  imine	  protecting	  groups,	  solvent,	  temperature,	   catalyst	   loading,	   and	   enone	   concentrations	   were	   varied	   (Equation	  3.51).86	  The	  best	   reactivities	  and	  selectivities	  were	  observed	  with	  10	  mol%	  of	   the	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binol	   phosphate	   33m	   and	   20	   mol%	   acetic	   acid	   in	   toluene	   at	   room	   temperature.	  Various	   aldimines	   were	   applied	   in	   the	   double	   Brønsted	   acid	  	  	  
Equation 3.50: Asymmetric reverse electron-demand aza Diels-Alder reaction of 
electron-rich alkene with 2-aza diene. 
NR
HO
+
Catalyst 33m (10 mol%)
Toluene, -10-0oC
OR HN
HO
ORAr
HN
HO
OEtPh
89% yield, 94% ee
(47h, -10oC)
HN
HO
On-BuPh
82% yield, 96% ee
(19h, -10oC)
HN
HO
On-Bu
Br
86% yield, 89% ee
(39 h, -10oC)
HN
HO
OCH2PhPh
76% yield, 91% ee
(42h, 0oC)
HN
HO
OPh
86% yield, 90% ee
(21h, -10oC)
HN
HO
OPh
95% yield, 97% ee
(145h, 4oC)  	  catalyzed	   enantioselective	   synthesis	   of	   isoquinuclidines	   under	   these	   optimized	  conditions.	   In	   general,	   aromatic	   as	   well	   as	   heteroaromatic	   substituted	  isoquinuclidines	   with	   electron	   withdrawing	   and	   electron-­‐donating	   substituents	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could	  be	   isolated	   in	   good	  yields,	  with	  high	   enantiomeric	   ratios	   and	  high	  exo/endo	  ratios.	   The	   relative	   and	   absolute	   structural	   configurations	   of	   the	   products	   were	  obtained	  by	  X-­‐ray	  crystal	  structure	  analysis. 
 
Equation 3.51: Rueping’s asymmetric aza Diels-Alder reaction of aldimine with 
cyclohexenone. 
AcOH (20 mol%)
33m (20 mol%)
toluene, rt
Ar
N
Br
+
O
N
O Ar H
Br
 
 
Equation 3.52: Gong’s asymmetric aza Diels-Alder reaction of aldimine with 
cyclohexenone. 
34c (5 mol%)
toluene, 20oC
Ar
N
PMP
+
O
N
H
Ar
PMP
O
 
 
Although the Biginelli reaction is a useful multicomponent reactions, in 
providing ready access to multifunctionalized 3,4-dihydropyrimidin-2-(1H)-ones, 
the catalyzed enantioselective version of the Biginelli reaction has been little 
explored.88 The highly enantioselective Biginelli reaction catalyzed by chiral 
phosphoric acid was reported by Gong and co-workers (Equation 3.53).89 A 
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range of 3,4-dihydropyrimidin-2-(1H)-ones were obtained with excellent 
enantioselectivities. The optimal chiral phosphoric acid, derived from H8-binol,  
 
Equation 3.53: Asymmetric Biginelli reaction catalyzed by chiral phosphoric acid. 
H
O
H2N NH2 OEt
S O O
+ +
NH
HN
CO2EtMe
S
33 or 34 (10 mol%)
CH2Cl2, 25oC
O
O
P
O
OH
33b
67% yield, 80% ee
O
O
P
O
OH
F
F
O
O
P
O
OH
CF3
CF3
CF3
CF333g
25% yield, 52% ee
O
O
P
O
OH
O
O
P
O
OH
F
F
O
O
P
O
OH
Cl
Cl
O2N
NO2
33s
41% yield, 53% ee
34b
84% yield, 85% ee
34e
45% yield, 70% ee
34c
24% yield, 68% ee
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afforded the reaction in high yields with excellent enantioselectivities of up to 
97% ee. A wide variety of substrates, including aldehydes and β-keto esters, 
could be tolerated. This reaction has the advantage of avoiding contamination by 
transition metals in the manufacture of the medicinally relevant chiral 3,4-
dihydropyrimidin-2-(1H)-ones. 
The asymmetric Biginelli reaction catalyzed by BINOL-derived phosphoric 
acids was investigated to produce the desired SNAP-7941 (41) 
dihydropyrimidones (DHPM) core (Equation 54).90 The use of methoxy  
 
Equation 3.54: Asymmetric synthesis of SNAP-7941 using chiral phosphoric as 
a catalyst. 
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methylacetoacetate 42a in the multicomponent reaction gave DHPM 44a in low 
yield and enantioselectivity. This observation is, again, attributed to an 
unfavorable hydrogen-bonding environment, because the use of 
methylacetoacetate 42b greatly improved yield and selectivity of the reaction. 
Optimal reaction conditions were achieved with a limiting amount of urea and an 
excess of both aldehyde and methylacetoacetate. DHPM 44b was synthesized in 
96% yield with 94.5:5.5 er, utilizing 3,3′-diphenyl-substituted BINOL-derived 
phosphoric acid catalyst 33b.  
The enantioselective Brønsted acid catalyzed Nazarov reaction was 
developed by Rueping and co-workers (Equation 3.55).91 This efficient method is 
not only the first example of an organocatalytic electrocyclic reaction but it also 
provides the corresponding cyclopentenones in good yields and with excellent 
enantioselectivities (86–98% ee). Compared to the metal-catalyzed reaction, 
special features of this new Brønsted acid catalyzed electrocyclization are the 
lower catalyst loadings (2 mol%), higher enantioselectivities, access to all 
possible stereoisomers, milder conditions and faster reaction times. 
 
Equation 3.55: Enantioselective Brønsted acid catalyzed Nazarov reaction. 
O
R2
O
R1 O
R1
R2
O
O
R1
R2
OCatalyst (2 mol%)
CHCl3, 0oC
+
Catalyst % yield 45/46 ee 45, ee 46
33l 95 3.5:1 90, 93
33m 86 2:1 89, 95
45 46
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3.2.4.4 Friedel-Crafts Reaction 
Antilla an co-workers have developed an efficient method for the highly 
enantioselective Friedel-Crafts reaction between pyrrole derivatives and N-acyl 
imines catalyzed by chiral phosphoric acids (Equation 3.56).92 When the 
observed  
 
Equation 3.56: Friedel-Crafts reaction between pyrrole derivatives and N-acyl 
imines catalyzed by chiral phosphoric acids. 
N
O
Ph
N
Me
+
(S)-Catalyst (5 mol%)
CH2Cl2, rt
NH
O
Ph
N
Me
O
O
P
O
OH
33m
82% yield
48% ee
O
O
P
O
OH
Si
Si
33r
72% yield
51% ee
Ph
Ph
Ph O
OPh
47
56% yield
25% ee
P
O
OH
 
 
steric and electronic effects of the substrates were controlled excellent 
enantiomeric excess and yields could be achieved using catalyst 33r. The 
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reaction conditions were optimized by studying different solvent systems, 
temperatures, studying the substituent effect on the imine, and the substituent 
effect on the pyrroles. The developed methodology was applied to the synthesis 
of a pyrrolo- [1,2-α]pyrazine without racemization. 
Akiyama et al have developed a chiral phosphoric acid catalyzed Friedel–
Crafts alkylation of indoles with nitroalkenes to generate Friedel–Crafts adducts 
with excellent enantioselectivities (Equation 3.57).93 They found that 3Å 
molecular sieves lead to an efficient Friedel–Crafts alkylation in the presence of a 
chiral phosphoric acid (33r). 
 
Equation 3.57: Chiral phosphoric acid catalyzed Friedel–Crafts alkylation of 
indoles with nitroalkenes. 
N
H
R1 R2
NO2+
N
H
R1
NO2R2
Catalyst R-33r (10 mol%)
Benzene/DCE 1:1
3ÅMS (10-40 mg)
- 35oC
 
 
3.2.4.5 Transfer Hydrogenations 
Although chemical hydrogenation normally requires a metal catalyst or 
use of stoichiometric amounts of metal hydrides, living organisms typically 
employ organic cofactors such as nicotinamide adenine dinucleoside (NADH) in 
combination with metalloenzymes.94 The organo-catalyzed transfer 
hydrogenation95 and reductive Michael reaction,96 both of which employ 
Hantzsch ester (46) as a model of NADH, were reported quite recently. A number 
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of groups have independently reported the enantioselective reduction of imines 
catalyzed by different phosphoric acids as a Brønsted acid. Rueping and co-
workers employed 20 mol % of chiral phosphoric acid, bearing 3,5-(CF3)2C6H3 
groups at the 3,3’-positions (33g), as the catalyst (Equation 3.58) for asymmetric 
hydrogenation.97  
 
Equation 3.58: Chiral phosphoric acid catalyzed asymmetric hydrogenation 
reaction. 
Ar CH3
N
PMP
N
H
CO2EtEtO2C
HH
ArH3C
HN
PMP
+
Catalyst 33g (20 mol%)
Benzene, 60oC
48  
 
List et al have reported highly efficient and enantioselective transfer 
hydrogenation of ketimines catalyzed by Brønsted acids (Equation 3.59).98 They 
synthesized and screened a variety of chiral phosphoric acid catalysts for the 
reduction of imine in the presence of Hantzsch ester. Highest selectivity was 
attained using triisopropylbenzene substituted chiral phosphoric acid (33i). A 
reasonable mechanism was proposed for the reaction using chiral Brønsted 
acids. Remarkable features of this process includes (a) its high yields and 
enantioselectivities, (b) its wide scope, including both aliphatic and aromatic 
amines, (c) its simplicity and practicality (in situ generation and reduction of 
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imines), and (d) the remarkably low catalyst loading, which so far is 
unprecedented in asymmetric Brønsted acid catalysis.  
 
Equation 3.59: List’s asymmetric transfer hydrogenation by Brønsted acids. 
R CH3
N
PMP
N
H
CO2EtEtO2C
HH
RH3C
HN
PMP
+
Catalyst 33i (1 mol%)
Toluene, 35oC
48  
 
MacMillan and co-workers found that bulky chiral phosphoric acid, bearing 
Ph3Si groups at the 3,3’-positions (33r), is the catalyst of choice for the reductive 
amination reaction (Equation 3.60).99 The three component transfer 
hydrogenation reaction starting from the aldehyde, amine, and Hantzsch ester 
proceeded smoothly in the presence of MS 5Å to give secondary amines with 
excellent enantioselectivities. Dialkyl ketones as well as alkyl aryl ketones proved 
to be good substrates, and even ethyl methyl ketone was reductively aminated 
with 88% ee. The single-crystal X-ray structure of a catalyst bound aryl imine was 
obtained which exhibited a remarkable correlation with MM3 calculations.  
The mechanism of the Hantzsch ester hydrogenation of imines catalyzed 
by chiral BINOL-phosphoric acid has been investigated using density functional 
theory (DFT) methods.100 Despite the importance of this reaction, there are a 
number of possible detailed mechanisms, and the preferred pathway has not 
been firmly established. Calculations show that the catalyst not only activates the 
imine group for the reaction by acting as a Brønsted acid, but also establishes an 
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interaction with the Hantzsch ester that can explain the enantioselectivity of the 
reaction. 
 
Equation 3.60: MacMillan’s three component transfer hydrogenation reaction. 
N
H
CO2EtEtO2C
HH
ArH3C
HN
+
Catalyst 33r (10 mol%)
5Å MS, 40-50oC
Benzene
R
O
Me
NH2
R'
+
R'
O
O
P
O
OH
Si
Si
33r
48
 
Rueping and co-workers extended the chiral phosphoric acid-catalyzed 
transfer hydrogenation to the reduction of quinolines (Equation 3.61),101 
benzoxazines,102 benzothiazines, and benzoxazinones (Equation 3.62). 
Reduction of benzoxazines, in particular, is highly selective, reducing the catalyst 
loading of 33k to as low as 0.01 mol % without considerable loss of reactivity or 
selectivity. They applied this methodology to the enantioselective synthesis of 
biologically active tetrahydroquinoline alkaloids such as (+)-galipinine. This 
reaction was further developed for the cascade reaction.103 
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Equation 3.61: Asymmetric reduction of quinolines using chiral phosphoric acid. 
N
H
CO2EtEtO2C
HH
+
Catalyst 33k (1-5 mol%)
Benzene, 60oC
N R N
H
R
48  
 
Equation 3.62: Asymmetric reduction of benzoxazines, benzothiazines, and 
benzoxazinones using chiral phosphoric acid. 
N
H
CO2EtEtO2C
HH
+
Catalyst 33k (0.1-1 mol%)
CHCl3, RT
N
X
R
X = O, S 48
(1.4 eqv.)
N
H
X
R
(51-95% (93-99%ee)
 
 
List and co-workers achieved the catalytic reductive amination of R-
branched aldehydes (Equation 3.63). On treatment of α-branched aldehydes and 
p-anisidine with 48 as a hydrogen source in the presence of 5 mol % of 33i, α-
substituted amines were obtained with high chemical yields with good to  
 
Equation 3.63: List’s catalytic reductive amination of R-branched aldehydes. 
N
H
CO2EtEtO2C
HH
+
Catalyst 33i (5 mol%)
5Å MS, Benzene, 6oCR
1
R2
CHO
+
R1
NHR3
R2
H2NR3
48
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excellent enantioselectivities by dynamic kinetic resolution.104 Different 
derivatives of 48 were also used as a hydrogen source in the reaction. 
Organocatalytic cascade reactions using chiral phosphoric acid derivative was 
subsequently achieved.105 
Asymmetric synthesis of trans-alkenyl α-amino esters was realized by 
chiral phosphoric acid catalyzed transfer hydrogenation of β,γ-alkynyl α-imino 
esters (Equation 3.64).106 Utilizing Hantzsch esters as the hydrogen donor, both 
the alkyne and imine moieties of β,γ-alkynyl α-imino esters were reduced to 
afford trans-alkenyl α-amino esters with up to 96% ee. 
 
Equation 3.64: Asymmetric synthesis of trans-alkenyl α-amino esters using 
chiral phosphoric acid. 
N
H
CO2EtEtO2C
HH
+
Catalyst 33m (1 mol%)
Et2O, rtN
PMP
CO2R'
R
HN
PMP
CO2R'
R
up to 96% ee48  
 
 Guo et al reported a transfer hydrogenation reaction using double axially 
chiral phosphoric acid (Equation 3.65).107 The use of the bis-BINOL scaffold to 
synthesize the chiral phosphoric acid is unique. In comparison to other chiral 
phosphoric acids, this bis-BINOL phosphoric acid shows higher efficiency.  
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Equation 3.65: Guo’s transfer hydrogenation reaction using double axially chiral 
phosphoric acid. 
N
H
CO2EtEtO2C
HH
+
Catalyst (1 mol%)
Et2O, 35
oC, 20h
N
R2
R1 N
H
R2
R1
O O
O O
P
O OH
O O
O OP
O OH
O O
O OP
O OH
O O
O O
P
O OH
49a
98% yield
70% ee
49b
99% yield
93% ee
49c
99% yield
85% ee
49d
99% yield
95% ee  
 
3.2.5  Novel Phosphoric Acids 
TADDOL-based phosphoric acid diesters 50 were synthesized and 
subjected to the Mannich-type reaction by Akiyama et. al. (Equation 3.66). 
Although 50a did not show significant catalytic activity, its derivative with p-
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CF3C6H4 group 50b exhibited high catalytic activity. The Mannich-type reaction 
proceeded smoothly to give β-amino esters with high enantioselectivity.108 
 
Equation 3.66: Asymmetric Mannich-type reaction using TADDOL-based 
phosphoric acid diesters catalyst. 
NAr
MeHO OTMS
OMe+
Catalyst 50 (5 mol%)
Toluene, -78oC
OHMe
NH
Ar
O
OMe
O
O O
O
Ar Ar
Ar Ar
P
O
OH
50a Ar = Ph
50b Ar = 4-CF3C6H4
 
 
Antilla and co-workers synthesized a novel phosphoric acid derivatives, 
starting from BINOL derivatives and (S)-VAPOL,109 and demonstrated its 
catalytic activity in the addition of sulfonamide to aldimines to produce protected 
aminals, which have been incorporated into peptide chains as retro-inverso 
peptide mimics (Equation 3.67).110 
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Equation 3.67: Asymmetric addition of sulfonamide to aldimines.  
Boc
NPh + H2NTs
Catalyst (5-10 mol%)
Et2O , RT
Boc
NH
Ph NHTs
O
O
P
O
OH
33p
99% yield, 71% ee
O
O
P
O
OH
33o
96% yield, 60% ee
Ph
Ph
O
O
P
O
OH
51
95%yield, 94% ee  
 
 Terada at el reported a new stronger chiral Brønsted acid (52) by 
modifying the chiral phosphoric acid.111 This catalyst was applied for direct 
Mannich reaction resulting in high yield and promising %ee (Equation 3.68). 
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Though the reaction is high yielding, the selectivity (%ee) is low. This could be 
reasoned as a compromise between the acidity and selectivity or functionality 
rotation around the nitrogen atom thereby reducing the commitment to selectivity.  
 
Equation 3.68: Terada’s new stronger chiral Brønsted acid catalyzed direct 
Mannich reaction. 
N
N
P
G
G
OH
O
O2S
O2S CF3
O2S
52a: G =
52b: G =
52c: G =
Ph
N
O
R1
H
+
O O Catalyst (1 mol%)toluene, r.t.
N
H
R1
Ph
Ac
Ac
O
 
 
 Yamamoto et al reported the formation of the super chiral Brønsted acid 
(53) (Equation 3.69) and using it for asymmetric Dield-Alder Reaction (Equation 
70).112 The previously known chiral phosphoric acids did not give any product or 
ee for asymmetric Dield-Alder Reaction, while the new super chiral Brønsted acid 
(53) gave high yield and ee for asymmetric Diels-Alder Reaction. Non-polar 
aromatic solvents were found to give higher yield and higher ee. Substrate 
scopes were studied by changing different functionality in the substrate system. 
237 
 
 
Equation 3.69: Synthesis of the super chiral Brønsted acid. 
Ar
OH
OH
Ar
POCl3 (1.2 equiv)
DMAP (2 equiv)
Et3N (7 equiv)
CH2Cl2
0oC ~ r.t., 2 h
TfNH2 (2 equiv)
EtCN
r.t. ~ reflux
Ar
O
O
Ar
P
O
HN Tf
53a Ar = Ph
53b Ar = 1,3,5-(i-Pr)3C6H2  
 
Equation 3.70: Asymmetric Dield-Alder Reaction using the super chiral Brønsted 
acid. 
O
Et Me
OSiR3
R1
Me
COEt
R1
R3SiO
+
53 (5 mol%)
toluene
-78oC, 12 h
up to 99% yield
and 92% ee  
 
 Yamamoto et. al. have reported Brønsted acid catalyzed asymmetric 
protonation reactions of silyl enol ethers using a chiral Brønsted acid catalyst in 
the presence of achiral Brønsted acid media (Equation 3.71).113 The versatility of 
the reaction was revealed using a wide variety of substituents. Additionally, the 
reactivity of this Brønsted acid is especially appealing for chiral phosphoric acid  
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Equation 3.71: Yamamoto’s Brønsted acid catalyzed asymmetric protonation 
reactions of silyl enol ethers using a chiral Brønsted acid catalyst. 
OTMS
Ph
O
Ph
Catalyst (10 mol%)
2,4,6-(CH3)3C6H2CO2H (1eqv.)
toluene, rt
O
O
P
O
OH
33i
0% yeild
O
O
P
O
SH
54
trace yield
O
O
P
O
NHTf
53b
98% yield, 77:23 er
O
O
P
S
NHTf
55a
97% yield, 89:11 er
O
O
P
Se
NHTf
56
97% yield, 86:14 er
O
O
P
S
NHTf
55b
97% yield, 99:9 er  
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catalysis in that the catalyst loading for this reaction can be decreased down to 
0.05 mol % without any significant loss of enantioselectivity. 
Gong et. al. reported an asymmetric three-component 1,3-dipolar 
cycloaddition reaction using different chiral phosphoric acids (33) and modified 
chiral phosphoric acid (57) between aldehydes, amino esters, and dipolarophiles 
(Equation 3.72).114 This reaction results in high yields and excellent 
enantioselectivities under mild conditions. The procedure is easy to perform and 
allows a rapid, diversity-oriented, and enantioselective synthesis of pyrrolidine 
derivatives. The concept that the stereoselectivity may be controlled by use of a 
chiral Brønsted acid bonded dipole may lead to new findings in asymmetric 
catalytic 1,3-dipolar addition reactions with dipolarophiles other than electron-
deficient olefins. 
Uraguchi et al designed a chiral tetraaminophosphonium salt (58) 
possessing the P-spirocyclic structure with its potential as an organic molecular 
catalyst has demonstrated in the application to the asymmetric direct Henry 
reaction (Equation 3.73).115 High yield and ee were attained with this new class 
of organocatalyst. 
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Equation 3.72: Gong’s asymmetric three-component 1,3-dipolar cycloaddition 
reaction using chiral phosphoric acids. 
CHO
NO2
+
H2N
CO2Et
CO2Et
+
CO2Me
CO2Me
N
H
CO2Et
CO2Et
CO2MeMeO2C
O2N
Catalyst (10 mol%)
CH2Cl2, rt, 24 h
3Ao MS
O
O
P
O
OH
33b
78% yield, 8% ee
O
O
P
O
OH
CF3
CF3
CF3
CF3
33g
88% yield, 25% ee
O
O
P
O
OH
NO2
NO2
33c
87% yield, 46% ee
O
O
P
O
OH
33i
78% yield, 23% ee
O
O
P
OH
O
O
O
P
HO
O
O
57
96% yield, 98% ee  
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Equation 3.73: Uraguchi’s asymmetric direct Henry reaction. 
NH
P
H
N
N
H
HN
H
H
Ar
Ar
Ar
Ar
Ph
O
H
NO2
R1
Ph
OH
R1
NO2
Catalyst 58 (5 mol%)
(M,S)-3/KOtBu
THF
-78oC, 8 h
+
58
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3.3  Results and Discussion 
(R)- 1,1’-dinaphthyl-2,2’-dioxathiepin (60a) and (R)-1,1’-dinaphthyl-2,2’-diylsulfate 
(63a) were synthesized following the procedure of Zhang et al (Equation 74) and 
Koy et al (Equation 3.75).116,117 Catalyst 61a was formed after addition of 1.0 
equivalent of HBF4.Et2O to 60a. Catalyst 62a was formed through the same 
procedure by addition of 0.5 equivalent of HBF4.Et2O. In a similar way, catalyst 
64a and 65a was also formed from compound 63a by adding the required 
amount of HBF4.Et2O (Equation 3.75). 
 
Equation 3.74: Synthesis of (R)-1,1’-dinaphthyl-2,2’-dioxathiepin (60a) and 
formation of catalyst 61a and 62a. 
OH
OH
O
O
S O
SOCl2
Pyridine
CH2Cl2
O
O
S O
HBF4.Et2O
(1.0 eqv)
HBF4
60a59a
61a
O
O
S O HBF4
62a
HBF4.Et2O
(0.5 eqv)
2
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Equation 3.75: Synthesis of (R)-1,1’-dinaphthyl-2,2’-diylsulfate (63a) and 
formation of catalyst 64a and 65a. 
OH
OH
O
O
S
O
SO2Cl2
Pyridine
O
O
S
O
HBF4.Et2O
(1 eqv)
HBF4
O
O
63a
O
O
S
O
HBF4
O
HBF4.Et2O
(0.5 eqv)
2
59a
64a65a  
OMe or MOM following the standard procedure.118 The protected BINOL was 
then lithiated by n-BuLi in the presence of an organic base such as tetramethyl 
diaminoethane (TMEDA).119 This was followed by subsequent addition of 
B(OMe)3 to form the appropriate boronic acid.120 These lithiated BINOLs were 
Derivatives of binaphthol were synthesized following the procedure of Wipf et al 
(Equation 3.76-82).120 Initially, the phenolic OH group of BINOL was protected 
with 
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Equation 3.76: Multistep synthesis of (R)-3,3’-Bis(4”-methylphenyl)-1,1’-
dinaphthyl-2,2’-dioxathiepin (60b) and subsequent catalyst 61b. 
OH
OH
O
O
S
SOCl2
Pyridine
CH3I OCH3
OCH3
1. n-BuLi, Et2O
2. B(OEt)3
3. HCl/H2O OCH3
OCH3
B(OH)2
B(OH)2
OCH3
OCH3
Pd(PPh3)4
4-Bromotoluene
Water/Dioxane
Qunatitative yield 70% yield
60% yield
85% yield
O
59 66 67
68a
60b
OCH3
OCH3
B(OH)2
B(OH)267
OH
OH
59b
OCH3
OCH3
BBr3, CH2Cl2 OH
OH
95% yield
68a 59b
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Equation 3.77: Multistep synthesis of (R)-3,3’-Bis(4”-methylphenyl)-2,2’-
dihydroxy-1,1’-dinaphthyl-2,2’-diylsulfate (63b) and subsequent catalyst 64b. 
OH
OH
CH3I OCH3
OCH3
1. n-BuLi, Et2O
2. B(OEt)3
3. HCl/H2O OCH3
OCH3
B(OH)2
B(OH)2
OCH3
OCH3
Pd(PPh3)4
4-Bromotoluene
Water/Dioxane
Qunatitative yield 70% yield
60% yield
59 66 67
68a
OCH3
OCH3
B(OH)2
B(OH)2
67
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Equation 3.78: Multistep synthesis of (R)-3,3’-Bis(naphthyl)-2,2’-dihydroxy-1,1’-
dinaphthyl-2,2’-diylsulfate (63c) and subsequent catalyst 64c. 
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O
O
S
O
SO2Cl2
Pyridine O
OCH3
OCH3
B(OH)2
B(OH)2
OCH3
OCH3
Pd(PPh3)4
1-Bromnaphthalene
Water/Dioxane
67
OH
OH
OH
OH
OCH3
OCH3
BBr3
CH2Cl2
68b
10% yield
68b 59C
59c 63c  
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Equation 3.79: Multistep synthesis of (R)-3,3’-Bis(mesitylene)-2,2’-dihydroxy-
1,1’-dinaphthyl-2,2’-diylsulfate (63d) and subsequent catalyst 64d. 
OH
OH
CH3I OCH3
OCH3
1. n-BuLi, Et2O
2. B(OEt)3
3. HCl/H2O OCH3
OCH3
B(OH)2
B(OH)2
OCH3
OCH3
Pd(PPh3)4
4-Bromomesitylene
Water/Dioxane
Qunatitative yield 70% yield
50% yield
59 66 67
68c
OCH3
OCH3
B(OH)2
B(OH)2
67
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Equation 3.80: Multistep synthesis of (R)-3,3’-Bis(anthracenyl)-2,2’-dihydroxy-
1,1’-dinaphthyl-2,2’-diylsulfate (63e) and subsequent catalyst 64e. 
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OCH3
OCH3
B(OH)2
B(OH)2
OCH3
OCH3
Pd(PPh3)4
Bromphenanthrene
Water/Dioxane
67 68d
O
O
S
O
SO2Cl2
Pyridine OOH
OH
OH
OH
OCH3
OCH3
BBr3
CH2Cl2
68d 59e
59e 63e  
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Equation 3.81: Multistep synthesis of (R)-3,3’-Bis(phenanthryl)-2,2’-dihydroxy-
1,1’-dinaphthyl-2,2’-diylsulfate (63f) and subsequent catalyst 64f. 
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OH
OH
OCH3
OCH3
BBr3
CH2Cl2
68e 59f  
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Equation 3.82: Multistep synthesis of (R)-3,3’-Bis(triphenylsilyl)-2,2’-dihydroxy-
1,1’-dinaphthyl-2,2’-diylsulfate (63g) and subsequent catalyst 64g. 
 
OCH2OCH3
OCH2OCH3
1) n-BuLi
2) Ph3SiCl
3) H2O/NH4Cl OCH2OCH3
OCH2OCH3
SiPh3
SiPh3
HCl/H2O
OH
OH
SiPh3
SiPh3
CH2Cl2
SO2Cl2O
O
SiPh3
SiPh3
S
HBF4
O
O
O
O
SiPh3
SiPh3
S
O
O
HBF4
N
N
69
70
59g63g
64g  
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Equation 3.83: Multistep synthesis of (R)-3,3’-Bis(tribenzylsilyl)-2,2’-dihydroxy-
1,1’-dinaphthyl-2,2’-diylsulfate (63h) and subsequent catalyst 64h. 
 
OCH2OCH3
OCH2OCH3
Qunatitative yield
1) n-BuLi
2) Ph3SiCl
3) H2O/NH4Cl OCH2OCH3
OCH2OCH3
SiBnz3
SiBnz3
HCl/H2O
OH
OH
SiBnz3
SiBnz3
Pyridine
SO2Cl2O
O
SiBnz3
SiBnz3
S
HBF4
O
O
O
O
SiBnz3
SiBnz3
S
O
O
HBF4
69
70b
59h63h
64h  
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also reacted with silyl compounds to form silyl derivatives.119 The BINOL-boronic 
acids were then subjected to Suzuki-coupling reaction to form the desired 
derivatized-BINOL.120 The final BINOL derivative was formed after deprotection 
of OMe or MOM. The overall yields of these derivatized BINOLs varies 
depending on the different substituents involved. Thus BINOL derivatives were 
reacted under basic conditions with SOCl2 or SO2Cl2 to form dioxathiepin (60) 
and diylsulfate (63) derivatives.  
Initially, the aza-Henry reaction (Equation 3.15) was performed with 
HBF4.Et2O to attain the racemic product of the reaction. After purification using 
gradient column chromatography (pentane:ethyl acetate), the pure sample was 
injected in the HPLC to determine the retention time for each of the two 
enantiomers. Then the reaction was performed with 0.1 equivalent amount of 
catalyst 61a (Figure 3.10). This led us to 3% ee of the product (Table 3.2). Using 
62a as a catalyst did not produce any ee for the reaction. On the other hand, 
using 64a (0.1 equivalent) as a catalyst generated 8% ee. This comparative 
study helped us to conclude that catalyst 64, in general, has a better asymmetric 
outcome in the reaction. Essentially, diylsulfates (63) are superior to their 
dioxathiepin (60) counterpart.  
Study of catalysts 71 and 72 showed very interesting results (Table 3.2, 
and Table 3.3) (Figure 3.10). Catalyst 71 produced 26% ee, while catalyst 72 
shows very  
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Figure 3.10: Developed chiral Brønsted acids which have great potential. 
O
O
S O HBF4
O
O
S
O
HBF4
O
R
R
R
R
61a R=H
61b R=
64a R=H
64b R=
64c R=
64d R=
64e R=
64f R= SiPh3
64g R= SiBnz3
O
O
S O HBF4
R
R 2
62a R=H
O
O
S
O
HBF4
O
R
R 2
NH2
NH2 HBF4
NH2
NH2
2HBF4
71
72
65a R=H
65b R=
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Table 3.2: Use of chiral dioxathiepin and diylsulfate derivatives bound with 
Brønsted acid for asymmetric aza-Henry reactions. 
Ph H
N
Ph
CH3O2N Ph
NO2
NH
Ph
+
1 eqv. 20 eqv.
Entry Catalyst Catalyst loading
(eqv.)
% conversion
by NMR
% ee
RT
Time (hr)
1 61a 0.1 192 18 3
2
64a 0.1 72 21 83
61b 0.1
4 64b 0.1 102 4a 42
549 56a 13
a Isolated yield
5
6
71
72
0.1
0.1 25 6
32 2676
72
7
8
65b 0.05 439 64a 13
64c 0.1 45 39a 79
 
 
low selectivity (6% ee). These results suggest that the ratio of chiral component 
to the Brønsted acid component could play an important role in asymmetry of the 
reaction. This phenomenon was also supported via changing the Brønsted acid 
to CF3SO3H. 
Applying this concept to our new chiral Brønsted acid system directed us to a 
very exciting avenue of results (Table 3.2). The attention switched towards 
catalyst 64 because of the better selectivity compared to catalyst 61. The next 
point of interest was to check the effect on ratio of the chiral component 63 to the 
Brønsted acid (HBF4.Et2O) (Table 3.4). This set of experiments revealed that 64a 
: HBF4 ratio 2:1 attains the highest amount of asymmetry. This finding does not 
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hold in the case of bulkiness at the 3,3’-position (Entry 6,Table 3.2). As a result, 
the focus was to find the best catalyst using a 1:1 ratio of the chiral component 
63 and the Brønsted acid. Next attempt was to increase the bulkiness at the 3,3’-
position of 63. Interestingly, 64c expressed a very promising result by attaining 
higher yield and ee in a shorter reaction time (Entry 5, Table 3.2). As expected 
the interest continued to increase the bulkiness at the 3,3’-position of chiral 
component 63 with the goal of high yield and selectivity. So far all the attempts to 
synthesize 63d, 63e, and 63g failed because of strong chlorinating capability of 
SO2Cl2. 63f was synthesized by changing the base to dimethylaminopyridine 
(DMAP) instead of pyridine. Further experiments are in the process to find the 
catalytic effect of 63f as a catalyst. 
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Table 3.3: Effect of changing Brønsted acid bound to chiral amines for 
asymmetric aza-Henry reaction. 
Ph H
N
Ph
CH3O2N Ph
NO2
NH
Ph
+
1 eqv. 20 eqv.
Catalyst Catalyst loading
(eqv.)
% conversion
by NMR
% ee
RT
Time (hr)
NH2
NH2
2HBF4
0.1 72 25 6
NH2
NH2
HBF4 0.1 76 32 26
NH2
NH2
CF3SO3H 0.1 93 26 26
NH2
NH2
CF3SO3H 0.05 77 5 12
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Table 3.4: Effect of different ratio of chiral component 63a and HBF4. 
Ph H
N
Ph
CH3O2N Ph
NO2
NH
Ph
+
1 eqv. 20 eqv.
O
O
S
O HBF4
O
RT
Time (hr) % conversion
by NMR
% ee
0.1 eqv. 0.1 eqv. 72 21 8
0.1 eqv. 0.05 eqv. 102 10 42
0.15 eqv. 0.05 eqv. 92 13 41
0.2 eqv. 0.05 eqv. 92 6 29
0.3 eqv. 0.05 eqv 92 11 34
0.1 eqv. 0.0 eqv. 92 2 14  
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3.3.1  Conclusion 
In conclusion, this reports the use of a complete new chiral Brønsted acid 
for asymmetric organic reactions. At present, further derivatization of these 
catalysts and exploring further applications of this new class of organocatalysts is 
under investigation. 
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3.4  Experimental 
3.4.1  General Procedure 
All organometallic operations were performed under a dry nitrogen atmosphere 
with standard Schlenk techniques. All of the glass flasks were flame dried under 
vacuum and filled with nitrogen prior to use. Column chromatography was 
performed with silica gel (40-140 mesh). HPLC grade CH2Cl2 was distilled under 
N2 from P2O5. HPLC grade pentane was distilled from sodium under an inert 
atmosphere immediately prior to use. Reagent grade Et2O and tetrahydrofuran 
were freshly distilled under a N2 atmosphere from sodium benzophenone ketyl. 
Benzaldehyde, p-tolualdehyde, and p-anisaldehyde were purified by extraction 
with NaHCO3 solution, washed with water, dried over Na2SO4, and distilled under 
vacuum. p-Nitrobenzaldehyde and p-chlorobenzaldehyde were purified by 
recrystallization from ethanol and dried under vacuum for several days. Ethyl 
diazoacetate (EDA) was obtained from Aldrich Chemical Co. 
All 1H (300 MHz), 13C NMR (75.5 MHz) were performed with a Bruker 
300 MHz NMR system and samples were dissolved in deuterated solvents. The 
chemical shifts (δ) are expressed in ppm relative to tetramethylsilane, and CDCl3 
was used as the solvent. FAB-MS was performed on a Micromass Autospec 
(Manchester, UK). Chiral HPLC was performed at room temperature utilizing a 
Regis chiral (S,S) Whelk-O-1 column. All HPLC were run using 1.5 mL/min flow 
rate with 98.5% hexane and 1.5% isopropyl alcohol mixture. 
 
 
263 
 
 
3.4.2  Synthesis of binephthyl derivative systems 
 
3.4.2.1 (R)-2,2’-Dimethoxy-1,1’-dinaphthyl  
A suspension of (R)-1,1’-bi-2-naphthol (28.10 g, 98.14 mmol) was heated 
in acetone to give a homogeneous solution (Equation 3.84). Potassium 
carbonate (47.47 g, 343.49 mmol) and methyl iodide (24.4 mL, 392.57 mmol) 
were added to the solution, and the mixture was heated at reflux for 24 h. 
Additional methyl iodide (24.4 mL, 392.57 mmol) was added, and heating was 
continued for 12 h. The solvent was evaporated to leave a volume of 200 mL, 
which was cooled to 25 °C and treated with 200 mL of water. The mixture was 
stirred for 8 h, and the resulting solid was washed with water and dried to afford 
30.14 g (98%) of (R)- 2,2’-Dimethoxy-1,1’-dinaphthyl120 as a white powder: 1H 
NMR δ: 7.98 (d, 2H), 7.86 (d, 2H), 7.46 (d, 2H), 7.31 (t, 2H), 7.21 (t, 2H), 7.10 (d, 
2H), 3.77 (s, 6H). 
 
Equation 3.84: Protection of BINOL with methoxy group. 
OH
OH
OMe
OMe
CH3I
K2CO3
Acetone
98%  
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3.4.2.2 (R)-2,2’-Dimethoxymethyl-1,1’-dinaphthyl  
(R)-binephthol ((R)-BINOL, 2 g, 6.98 mmol) and NaH (60% dispersion in 
mineral oil, 0.42 g, 17.46 mmol) was taken in a round bottom flask under N2-
environment at 0oC (Equation 3.85). This was dissolved in 40 mL THF followed 
by addition of MOMBr (1.14 mL, 13.97 mmol) at 0oC. The resulting mixture was 
gradually allowed to warm to room temperature and left stirring for 1 h. Water 
was added to quench the reaction. The organic layer was separated and the 
aqueous layer was extracted with Et2O. The combined organic layers were dried 
with Na2SO4, and after evaporation (R)-1,1’-bi-2-methoxymethyloxynaphthalene 
was obtained in a quantitative yield.118 
 
Equation 3.85: Protection of BINOL with methoxy methyl group. 
OH
OH
OMOM
OMOM
MOMBr
NaH
THF, rt
 
 
3.4.2.3 (R)-3,3’-Bis(dihydroxyborane)-2,2’-dimethoxy-1,1’-dinaphthyl 
To a solution of TMEDA (3.20 mL, 21.38 mmol) in ether (50 mL) was 
added at room temperature 2.5 M n-BuLi in hexane (8.55 mL, 21.38 mmol) 
(Equation 3.86). The solution was stirred for 30 min, solid (R)-2,2’-dimethoxy-
1,1’-dinaphthyl (2.24 g, 7.12 mmol) was added in one portion, and the reaction 
mixture was stirred for 3 h. The resulting light brown suspension was cooled to -
78 °C, and ethyl borate (7.47 mL, 43.89 mmol) was added over a period of 10 
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min. The solution was allowed to warm to room temperature and stirred 
overnight. The reaction mixture was cooled to 0 °C, 1 M HCl solution (100 mL) 
was added, and the resulting solution was stirred for 2 h at room temperature. 
The organic layer was washed with 1 M HCl solution and brine, dried (Na2SO4), 
and concentrated in vacuum. The resulting pale yellow solid was recrystallized 
from toluene to give 2.04 g (71%) of (R)-3,3’-Bis(dihydroxyborane)-2,2’-
dimethoxy-1,1’-dinaphthyl as colorless crystals.120 1H NMR δ: 8.62 (s, 2H), 7.99 
(d, 2H), 7.44 (t, 2H), 7.32 (td, 2H), 7.16 (d, 2H), 6.10 (s, 4H, OH), 3.31 (s, 6H). 
 
Equation 3.86: Synthesis of methoxy protected BINOL boronic acid. 
OMe
OMe
OMe
OMe
1. n-BuLi, TMEDA, Et2O, rt
2. (EtO)3B, -78
oC to rt
3. HCl
B(OH)2
B(OH)2
71%  
 
3.4.2.4 (R)-3,3’-Bis(4”-methylphenyl)-2,2’-dihydroxy-1,1’-dinaphthyl 
4-Bromotoluene (1.49 g, 8.69 mmol), Ba(OH)2 (1.49 g, 8.69 mmol), and 
Pd(PPh3)4 (134 mg, 116 mmol) were added to a solution of (R)-3,3’-
Bis(dihydroxyborane)-2,2’-dimethoxy-1,1’-dinaphthyl (980 mg, 2.89 mmol) in 
degassed dioxane/water (20 mL, 3:1) (Equation 3.87).120 The reaction mixture 
was heated at reflux for 24 h and cooled to room temperature. Dioxane was 
removed, and the resulting residue was redissolved in methylene chloride, the 
washed with 1 N HCl solution and brine, dried (using Na2SO4), and concentrated 
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in vacuum to give crude coupling products. Then it was dissolved in 50 mL 
CH2Cl2. 1.0 M solution of BBr3 in CH2Cl2 (17.39 mL, 17.39 mmol) was added to 
the solution at 0 °C. The reaction mixture was warmed to room temperature, 
stirred for 24 h, and quenched with water (1 mL) in an ice bath. The mixture was 
poured into a stirred mixture of CH2Cl2 and water. The organic layer was washed 
with brine, dried over Na2SO4, and concentrated under vacuum. Chromatography 
on SiO2 (hexanes/EtOAc, 8:1) gave 660 mg (50%) of (R)-3,3’-Bis(4”-
methylphenyl)-2,2’-dihydroxy-1,1’-dinaphthyl as a solid.121 1H NMR δ: 8.12 (s, 
2H), 8.00 (d, 2H), 7.76 (d, 4H), 7.45 (td, 2H), 7.37 (t, 8H), 5.61 (s, 2H); 13C NMR 
δ: 150.3, 137.5, 137.1, 134.6, 133.0, 131.1, 130.7, 130.3, 129.5, 129.2, 128.8, 
128.4, 127.7, 127.1, 126.8, 124.3, 124.2, 112.6, 21.3.  
 
Equation 3.87: Synthesis of (R)-3,3’-bis(4”-methylphenyl)-2,2’-dihydroxy-1,1’-
dinaphthyl by Suzuki coupling followed by deprotection reaction. 
OMe
OMe
B(OH)2
B(OH)2
OH
OH
1. 4-Bromotoluene
    Pd(PPh3)4
    Ba(OH)2
    dioxane/water
2. BBr3
 
 
3.4.2.5 (R)-3,3’-Bis(1”-naphthyl)-2,2’-dihydroxy-1,1’-dinaphthyl 
1-Bromonaphthalene (4.28 g, 20.68 mmol), Ba(OH)2⋅ (3.54 g, 20.68 
mmol), and Pd(PPh3)4 (318 mg, 0.27 mmol) were added to a solution of (R)-3,3’-
bis(dihydroxyborane)-2,2’-dimethoxy-1,1’-dinaphthyl (2.62 g, 6.89 mmol) in 
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degassed dioxane/water (100 mL, 3:1) (Equation 3.88).120 The reaction mixture 
was heated at reflux for 24 h and cooled to room temperature. Dioxane was 
removed, and the resulting residue was redissolved in methylene chloride, 
washed with 1 N HCl acid solution and brine, dried (using Na2SO4), and 
concentrated in vacuum to give crude coupling products. Then it was dissolved in 
35 mL CH2Cl2. 2.60 mL BBr3 (27.58 mmol) was added to the solution at 0 °C. 
The reaction mixture was warmed to room temperature, stirred for 24 h, and 
quenched with water (1 mL) in an ice bath. The mixture was poured into a stirred 
mixture of CH2Cl2 and water. The organic layer was washed with brine, dried 
over Na2SO4, and concentrated under vacuum. Chromatography on SiO2 
(hexanes/EtOAc, 8:1) gave 1.41 g (38%) of (R)-3,3’-bis(1”-naphthyl)-2,2’-
dihydroxy-1,1’-dinaphthyl as a solid.122 1H NMR δ: 8.03 (d, 2H), 7.96 (q, 6H), 
7.84 (d, 2H,), 7.30-7.8 (m, 20H), 5.1-5.3 (b, OH). 13C NMR δ:  131.9, 128.6, 
128.3, 127.9, 127.2, 126.3, 125.9, 125.4, 124.6, 124.4, 124.1. 
 
Equation 3.88: Synthesis of (R)-3,3’-bis(1”-naphthyl)-2,2’-dihydroxy-1,1’-
dinaphthyl by Suzuki coupling followed by deprotection reaction. 
OMe
OMe
B(OH)2
B(OH)2
OH
OH
1. 1-Bromonaphthalene
    Pd(PPh3)4
    Ba(OH)2
    dioxane/water
2. BBr3
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3.4.2.6 (R)-3,3’-Bis-(2-mesityl)-2,2’-dihydroxy-1,1’-dinaphthyl 
2-Bromomesitylene (5.66 g, 19.97 mmol), Ba(OH)2⋅ (3.42 g, 19.97 mmol), 
and Pd(PPh3)4 (307 mg, 0.27 mmol) wew added to a solution of (R)-3,3’-
bis(dihydroxyborane)-2,2’-dimethoxy-1,1’-dinaphthyl (2.53 g, 6.66 mmol) in 
degassed dioxane/water (100 mL, 3:1) (Equation 3.89).120 The reaction mixture 
was heated at reflux for 24 h and cooled to room temperature. Dioxane was 
removed, and the resulting residue was redissolved in methylene chloride, 
washed with 1 N HCl acid solution and brine, dried (using Na2SO4), and 
concentrated in vacuum to give crude coupling products. Then it was dissolved in  
 
Equation 3.89: Synthesis of (R)-3,3’-bis-(2-mesityl)-2,2’-dihydroxy-1,1’-
dinaphthyl by Suzuki coupling followed by deprotection. 
OMe
OMe
B(OH)2
B(OH)2
OH
OH
1. Bromomesitylene
Pd(PPh3)4
Ba(OH)2
dioxane/water
2. BBr3
 
 
35 mL CH2Cl2. 6.17 mL BBr3 (64.74 mmol) was added to the solution at 0 °C. 
The reaction mixture was warmed to room temperature, stirred for 24 h, and 
quenched with water (1 mL) in an ice bath. The mixture was poured into a stirred 
mixture of CH2Cl2 and water. The organic layer was washed with brine, dried 
over Na2SO4, and concentrated under vacuum. Chromatography on SiO2 
(hexanes/EtOAc, 8:1) gave 0.63 g (14.27%) of (R)-3,3’-bis(2”-mesityl)-2,2’-
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dihydroxy-1,1’-dinaphthyl as a solid.113 1H NMR (300 MHz, CDCl3) δ = 7.84 (d, 
2H), 7.72 (s, 2H), 7.36-7.23 (m, 6 H), 6.98 (s, 4H), 5.00 (s, 2H), 2.31 (s, 6H), 2.13 
(s, 6H), 2.06 (s, 6H) 
 
3.4.2.7 (R)-3,3’-Bis(9”-phenanthryl)-2,2’-dihydroxy-1,1’-dinaphthyl 
9-Bromonaphenanthrene (2.13 g, 8.28 mmol), Ba(OH)2⋅ (1.42 g, 8.29 
mmol), and Pd(PPh3)4 (128 mg, 0.11 mmol) were added to a solution of (R)-3,3’-
Bis(dihydroxyborane)-2,2’-dimethoxy-1,1’-dinaphthyl (1.05 g, 2.76 mmol) in 
degassed dioxane/water (40 mL, 3:1) (Equation 3.90).120 The reaction mixture 
was refluxed for 24 h and cooled to room temperature. Dioxane was removed, 
and the resulting residue was redissolved in CH2Cl2, washed with 1 N HCl acid 
solution and brine, dried (using Na2SO4), and concentrated in vacuum to give 
crude coupling products. Then it was dissolved in 20 mL CH2Cl2. 1.04 mL  
 
Equation 3.90: Synthesis of (R)-3,3’-bis(9”-phenanthryl)-2,2’-dihydroxy-1,1’-
dinaphthyl by Suzuki coupling followed by deprotection reaction. 
OMe
OMe
B(OH)2
B(OH)2
OH
OH
1. 9-Bromophenanthrene
Pd(PPh3)4
Ba(OH)2
dioxane/water
2. BBr3
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BBr3 (11.05 mmol) was added to the solution at 0 °C. The reaction mixture was 
warmed to room temperature, stirred for 24 h, and quenched with water (1 mL) in 
an ice bath. The mixture was poured into a stirred mixture of CH2Cl2 and water. 
The organic layer was washed with brine, dried over Na2SO4, and concentrated 
under vacuum. Chromatography on SiO2 (hexanes/EtOAc, 8:1) gave 0.66 g 
(44%) of (R)-3,3’-Bis(9”-phenanthryl)-2,2’-dihydroxy-1,1’-dinaphthyl as a solid.123 
1H NMR δ: 8.70 – 8.90 (m, 2H), 8.10 (dq, 1H), 7.80-8.00 (m, 4H), 7.60-7.8 (m, 
5H), 7.40-7.60 (m, 4H), 5.2-5.3 (b, 2H).  
 
3.4.2.8  (R)-3,3’-Bis(9”-anthracenyl)-2,2’-dihydroxy-1,1’-dinaphthyl 
9-Bromoanthracene (1.00 g, 3.88 mmol), Ba(OH)2⋅ (666 mg, 3.88 mmol), 
and Pd(PPh3)4 (60 mg, 0.05 mmol) were added to a solution of (R)-3,3’-
Bis(dihydroxyborane)-2,2’-dimethoxy-1,1’-dinaphthyl (492 mg, 1.29 mmol) in 
degassed dioxane/water (40 mL, 3:1) (Equation 3.91).120 The reaction mixture 
was refluxed for 24 h and cooled to room temperature. Dioxane was removed, 
and the resulting residue was redissolved in CH2Cl2, washed with 1 N HCl 
solution and brine, dried (using Na2SO4), and concentrated in vacuum to give 
crude coupling products. Then it was dissolved in 50 mL CH2Cl2. 1.82 mL BBr3 
(19.29 mmol) was added to the solution at 0 °C. The reaction mixture was 
warmed to room temperature, stirred for 24 h, and quenched with water (1 mL) in 
an ice bath. The mixture was poured into a stirred mixture of CH2Cl2 and water. 
The organic layer was washed with brine, dried over granular Na2SO4, and 
concentrated under vacuum. Chromatography on SiO2 (hexanes/EtOAc, 8:1) 
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gave 0.60 g (73%) of (R)-3,3’-Bis(9”-anthraceneyl)-2,2’-dihydroxy-1,1’-dinaphthyl 
as a solid.124 1H NMR (CDCl3, 300 MHz) δ : 8.24 (s, 2H), 8.03 (m, 2H), 7.86 (m, 
2H), 7.80 (d), 7.63-7.75 (m, 8H), 7.10-7.30 (m, 12H), 6.94 (m, 2H), 5.10 (s, 2H, 
OH). 
 
Equation 3.91: Synthesis of (R)-3,3’-bis(9”-anthracenyl)-2,2’-dihydroxy-1,1’-
dinaphthyl. 
OMe
OMe
B(OH)2
B(OH)2
OH
OH
1. 9-Bromoanthracene
    Pd(PPh3)4
    Ba(OH)2
    dioxane/water
2. BBr3
 
 
4.2.9  (R)-3,3’-Bis(triphenylsilyl)-2,2’-dihydroxy-1,1’-dinaphthyl 
MOM protected BINOL (2.61 g, 6.98 mmol) was dissolved in Et2O (20 mL) 
followed by dropwise addition of nBuLi (6.98 mL, 2.5 M, 17.46 mmol) over 5 mins 
at room temperature (Equation 3.92).99 The resulting suspension was stirred at 
room temperature for 1 hour 30 mins and a color change was observed over the 
initial 30 mins from a yellow solution to a brown suspension. The mixture was 
cooled to 0 °C and THF (40 mL) was added. After a further 15 mins at 0°C a 
solution of Ph3SiCl (5.15 g, 17.46 mmol) in THF (20 mL) was added. The reaction 
mixture was warmed to room temperature and stirred for 30 hours. After addition 
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of the THF and Ph3SiCl the color darkened from light brown to very dark brown 
over the first one hour. The color faded through green to orange and finally pale 
yellow over the 30 hour period. The reaction was quenched by addition of 
saturated NH4Cl, then extracted with CH2Cl2 as an organic solvent. The organics 
were washed with brine and dried over granular Na2SO4, filtered and 
concentrated to yield the crude product as viscous yellow oil. The product was 
purified by gradient silica column chromatography using pentane and 
ethylacetate solvent system. Then the product was dissolved in dioxane (20 mL) 
and added 5 mL concentrated HCl acid to the stirring solution. After 24 hours the 
reaction mixture was neutralized by adding saturated NaHCO3 solution and the 
product was extracted using CH2Cl2 as an organic solvent. Then it was dried over 
granular Na2SO4 and solvent was removed by rotary evaporation. The product 
was separated by a column chromatography using gradient pentane/EtOAc 
mixture.99 1H NMR (300 MHz, C6D6) δ = 4.68 (s, 2H, OH), 6.90-7.38 (m, 26H, 
ArH), 7.80-7.84 (m, 12H, ArH), 8.14 (s, 2H, ArH); 
 
Equation 3.92: Synthesis of (R)-3,3’-bis(triphenylsilyl)-2,2’-dihydroxy-1,1’-
dinaphthyl. 
OMOM
OMOM
OMOM
OMOM
SiPh3
SiPh3
n-BuLi
Ph3SiCl OH
OH
SiPh3
SiPh3
HCl
Dioxane
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3.4.2.10  (R)- 1,1’-dinaphthyl-2,2’-dioxathiepin 
Under N2-environment (R)-BINOL (0.38 g, 1.33 mmol) was dissolved in 10 
mL CH2Cl2 at 0oC followed by addition of pyridine (2.146 mL, 26.54 mmol). 
SOCl2 (0.24 mL, 3.31 mmol) was slowly added to the stirring mixture (Equation 
3.93). After addition of SOCl2 the solution was refluxed for 3 hours. Then it was 
cooled to room temperature. Saturated citric acid solution was added to quench 
the reaction and then extracted the product three time with 15mL portion of 
CH2Cl2. Then washed the collected organic layer three times with saturated 
NaHCO3 solution and dried over MgSO4. After removing the solvent by rotary 
evaporation 75% (0.33 g) product was isolated.116 1H NMR (300 MHz, CDCl3) δ = 
8.04-8.07 (d, 2H), 7.98-7.99 (d, 2H), 7.48-7.64 (m, 6H), 7.34-7.44 (m, 2H). 
 
Equation 3.93: Synthesis of (R)- 1,1’-dinaphthyl-2,2’-dioxathiepin. 
OH
OH
O
O
SOCl2
Pyridine
80oC
S O
 
 
4.2.11  (R)-3,3’-Bis(4”-methylphenyl)-1,1’-dinaphthyl-2,2’-dioxathiepin 
Under N2-environment (R)-3,3’-Bis(4”-methylphenyl)-2,2’-dihydroxy-1,1’-
dinaphthyl (0.70 g, 1.50 mmol) was dissolved in 10 mL CH2Cl2 at 0oC followed by 
addition of pyridine (2.40 mL, 30.04 mmol) (Equation 3.94). SOCl2 (0.27 mL, 3.75 
mmol) was slowly added to the stirring mixture. After addition of SOCl2 the 
solution was refluxed for 3 hours. Then it was cooled to  
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room temperature. Saturated citric acid solution was added to quench the 
reaction and the extracted the product three time with 15mL portion of CH2Cl2. 
Then washed the organic layer three times with NaHCO3 solution and dried over 
MgSO4. After removing the solvent by rotary evaporation 70% product was 
isolated. 1H NMR (300 MHz, CDCl3) δ = 7.64–8.6 (m, 8H), 7.50-7.6 (m, 10H), 
7.34-7.43 (m, 10H), 2.50 (s, 6H). 13C NMR (DMSO, 75.4 MHz) δ: 152.7, 137.9, 
135.9, 130.7, 130.6, 129.8, 129.7, 129.4, 129.3, 128.9, 128.5, 128.4, 127.0, 
126.9, 126.7, 126.6, 126.5, 126.3, 124.2, 117.7, 21.2. MS calculated for 
C34H24O3S 512, found 512.  
 
Equation 3.94: Synthesis of (R)-3,3’-bis(4”-methylphenyl)-1,1’-dinaphthyl-2,2’-
dioxathiepin. 
OH
OH
O
O
SOCl2
Pyridine
80oC
S O
 
 
3.4.2.12  (R)-1,1’-dinaphthyl-2,2’-diylsulfate 
Under N2-atmosphere (R)-1,1’-bi-2-naphthol (6.84 g, 23.88 mmol) was 
dissolved in 30.78 mL (380 mmol) pyridine. At 0oC SO2Cl2 (2.51 mL, 31.05 mmol) 
was added slowly (Equation 3.95). Then the solution was heated to 90oC for 30 
minutes. The reaction was quenched by neutralizing with 5 M HCl solution. The 
total mixture was heated to boiling for 10 minutes. The product was filtered as 
275 
 
 
nice orange colored solid in 40% yield.117 1H NMR (300 MHz, CDCl3) δ = 8.13-
8.17 (d, 2H), 8.03-8.06 (d, 2H), 7.66-7.71 (d, 2H), 7.55-7.65 (m, 4H), 7.40-7.47 
(m, 2H). 
 
Equation 3.95: Synthesis of (R)-1,1’-dinaphthyl-2,2’-diylsulfate. 
OH
OH
O
O
SO2Cl2
Pyridine
80oC
S
O
O
 
 
3.4.2.13 (R)-3,3’-Bis(4”-methylphenyl)-1,1’-dinaphthyl-2,2’-diylsulfate 
Under N2-atmosphere (R)-3,3’-Bis(4”-methylphenyl)-2,2’-dihydroxy-1,1’-
dinaphthyl (0.49 g, 1.05 mmol) was dissolved in 6 mL pyridine. At 0oC SO2Cl2 
(0.11 mL, 1.44 mmol) was added slowly (Equation 3.96).117 Then the solution 
was heated at 90oC for 30 minutes. The reaction was quenched by neutralizing 
with 5 M HCl solution. The total mixture was heated to boiling for 10 minutes. The  
 
Equation 3.96: Synthesis of (R)-3,3’-bis(4”-methylphenyl)-1,1’-dinaphthyl-2,2’-
diylsulfate. 
OH
OH
O
O
SO2Cl2
Pyridine
80oC
S
O
O
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product (0.15 g, 0.28 mmol, 27% yield) was filtered as nice orange colored solid. 
1H NMR (300 MHz, CDCl3) δ = 8.15 (s, 2H), 8.05 (m, 4H), 7.55-7.65 (m, 8H), 
7.40-7.7 (m, 2H), 7.30-7.37 (d, 6H), 2.45 (s, 6H). 13C NMR (CDCl3, 75.4 MHz) δ: 
132.8, 129.5, 129.2, 128.7, 128.6, 127.6, 127.0, 126.8, 119.9, 21.2. MS 
calculated for C34H24O4S 528, found 528.  
 
3.4.2.14 (R)-3,3’-Bis(1”-nephthyl)-1,1’-dinaphthyl-2,2’-diylsulfate 
Under N2-atmosphere (R)-3,3’-Bis(1”-naphthyl)-2,2’-dihydroxy-1,1’-qdinaphthyl 
(2.54 g, 4.71 mmol) was dissolved in 20 mL pyridine (Equation 3.97).117 At 0oC 
SO2Cl2 (0.57 mL, 7.07 mmol) was added slowly. Then the solution was heated at 
90oC for 30 minutes. The reaction was quenched by neutralizing with 5 M HCl 
acid solution. The total mixture was heated to boiling for 10 minutes. The product  
 
Equation 3.97: Synthesis of (R)-3,3’-bis(1”-nephthyl)-1,1’-dinaphthyl-2,2’-
diylsulfate. 
OH
OH
O
O
SO2Cl2
Pyridine
80oC
S
O
O
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(0.0050 g) was filtered as nice white solid. 1H NMR (300 MHz, CDCl3) δ = 8.16 
(m, 2H), 8.06 (m, 2H), 7.94 (m, 4H), 7.30-7.9 (m, 12H). 13C NMR (CDCl3 75.4 
MHz) δ = 133.8, 133.1, 128.8, 128.6, 128.2, 127.2, 127.1, 126.3, 125.7, 125.3, 
124.6. MS calculated for C40H24O4S 600, found 600.  
 
3.4.2.15 (R)-3,3’-Bis(mesityl)-1,1’-dinaphthyl-2,2’-diylsulfate 
Under N2-atmosphere (R)-3,3’-Bis(mesityl)-2,2’-dihydroxy-1,1’-dinaphthyl 
(0.2 g, 0.31 mmol) was dissolved in 20 mL pyridine (Equation 3.98).117 At 0oC 
SO2Cl2 (0.03 mL, 0.37 mmol) was added slowly. Then the solution was heated at 
90oC for 30 minutes. The reaction was quenched by neutralizing with 5 M HCl 
solution. The total mixture was heated to boiling for 10 minutes. Different 
fractions were isolated by column chromatography. None of the fraction was 
found to be the product.  
 
Equation 3.98: Failed synthesis of (R)-3,3’-Bis(mesityl)-1,1’-dinaphthyl-2,2’-
diylsulfate. 
 
OH
OH
O
O
SO2Cl2
Pyridine
80oC
S
O
O0% yield
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3.4.2.16 (R)-3,3’-Bis(9”-anthracenyl)-1,1’-dinaphthyl-2,2’-diylsulfate 
Under N2-atmosphere (R)-3,3’-Bis(9”-anthracenyl)-2,2’-dihydroxy-1,1’-
dinaphthyl (0.2 g, 0.31 mmol) was dissolved in 20 mL pyridine (Equation 3.99).117 
At 0oC SO2Cl2 (0.03 mL, 0.37 mmol) was added slowly. Then the solution was 
heated at 90oC for 30 minutes. The reaction was quenched by neutralizing with 5 
M HCl solution. The total mixture was heated to boiling for 10 minutes. Different 
fractions were isolated by column chromatography. None of the fraction was 
found to be the product.  
 
Equation 3.99: Failed synthesis of (R)-3,3’-Bis(9”-anthracenyl)-1,1’-dinaphthyl-
2,2’-diylsulfate. 
OH
OH
O
O
SO2Cl2
Pyridine
80oC
S
O
O0% yield
 
 
3.4.2.17 (R)-3,3’-Bis(phenanthryl)-1,1’-dinaphthyl-2,2’-diylsulfate 
Under N2-atmosphere (R)-3,3’-Bis(phenanthryl)-2,2’-dihydroxy-1,1’-
dinaphthyl (0.93 g, 1.46 mmol) was dissolved in 30 mL pyridine (Equation 
3.100).117 At 0oC SO2Cl2 (0.17 mL, 2.18 mmol) was added slowly. Then the 
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solution was heated at 90oC for 30 minutes. The reaction was quenched by 
neutralizing with 5 M HCl acid solution. The total mixture was heated to boiling 
for 10 minutes. Different fractions were isolated by column chromatography. 
None of the fraction was found to be the product.  
 
Equation 3.100: Failed synthesis of (R)-3,3’-Bis(phenanthryl)-1,1’-dinaphthyl-
2,2’-diylsulfate. 
OH
OH
O
O
SO2Cl2
Pyridine
80oC
S
O
O0% yield
 
 
4.2.18  (R)-3,3’-Bis(triphenylsilyl)-2,2’-dihydroxy-1,1’-dinaphthyl-2,2’-
diylsulfate 
Under N2-atmosphere (R)-3,3’-Bis(triphenylsilyl)-2,2’-dihydroxy-1,1’-
dinaphthyl (0.1 g, 0.13 mmol) was dissolved in 10 mL pyridine (Equation 
3.101).117 At 0oC SO2Cl2 (0.01 mL, 0.19 mmol) was added slowly. Then the 
solution was heated at 90oC for 30 minutes. The reaction was quenched by 
neutralizing with 5 M HCl solution. The total mixture was heated to boiling for 10 
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minutes. Different fractions were isolated by column chromatography. None of 
the fraction was found to be the product.  
Equation 3.101: Failed synthesis of (R)-3,3’-bis(triphenylsilyl)-2,2’-dihydroxy-
1,1’-dinaphthyl-2,2’-diylsulfate. 
OH
OH
O
O
SO2Cl2
pyridine, RT
S
O
O
SiPh3
SiPh3
SiPh3
SiPh3  
 
Under N2-atmosphere (R)-3,3’-Bis(triphenylsilyl)-2,2’-dihydroxy-1,1’-
dinaphthyl (0.1 g, 0.13 mmol) and dimethylaminopyridine (0.31 g, 2.55 mmol) 
were dissolved in 2 mL CH2Cl2 (Equation 3.102). At 0oC SO2Cl2 (0.01 mL, 0.19 
mmol) was added slowly. Then the solution was allowed to reach room 
temperature and stirred for 24hrs. The reaction was quenched by neutralizing 
with saturated solution of citric acid. The total mixture was heated to boiling for 
10 minutes. 0.02 g product was isolated by column chromatography. 1H NMR 
(300 MHz, CDCl3) δ = 8.21 (s, 2H), 7.87 (d, 2H), 7.61-7.70 (m, 23H), 7.35-7.50 
(m, 41H). 13C NMR (CDCl3 75.4 MHz) δ = 151.0, 142.3, 142.0, 136.6, 136.2, 
135.9, 134.9, 133.4, 133.2, 131.5, 130.0, 129.6, 129.4, 128.8, 127.8, 127.7, 
126.9, 126.5, 123.8, 123.3. MS calculated for C56H40O4SSi2 865, found 865. 
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Equation 3.102: Synthesis of (R)-3,3’-bis(triphenylsilyl)-2,2’-dihydroxy-1,1’-
dinaphthyl-2,2’-diylsulfate. 
OH
OH
O
OSO2Cl2
CH2Cl2, RT
S
O
O
SiPh3
SiPh3
SiPh3
SiPh3
N
N
 
 
3.4.2.19 (R)-3,3’-Bis(tribenzylsilyl)-2,2’-dihydroxy-1,1’-dinaphthyl-2,2’-
diylsulfate 
Under N2-atmosphere (R)-3,3’-Bis(tribenzylsilyl)-2,2’-dihydroxy-1,1’-
dinaphthyl (4.39 g, 4.97 mmol) was dissolved in 100 mL pyridine (Equation 
3.103).117 At 0oC SO2Cl2 (0.60 mL, 7.42 mmol) was added slowly. Then the 
solution was heated at 90oC for 30 minutes. The reaction was quenched by 
neutralizing with 5 M HCl solution. The total mixture was heated to boiling for 10 
minutes. Different fractions were isolated by column chromatography. None of 
the fraction was found to be the product.  
 
Equation 3.103: Failed synthesis of (R)-3,3’-bis(tribenzylsilyl)-2,2’-dihydroxy-
1,1’-dinaphthyl-2,2’-diylsulfate. 
OH
OH
O
O
SO2Cl2
pyridine, RT
S
O
O
SiBn3
SiBn3
SiBn3
SiBn3  
282 
 
 
 
3.4.3  General procedure for the synthesis of N-benzylidene 
arylimines 
Amine and aldehyde were dissolved in equimorar amount in ethanol 
solvent and refluxed for an hour. After cooling it to room temperature water was 
added slowly to crystallize the product in almost quantative yield.125 
 
3.4.3.1  Synthesis of N-benzylidenephenylimines 
Benzaldehyde (1g, 9.42 mmol) and aniline (0.88g, 9.45 mmol) were 
dissolved in 20 mL ethanol (Equation 3.104). The solution was cooled to room 
temperature after refluxing for an hour. The water was slowly added to crystallize 
the product. The product was isolated by vacuum filtration in 85% yield.125 1H 
NMR (300 MHz, CDCl3) δ = 8.64 (s, 1H), 7.39-7.48 (m, 4H), 7.29-7.34 (m, 3H), 
7.06-7.09 (dd, 1H), 6.95-6.7.00 (dt, 1H).  
 
Equation 3.104: Synthesis of N-benzylidenephenylimines. 
 
 
 
 
3.4.3.2  Synthesis of N-benzylidene-4-methoxyphenylimines 
283 
 
 
p-Methoxybenzaldehyde (4.93g, 36.21 mmol) and aniline (3.37g, 36.21 
mmol) were dissolved in 20 mL ethanol (Equation 3.105).125 The solution was 
cooled to room temperature after refluxing for an hour. The water was slowly 
added to crystallize the product. The product was isolated by vacuum filtration in 
90% yield.126 1H NMR (300 MHz, CDCl3) δ = 8.41 (s, 1H), 7.87 (d, 2H), 7.50 (d, 
2H), 7.30 (m, 3H), 7.00 (d, 2H), 3.89 (s, 3H). 
 
Equation 3.105: Synthesis of N-benzylidene-4-methoxyphenylimines. 
 
 
3.4.3.3 Synthesis of N-benzylidene-2,4,5-trimethoxyphenylimines 
2,4,5-Trimethoxybenzaldehyde (1.00 g, 5.09 mmol) and aniline (0.47 g, 
5.1 mmol) were dissolved in 10 mL ethanol (Equation 3.106).125 The solution was 
cooled to room temperature after refluxing for an hour. The water was slowly 
added to crystallize the product. The product was isolated by vacuum filtration in 
92% yield.127 1H NMR (300 MHz, CDCl3) δ = 8.86 (s, 1H), 7.85 (s, 1H), 7.36 (m, 
2H), 7.20 (m, 3H), 6.53 (s, 1H), 3.97 (s, 3H), 3.96 (s, 3H), 3.90 (s, 3H). 
 
 
Equation 3.106: Synthesis of N-benzylidene-2,4,5-trimethoxyphenylimines. 
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3.4.3.4  Synthesis of N-benzylidene-2-nitrophenylimines 
2-Nitrobenzaldehyde (1.00 g, 6.62 mmol) and aniline (0.62 g, 6.62 mmol) 
were dissolved in 10 mL ethanol (Equation 3.107).125 The solution was cooled to 
room temperature after refluxing for an hour. The water was slowly added to 
crystallize the product. The product was isolated by vacuum filtration in 88% 
yield.128 1H NMR (300 MHz, CDCl3) δ = 9.23 (s, 1H), 8.36 (d, 1H), 8.10 (d, 1H), 
7.77 (m, 1H), 7.72 (m, 1H), 7.65 (m, 2H), 7.32 (m, 3H). 
 
Equation 3.107: Synthesis of N-benzylidene-2-nitrophenylimines. 
 
 
3.4.3.5  Synthesis of N-benzylidene-4-chlorophenylimines 
4-Chlorobenzaldehyde (1.00 g, 7.11 mmol) and aniline (0.66 g, 7.11 
mmol) were dissolved in 10 mL ethanol (Equation 3.108).125 The solution was 
cooled to room temperature after refluxing for an hour. The water was slowly 
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added to crystallize the product. The product was isolated by vacuum filtration in 
89% yield.126 1H NMR (300 MHz, CDCl3) δ = 8.45 (s, 1H), 7.87 (d, 2H), 7.50 (m, 
4H), 7.30 (m, 3H). 
 
Equation 3.108: Synthesis of N-benzylidene-4-chlorophenylimines. 
 
 
3.4.3.6 Synthesis of N-benzylidene-2,4-dichlorophenylimines 
2,4-Dichlorobenzaldehyde (1.00 g, 5.71 mmol) and aniline (0.53 g, 5.71 
mmol) were dissolved in 10 mL ethanol (Equation 3.109).125 The solution was 
cooled to room temperature after refluxing for an hour. The water was slowly 
added to crystallize the product. The product was isolated by vacuum filtration in 
80% yield.129 1H NMR (300 MHz, CDCl3) δ = 9.10 (s, 1H), 8.45 (d, 1H), 7.30-7.60 
(m, 8H). 
 
 
 
 
 
Equation 3.109: Synthesis of N-benzylidene-2,4-dichlorophenylimines. 
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3.4.3.7 Synthesis of N-benzylidene-4-phenylphenylimines 
4-Phenylbenzaldehyde (1.00 g, 5.48 mmol) and aniline (0.51 g, 5.48 
mmol) were dissolved in 10 mL ethanol (Equation 3.110).125 The solution was 
cooled to room temperature after refluxing for an hour. The water was slowly 
added to crystallize the product. The product was isolated by vacuum filtration in 
90% yield.130 1H NMR (300 MHz, CDCl3) δ = 8.50 (s, 1H), 8.02 (d, 2H), 7.69 (m, 
4H), 7.50 (m, 5H), 7.28 (m, 3H). 
 
Equation 3.110: Synthesis of N-benzylidene-4-phenylphenylimines. 
 
 
 
3.4.4  General procedure for the aza-Henry reaction 
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Catalytic amount of the sulfate was dissolved in CH2Cl2 in a round-bottom 
flask followed by addition of equimolar amount of HBF4.Et2O. The solvent was 
removed by rotary evaporator. Imine (1 equivalent) was added to the flask under 
N2-atmosphere. Then excess CH3NO2 (100 equivalent amount) was added to the 
reaction mixture as a solvent as well as a reagent. The reaction mixture was 
allowed to stir at room temperature for time till the completion of the reaction. 
Then the reaction mixture was passed through a silica plug to quench the 
reaction. The product was isolated after column chromatography. 
 
3.4.4.1  Synthesis of 2-(phenyl)-2-(phenylamino)-nitroethane 
Under nitrogen, N-benzylidenephenylimines (0.5g, 2.76 mmol) was 
dissolve in nitromethane (15.03 mL, 276 mmol) followed by addition of 
HBF4.Et2O (37µL, 0.276 mmol) (Equation 3.111). Then the reaction mixture was 
stirred until the reaction was deemed complete. Then the product was isolated by 
doing column chromatography with a gradient pentane and ethyl acetate mixture. 
1H NMR (300 MHz, CDCl3) δ = 7.36-7.47 (m, 5H), 7.14-7.20 (t, 2H), 6.75-6.80 (t, 
1H), 6.62-6.65 (d, 2H), 5.15-5.25 (m, 1H), 4.73-4.75 (d, 2H), 4.42 (s, 1H, NH). 
 
Equation 3.111: Synthesis of 2-(phenyl)-2-(phenylamino)-nitroethane. 
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3.4.4.2 Synthesis of 2-(2,4,5-trimethoxyphenyl)-2-(phenylamino)-
nitroethane 
Under nitrogen, N-benzylidene-2,4,5-trimethoxyphenylimines (0.5g, 1.51 
mmol) was dissolve in nitromethane (8.20 mL, 151 mmol) followed by addition of 
HBF4.Et2O (20µL, 0.15 mmol) (Equation 112). Then the reaction mixture was 
stirred until the reaction was deemed complete. Then the product was isolated by 
doing column chromatography with a gradient pentane and ethyl acetate mixture. 
1H NMR (300 MHz, CDCl3) δ: 7.07-7.13 (t, 2H), 6.84 (s, 1H), 6.62-6.72 (m, 3H), 
6.54 (s, 1H), 5.34-5.38 (t, 1H), 4.67-4.76 (m, 2H), 4.09 (s, 3H), 3.92 (s, 3H), 3.71 
(s, 3H). 
 
Equation 3.112: Synthesis of 2-(2,4,5-trimethoxyphenyl)-2-(phenylamino)-
nitroethane. 
 
 
3.4.4.3 Synthesis of 2-(4-phenyl-phenyl)-2-(phenylamino)-nitroethane 
Under nitrogen, N-benzylidene-4-phenylphenylimines (0.5g, 1.57 mmol) 
was dissolve in nitromethane (8.56 mL, 157 mmol) followed by addition of 
HBF4.Et2O (21µL, 0.16 mmol) (Equation 3.113). Then the reaction mixture was 
stirred until the reaction was deemed complete. Then the product was isolated by 
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doing column chromatography with a gradient pentane and ethyl acetate mixture. 
1H NMR (300 MHz, CDCl3) δ: 8.06-8.09 (d, 1H), 7.70-7.80 9 (m, 2H), 7.55-7.64 
(t, 1H), 7.46-7.52 (t, 1H), 7.07-7.13 (t, 2H), 6.70-6.75 (t, 1H), 6.49-6.52 (d, 2H), 
5.84 (m, 1H), 4.98-5.03 (dd, 1H), 4.79 (dd, 1H). 
 
Equation 3.113: Synthesis of 2-(4-phenyl-phenyl)-2-(phenylamino)-nitroethane. 
 
 
3.4.4.4  Synthesis of 2-(2-nitrophenyl)-2-(phenylamino)-
nitroethane 
 Under nitrogen, N-benzylidene-2-nitrophenylimines (0.5g, 1.74 mmol) was 
dissolve in nitromethane (9.49 mL, 174 mmol) followed by addition of HBF4.Et2O 
(24µL, 0.17 mmol) (Equation 3.114). Then the reaction mixture was stirred until 
the reaction was deemed complete. Then the product was isolated by doing 
column chromatography with a gradient pentane and ethyl acetate mixture. 1H 
NMR (300 MHz, CDCl3) δ: 8.10-8.11 (d, 1H), 7.70-7.74 (d, 1H), 7.58-7.64 (t, 1H), 
7.44-7.54 (t, 1H), 7.08-7.14 (2H), 6.70-6.78 (t, 1H), 6.49-6.53 (d, 2H), 5.85 (m, 
1H), 4.98-5.07 (dd, 1H), 4.9 (s, 1H). 
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Equation 3.114: Synthesis of 2-(2-nitrophenyl)-2-(phenylamino)-nitroethane. 
 
 
3.4.4.5 Synthesis of 2-(4-methoxyphenyl)-2-(phenylamino)-nitroethane 
 
Under nitrogen, N-benzylidene-4-methoxyphenylimines (0.5g, 1.82 mmol) 
was dissolved in nitromethane (9.93mL, 182 mmol) followed by addition of 
HBF4.Et2O (25µL, 0.18 mmol) (Equation 3.115). Then the reaction mixture was 
stirred until the reaction was deemed complete. Then the product was isolated by 
doing column chromatography with a gradient pentane and ethyl acetate mixture. 
1H NMR (300 MHz, CDCl3) δ: 7.31-7.34 (d, 2H), 7.14-7.20 (t, 2H), 6.90-6.93 (d, 
2H), 6.72-6.80 (t, 1H), 6.63-6.66 (d, 2H), 5.10-5.20 (t, 1H), 4.69-4.72 (dd, 2H), 
3.81 (s, 3H). 
 
Equation 3.115: Synthesis of 2-(4-methoxyphenyl)-2-(phenylamino)-nitroethane. 
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3. 8 Results and Disscussion for  Oxazinanones  
Equation 3.84: Reaction of 1,3-oxazinan-2-one  
10 mol% HBF4  OEt2
CH2Cl2, 2-3 hr, rt
N
Boc
OHN
O
R R
1 2  
 
Nitro-Mannich (or aza-Henry) reactions involve catalytic formation of β-nitro amines from 
Boc-imines and nitroalkanes. Recently, there has been a surge of research in this area of 
organic chemistry due to the importance of β-nitro amines in organic syntheses.1 For example, 
the organocatalytic nitro-Mannich reaction2,3 has newly become an essential reaction in this area 
of research, while Brønsted acids4,5 have been found to be especially effective catalysts. 
Johnston et al. have investigated several aspects of the chiral Brønsted acid-catalyzed nitro-
Mannich reactions of Boc-imines and nitromethane.4b,c At about the same time, using various 
nitroalkanes to aromatic N-Boc imines, Jacobsen et. al. reported thiourea-catalyzed nitro-
Mannich reactions.5d These reactions ultimately form β-nitro amines in excellent yields and in 
high enantioselectivity.  
Our group is actively working with strong Brønsted acid-catalyzed organic reactions in the 
synthesis of important building blocks of biologically active compounds.6 In order to expand the 
scope of strong Brønsted acid-catalyzed reactions in organic chemistry; we investigated nitro-
Mannich reactions using Boc-imine with nitromethane in the presence of fluoroboric acid 
(HBF4.OEt2). Surprisingly, nitromethane did not participate in the reaction and no formation of β-
nitro amine product was observed. Instead, we observed the formation of 1,3-oxazinan-2-one in 
high yield (equation 3.85).  
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Herein, we report on an unprecedented catalytic tandem elimination-cycloaddition reaction in 
which the formation of oxazinanones occurs when employing various Boc-imines in the 
presence of a strong Brønsted acid. 
 
Equation 3.85: Reaction of 1,3-oxazinan-2-one instead of Aza henry product 
N
Boc
OHN
O
CH3NO2 , rt
+
HN
NO2
Boc
2 (75 %)1 β-nitroamine (0%)
10 mol% HBF4    OEt2
 
 
 The major difference in our reaction conditions compared to the aforementioned nitro-Mannich 
reactions is the use of fluoroboric acid. In order to determine whether fluoroboric acid is 
exclusively unique, we screened several Brønsted acids (Table 1). Several attempts, including a 
control reaction and reactions employing weaker acids such as acetic acid or triflyl amide, did 
not yield any oxazinanone product. However, by employing stronger acids such as 
trifluoroacetic acid, oxazinanone product was efficiently produced in yields of 40% (Table 3.5, 
entries 4-5). Indeed, Brønsted acids with lower pKas7 provided even greater yields of 
oxazinanone product. Ultimately, the stronger triflic and fluoroboric acids were found to be the 
most effective catalysts for the reaction as shown in Table 1. A 10 mol% catalyst loading was 
also found to be most effective; however, an increase in the catalyst loading does not improve 
the yield. 
 
 
304 
 
 
In order to determine the scope of this unprecedented reaction, a number of various Boc-
imines were subjected to the newly optimized reaction conditions. Both aromatic and aliphatic 
Boc-imine provided the corresponding oxazinanones in good yields. However, aromatic imines 
(Table 3.5, entries 1-8) were found to be more reactive in these cyclization reactions, resulting 
in high yields of oxazinanones (65-75%). Electron donating or electron withdrawing groups did 
not appreciably affect the yields of the products. An aliphatic N-Boc-imine (Table 3.5, entry 9) 
could also be used in these reactions with a moderate yield of 50%.  
Table 3.5. Optimization of the solvent system. 
10 mol% HBF4    OEt2
Solvent, rt
N
Boc
OHN
O
 
entry solvent yield (%) 
1 dichloromethane 70 
2 THF 60 
3 acetonitrile 70 
4 DMF 0 
5 toluene 0 
6 75% toluene in dichloromethane 35 
7 methanol 20 
8 nitromethane 70 
 
To understand the mechanism of the reaction, we investigated the reaction by NMR 
spectroscopy.1H NMR revealed the presence of 2-methylpropene (Figure 1) in the reaction 
mixture which is likely formed from the decomposition of the protonated N-Boc imine 3 (Scheme 
2). The resulting 2-methylpropene reacts with Boc-imine in the presence of acid, followed by 
cyclization to form the oxazinanone product 2. Evidence of this process is also supported 
directly by observation using NMR. Indeed, the formation of the phenylmethaniminium ion (5, 
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Figure 3.11) in the reaction mixture is believed to result from the rapid decarboxylation of 4. 
Several other intermittent species are observed by low temperature NMR, the exact nature of 
which is still under investigation.    
 
 
Table 3.6. Optimized HBF4.OEt2-catalyzed reactions of Boc-imine 
 
 
 
entry imine product Yield
[a] 
(%) 
1 
N
Boc
 
OHN
O
 
75 
2 
  
70 
3 
N
Boc
Cl  
OHN
O
Cl  
75 
4 
N
Boc
F  
OHN
O
F  
75 
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5 
N
Boc
 
OHN
O
 
72 
6 
 
OHN
O
 
72 
7 
N
Boc
 
OHN
O
 
70 
8 
  
74 
9 
N
Boc
 
OHN
O
 
50 
[a] Isolated yields, the average of at least two runs. In a typical reaction, the N-Boc-imines (1.5 
mmol) were dissolved in 5 ml CH2Cl2 under a N2 atmosphere and stirred 2-3h at room  
temperature with 10 mol% of the Brønsted acid such as fluorobric acid or triflic acid. Acid was 
removed from the reaction mixture by passing the solution through a plug of neutral alumina. 
The solvent was removed under reduced pressure and the pure oxazinanone was recrystallized 
from 5-10% CH2Cl2 in pentane. 
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Figure 3.11. 1H NMR (δ=1.77 and 4.71ppm) of 2-methylpropene  and phenylmethaniminium ion 
(δ=8.55 and 11.9ppm) in reaction mixture. 
 
N
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Scheme 3.3. Proposed mechanism
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     In order to substantiate the formation of 2-methypropene as an intermediate, the reaction 
was carried out by adding excess 2-methylpropene. The yield of oxazinanone product 2 was 
improved up to 95%, corroborating our proposed mechanism.  In addition, to verify the 
incorporation of added 2-methylpropene in the product, a reaction was conducted with fresh 
Boc-imine and 2-methylpropene-1,1-d2 in the presence of fluoroboric acid.  The results were just 
as expected, 82% of the product was incorporated with deuterium (Scheme 3.3) confirming our 
assumptions of 2-methylpropene in the reaction. 
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Scheme 3.4. HBF4·OEt2 reaction of Boc-imine and 2-methylpropene-1,1-d2. 
CH2Cl2, 2-3 hr, rt
N
Boc
+
DD
HN O
O
Ph
DD
HN O
O
Ph
HH
82% 18%
+
10 mol% HBF4    OEt2
 
 
Figure 3.12. 1H NMR (δ=1.77 and 4.71ppm)  and 2H NMR (δ=1.77 and 4.71ppm) of 2-
methylpropene  and of 4-phenyl-6-aryl-1,3-oxazinan-2-one-5,5-d2 (δ=8.55 and 11.9ppm) in a 
mixture of 18% to 82% respectely. 
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To further understand the mechanism of the reaction, a competitive experiment was carried out 
in the presence of 1.2 equiv of styrene. In this situation, both alkenes, 2-methylpropene from 1 
and styrene, competed with fresh Boc-imine to form the corresponding oxazinanone product. 
The reaction provided 4,6-diphenyl-(1,3)-oxazinan-2-one 6 along with 4-Phenyl-6,6-dimethyl-
(1,3)-oxazinan-2-one, 2 (Scheme 3.4), which strongly supports the proposed mechanism. 
Recently, a similar mechanism was proposed for the formation of selective oxazinanone ring 
systems using triflic acid-catalyzed reactions of vinylidene cyclopropanes with Boc-imines.8  
 
Scheme 3.5 HBF4·OEt2reaction of Boc-imine and styrene. 
N
O
O
1
OHN
O
2 (30%)
+
OHN
O
6 (60%)
+
CH2Cl2, rt
10 mol% HBF4    OEt2
 
This intermolecular reaction facilitated the generation of oxazinanones simply by Boc-imines 
reacting with different styrene derivatives. More exactly, several styrene derivatives were 
reacted with Boc-imines to form the corresponding oxazinanones in good yield (Table 4). 
Interestingly, α-methylstyrene (Table 4, entry 4) produced an oxazinanone possessed of a fairly 
congested tertiary carbon center with the highest yield of all. As shown in the earlier proposed 
mechanism (scheme 3.3), the high yield of this product is accounted for by the increased 
relative stability of the tertiary benzylic carbocation. This latter result, concerning tolerance of 
steric congestion and the lack of discrimination concerning styrenes containing either EWG or 
EDG groups (table 3.7, entries 2 and 3), further exemplifies the robustness and versatility of this 
reaction. In 1990, Overman reported a closely related reaction which involved intramolecular 
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Boc-iminium ion-alkyne cycloaddition to form tricyclic systems containing the oxazinanone ring 
system.9  
  In all these intermolecular reactions, we observed formation of only the syn-diastereomer. The 
configuration of the product was determined by comparing the spin-spin coupling constants with 
known reported syn-compounds.10 The six-membered transition state A, where both bulky aryl 
groups are equatorial positions (syn) will be favorable over transition state B with one aryl group 
at an axial position (Scheme 3.6). As a result, syn-4,6-diaryloxazinanone 6 is expected to be 
the only or a major product. 
Scheme 3.6. Proposed rationale for the stereoselective formation of 4,6-Diphenyloxazinanone.  
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To our knowledge, the reaction depicted in Scheme 1 is the first recorded tandem 
elimination-cycloaddition reaction for the synthesis of an oxazinanone ring system. To date, all 
of the reported syntheses for making the oxazinanones 2 require three or more steps.11 The 
chiral oxazinanones are employed as  auxiliaries for asymmetric enolate alkylation and aldol 
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reactions,11b and also in the synthesis of oxazolidinone derivatives.12 Oxazinanone derivatives 
are of interest because they exhibit antibacterial activity against Gram-positive bacteria and are 
useful as PR modulators.13 Chiral Brønsted acid-catalyzed syntheses of optically active analogs 
of oxazinanones are currently under investigation. 
Table 3.7  HBF4.OEt2-catalyzed reactions of Boc-imine and styrene derivatives. 
entry styrene product 
yielda 
(%) 
1 
X
 
OHN
O
 
72 
2 
Cl  
OHN
O
Cl 
70 
3 
X
 
OHN
O
 
70 
4 
X
 
 
75 
5 
X
 
OHN
O
 
68 
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a Isolated yields, the average of at least two runs. In a typical reaction, the N-Boc-imines (1.3 
mmol) and styrene derivative (1.6 mmol ) were dissolved in 5 ml CH2Cl2 under a N2 atmosphere 
and stirred 2-3h at room temperature with 10 mol% fluorobric acid. Acid was removed from the 
reaction mixture by passing the solution through a plug of neutral alumina. The solvent was 
removed under reduced pressure and the pure oxazinanone was recrystallized from 10% 
CH2Cl2 in pentane. 
In summary, a new carbon-carbon bond formation reaction has been developed using 
Brønsted acid catalysis. Cyclic oxazinanones are produced from Boc-imines in one step, 
resulting in medium to high yields. The atom-economic process presented here in Scheme 1 is 
unprecedented in the area of organic chemistry and should extend the scope of C-C bond 
forming reactions.   
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3.6 Experimental  
	  
General	  considerations:	  All	  oxazinanones	  syntheses	  were	  carried	  out	  under	  standard	  Sclenk	  techniques.	  
All	  of	  the	  glass	  flasks	  were	  dried	  in	  the	  oven.	  Proton	  and	  carbon	  spectra	  were	  obtained	  on	  300	  MHz	  
NMR	  spectrometer	  unless	  stated	  otherwise.	  The	  chemical	  shifts	  (δ)	  are	  expressed	  in	  ppm	  relative	  to	  
tetramethylsilane	  and	  CDCl3	  was	  used	  as	  the	  solvent.	  Previously	  reported	  compounds	  were	  identified	  by	  
1H	  NMR.	  All	  new	  compounds	  were	  additionally	  characterized	  by	  13C	  NMR	  and	  elemental	  analysis.	  
HPLC	  reagent	  grade	  CH2Cl2	  was	  distilled	  under	  nitrogen	  from	  P2O5.	  Technical	  grade	  pentane	  was	  stirred	  
with	  sulfuric	  acid	  overnight	  and	  then	  washed	  with	  saturated	  NaHCO3	  and	  stored	  over	  Na2SO4.	  The	  
pentane	  was	  then	  distilled	  under	  nitrogen	  from	  sodium.	  Reagent	  garde	  diethyl	  ether	  and	  THF	  were	  
freshly	  distilled	  under	  a	  nitrogen	  atmosphere	  from	  sodium	  benzophenone	  ketyl.	  HPLC	  grade	  methanol	  
was	  distilled	  under	  nitrogen	  from	  magnesium	  iodide.	  Boc-­‐imines	  were	  freshly	  prepared	  based	  on	  the	  
adaptation	  of	  reported	  procedures	  1.	  	  All	  other	  reagents	  were	  used	  as	  supplied.	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
315 
 
General	  Procedure	  for	  the	  Synthesis	  of	  4-­‐Aryl-­‐6,6-­‐dimethyl-­‐(1,3)-­‐oxazinan-­‐2-­‐one:	  For	  each	  experiment	  
described	  in	  Scheme	  1,	  1.0-­‐5.0	  mmol	  of	  the	  Boc-­‐protected	  imine	  was	  dissolved	  in	  5-­‐25	  ml	  of	  freshly	  
distilled	  dichloromethane	  under	  nitrogen.	  A	  0.1	  equiv	  sample	  of	  the	  appropriate	  catalyst	  was	  added	  and	  
then	  the	  reaction	  mixture	  was	  stirred.	  The	  reaction	  mixture	  was	  allowed	  to	  stir	  until	  the	  completion,	  
monitored	  by	  NMR	  spectroscopy.	  The	  reaction	  mixture	  was	  then	  filtered	  through	  an	  alumina	  plug	  and	  
the	  solvent	  removed	  by	  rotary	  evaporation.	  Product	  was	  crystallized	  from	  5-­‐10%	  dichloromethane	  in	  
pentane	  and	  identified	  by	  comparing	  spectra	  to	  known	  1H	  NMR.	  	  1H,	  13C	  NMR,	  High	  resolution	  Mass	  
spectra	  and	  elemental	  analysis	  were	  applied	  to	  characterize	  the	  new	  compounds.	  
 
 
 
 
 
10 mol% HBF4.OEt2
CH2Cl2, 2-3 hr, RT
N
Boc
OHN
O
RR  
General Procedure for the Synthesis of 4-phenyl-6-aryl-1,3-oxazinan-2-one: For each 
experiment described in Scheme 2, 1.0-5.0 mmol of the Boc-protected imine was dissolved in 5-
25 ml of freshly distilled dichloromethane under nitrogen. A 0.1 equiv sample of the appropriate 
catalyst was added followed by 1.2 equiv of respective alkenes and then the reaction mixture was 
stirred. The reaction mixture was allowed to stir until the completion, monitored by NMR 
spectroscopy. The reaction mixture was then filtered through an alumina plug and the solvent 
removed by rotary evaporation.  Desired product was then crystallized from 20% 
dichloromethane in pentane and identified by comparing spectra to known 1H NMR.  1H, 13C 
NMR and High resolution Mass spectra were applied to characterize the new compounds. 
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N
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HBF4.OEt2 (10 mol %)
CH2Cl2 , RT
+ +
	  
General	  Procedure	  for	  the	  Synthesis	  of	  4-­‐phenyl-­‐6-­‐aryl-­‐1,3-­‐oxazinan-­‐2-­‐one-­‐5,5-­‐d2:	  1.0-­‐5.0	  mmol	  of	  the	  
Boc-­‐protected	  imine	  was	  dissolved	  in	  5-­‐25	  ml	  of	  freshly	  distilled	  dichloromethane	  under	  nitrogen.	  A	  0.1	  
equiv	  sample	  of	  the	  appropriate	  catalyst	  was	  added	  followed	  by	  excess	  of	  methylpropene-­‐1,1-­‐d2	  and	  
then	  the	  reaction	  mixture	  was	  stirred.	  The	  reaction	  mixture	  was	  allowed	  to	  stir	  until	  the	  completion,	  
monitored	  by	  TLC.	  The	  reaction	  mixture	  was	  then	  filtered	  through	  an	  alumina	  plug	  and	  the	  solvent	  
removed	  by	  rotary	  evaporation.	  	  Desired	  product	  was	  then	  crystallized	  from	  20%	  dichloromethane	  in	  
pentane	  and	  identified	  by	  comparing	  spectra	  to	  known	  1H	  NMR.	  	  1H,	  13C	  NMR	  and	  High	  resolution	  Mass	  
spectra	  were	  applied	  to	  characterize	  the	  new	  compounds.	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10 mol% HBF4.OE t2
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Characterization data for products shown in Table 3 
OHN
O
	  
4-­‐Phenyl-­‐6,6-­‐dimethyl-­‐(1,3)-­‐oxazinan-­‐2-­‐one	  (Table	  3,	  entry	  1).	  	  
The	  general	  procedure	  was	  followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  (300	  mg,	  1.5	  mmol),	  HBF4.OEt2	  (200	  µL,	  0.15	  
mmol)	  and	  CH2Cl2	  (5	  mL)	  were	  used	  to	  obtained	  the	  product	  (225	  mg,	  75%	  yield)	  as	  a	  yellow	  solid,	  m.	  p.	  
155-­‐156	  oC.	  Crystallization	  solvent	  was	  5%	  CH2Cl2	  in	  pentane.	  	  
1H	  NMR	  (300	  MHz,	  CDCl3):	  δ	  1.45	  (s,	  3H),	  1.53	  (	  s,	  3H),	  1.85	  (t,	  1H,	  J=	  13.7,11.9	  Hz),	  2.03	  (dd,	  1H,	  J=	  13.8,	  
4.8	  Hz),	  4.62	  (dd,	  1H,	  J=	  11.8,4.7	  Hz),	  6.25	  (s,	  br,	  1H,	  NH),	  7.30-­‐7.45	  (m,	  5H,	  Ph)	  .	  	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  25.6,	  29.4,	  42.0,	  53.0,	  78.5,	  126.1,	  128.5,	  129.1,	  140.9,	  and	  154.0.  
HRMS (ESI) (M + H)+, Calcd. for C12H15NO2 206.1181; Found 206.1175. 
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4-­‐methoxyphenyl-­‐6,6-­‐dimethyl-­‐(1,3)-­‐oxazinan-­‐2-­‐one	  (Table	  3,	  entry	  2).	  The	  general	  procedure	  was	  
followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  (300	  mg,	  1.3	  mmol),	  HBF4.OEt2	  (175	  µL,	  0.13	  mmol)	  and	  CH2Cl2	  (5	  ML)	  were	  
used	  to	  obtained	  the	  product	  (210	  mg,	  70%	  yield)	  as	  a	  yellow	  solid,	  m.	  p.	  146-­‐147	  oC.	  Crystallization	  
solvent	  was	  5%	  CH2Cl2	  in	  pentane.	  	  	  
1H	  NMR	  (300	  MHz,	  CDCl3):	  δ	  1.52	  (s,	  3H),	  1.67	  (	  s,	  3H),	  1.85	  (t,	  1H,	  J=11.8	  Hz),	  2.02	  (dd,	  1H,	  J=	  13.8,	  4.7	  
Hz),	  3.83	  (s,3H),	  4.58	  (dd,	  1H,	  J=	  11.8,4.7	  Hz),	  5.31	  (s,	  br,	  1H,	  NH),6.94	  (d,2H,	  Ph),7.25-­‐7.29	  (d,	  2H,	  Ph)	  .	  	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  25.2,	  29.4,	  42.0,	  52.4,	  55.2,	  78.4,	  114.3,	  127.3,	  132.7,	  153.6,	  and	  159.6.	  	  
HRMS (ESI) (M + H)+, Calcd. for C13H17NO3 236.1287; Found 236.1281.	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4-­‐Chlorophenyl-­‐6,6-­‐dimethyl-­‐(1,3)-­‐oxazinan-­‐2-­‐one	  (Table	  3,	  entry	  3).	  	  
The	  general	  procedure	  was	  followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  (300	  mg,	  1.3	  mmol),	  HBF4.OEt2	  (175	  µL,	  0.13	  
mmol)	  and	  CH2Cl2	  (5	  mL)	  were	  used	  to	  obtained	  the	  product	  (225	  mg,	  75%	  yield)	  as	  a	  white	  solid,	  m.	  p.	  
170-­‐171	  oC.	  Crystallization	  solvent	  was	  5-­‐10%	  CH2Cl2	  in	  pentane.	  
1H	  NMR	  (300	  MHz,CDCl3):	  δ	  1.45	  (s,	  3H),	  1.52	  (	  s,	  3H),	  1.80	  (t,	  1H,	  J=13.7,	  11.8	  Hz),	  2.00	  (dd	  ,	  1H,	  J=	  13.8,	  
4.7	  Hz),	  	  4.61	  (dd,	  1H,	  J=	  11.8,4.7	  Hz),	  5.90	  (s,	  br,	  1H,	  NH),	  7.27-­‐7.30	  (d,	  2H,	  Ph)	  7.36-­‐7.39	  (d,	  2H,	  Ph)	  	  .	  	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  25.2,	  29.3,	  41.9,	  52.4,	  78.4,	  127.4,	  129.2,	  139.3,	  and	  153.9.	  	  
HRMS (ESI) (M + H)+, Calcd. for C13H17NO3 236.1287; Found 236.1294.	  
OHN
O
F 	  
4-­‐Fluorophenyl-­‐6,6-­‐dimethyl-­‐(1,3)-­‐oxazinan-­‐2-­‐one	  (Table	  3,	  entry	  4).	  	  
The	  general	  procedure	  was	  followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  (300	  mg,	  1.3	  mmol),	  HBF4.OEt2	  (175	  µL,	  0.13	  
mmol)	  and	  CH2Cl2	  (5	  mL)	  were	  used	  to	  obtained	  the	  product	  (225	  mg,	  75%	  yield)	  as	  a	  yellow	  solid,	  m.	  p.	  
125-­‐126	  oC.	  Crystallization	  solvent	  was	  5%	  CH2Cl2	  in	  pentane.	  
1H	  NMR(300	  MHz,CDCl3):	  δ	  1.45	  (s,	  3H),	  1.52	  (	  s,	  3H),	  1.80	  (t,	  1H,	  J=13.8,12.0	  Hz),	  2.00	  (dd,	  1H,	  J=	  13.8,	  
4.7	  Hz),	  	  4.60	  (dd,	  1H,	  J=	  12.0,4.7	  Hz),	  5.85	  (s,	  br,	  1H,	  NH),	  7.05-­‐7.11	  (t,	  2H,	  Ph)	  7.28-­‐7.35	  (m,	  2H,	  Ph)	  .	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  25.2,	  29.3,	  42.0,	  52.3,	  78.4,	  115.8,	  116.0,	  127.7,	  127.8,	  128.2,	  136.5,	  153.7.	  	  
HRMS (ESI) (M + H)+, Calcd. for C12H14FNO2 224.1087; Found 224.1080.	  
320 
 
OHN
O
	  
4-­‐Methylphenyl-­‐6,6-­‐dimethyl-­‐(1,3)-­‐oxazinan-­‐2-­‐one	  (Table	  3,	  entry	  5).	  	  
The	  general	  procedure	  was	  followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  (300	  mg,	  1.4	  mmol),	  HBF4.OEt2	  (190	  µL,	  0.14	  
mmol)	  and	  CH2Cl2	  (5	  mL)	  were	  used	  to	  obtained	  the	  product	  (215	  mg,	  72%	  yield)	  as	  a	  white	  solid,	  m.	  p.	  
132-­‐133	  oC.	  Crystallization	  solvent	  was	  5%	  CH2Cl2	  in	  pentane.	  
1H	  NMR(300	  MHz,CDCl3):	  δ	  1.42	  (s,	  3H),	  1.50	  (	  s,	  3H),	  1.80	  (t,	  1H,	  J=13.7,	  11.8	  Hz),	  2.00	  (dd,	  1H,	  J=	  13.8,	  
4.7	  Hz),	  2.35	  (s,3H),	  4.60	  (dd,	  1H,	  J=	  11.8,4.7	  Hz),	  5.92	  (s,	  br,	  1H,	  NH),	  7.2-­‐7.3	  (m,	  4H,	  Ph)	  .	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  21,	  25.2,	  29.3,	  42.0,	  52.6,	  78.3,	  126.4,	  129.5,	  137.8,	  138.5,	  153.9.	  
HRMS (ESI) (M + H)+, Calcd. for C13H17NO2 220.1338; Found 220.1331.	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4-­‐Ethylphenyl-­‐6,6-­‐dimethyl-­‐(1,3)-­‐oxazinan-­‐2-­‐one	  (Table	  3,	  entry	  6).	  	  
The	  general	  procedure	  was	  followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  (300	  mg,	  1.3	  mmol),	  HBF4.OEt2	  (175	  µL,	  0.13	  
mmol	  )	  and	  CH2Cl2	  (5	  mL)	  were	  used	  to	  obtained	  the	  product	  (215	  mg,	  72%	  yield)	  as	  a	  yellow	  solid,	  m.	  p.	  
145-­‐147	  oC.	  Crystallization	  solvent	  was	  5%	  CH2Cl2	  in	  pentane.	  
1H	  NMR(300	  MHz,CDCl3):	  δ	  1.25	  (t,	  3H,	  J=	  7.6	  Hz),	  1.46	  (s,	  3H),	  1.51	  (	  s,	  3H),	  1.82	  (t,	  1H,	  J=13.7,	  11.8	  Hz),	  
2.00	  (dd,	  1H,	  J=	  13.8,	  4.7	  Hz),	  2.65	  (q,	  2H,	  J=7.6	  Hz),	  4.60	  (dd,	  1H,	  J=	  11.7,4.7	  Hz),	  5.72	  (s,	  br,	  1H,	  NH),	  
7.2-­‐7.3	  (m,	  4H,	  Ph)	  .	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  15.4,	  25.2,	  28.4,	  29.4,	  42.0,	  52.6,	  78.4,	  126.0,	  128.4,	  138.0,	  144.5,	  153.9.	  
HRMS (ESI) (M + H)+, Calcd. for C14H19NO2 234.1494; Found 234.1490.	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4-­‐isopropylphenyl-­‐6,6-­‐dimethyl-­‐(1,3)-­‐oxazinan-­‐2-­‐one	  (Table	  3,	  entry	  7).	  	  
The	  general	  procedure	  was	  followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  (300	  mg,	  1.2	  mmol),	  HBF4.OEt2	  (175	  µL,	  0.13	  
mmol	  )	  and	  CH2Cl2	  (5	  mL)	  were	  used	  to	  obtained	  the	  product	  (210	  mg,	  70%	  yield)	  as	  a	  yellow	  solid,	  m.	  p.	  
185-­‐187	  oC.	  Crystallization	  solvent	  was	  5%	  CH2Cl2	  in	  pentane.	  
1H	  NMR(300	  MHz,CDCl3):	  δ	  1.25	  (d,	  6H,	  J=	  6.9	  Hz),	  1.45	  (s,	  3H),	  1.53	  (	  s,	  3H),	  1.85	  (t,	  1H,	  J=12	  Hz),	  2.00	  
(ddd,	  1H,	  J=	  13.8,	  4.7	  Hz,	  1.5	  Hz),	  2.92	  (m,	  1H,	  J=	  6.9	  Hz),	  4.60	  (dd,	  1H,	  J=	  12,4.8	  Hz),	  5.42	  (s,	  br,	  1H,	  NH),	  
7.2-­‐7.3	  (m,	  4H,	  Ph)	  .	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  23.8,	  25.2,	  29.3,	  33.7,	  42.0,	  52.7,	  78.4,	  81.6,	  126.0,	  127.0,	  138.1,	  149.2,	  
153.7.	  
HRMS (ESI) (M + H)+, Calcd. for C15H21NO2 248.1651; Found 248.1659.	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4-­‐(3-­‐methoxyphenyl)-­‐6,6-­‐dimethyl-­‐1,3-­‐oxazinan-­‐2-­‐one	  (Table	  3,	  entry	  8).	  	  
The	  general	  procedure	  was	  followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  	  (300	  mg,	  1.3	  mmol),	  HBF4.OEt2	  (175	  µL,	  0.13	  
mmol)	  and	  CH2Cl2	  (5	  mL)	  were	  used	  to	  obtained	  the	  product	  (223	  mg,	  74%	  yield)	  as	  a	  yellow-­‐white	  solid,	  
m.	  p.	  157-­‐158	  oC.	  Crystallization	  solvent	  was	  5%	  CH2Cl2	  in	  pentane.	  
1H	  NMR(300	  MHz,CDCl3):	  δ	  1.44	  (s,	  3H),	  1.51	  (	  s,	  3H),	  1.83	  (t,	  1H,	  J=12	  Hz),	  2.03	  (ddd,	  1H,	  J=	  13.8,	  4.7	  Hz,	  
1.5	  Hz),	  3.82	  (s,	  3H),	  4.60	  (dd,	  1H,	  J=	  12,4.8	  Hz),	  5.67	  (s,	  br,	  1H,	  NH),	  6.85-­‐6.92	  (m,	  3H,	  Ph)	  7.26-­‐7.32	  (m,	  
1H,	  Ph)	  .	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  25.2,	  29.3,	  41.8,	  52.9,	  55.2,	  78.4,	  111.5,	  113.8,	  118.2,	  	  130.0,	  142.5,	  153.8,	  
160.0.	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HRMS (ESI) (M + H)+, Calcd. for C13H17NO3 236.1287; Found 236.1294	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4-­‐cyclohexyl-­‐6,6-­‐dimethyl-­‐1,3-­‐oxazinan-­‐2-­‐one	  (Table	  3,	  entry	  9)	  :	  The	  general	  procedure	  was	  followed	  
(2-­‐3	  hrs).	  Boc-­‐imine	  (Table	  3,	  entry	  9)	  (280	  mg,	  1.3	  mmol),	  HBF4.OEt2	  (175	  µL,	  0.13	  mmol)	  and	  CH2Cl2	  (5	  
mL)	  were	  used	  to	  obtained	  the	  product	  (142	  mg,	  50%	  yield)	  as	  a	  white	  solid,	  m.	  p.	  136-­‐137	  oC.	  
Crystallization	  solvent	  was	  5%	  CH2Cl2	  in	  pentane.	  
	  1H	  NMR	  (300	  MHz,	  CDCl3):	  δ	  1.00	  (m,	  2H),	  1.13	  (m,	  3H),	  1.39	  (s,	  3H),	  1.42	  (s,	  3H),	  1.63	  (m,	  3H),	  1.65(m,	  
5H),	  3.30	  (m,	  1H),	  5.17(s,	  1H,	  NH).	  	  
13C	  NMR	  (300	  MHz,	  CDCl3):	  δ	  24.9,	  25.8,	  26.2,	  27.7,	  28.4,	  29.6,	  35.1,	  42.1,	  52.6,	  77.8,	  and	  154.6.	  	  
HRMS (ESI) (M + H)+, Calcd. for C12H21NO2 212.1651; Found 212.165	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4,6-­‐diphenyl-­‐1,3-­‐oxazinan-­‐2-­‐one	  (	  Table	  4,	  entry	  1):	  	  
The	  general	  procedure	  was	  followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  (300	  mg,	  1.3	  mmol),	  styrene	  (166	  mg,	  1.6	  
mmol),	  HBF4.OEt2	  (175	  µL,	  0.13	  mmol)	  and	  CH2Cl2	  (10	  mL)	  were	  used	  to	  obtained	  the	  product	  (237	  mg,	  
72%	  yield)	  as	  a	  white	  solid,	  m.	  p.	  198-­‐199	  oC.	  Crystallization	  solvent	  was	  10%	  CH2Cl2	  in	  pentane.	  
1H	  NMR	  (300	  MHz,	  CDCl3):	  δ	  	  2.06	  (ddd,	  1H,	  J=	  14.4,	  11.9,	  11.6	  Hz),	  2.42	  (dddd,	  1H,	  J=	  14.1,	  4.2,	  2.1,	  1.8),	  
4.80	  (dd,	  1H,	  J=	  11.5,	  4.5	  Hz),	  5.40	  (dd,	  1H,	  J=	  11.7,	  2.0	  Hz),	  5.52	  (s,	  br,	  1H,	  NH),	  7.32-­‐7.45	  (m,	  10H,	  Ph).	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  39.1,	  55.8,	  78.4,	  125.7,	  126.0,	  128.5,	  128.6,	  129.1,	  138.4,	  140.4,	  153.8.	  
HRMS (ESI) (M + H) +, Calcd. for C16H15NO2 254.1181; Found 254.1177. 
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6-­‐(4-­‐chlorophenyl)-­‐4-­‐phenyl-­‐1,3-­‐oxazinan-­‐2-­‐one(	  Table	  4,	  entry	  2):	  
The	  general	  procedure	  was	  followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  (300	  mg,	  1.3	  mmol),	  1-­‐chloro-­‐4-­‐vinylbenzene	  
(221	  mg,	  1.6	  mmol),	  HBF4.OEt2	  (175	  µL,	  0.13	  mmol)	  and	  CH2Cl2	  (10	  mL)	  were	  used	  to	  obtained	  the	  
product	  (254	  mg,	  70%	  yield)	  as	  a	  white	  solid,	  m.	  p.	  194-­‐195	  oC.	  Crystallization	  solvent	  was	  10%	  CH2Cl2	  in	  
pentane.	  
1H	  NMR	  (300	  MHz,	  CDCl3):	  δ	  	  2.1	  (ddd,	  1H,	  J=	  13.9,11.9,	  11.6	  Hz),	  2.4	  (dddd,	  1H,	  J=	  14.1,	  4.5,	  2.4,	  2.1	  Hz	  ),	  
4.80	  (dd,	  1H,	  J=	  11.5,	  4.5	  Hz),	  5.31	  (s,	  br,	  1H,	  NH),	  5.44	  (dd,	  1H,	  	  J=	  11.7,	  2.0	  Hz),	  7.35-­‐7.45	  (m,	  9H,	  Ph)	  .	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  39.1,	  55.7,	  77.7,	  125.9,	  127.1,	  128.8,	  128.6,	  129.1,	  136.9,	  140.1,	  153.5.	  
HRMS (ESI) (M + H)+, Calcd. for C16H14ClNO2 280.0791; Found 280.0782. 
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4-­‐phenyl-­‐6-­‐p-­‐tolyl-­‐1,3-­‐oxazinan-­‐2-­‐one	  (	  Table	  4,	  entry	  3):	  
The	  general	  procedure	  was	  followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  1	  (300	  mg,	  1.3	  mmol),	  1-­‐methyl-­‐4-­‐vinylbenzene	  
(190	  mg,	  1.6	  mmol),	  HBF4.OEt2	  (175	  µL,	  0.13	  mmol)	  and	  CH2Cl2	  (	  10	  mL)	  were	  used	  to	  obtained	  the	  
product	  (245	  mg,	  70%	  yield)	  as	  a	  white	  solid,	  m.	  p.	  182-­‐183	  oC.	  Crystallization	  solvent	  was	  10%	  CH2Cl2	  in	  
pentane.	  
1H	  NMR	  (300	  MHz,CDCl3):	  δ	  	  2.1	  (ddd,	  1H,	  J=	  14.0,	  11.8,	  11.6	  Hz),	  2.36	  (s,3H),	  2.41	  (dddd,	  1H,	  J=	  4.5,	  2.4,	  
2.1	  Hz,	  some	  peaks	  overlap	  with	  -­‐CH3	  absorption),	  4.78	  (dd,	  1H,	  J=	  11.5,	  4.5	  Hz),	  5.40(s,	  br,	  1H,	  NH),	  
5.45(m,	  1H),7.2-­‐7.4	  (m,	  9H,	  Ph)	  .	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  21.0,	  39.1,	  55.8,	  78.4,	  125.3,	  125.7,	  126.0,	  128.6,	  129.1,	  129.2,	  135.4,	  138.3,	  
140.5,	  153.9.	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HRMS (ESI) (M + H)+, Calcd. for C17H17NO2 268.1338; Found 268.1343. 
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6-­‐methyl-­‐4,6-­‐diphenyl-­‐1,3-­‐oxazinan-­‐2-­‐one	  (	  Table	  4,	  entry	  4	  ):	  
The	  general	  procedure	  was	  followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  1	  (300	  mg,	  1.3	  mmol), 1-(prop-1-en-2-yl) 
benzene (190 mg, 1.6 mmol),	  HBF4.OEt2	  (175	  µL,	  0.13	  mmol)	  and	  CH2Cl2	  (10	  mL)	  were	  used	  to	  
obtained	  the	  product	  (243	  mg,	  75%	  yield)	  as	  a	  white	  solid,	  m.	  p.	  198-­‐199	  oC.	  Crystallization	  solvent	  was	  
10%	  CH2Cl2	  in	  pentane.	  
1H	  NMR	  (300	  MHz,	  CDCl3):	  δ	  1.87	  (s,	  3H),	  2.1	  (t,	  1H,	  J=	  13.8,	  11.7	  Hz),	  2.41	  (dd,	  1H,	  J=	  13.9,	  3.8	  Hz),	  4.78	  (	  
dd,	  1H,	  J=	  11.4,	  4.7	  Hz),	  5.37	  (s,	  br,	  1H,	  NH),	  7.3-­‐7.5	  (m,	  10H,	  Ph)	  .	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  26.1,	  42.6,	  53.1,	  81.2,	  123.9,	  126.1,	  127.5,	  128.3,	  128.4,	  129.0,	  140.4,	  153.4.	  
HRMS (ESI) (M + H)+, Calcd. for C17H17NO2 268.1338; Found 268.1335.	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6-(naphthalen-1-yl)-4-phenyl-1, 3-oxazinan-2-one (Table	  4,	  entry	  5	  ): 
The	  general	  procedure	  was	  followed	  (2-­‐3	  hrs).	  Boc-­‐imine	  (300	  mg,	  1.3	  mmol), 2-vinylnaphthalene 
(246 mg, 1.6 mmol),	  HBF4.OEt2	  (175	  µL,	  0.13	  mmol)	  and	  CH2Cl2	  (10	  mL)	  were	  used	  to	  obtained	  the	  
product	  (269	  mg,	  68%	  yield)	  as	  a	  yellow	  solid,	  m.	  p.	  217-­‐218	  oC.	  Crystallization	  solvent	  was	  10%	  CH2Cl2	  in	  
pentane.	  
1H	  NMR	  (300	  MHz,	  CDCl3):	  δ	  2.15	  (ddd,	  1H,	  J=	  14.0,	  11.9,	  11.6	  Hz),	  2.50	  (dddd,	  1H,	  J=	  13.8,	  4.5,	  2.1,	  1.8	  
Hz	  ),	  4.84	  (dd,	  1H,	  J=	  11.5,4.5	  Hz),	  5.39	  (s,	  br,	  1H,	  NH),	  5.63	  (dd,	  1H,	  J=	  11.7,	  1.7	  Hz),	  7.3-­‐7.5	  (m,	  10H,	  Ph)	  
.	  
13C	  NMR	  (75	  MHz,	  CDCl3):	  δ	  39.1,	  55.8,	  78.5,	  123.3,	  124.8,,	  126.0,	  126.3,	  127.6,	  128.0,	  128.5,	  128.5,	  
129.1,	  133.2,	  135.7,	  140.3,	  153.9. 
HRMS (ESI) (M + H)+, Calcd. for C20H17NO2 304.1338; Found 304.1346. 
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Appendix A 
Part I: Synthesis and Biological Evaluations of Potent Class I 
Selective Histone Deacetylase inhibitors 
	  
	  
O
STrt  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H:	  ju112211	  Exp	  1.	  	  	  500	  user:	  ju	  
BS110111	  Exp	  1.	  	  300	  user:	  nmr	  
13C:	  Fuse,	  Shinichiro,	  et	  al.	  Total	  Synthesis	  
of	  Spiruchostatin	  B	  Aided	  by	  an	  Automated	  
Synthesizer.	  Org.	  Biomol.	  Chem.	  2011,	  9,	  	  
3825-­‐3833.	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1H:	  ju010411	  Exp	  2.	  	  	  300	  user:	  nmr	  
13C:	  BS061812	  Exp	  5.	  	  	  300	  user:	  BS	  
 
OH
STrt
O
t-BuO  
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1H:	  BS072312	  Exp	  5.	  	  	  300	  user:	  BS	  
13C:	  ju072412	  Exp	  6.	  	  	  500	  user:	  ju	  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OH
STrt
O
HO
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1H:	  ju062012	  Exp	  1.	  	  	  500	  user:	  ju	  
extra1H:	  ju062112	  Exp.	  1	  	  	  500	  user:	  ju	  
13C:	  ju062112	  Exp	  2.	  	  	  500	  user:	  ju	  
 
 
OH
S
O
HO
*
2
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1H:	  BS062712	  Exp	  2.	  	  	  300	  user:	  BS	  
13C:	  BS062712	  Exp	  4.	  	  	  300	  user:	  BS	  
 
OH
S
O
t-BuO
*
2
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1H:	  ju072412	  Exp	  8.	  	  	  500	  user:	  ju	  
13C:	  ju072412	  Exp	  12.	  	  	  500	  user:	  ju	  
OH
STrt
O
S
N
H
O
OH  
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1H:	  ju012712	  Exp	  2.	  	  	  300	  user:	  nmr	  
13C:	  ju072412	  Exp	  4.	  	  	  500	  user:	  ju	  
OH
STrt
O
S
N
H
O
O  
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1H:	  djm070312	  Exp	  4.	  	  300	  user:	  djm	  	  
1H:	  djm060112	  Exp	  3.	  	  300	  user:	  djm	  
13C:	  ju071112	  Exp	  5.	  	  	  500	  user:	  ju	  
13C:	  djm060112	  Exp	  4.	  	  300	  user:	  djm	  
	  
 
OH
S
O
S
N
H
O
O
*
2
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1H:	  djm070312	  Exp	  9.	  	  	  300	  user:	  djm	  
13C:	  djm070312	  Exp	  10.	  	  	  300	  user:	  djm	  
1H:	  ju073012	  Exp	  1.	  	  	  500	  user:	  ju	  
13C:	  BS072612	  Exp	  2.	  	  	  300	  user:	  BS	  
HSQC:	  	  ju073012	  Exp	  5.	  	  500	  user:	  ju	  
COSY:	  	  ju073012	  Exp	  2.	  	  500	  user:	  ju	  
 
	  
OH
S
O
S
N
H
O
OH
*
2
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HSQC:	  1H/13C	  
COSY:	  1H/1H	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1H:	  BS073112	  Exp	  4.	  	  	  300	  user:	  BS	  
13C:	  BS073112	  Exp	  5.	  	  	  300	  user:	  BS	  
HSQC:	  	  BS073112	  Exp	  11.	  	  	  300	  user:	  BS	  
COSY:	  	  BS073112	  Exp	  6.	  	  	  300	  user:	  BS	  
13C	  dept-­‐135	  BS080112	  Exp	  1.	  	  300	  user:	  BS	  
13C	  dept-­‐135	  BS080112	  Exp	  2.	  	  300	  user:	  BS	  
	  
OHO
NH
O NH
O
OH
S
TrtS
TrtS
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HSQC:	  1H/13C	  
COSY:	  1H/1H	  
344	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C:	  Dep-­‐135	  
13C:	  Dep-­‐90	  
345	  
	  
1H:	  ju081512	  Exp	  5.	  	  	  500	  user:	  ju	  
13C:	  ju081512	  Exp	  8.	  	  	  500	  user:	  ju	  
COSY:	  	  ju081512	  Exp.	  6	  	  500	  user:	  ju	  
	  
13C	  Dept-­‐135:	  ju081512	  Exp	  9.	  	  500	  user:	  ju	  
13C	  Dept-­‐90:	  	  ju081512	  Exp	  10.	  	  500	  user:	  ju	  
HSQCGP:	  	  ju081512	  Exp	  7.	  	  500	  user:	  ju	  
 
OHO
NH
O NH
O
OH
S
S
S
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13C:	  Dep-­‐90	  
13C:	  Dep-­‐135	  
347	  
	  
 
 
 
COSY:	  1H/1H	  
HSQC:	  1H/13C	  
348	  
	   1H:	  ju091312	  Exp	  1.	  	  	  300	  user:	  ju	  
COSY:	  ju091312	  Exp	  2.	  	  300	  user:	  ju	  
13C:	  BS122912	  Exp	  6.	  	  300	  user:	  BS	  
13C	  Dept-­‐135:	  ju091312	  Exp	  7.	  	  300	  user:	  ju	  
13C	  Dept-­‐90:	  	  ju011713	  Exp	  1.	  	  300	  user:	  ju	  
1.)	  HSQCGP:	  ju091312	  Exp	  3.	  	  300	  user:	  ju	  
2.)	  Extra:	  HSQCGP:	  BS010313-­‐2	  Exp	  3.	  	  300	  user:BS	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13C:	  Dep-­‐90	  
13C:	  Dep-­‐135	  
COSY:	  1H/1H	  
350	  
	  
 
 
 
 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
HSQC:	  1H/13C	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1H:	  ju011712	  Exp	  3.	  	  	  300	  user:	  nmr	  
13C:	  ju011812	  Exp	  2.	  	  	  300	  user:	  nmr	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1H:	  djm061912	  Exp	  1.	  	  	  300	  user:	  djm	  
13C:	  BS013112	  Exp	  2.	  	  	  300	  user:	  BS	  
	  
OH
STrt
O
N
H
O
OH  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
353	  
	  
1H:	  BS062612	  Exp	  2.	  	  	  300	  user:	  BS	  
13C:	  ju062012	  Exp	  1.	  	  	  300	  user:	  ju	  
OH
S
O
N
H
O
OH
*
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1H:	  BS101512	  Exp	  1.	  	  	  300	  user:	  BS	  
13C:	  BS101512	  Exp	  2.	  	  	  300	  user:	  BS	  
OH
S
O
N
H
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O
*
2
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1H:	  BS0127122	  Exp	  1.	  	  	  300	  user:	  BS	  
13C:	  ju012712	  Exp	  3.	  	  	  300	  user:	  nmr	  OH
STrt
O
N
H
O
O  
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1H:	  BS013112	  Exp	  3.	  	  	  300	  user:	  BS	  
13C:	  BS013112	  Exp	  4.	  	  	  300	  user:	  BS	  
OH
STrt
O
N
H
O
OH  
 
 
 
 
 
 
 
 
 
 
	  
357	  
	  
1H:	  	  	  ju062012	  Exp	  4.	  	  	  500	  user:	  ju	  
13C:	  BS062612	  Exp	  4.	  	  	  300	  user:	  BS	  OH
S
O
N
H
O
OH
*
2
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1H:	  BS101512	  Exp.	  3	  	  300	  user:	  BS	  
13C:	  BS101512	  Exp.	  4	  	  300	  user:	  BS	  
OH
S
O
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O
*
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1H:	  ju021712	  Exp	  1.	  	  	  300	  user:	  nmr	  
13C:	  ju021712	  Exp	  2.	  	  	  300	  user:	  nmr	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1H:	  djm061912	  Exp	  2.	  	  	  300	  user:	  djm	  
13C:	  ju022012	  Exp	  2.	  	  	  300	  user:	  nmr	  
OH
STrt
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O
OH 	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1H:	  ju062112	  Exp	  1.	  	  	  300	  user:	  ju	  
13C:	  ju062112	  Exp	  2.	  	  	  300	  user:	  ju	  
OH
S
O
N
H
O
OH
*
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1H:	  ju101412	  Exp	  1.	  	  	  300	  user:	  ju	  
13C:	  ju101412	  Exp	  2.	  	  	  300	  user:	  ju	  
13C	  Dept-­‐135:	  ju101412	  Exp	  3.	  	  	  300	  user:	  ju	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1H:	  ju072312	  Exp	  2.	  	  	  300	  user:	  ju	  
13C:	  ju072412	  Exp	  7.	  	  	  500	  user:	  ju	  
1H:	  djm091312	  Exp	  1.	  	  	  300	  user:	  djm	  
13C:	  djm091312	  Exp	  4.	  	  	  300	  user:	  djm	  
S
NH3
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1H:	  ju091412	  Exp	  1	  	  	  300	  user:	  ju	  
13C:	  ju091412	  Exp	  2.	  	  	  300	  user:	  ju	  
NH3
O
O
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1H:	  djm072412	  Exp	  1.	  	  	  300	  user:	  djm	  
13C:	  ju072412	  Exp.	  14	  	  	  500	  user:	  ju	  
NH2
O
O STrt
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1H:	  ju072312	  Exp	  2.	  	  	  300	  user:	  ju	  
13C:	  ju072412	  Exp	  7.	  	  	  500	  user:	  ju	  
NH3
O
O
Cl
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1H:	  ju072312	  Exp	  1.	  	  	  300	  user:	  ju	  
N
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O P N 3
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MS (MALDI) Exact Mass Calc for C15H24N2O5S3 (M-1)- :407.08, Found: 407.05 
 
 
 
 
 
 
 
 
 
OO
NH
O NH
O
OH
S
S
S
 
MS (MALDI) Exact Mass Calc for C15H24N2O5S3 (M+Na)+ :431.78, Found: 431.07 
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MS (MALDI) Exact Mass Calc for C26H44N2O8S2 (M-1)- :575.25, Found: 575.26 
 
 
 
 
 
 
 
 
 
MS (MALDI) Exact Mass Calc for C26H44N2O8S2 (M+Na)+ :599.23, Found: 599.23 
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MS (MALDI) Exact Mass Calc for C28H48N2O8S2 (M)- :604.29, Found: 604.02 
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MS (MALDI) Exact Mass Calc for C28H48N2O8S2 (M)- :604.29, Found: 604.05 
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MS (MALDI) Exact Mass Calc for C26H44N2O8S2 (M+Na)+ :599.24, Found: 599.23 
 
 
 
 
 
 
 
 
 
 
 
 
 
MS (MALDI) Exact Mass Calc for C26H44N2O8S2 (M-1)- :575.25, Found: 575.26 
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MS (MALDI) Exact Mass Calc for C24H40N2O8S2 (M-1)- :547.22, Found: 547.23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MS (MALDI) Exact Mass Calc for C24H40N2O8S2 (M+Na)+ :571.22, Found: 571.21 
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MS (MALDI) Exact Mass Calc for C26H44N2O8S2 (M)- 604.06, Found: 604.05 
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MS (MALDI) Exact Mass Calc for C24H40N2O8S4 (M+22.99)+: 635.16, Found: 635.16 
 
 
 
 
 
 
 
 
 
 
 
 
MS (MALDI) Exact Mass Calc for C24H40N2O8S4 (M-1)-: 611.17, Found: 611.15 
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MS (MALDI) Exact Mass Calc for C26H44N2O8S4 (M+22.99)+: 663.19, Found: 663.19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MS (MALDI) Exact Mass Calc for C26H44N2O8S4 (M-1)-: 639.20, Found: 642.20 
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MS (MALDI) Exact Mass Calc for C14H22O6S2 (M-1)-: 349.08, Found: 349.07 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MS (MALDI) Exact Mass Calc for C14H22O6S2 (M+Li)+: 361.08, Found: 361.07 
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*
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MS (MALDI) Exact Mass Calc for C22H38O6S2 (M+Na)+: 485.19, Found: 485.18 
 
 
 
 
 
 
 
 
 
 
 
 
 
MS (MALDI) Exact Mass Calc for C22H38O6S2 (M-1)-: 461.21, Found: 460.13 
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MS (MALDI) Exact Mass Calc for C53H54N2O5S3 (M+Na)+: 917.31, Found: 917.30 
 
 
 
 
 
 
 
 
 
 
 
MS (MALDI) Exact Mass Calc for C53H54N2O5S3 (M-1)-: 893.34, Found: 893.40 
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MS (MALDI) Exact Mass Calc for C54H56N2O5S3 (M+Na)+: 931.32, Found: 931.31 
 
 
 
 
 
 
 
 
 
 
 
 
 
MS (MALDI) Exact Mass Calc for C54H56N2O5S3 (M-1)-: 907.18, Found: 924.18 
(M+H2O = 924.18)  
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HPLC Data for separation 
 
TDF1:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-C18, 
3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and 
the detection wave length was set up at 210 nm. The peak was collected at 8-
12min. Then this peak was injected in HPLC (Varian ProStar) with the column 
(Prep-C18, 21.2x250 mm, 10 um) system and 40 % ACN/H2O was used to eluted 
the column under the flow rate of 8ml/min. The wave length was set up at 200 nm 
to detect the compound and the pure compound was collected at 12-14.5min 
HPLC Data for separation 
      
 FC condition Rt-FC HPLC 
condition 
Rt-HPLC Pure amount 
TDF1 0-20min 20-
100%ACN 
20ml/min 
8-12min 40% ACN 12-14.5min 95mg 
TDF1t  15-20min 70% ACN 22-25 min 185mg 
TDF2  8-12min 35% ACN 16-20min 25mg 
TDF2m  12-15min 40% ACN 19-21min 185mg 
TDF3  8-10min 35% ACN 
8ml/min 
10-13.5min 125mg 
TDF3m  12-15min 40% ACN 17-19 min 158mg 
TDF4  8-12min 40% ACN 15.5-21min 31mg 
TDF4m  12-15min 50% ACN 25-31 min 87mg 
TDF5  8-12min 40% ACN 17-24.5min 146mg 
TDF5m  12-15min 50% ACN 27-32 min 130mg 
TDF6  8-12min 35% ACN 13-18.5min 40mg 
TDF6m  12-15min 50% ACN 12-17 min 90mg 
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TDF1t:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-C18, 
3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and 
the detection wave length was set up at 210 nm. The peak was collected at 15-20 
min. Then this peak was injected in HPLC (Varian ProStar) with the column (Prep-
C18, 21.2x250 mm, 10 um) system and 70 % ACN/H2O was used to elute the 
column under the flow rate of 8ml/min. The wave length was set up at 200 nm to 
detect the compound and the pure compound was collected at 22-25min.  
TDF2:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-C18, 
3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and 
the detection wave length was set up at 210 nm. The peak was collected at 8-
12min. Then this peak was injected in HPLC (Varian ProStar) with the column 
(Prep-C18, 21.2x250 mm, 10 um) system and 35 % ACN/H2O was used to elute 
the column under the flow rate of 8ml/min. The wave length was set up at 200 nm 
to detect the compound and the pure compound was collected at 16-20min.  
TDF2m:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-C18, 
3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and 
the detection wave length was set up at 210 nm. The peak was collected at 12-15 
min. Then this peak was injected in HPLC (Varian ProStar) with the column (Prep-
C18, 21.2x250 mm, 10 um) system and 40 % ACN/H2O was used to elute the 
column under the flow rate of 8ml/min. The wave length was set up at 200 nm to 
detect the compound and the pure compound was collected at 19-21min.  
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TDF3:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-C18, 
3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and 
the detection wave length was set up at 210 nm. The peak was collected at 8-
10min. Then this peak was injected in HPLC (Varian ProStar) with the column 
(Prep-C18, 21.2x250 mm, 10 um) system and 35 % ACN/H2O was used to elute 
the column under the flow rate of 8ml/min. The wave length was set up at 200 nm 
to detect the compound and the pure compound was collected at 10-13.5min.  
TDF3m:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-C18, 
3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and 
the detection wave length was set up at 210 nm. The peak was collected at 12-15 
min. Then this peak was injected in HPLC (Varian ProStar) with the column (Prep-
C18, 21.2x250 mm, 10 um) system and 40 % ACN/H2O was used to elute the 
column under the flow rate of 8ml/min. The wave length was set up at 200 nm to 
detect the compound and the pure compound was collected at 17-19 min.  
 
TDF4:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-C18, 
3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and 
the detection wave length was set up at 210 nm. The peak was collected at 8-
12min. Then this peak was injected in HPLC (Varian ProStar) with the column 
(Prep-C18, 21.2x250 mm, 10 um) system and 40 % ACN/H2O was used to eluted 
the column under the flow rate of 8ml/min. The wave length was set up at 200 nm 
to detect the compound and the pure compound was collected at 15.5-21min.  
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TDF4m:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-C18, 
3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and 
the detection wave length was set up at 210 nm. The peak was collected at 12-15 
min. Then this peak was injected in HPLC (Varian ProStar) with the column (Prep-
C18, 21.2x250 mm, 10 um) system and 50 % ACN/H2O was used to elute the 
column under the flow rate of 8ml/min. The wave length was set up at 200 nm to 
detect the compound and the pure compound was collected at 25-31min.  
TDF5:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-C18, 
3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and 
the detection wave length was set up at 210 nm. The peak was collected at 8-
12min. Then this peak was injected in HPLC (Varian ProStar) with the column 
(Prep-C18, 21.2x250 mm, 10 um) system and 40 % ACN/H2O was used to elute 
the column under the flow rate of 8ml/min. The wave length was set up at 200 nm 
to detect the compound and the pure compound was collected at 17-24.5min.  
TDF5m:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-C18, 
3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and 
the detection wave length was set up at 210 nm. The peak was collected at 12-15 
min. Then this peak was injected in HPLC (Varian ProStar) with the column (Prep-
C18, 21.2x250 mm, 10 um) system and 50 % ACN/H2O was used to elute the 
column under the flow rate of 8ml/min. The wave length was set up at 200 nm to 
detect the compound and the pure compound was collected at 27-32min. 
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TDF6:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-C18, 
3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and 
the detection wave length was set up at 210 nm. The peak was collected at 8-
12min. Then this peak was injected in HPLC (Varian ProStar) with the column 
(Prep-C18, 21.2x250 mm, 10 um) system and 35 % ACN/H2O was used to eluted 
the column under the flow rate of 8ml/min. The wave length was set up at 200 nm 
to detect the compound and the pure compound was collected at 13-18.5min.  
TDF6m:  The crude reaction system was firstly purified by Hi-Flash Column (ODS-C18, 
3.0x16.5 cm, 50 um, Yamazen A1-580), 0-20min 20-100% ACN/H2O 20ml/min and 
the detection wave length was set up at 210 nm. The peak was collected at 12-15 
min. Then this peak was injected in HPLC (Varian ProStar) with the column (Prep-
C18, 21.2x250 mm, 10 um) system and 50 % ACN/H2O was used to elute the 
column under the flow rate of 8ml/min. The wave length was set up at 200 nm to 
detect the compound and the pure compound was collected at 12-17min. 
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Updated list of derivatives from UWM Chemistry 
List of Chemical purity with 1H 13C NMR data and pure amount. 
  
 Derivatives Pure 
amount 
LC/MS NMR 
1H 
NMR 
13C 
HRMS Exact 
1 TDF1 >50mg √ √ √ √ 95mg 
2 TDF1t >50mg √ √ √ √ 185mg 
3 TDF2 25mg √ √ √ √ 25mg 
4 TDF2m >50mg √ √ √ √ 185mg 
5 TDF3 >50mg √ √ √ √ 125mg 
6 TDF3m >50mg √ √ √ √ 158mg 
7 TDF4 31mg √ √ √ √ 31mg 
8 TDF4m >50mg √ √ √ √ 87mg 
9 TDF5 >50mg √ √ √ √ 146mg 
10 TDF5m >50mg √ √ √ √ 130mg 
11 TDF6 40mg √ √ √ √ 40mg 
12 TDF6m >50mg √ √ √ √ 90mg 
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1. TDF1: After purification, about 95mg pure sample was obtained and the 
molecular weight was confirmed by LC/MS. 
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2. TDF1t: After purification, about 185mg pure compound was obtained and the 
molecular weight was confirmed by LC/MS.  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 3 4
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1516171819
20
21 22
05221209.D: TIC ±All
05221209.D: UV Chromatogram, 200 nm
05221209.D: EIC 460-510 ±All
05221209.D: EIC 230-280 ±All
0.0
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3. TDF2:  the pure compound was purified , obtained 25mg and confirmed by 
LC/MS,  
 
 
  
 
 
 
 
  
1
23
5
6
4
06141208.D: TIC ±All
06141208.D: UV Chromatogram, 200 nm
1
2
3
4
7x10
Intens.
0
100
200
300mAU
0.5 1.0 1.5 2.0 2.5 3.0 3.5 Time [min]
337.7
610.2
4. -MS, 1.2-1.8min
0.0
0.5
1.0
1.5
2.0
6x10
Intens.
300 400 500 600 700 800 900 m/z
346.3 427.9
610.8
711.4
3. +MS, 1.4-1.8min
0
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4
5x10
Intens.
300 400 500 600 700 800 900 m/z
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4. TDF2m: After purification, three fragments were collected 15mg, 185mg, and 
12mg. Their molecular weight matched the expected one by LC/MS.   
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TDF2m -1 
 
 
 
 
 
 
 
 
TDF2m -2 
   
 
TDF2m -3 
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141516
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06011200.D: TIC ±All
06011200.D: UV Chromatogram, 200 nm
0.0
0.5
1.0
1.5
2.0
7x10
Intens.
-200
0
200
400
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800mAU
0 1 2 3 4 5 6 7 8 Time [min]
435.9 498.7
563.2
595.3
626.5
663.6
3. -MS, 3.6-4.1min
0.0
0.5
1.0
1.5
2.0
5x10
Intens.
400 450 500 550 600 650 700 750 m/z
11
12 131415
1617181920 211
2
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06011201.D: TIC ±All
06011201.D: UV Chromatogram, 200 nm
0
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3
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0
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0 1 2 3 4 5 6 7 8 9 Time [min]
416.5 524.7
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0
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5
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06011203.D: TIC ±All
06011203.D: UV Chromatogram, 200 nm
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0
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mAU
0 1 2 3 4 5 6 7 8 Time [min]
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529.7
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2. -MS, 4.0-4.4min
0.0
0.5
1.0
1.5
5x10
Intens.
400 450 500 550 600 650 700 750 m/z
416.5 447.7 526.0557.1
589.4
621.1
653.5 689.2
1. -MS, 3.4-4.0min
0.0
0.5
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1.5
2.0
5x10
Intens.
400 450 500 550 600 650 700 750 m/z
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5. TDF3:  The sample is very polar and had to increase solvent system to 
dissolve. 125mg was obtained  
 
 
6. TDF3m: The sample was run and the target compound was determined by 
LC/MS. Total amount: 158mg. 
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05241215.D: TIC ±All
05241215.D: UV Chromatogram, 200 nm
05241215.D: EIC 400-500 ±All
0.0
0.5
1.0
1.5
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2.0
6x10
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200 300 400 500 600 700 800 900 m/z
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7. TDF4: the structure was confirmed by LC/MS. Total amount: 31mg. 
8.  
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3. +MS, 2.0-2.7min
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9. TDF5: After purification, total 146mg pure compound was obtained. The 
molecular weight was confirmed by LC/MS.  
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10. TDF6: After purification, total 40mg pure compound was obtained. The molecular 
weight was confirmed by LC/MS.  
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   Working Group: Dr. Cheng 
  Joe Ulicki 
  Dr. Cheng Wang 
  Sreya Biswas 
 Approval Date: 06/2012  
 Expiration Date: to 05/2015 
 Modification:  
 
University of Wisconsin - Milwaukee      
Department of University Safety & Assurances 
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE PROTOCOL REVIEW FORM 
Coversheet 
Principal Investigator/Project Director: Yi-Qiang Cheng 
Department: Biological Sciences 
Telephone Number: 229-4739 
Email address: ycheng@uwm.edu 
Protocol Title: Assessment of Acute Toxicity and Efficacy of New Chemical Compounds in 
Mice 
Pain or Distress Classification (B,C,D,E): E 
See Appendix B for USDA Classifications. 
This protocol is a (an):  
NOTE: to check a box, highlight the box and then right click and click “Properties” then under “Default 
Value” click the option as “Checked” then click “OK”: 
  Original  Continuation  Modification (FAQ4)  Resubmission 
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If resubmission or continuation application, please give previous protocol number:  
Do you have current (or pending) funding for this project: Yes 
Funding Source (grant, Department, start-up, etc.): NIH/NCI 
Grant #: R01CA512212 
Title of Grant (if different from protocol title): Discover and Engineer New Histone 
Deacetylase Inhibitors as Anticancer Agents 
If the funding agency is NIH or NSF or any agency requiring an “official” ACUC approval 
letter, list program area, contact person, title, and address: 
 
 
This protocol is for: 
  Research  Teaching* Breeding Holding 
(*note: the observation of ongoing approved protocols is exempt) 
Duration of project (3 year maximum) 
Start date/End date (month/year): 06/2012 to 05/2015 
Building, facility or site where the animals will be housed:  Lapham Hall - UWM ARC 
(If in ARC facilities complete the application for Use of ARC Facilities Form. )  
Identify the person or unit responsible for daily animal care: UWM ARC 
List all personnel working with animals below: 
 
1 Last name, first name: Cheng, Yi-Qiang 
Phone/email: 229-4739/ycheng@uwm.edu 
UWM student or employee?  Faculty member 
UWM certification for animal use?  (Certification pending) 
2 Last name, first name: Ulicki, Joseph 
Phone/email: jsulicki@uwm.edu 
UWM student or employee? Graduate student 
UWM certification for animal use? Yes 
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3 Last name first name: Matson, Vyara 
Phone/email: kamenova@uwm.edu 
UWM student or employee? Graduate student 
UWM certification for animal use? Yes 
 
4 Last name first name: Biswas, Sreya 
Phone/email: biswas@uwm.edu 
UWM student or employee? Graduate student 
UWM certification for animal use? (Certification pending) 
 Personnel unknown at this time.  Animal Care Program will be notified prior to animal 
use and personnel will be certified. 
UW-Milwaukee has on file with the Public Health Service a written Assurance, which 
commits UW-Milwaukee to following the standards and regulations established by the 
Animal Welfare Act and the Health Research Extension Act.   
UW-Milwaukee has established the Institutional Animal Care Committee (IACUC) to 
review and approve proposals for the use of animals in research and teaching.  The 
IACUC will determine if these proposals are consistent with these regulations and 
requirements.  The IACUC is responsible for the welfare of "any live vertebrate animal 
used or intended for use in research, experimentation, testing, training, or related purpose" 
if these animals are maintained at UW-Milwaukee or used under funds administered by 
UW-Milwaukee. 
I certify that I have read the above statement and will adhere to all regulations 
concerning the use of animals in research and teaching, and that I will notify the IACUC 
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in writing of any changes in this Protocol Form before proceeding with any animal 
experimentation. 
I further certify that personnel will not perform any animal procedures until they 
have been certified by the animal care program personnel. 
I will ensure that all personnel are enrolled in the Occupational Health and Safety 
Program prior to their contact with animals. 
  
I will provide emergency SOPs and after hours contact if needed. 
 
     June 21, 2012 
Signature      Date 
 
PROTOCOL FORM 
 
1st  Species of Animals (Scientific and common name): Mus musculus (mice), regular (BALB/c) 
and athymic (nu/nu) 
Total Number Per Year: 110 regular mice and 440 athymic nude mice (10 regular mice and 44 
athymic nude mice per compound; estimated testing of 7 new compounds and 3 reference 
compounds per year; plus 10 regular mice for training). 
Source of animals (e.g., commercial, UWM breeding colony, outside institution, or other): Athymic 
(nu/nu) mice will be purchased from the Jackson Laboratory (Bar Harbor, ME), regular mice will 
be either purchased from the same source or obtained from the surplus of the Steeber 
Laboratory’s mouse colony. 
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(NOTE:  for transgenic/knockout, mutagenesis or selective breeding programs, complete 
Appendix A). 
2) Will any animals listed in question 1 be used for training purposes for laboratory 
personnel?  Yes   No 
If yes, how many?: 10 
3)  Is the species endangered or protected? If no, check the appropriate box and proceed to 
question 4.  If yes, provide appropriate documentation (e.g., license number, copy of scientific 
collection permit, etc.). 
No 
Yes   
Specify:  
 
 
4)  Is any special care necessary for the animals? (i.e., beyond basic husbandry practices?) 
No 
Yes 
Specify:   
Provide a scientific justification if the care requirements are outside of the 
recommendations in the “Guide for the Care and Use of Laboratory Animals” :  
5)  Are there any special housing requirements for the animals? 
No 
Yes 
Specify: Mice will be kept in barrier housing. 
Provide a scientific justification if the housing requirements are outside of the 
recommendations in the “Guide for the Care and Use of Laboratory Animals” :  
6)  Briefly explain in language understandable to a layperson the aim of the study and 
why the study is important to human or animal health, the advancement of knowledge or 
the good of society.  Note: If this is an educational project, clearly state the educational goals. 
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      The overall goal of the federally funded project is to identify new anticancer lead compounds 
generated through de novo (i.e., new) discovery and biological or chemical engineering. The 
term “lead compound” is a standard usage in the field of drug discovery and development; it 
does not mean a compound made from the element lead (Pb). A qualified lead compound has 
to be either more effective against human tumors and/or less toxic to normal 
cells/tissues/organs than three reference compounds of the class (FK228, thailandepsin A, 
thailandepsin B), thus can lead to additional studies. Acute toxicity will be assessed first in 
normal mice, while effectiveness will be assessed subsequently in immune system deficient 
(i.e., nude) mice that have been transplanted with human tumors. 
      This study will provide critical experimental data required for the continuous assessment of 
newly discovered or engineered chemical compounds on large animal models and perhaps on 
cancer patients. 
7)  Are the animals from a UWM breeding colony?  If no, check the appropriate box and 
proceed to question 8.  If yes, answer questions 7a, 7b, 7c, and 7d.  NOTE: for 
transgenic/knockout, mutagenesis or selective breeding programs also complete appendix A. See FAQ 1 
No       
Breeding protocol on file; Protocol number:    
 
    
 
7a)  Number of adult breeders used per year: 
7b)  Anticipated total number of offspring for each species that will be produced (total 
per year): 
7c)  Anticipated number of offspring that will be used for experiments:  
7d)  What will be done with the surplus? (Note: the number of animals listed in 7b should total 
7c plus 7d). 
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  8)  Check off all procedures listed below that apply to this study.  If you did not check off 
any of the procedures, check N/A and proceed to question 9.  If you checked off one or more of 
the procedures answer questions 8a, 8b, 8c and 8d.   
N/A 
Experimental procedures that require food restriction (do not check box for pre-anesthetic 
fasting, or restricted feeding to control obesity) 
Experimental procedures that require fluid restriction. (More than 5 hours for rodents). 
8a)  Provide the length of time of the food and/or fluid restriction on both daily basis 
and throughout the experiment: 
 
 
8b)   Provide a scientific justification for the food and/or fluid restriction:  
8c) Describe how animal health is monitored (e.g. body weight, urine/fecal output, food/fluid 
consumed, etc.) :  
8d) Describe steps taken to ensure adequate nutrition/hydration during the restricted 
period:  
9)   If the animals require a special diet (commercial or non-commercial prepared diet that has 
ingredient(s) altered compared to maintenance diets) answer the following questions.  If not, 
check N/A and proceed to question 10.   
N/A 
For commercially prepared diets: 
9a)  Provide the name/source of the diet:  
9b)  Describe how the diet is altered:  
9c)  Provide a scientific justification for the use of the diet here or in question 11: 
 
     For non-commercially prepared diets: 
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9d) What is the formulation of the diet: 
 
   
9e) Location of diet preparation:      
9f) Who will prepare the diet and what are their qualifications to do so:  
9g) Provide a scientific justification for the use of the diet:   
10)  Will environmental enrichment devices be used (e.g. group housing, toys, foraging devices 
or treats)?   
Yes     List types of enrichment:  Group housing, Enviro-Dri bedding. 
No     Provide a scientific justification:   
11)  Specify all animal procedures outside of normal husbandry. For holding protocols 
check N/A and proceed to question 12.  For breeding protocols describe the breeding scheme, 
weaning ages, etc.  For all other protocols, this description should allow the IACUC to 
understand the experimental course of an animal from its entry into the experiment to the 
endpoint of the study.  
 N/A Holding Protocol 
Specifically address the following in essay format: 
Sequence, frequency and duration of procedures;  
Animal numbers used in each procedure;  
Substances given to animals (drugs, infectious agents, adjuvants, etc.; dose, sites, volume, 
route, and schedules);  
Blood withdrawals (volume, frequency, withdrawal sites, and methodology);  
How surgical procedures are involved (provide details of survival and non-survival surgical 
procedures in question 27 and perfusions as part of question 25b);  
How nutritional intervention is involved (provide specific details in questions 8 or 9)see 
FAQ2;   
Describe social or environmental manipulation;   
Describe biological samples taken;   
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Describe methods of physical restraint and length of time animal(s) are restrained.  
Describe acclimation procedures.  
 Prior to the actual experiments described in the following paragraphs, 10 surplus regular 
mice from the Steeber Lab’s colony will be used for initial training purpose and Dr. Douglas 
Steeber will act as a collaborator on the project and provide training. 
 Standard protocols posted by the US National Cancer Institute (NCI) Developmental 
Therapeutic Program (DTP) (http://dtp.cancer.gov/screening.html) will be closely followed to 
assess the acute toxicity (as expressed by maximal tolerated dose, MTD) and efficacy of a 
given lead anticancer compound. 
 
(1) Compounds selected for in vivo testing should have been pre-screened by in vitro enzyme 
assays (performed separately) to show adequate histone deacetylase inhibitory activities. 
Compounds (including 3 reference compounds) will be dissolved in the standard DST 
vehicle (10% DMSO in saline/0.05% Tween 80) for both acute toxicity testing and efficacy 
testing. 
(2) Cultivation of colon cancer cell lines. One human colon tumor cell line (COLO205) will be 
tested in this study. This cell line will be grown in RPMI medium supplemented with 10% 
FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.1% β-
mercaptoethanol, at 37°C in a humidified chamber under 5% CO2 in air. 
(3) Establishment of human colon cancer xenografts. Athymic nude mice (nu/nu) (4-6 wks of 
age) will be purchased from the Jackson Laboratory (Bar Harbor, ME). All animals will be 
maintained on a 12 hr light/12 hr dark schedule with free access to laboratory chow and 
water.  Tumors will be induced by injecting tumor cells (5 x 104 cells) subcutaneously into 
the rear flank of nude mice. Following injection the mice will be randomized into control or 
treatment groups and identified using numbered ear tags. Primary tumor growth will be 
monitored daily by palpation. Once a tumor is detected its growth will be monitored every 
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other day using caliper measurements with size calculated as: tumor volume = length x 
width2/2.  
(4) Evaluation of the acute toxicity of anticancer lead compounds. Generally, the determination 
of maximum tolerated dose (MTD) is performed in a way that conserves compound and 
minimizes the number of animals sacrificed. Thus, a single mouse is given a single injection 
(IP, IV or SC, to be determined) of 200 mg/kg (or lower if the compound is anticipated to be 
extremely potent); a second mouse receives a dose of 100 mg/kg and a third mouse 
receives a single dose of 50 mg/kg. The mice are observed for a period of 2 weeks. They 
are sacrificed if they lose more than 20% of their body weight or if there are other signs of 
significant toxicity. If all 3 mice must be sacrificed, the next 3 dose levels (25, 12.5 and 6.25 
mg/kg) are tested in a similar manner. This process is repeated until a tolerated dose is 
found. The last testing will be repeated once. This dose is then designated the MTD and is 
used to calculate the amount of material administered to mice during efficacy testing. The 
mice are allowed ad libitum feed and water. Dose volumes are generally 0.1 ml/10 grams 
body weight. It is estimated that 10 regular mice [(3 + 3 x 2) for actual testing, plus 1 
additional mouse as backup] will be needed for each compound. 
(5) Evaluation of the efficacy of anticancer lead compounds. For efficacy studies, mice bearing 
human xenograft tumors will be used once the tumor volume reaches 150-200 mm3 as 
described above. When the tumor volume reaches the appropriate size, the mice will 
receive an intravenous injection of the appropriate volume of DST buffer (vehicle control; n = 
10), or escalating doses of compound solution up to one-fifth of the previously determined 
MTD (e.g., if the MTD = 50 mg/kg, then doses of 0.1, 1.0 and 10 mg/kg will be used) (n = 
10). Tumor volumes will be measured as above for 3-6 weeks following injection in a blinded 
manner. Mice will be euthanized at the end of the study or when tumors become ulcerated 
or when tumor growth surpasses the maximum volume of 2000 mm3. Tumors will be excised 
at appropriate time points for additional ex vivo evaluations. Thus, for each compound, 1 
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tumor line x (3 + 1) doses x 10 mice/group = 40 total mice. In our experience ~10% of the 
mice will be lost due to technical problems (e.g., failure to grow tumor, unsuccessful tail vein 
injection) or overly aggressive tumor growth. Therefore, we are increasing the number of mice 
to 40 + 4 = 44 for each compound to be tested. 
(6) Statistical analysis. Statistical differences between treatment groups will be assessed by 
ANOVA and Student’s t-test for unpaired data between two groups. The level of significance 
is set at P < 0.05. If P < 0.05, Tukey-Kramer multiple comparisons post-tests will be 
performed. Power calculations for the efficacy studies are based on the assumption that a 
meaningful decrease in tumor volume is 20%, which will be detected using a one-tailed 
(two-group) t-test with alpha set at 0.05. The intra-group standard deviation is set at 15% of 
the mean value. With a group size of 10 animals per group, the power is 0.89. With a 
smaller inter-group decrease in tumor volume of 10%, the study would still have adequate 
power (0.70) with 10 animals per group. 
 
12)   Are you mixing your own non-pharmaceutical grade compounds for administration 
to the animals?  If not, check No and proceed to question 13.  
Note: OLAW and USDA consider that the use of non-pharmaceutical grade compounds link 
should be based on:  
• scientific necessity;  
• no availability of an acceptable veterinary or human pharmaceutical-grade compound; and  
• specific review and approval by the IACUC.  
 
 No    
 Yes 
If yes, please check the following boxes: 
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I assure that steps will be taken during the preparation of the compound to ensure sterility 
(if injectable), that the appropriate pH will be established and that an appropriate vehicle will 
be used. 
  I assure that the compound will be labeled with an appropriated shelf life and that 
monitoring procedures will be established to adhere to this. 
Comments: We will prepare the highest possible quality of compounds (≥98% purity) in the 
standard vehicle for this proposed animal study. 
13)   Standard Operating Procedures (SOP) for Animal Husbandry:  Have you provided an 
SOP for animal care and a disaster plan to the Department of University Safety and 
Assurances for review and approval?  Note: These plans need to be approved prior to 
receiving animals.  Check N/A if animals are housed in ARC facilities where these plans are in 
place and proceed to question 14. 
Yes 
N/A 
 
 
14a)   Transportation Procedures:  Will animals be transported to/from UWM facilities or 
between UWM facilities and other institutions or facilities? NOTE: Does not apply to 
animals received by commercial vendors.  If no, check No and go to question 15.  If Yes, 
check appropriate boxes below and complete the questions. 
No 
Yes    
Where will the animals be transported to/from: 
 
 
Describe the care of the animals during transport:   
15)   Quarantine Procedures:  Will you be using vertebrate animals that were acquired 
outside of UWM breeding colonies or commercial vendors? If no, check No and proceed to 
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question 16.  If yes, explain how your quarantine procedures are designed to reduce the 
possibility of disease transmission to vertebrate animals within the new facility. 
N/A 
Yes 
Quarantine Procedures (See Quarantine Procedures for Mammals): 
 
 
16)  Will you be capturing animals in the field? If no, check No and proceed to question 17.  
If yes, answer question 16a. 
No 
Yes 
16a)   Describe the specific capture techniques you will use for each species:  
17)  Explain your rationale for animal use.  Check N/A for Holding or Breeding protocol.  The 
rationale should include reasons why non-animal models cannot be used.  Recommended key 
words for literature search for alternatives include, “alternative, reduction, refinement, 
replacement”. See Alternatives website.   NOTE: If this is an educational project, provide assurance 
that the use of alternative methods (i.e. computer simulation models, videotapes) has been considered to 
meet these goals: 
Rationale: This research design of animal studies is to identify new anticancer lead compounds 
that are either more efficacious against human tumors than three reference compounds of the 
same class (FK228, thailandepsin A and thailandepsin B) and/or less toxic to normal 
cells/tissues/organs. It will provide critical experimental data required for the continuous 
assessments of newly discovered or engineered chemical compounds on large animal models 
and perhaps on cancer patients. There are no non-animal alternatives because cell cultures or 
other in vitro methods cannot provide a holistic assessment of the toxicity or efficacy of 
anticancer effects. 
18)  Justify the appropriateness of the species selected. (The species should be the lowest 
possible on the phylogenetic scale.) Check N/A for Holding or Breeding protocol. 
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N/A-Holding protocol; based on experimental protocols 
N/A-Breeding protocol; based on experimental protocols 
Justification: The regular and athymic (nu/nu) nude mice are the standard laboratory animal 
models for in vivo anticancer studies. Standard protocols posted by the US National Cancer 
Institute (NCI) Developmental Therapeutic Program (DTP) (http://dtp.cancer.gov/screening.html) 
will be closely followed to assess the acute toxicity (as expressed by maximal tolerated dose, 
MTD) and efficacy of a given lead anticancer compound. 
19)  Justify the numbers of animals to be used.  (check all that apply) 
Pilot study or preliminary project, group variances unknown at present (Suggestion: minimal 
number of animals should be requested) 
For the acute toxicity testing, the determination of maximum tolerated dose (MTD) is performed 
in a way that conserves compound and minimizes the number of animals sacrificed. For each 
compound, each round of testing will need only 3 mice, each to receive a single injection (IP, IV 
or SC) of 200 mg/kg, 100 mg/kg or 50 mg/kg body weight of compound. The mice are observed 
for a period of 2 weeks. They are sacrificed if they lose more than 20% of their body weight or if 
there are other signs of significant toxicity. If all 3 mice must be sacrificed, the next 3 dose levels 
(25, 12.5 and 6.25 mg/kg) are tested in a similar manner. This process is repeated until a 
tolerated dose is found. The last testing will be repeated once. It is estimated that 10 regular 
mice [(3 + 3 x 2) for actual testing, plus 1 additional mouse as backup] will be needed for each 
compound. 
For efficacy studies, mice bearing human xenograft tumors will be used once the tumor volume 
reaches 150-200 mm3 as described above. When the tumor volume reaches the appropriate 
size, the mice will receive an intravenous injection of the appropriate volume of DST buffer 
(vehicle control; n = 10), or escalating doses of compound solution up to one-fifth of the 
previously determined MTD (e.g., if the MTD = 50 mg/kg, then doses of 0.1, 1.0 and 10 mg/kg 
will be used) (n = 10). Tumor volumes will be measured as above for 3-6 weeks following 
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injection in a blinded manner. Mice will be euthanized at the end of the study or when tumors 
become ulcerated or when the tumor weight exceeds 10% of the animal’s normal body weight. 
Tumors will be excised at appropriate time points for additional ex vivo evaluations. Thus, for 
each compound, 1 tumor line x (3 + 1) doses x 10 mice/group = 40 total mice. In our experience 
~10% of the mice will be lost due to technical problems (e.g., failure to grow tumor, unsuccessful 
tail vein injection) or overly aggressive tumor growth. Therefore, we are increasing the number of 
mice to 40 + 4 = 44 for each compound to be tested. 
Based on the statistical analysis, the number of animals requested is the minimum necessary 
to achieve significant results 
Based on the PI’s experience using these methods in similar studies, and review of related 
use in peer reviewed published studies, the number of animals requested is the minimum 
necessary to meet the scientific objectives of the proposed research and to provide scientifically 
meaningful data 
Based on the standard protocols posted by the US National Cancer Institute (NCI) 
Developmental Therapeutic Program (DTP) (http://dtp.cancer.gov/screening.html). 
20) Provide written assurance that the activity does not unnecessarily duplicate previous 
experiments.  Check N/A for Holding or Breeding protocols. 
N/A 
Literature search conducted. 
            Name of search utilized: Over the last two years of project development, we have 
routinely and extensively searched the literature and patents to ensure that our studies will not 
duplicate any previous studies and to ensure that our project will have the highest probability to 
succeed. Our methods of literature and patent search include MEDLINE/PubMed, US National 
Library of Medicine, SciFinder Scholar, USPTO Patent search. 
            Key words used: depsipeptide, FK228, histone deacetylase inhibitor, thailandepsin 
            Date the search was completed: October 2009, and again in May 2012 
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            Years searched: all up to 2009 and 2012, respectively 
Consultation with colleagues (qualifications, dates and content of consult):  
21) CHECK OFF ALL PROCEDURES LISTED BELOW THAT APPLY TO THIS STUDY:  
(These procedures may cause more than slight or momentary pain and /or distress.)  Check N/A and 
proceed to question 22 if none of these procedures apply.  If you checked off one or more 
procedures, answer questions 21a, 21b, 21c and 21d.    
NOTE: Non-invasive procedures such as needle aspiration, parenteral injections of non-irritating 
substances, blood collection from a common peripheral vein per standard veterinary practice and manual 
restraint that is no longer than would be required for a simple exam are not considered to cause more 
than momentary pain or distress.) 
N/A 
 
a.  Surgical procedures (including terminal surgeries which are considered painful procedures 
alleviated by anesthesia- USDA Policy 11).   NOTE: do not check for tissue perfusions-answer 
question 25b 
b.  Administration of Freunds complete adjuvant. 
c.  Ocular and skin irritancy testing. 
d.  Complete Food or water deprivation beyond that necessary for normal pre-surgical 
preparation. 
e.  Noxious electrical shock that is not immediately escapable. 
f.   Paralysis or immobility in a conscious animal. 
g.  Electro-fishing, gill netting, seining, fyke netting, hook-and-line fishing, mist netting of 
birds, live trapping. 
h.  Administration of chemical or biological agents at doses known to cause more than 
momentary pain or distress or alter the normal physiology of the animal over time. 
i.   Any activity intended to induce a stress response. 
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j.   Prolonged forced confinement in a small enclosure. 
k.  Other: Although very common procedures, tumor implantation (xenograft) and injection of 
a lead compound may cause more than momentary pain and distress. 
22) Note:  If you did not check off any of the items listed in question 21 you should check 
non-applicable in this question and proceed to question 23.  Federal regulations require 
consideration of the use of alternatives to the use of animals in procedures that may cause 
more than momentary or slight pain or distress to animals whether relieved or not (examples 
listed above).   Alternatives include the concepts of replacement of vertebrate animals with in 
vitro modes, computer models or less sentient animals; refinement of experimental procedures 
to minimize pain or distress (e.g. early endpoints, use of analgesics, anesthetics or sedatives; 
techniques that reduce stress to the animal) or reduction in the number of animals by using 
appropriate statistical methods in the design and analysis of the study, reduction in variability by 
using animals of defined genetic or microbiological status, and maximizing the data gained from 
an individual animals. 
N/A 
22a)  On what basis are the procedures that may cause more than momentary pain or 
distress justified: There are no non-animal alternatives because cell cultures or other in 
vitro methods cannot provide a holistic assessment of the toxicity or efficacy of anticancer 
effects of lead compounds. 
22b)  Indicate how alternatives to procedures (checked off in 21) which may cause 
more than momentary pain or distress were considered in the design of the study, or 
why alternatives to procedures that may cause more than momentary pain or distress 
were not found to be suitable for accomplishing the goals of the study: Animal model 
studies provide the best pre-clinical information on the efficacy of lead compounds in the 
treatment of human tumors. There are no non-animal alternatives because cell cultures or 
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other in vitro methods cannot provide a holistic assessment of the toxicity or efficacy of 
anticancer effects of lead compounds. 
22c)   Methods used to search for alternatives to procedures that may cause more 
than  momentary pain or distress (indicate all that apply): 
 
 
Literature search conducted. (See Alternatives website for resources to assist in the 
search)  Note:  Recommended key words include: “alternative, reduction, refinement, replacement” 
 
Name of search utilized: MEDLINE/PubMed, National Library of Medicine, SciFinder  
   Scholar, USPTO patent search. 
Key words used: Cancer therapy, pre-clinical test, animal model, non-animal model, in   
   combination with alternative, reduction, refinement, or replacement 
Date the search was completed: May 2012 
Years searched: all up to 2012 
 Consultation with colleagues (qualifications, dates and content of consult):  
 Other information services utilized.  Elaborate, providing specific information.  
22d)  Describe any discomfort or pain or alterations in normal physiology that may result 
from this procedure in the short term and long term.  What will you do to minimize the 
chances of or relieve this discomfort and assure that no animal experiences undue pain 
or distress during the course of your research? Behavioral and physiological 
endpoints Include drugs, dosages, nursing care, mechanical devices, humane 
euthanasia, etc. Provide a scientific justification if appropriate anesthetics, analgesics or 
tranquilizer drugs cannot be utilized: 
As a standard procedure, human tumors xenografted onto athymic (nu/nu) mice does not seem 
to invoke chronic pain and discomfort, according to the vast pool of literature. However, if the 
tumors grow to the point in which pain may become a factor (e.g. tumor leads to bleeding or 
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rupture, or tumor impedes mobility, or tumor growth surpasses the maximum volume of 2000 
mm3), the animals will be humanely euthanized.    
23) Describe how frequently you will monitor your animals to ensure they are not 
experiencing pain or discomfort from your procedures or from unanticipated illness or 
injury, and state what you will do with any animals that may become ill or injured: 
Immediately after administration of lead compound solution, animals will be observed for at least 
two hours, and if acute undesirable reactions to injected compounds are observed (e.g. shock 
and/or seizure), or the animals become apparently ill or injured during the course of testing, they 
will be humanely euthanized with CO2. Otherwise the animals will be visually checked daily, 
including all tumor-bearing mice, and weighed once every three days for 3-6 weeks, in 
concurrence with the measuring of tumor sizes. All animals will be euthanized at appropriate 
times (see Item 24). Visible tumors from euthanized mice will be harvested, photographed and 
tested for redox content. The remaining corpse of euthanized mice will be kept in the 
radiation/bioharzard freezer for disposal. 
24) Will the experiments induce chronic disease, tumors or radiation sickness?  If no, 
check No and proceed to question 25.  If yes, describe the criteria (behavioral and 
physiological endpoints) for termination of the affected animals. 
No 
Yes 
Criteria for termination: Tumors will be induced subcutaneously in animals as a consequence 
of xenografting and for the purpose of experiment before the administration of lead compound 
solution. It is expected that tumor growth will be curbed, reduced or completely cured after the 
administration of anticancer compounds. However, if acute undesirable reactions to the lead 
compounds (e.g. shock and/or seizure) are observed, or when the weight loss reaches 20% 
compared to vehicle controls, or tumor impedes mobility, or the animals show inability to eat or 
drink, or infection develops, of signs of severe organ system dysfunction are observed, or the 
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animals are found in a moribund state, or the tumor growth surpasses the maximum volume of 
2000 mm3, the animals will be euthanized immediately. All surviving mice will be euthanized 
upon completion of the studies. 
25) Describe the ultimate disposition of animals at the end of the study.  If some or all are 
euthanized, answer yes to 25a and describe the methods of euthanasia (see CO2 SOP) used 
and include all drugs, doses and routes of injection. If euthanasia methods differ from the 2007 
AVMA Panel on Euthanasia provide a scientific justification.  
If some or all the animals will be perfused, check the box in 25b, list the person responsible for 
anesthesia, the dose of anesthetic used and the procedure and agents used to perfuse.   
If some or all the animal will not be euthanized check the appropriate box in 25c. 
25a) Yes (euthanized) 
Method (include drugs, doses and routes of injection): The animals will be euthanized with 
CO2, following the SOP. 
If a physical method is used, name the person performing the procedure:  
 
 
Experience/training:  
26) Does the project involve the use of hazardous agents to the humans working with the 
living animals (not tissues)? If no, check No and proceed to question 27.  If yes, check the 
appropriate box(s) below and list the agent(s).  Note: the appropriate forms listed below will need to 
be submitted to appropriate personnel in the Department of University Safety and Assurances for review 
along with the IACUC protocol. Approval is needed prior to receiving IACUC final approval.  Delays in 
approval will result if the forms are not submitted. 
No 
Yes      Appropriate forms have been submitted 
 Yes       Date if form previously approved: 
Chemicals hazardous to humans  (see FAQ 5  for definition)  DMSO 
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If checked, please list agent(s): Anticancer compound FK228, thailandepsina, and 
derivatives 
If checked, please complete the Investigations Involving the Use of Hazardous 
Chemicals form or check the appropriate box(s) below: 
MS-222. I have read the SOP  and am using MS-222 as prescribed by the  SOP.  I have 
trained my staff accordingly.  
 
I have modified the SOP to accurately reflect the handling and control measures for use 
of MS-222 and will submit the form.  (Click “Enable Macros” when opening the SOP and 
“Save As” when completed.) 
Isoflurane.  I am familiar with the safety procedures for the use of Isoflurane link and have 
trained my staff accordingly.   
Formaldehyde.  I have read the SOP  and am using Formaldehyde as prescribed by the 
SOP.  I have trained my staff accordingly. 
I have modified the SOP to accurately reflect the handling and control measures for use 
of Formaldehyde and will submit the form.  (Click “Enable Macros” when opening the SOP 
and “Save As” when completed.) 
 DMSO.  I have read the SOP  and am using DMSO as prescribed by the SOP.  I have 
trained my staff accordingly. 
 I have modified the SOP to accurately reflect the handling and control measures for use 
of DMSO and will submit the form.  (Click “Enable Macros” when opening the SOP and 
“Save As” when completed.) 
Radionuclides 
       If checked, please list agent(s):    
 
   
       If checked, please complete the Animal Use of Radionuclides form  
rDNA             If checked, please list agent(s):  
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If checked, please complete the cover sheet and one of the registration forms below: 
Registration Cover Sheet for all Recombinant DNA Research        
Recombinant DNA Registration Form for Exempt Research  
Recombinant DNA Registration Form for Non-exempt Research  
Biological agents or Biological Toxin     If checked, please list agent(s):  
       If checked, please complete  one of the registration forms below: 
       Biological Agent Registration Form  
       Biological Toxin Registration Form  
QUESTIONS FOR PROJECTS INVOLVING SURGICAL PROCEDURES 
27)    Does the project involve surgical procedures?  If no, check No.  If yes, check the 
appropriate box(s) and proceed to 27a.  See Guidelines for Rodent/Avian Surgery  
No 
Major--Penetrates and/or exposes body cavity or produces substantial impairment of physical 
or physiological functions (i.e. laparotomy, thoracotomy and craniotomy.) 
Minor --Does not expose body cavity and causes little or no physical impairment (i.e. 
subcutaneous implants.) 
Survival 
Non-survival--An animal is euthanized before recovery from anesthesia. (for perfusion 
procedures answer question 23b   
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Pictures from the mice lab 
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Appendix B 
 
Chapter II: AQUEOUS COMPLEXES FOR EFFICIENT SIZE-BASED 
SEPARATION OF AMERICIUM FROM CURIUM 
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I. Analytical Data 
i. 1H  and 13C of dimethyl pyridine-2,6-dicarboxylate 
 
 
N
O
O O
O  
 
 
 
  
1H:	  	  ju020413	  Exp	  1	  	  User:	  ju	  	  500	  
13C:  ju020413 Exp 2 User: ju 500 
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ii. 1H  and 13C of methyl 6-(hydroxymethyl)picolinate 
	  
 
 
N
O
O OH
 
 
 
 
 
 
  
1H:	  	  ju020413	  Exp	  4	  	  User:	  	  ju	  	  300	  
13C:  ju020413 Exp 5 User: ju 300 
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iii. 1H  and 13C of methyl 6-(bromomethyl)picolinate 
	  
 
N
O
O Br
 
 
 
 
 
  
1H:	  	  djm020813	  Exp	  1	  	  User:	  djm	  	  300	  
13C:  ju020413 Exp 7 User: ju 300 
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iv. 1H , 13C  and COSY (1H, 1H ) of 1,4,10,13-tetraoxa-7,16-
diazacyclo-octadecane 
 
O
O
N
H
O
O
H
N  
 
 
 
1H:	  	  ju020613	  Exp	  1	  	  User:	  ju	  	  300	  
13C:  ju020613 Exp 2 User: ju 300 
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v. 1H  and 13C  of N,N′-Bis[(6-methoxycarbonyl-2-pyridyl)methyl]-
1,7-diaza-12-crown-4 
	  
 
 
OO
N
O O
NN
O
O
N
O
O
 
 
 
 
 
 
] 
vi. 1H  and 13C  of N,N′-Bis[(6-carboxy-2-pyridyl)methyl]-1,7-diaza-
12-crown-4 (H2bp12c4·4HCl) 
	  
1H:	  	  ju020613	  Exp	  1	  	  User:	  ju	  	  300	  
13C:  ju020613 Exp 2 User: ju 300 
1H:	  	  djm021213	  Exp	  1	  	  User:	  ju	  	  300	  
13C:  djm021213 Exp 2 User: ju 300 
COSY:  djm021213 Exp 4  User:  djm 300 
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vii. 1H  of Methyl 6-(2-vinyl)picolinate 
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viii. 1H  of Methyl 6-(2-hydroxyethyl)picolinate 
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ix. 1H  of Methyl 6-(2-chloroethyl)picolinate 
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x. 1H ,13C and MS of Methyl 2-Pyridinecarboxylic acid, 6,6'-
[(1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis-
(ethylene)]bis-, 2,2'-dimethyl ester 
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xi. 1H  and MS of Methyl 2-Pyridinecarboxylic acid, 6,6'-[(1,4,10,13-
tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(ethylene)]bis 
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Appendix C 
 
PART III:  DESIGNING STRONG CHIRAL BRØNSTED ACIDS AND THEIR 
APPLICATION FOR OXAZINANONES DERIVATIZATION AND THE AZA-HENRY 
REACTION 
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13C NMR for  
NH2
 
 
160165170175180185190 ppm
15
8.
61
15
9.
32
15
9.
60
16
9.
84
17
5.
31
19
4.
13
A
126127128129130131132133134135136137138139 ppm
12
5.
16
12
6.
27
12
6.
81
12
6.
89
12
7.
22
12
7.
31
12
7.
59
12
8.
84
12
9.
64
12
9.
81
12
9.
90
13
0.
12
13
0.
36
13
0.
68
13
1.
35
13
3.
23
13
5.
45
13
6.
32
13
7.
19
13
8.
22
13
9.
20
13
9.
52
A	  = C H
A A
A
 
 
 
 
 
 
 
 
 
478 
 
2D NMR for  
NH2
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